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SUMMARY Nuclear	   Receptor	   CoRepressor-­‐1	   (NCOR1)	   controls	   the	   actions	   of	   multiple	  transcription	   factors	   including	  nuclear	  receptors	  (NR).	  The	  prostate	  malignant	  cell	  line	  PC-­‐3,	   displays	   a	   significant	  differential	   expression	  of	   a	   cohort	  of	   corepressors	  (NCOR1,	  RIP140,	  LCOR,	  SLIRP)	  and	  subsequent	  loss	  of	  responsiveness	  to	  NR	  ligands,	  including	  those	  for	  PPAR	  and	  VDR,	  compared	  to	  the	  non-­‐malignant	  cell	  line	  RWPE1	  at	  a	   transcriptional	  and	  phenotypical	   level.	  NR	   insensitivity	  can	  be	  antagonized	  by	  using	  the	  histone	  deacetylase	  inhibitor	  SAHA	  in	  combination	  with	  the	  PPARα	  and	  -­‐γ	  ligand	   bezafibrate.	   Microarray	   approaches	   revealed	   co-­‐treatment	   restored	   PPAR	  transcriptional	   actions	   towards	   target	   genes	   (e.g.	   CDKN1A,	   PTGS2,	   ALOX5,	   CDC2,	  
TGFBRAP1).	   NCOR1-­‐knock	   down	   by	   shRNA	   restored	   partially	   the	   transcriptional	  abilities	  of	  PPARs	  upon	  treatment	  with	  bezafibrate,	  mimicking	  the	  effect	  of	  SAHA	  on	  the	  genes	  identified.	  Interestingly,	  shNCOR1-­‐PC-­‐3	  were	  more	  sensitive	  towards	  the	  PPARα	   and	  PPARγ	   ligands,	   ETYA	   and	  EPA	   respectively,	   but	  were	  unresponsive	   to	  1,25(OH)2-­‐D3	   and	   T3.	   This	   was	   reflected	   at	   the	   transcriptional	   level	   where	   in	  bezafibrate-­‐treated	  shNCOR1-­‐PC-­‐3	  the	  expression	  of	  PPAR	  target	  genes	  (TGFBRAP1,	  
CDKN1A,	  ALOX5,	  CDC2)	  was	  restored	  mirroring	  the	  activity	  of	  SAHA.	  To	  profile	  the	  transcriptome	   regulated	   by	   NCOR1	   during	   the	   cell	   cycle	   a	  microfluidic	   gene	   card	  approach	  was	  undertaken.	  PC-­‐3	  cells	  were	  FACS	  sorted	  in	  G1,	  S	  and	  G2	  phases	  and	  demonstrated	  that	  shNCOR1-­‐PC-­‐3	  cells	  restored	  the	  basal	  levels	  of	  key	  regulators	  of	  cell	   viability	   such	   as	  histone	  modifiers,	  CDKN1A,	  TP53	   and	  CDH1.	   ChIP	   analysis	   in	  siNCOR1-­‐PC-­‐3	  cells	  also	  revealed	  that	  NCOR1	  controls	  the	  epigenetic	  modifications	  at	  the	  CDKN1A	  and	  TGFBRAP1	  TSS	  differentially	  modulating	  H3K9	  acetylation	  upon	  bezafibrate	  treatment,	  reflecting	  mRNA	  accumulation	  data.	  The	  contribution	  of	  NCOR1	  and	  NCOR2/SMRT	  in	  prostate	  development	  is	  unknown.	  To	   identify	   these	   functions	   more	   accurately	   Ncor1,	   and	   Ncor2/Smrt,	   are	   being	  knocked	  out	  in	  mice	  in	  prostate-­‐specific	  manner	  using	  a	  Cre/Lox-­‐P	  strategy	  where	  the	   Cre	   enzyme	   is	   controlled	   by	   the	   modified	   prostate-­‐specific	   rat	   probasin	  promoter,	  ARR2PB.	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  Male	  accessory	  sex	  organs	  of	  the	  adult	  male	  rat.	  A,	  anterior	  view;	  B,	  lateral	  view;	  C,	  anterior	  view	  with	  the	  bladder	  deflected	  caudally.	  Ampullary	  gland	  of	  the	  vas	  deferens	  (AG);	  bladder	  (B);	  coagulating	  gland	  (CG);	  dorsal	  prostate	  (DP);	  lateral	  prostate	  (LP);	  seminal	  vesicle	  (SV);	  ventral	  prostate	  (VP);	  vas	  deferens	  (VD);	  deferential	  vein	  (DV).	  Image	  taken	  from	  [2] ......................................................................34	  
Fig	  1.2	  –	  A	  diagram	  of	  the	  prostate	  ductal-­‐cross	  section	  is	  shown	  with	  labels	  indicating	  cell	  types	  that	  are	  present	  in	  prostatic	  ducts	  including	  luminal	  secretory	  epithelial	  cells,	  basal	  epithelial	  cells,	  neuroendocrine	  cells,	  stromal	  smooth	  muscle	  cells,	  and	  stem	  cell	  candidates.	  Beneath	  the	  label	  for	  each	  cell	  type	  is	  a	  list	  of	  differentiation	  markers	  commonly	  used	  to	  distinguish	  these	  cell	  types.	  In	  the	  case	  of	  stem	  cell	  candidates,	  two	  studies	  have	  associated	  expression	  of	  either	  a	  set	  of	  markers	  including	  cytokeratins	  5,	  14,	  8,	  18,	  and	  19,	  GSTpi,	  and	  p63	  	  or	  high	  expression	  of	  α2β1-­‐integrin	  with	  rare	  basal	  cells	  proposed	  as	  prostatic	  epithelial	  stem	  cell	  candidates.	  Image	  taken	  from	  [8]. ......................................................................36	  
Fig	  1.3	  –	  Rat	  prostate	  developmental	  stages,	  timeline	  and	  morphoregulatory	  gene	  expression.	  The	  days	  of	  fetal	  and	  postnatal	  life	  are	  shown	  at	  the	  bottom.	  Ventral	  prostate	  morphology	  and	  developmental	  stages	  (top)	  are	  sequentially	  aligned	  to	  the	  corresponding	  days	  that	  they	  appear.	  Note	  that	  cellular	  differentiation	  occurs	  during	  the	  later	  days	  of	  branching	  morphogenesis	  as	  indicated	  by	  blue-­‐striped	  lines.	  Temporal	  patterns	  of	  morphoregulatory	  genes	  expression	  are	  shown	  in	  black-­‐gray-­‐white	  bars	  representing	  relative	  levels	  of	  gene	  expression	  as	  determined	  by	  quantitative	  real-­‐time	  reverse-­‐transcriptase	  polymerase	  chain	  reaction.	  Image	  taken	  from	  [17]....................................................................................................................................41	  
Fig	  1.4	  –	  Schematic	  representation	  of	  testosterone	  metabolites.	  The	  5α-­‐reductases	  enzyme	  catalyzes	  the	  conversion	  of	  testosterone	  to	  5α-­‐dihydrotestosterone	  (DHT);	  the	  β-­‐hydroxysteroid	  dehydrogenase	  converts	  testosterone	  into	  androstenedione;	  the	  aromatase	  enzymes	  can	  convert	  further	  the	  androstenedione	  into	  estrogen. ....44	  
Fig	  1.5	  –	  The	  progenitor	  origin	  of	  cancer.	  Epithelial	  or	  neuroendocrine	  cells	  may	  acquire	  epigenetic	  modifications	  and	  genetic	  mutations	  through	  DNA	  damage,	  oxidative	  stress,	  etc.	  during	  the	  process	  of	  differentiation.	  The	  phenotypic	  characteristics	  of	  the	  cancer	  would	  therefore	  be	  determined	  by	  the	  stem	  or	  progenitor	  cell-­‐of-­‐origin.	  From	  left	  to	  right	  (undifferentiated	  to	  differentiated	  cells)	  is	  shown	  how	  the	  initial	  onset	  of	  stem	  cells	  can	  differentiate	  into	  specific	  malignancies.	  Figure	  taken	  from	  [44]. ................................................................................50	  
Fig	  1.6	  –	  Genetics	  alterations	  during	  prostate	  cancer	  progression.	  Photomicrographs	  of	  hematoxylin	  and	  eosin-­‐stained	  sections	  representative	  of	  the	  indicated	  tissue	  or	  lesion	  (10x	  original	  magnification,	  40x	  inserts).	  Arrows	  indicate	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proposed	  routes	  of	  progression	  from	  normal	  (NOR)	  prostate	  glands	  to	  precursor	  lesions	  (PIN,	  PIA)	  to	  localized	  PCa	  to	  metastatic	  disease	  (MET).	  Pathway	  and	  candidate	  gene	  names	  in	  blue	  or	  red	  represent	  genes	  and	  pathways	  underexpressed	  or	  overexpressed,	  respectively,	  during	  the	  indicated	  transition.	  Figure	  taken	  from	  [52]..............................................................................................................................................53	  
Fig	  1.7	  –	  Results	  of	  the	  simulation	  with	  ODEs.	  The	  accumulation	  of	  three	  different	  species	  x	  (blue),	  y	  (violet)	  and	  a	  (yellow)	  based	  on	  the	  reaction	  x	  →	  y	  →	  a.	  Time	  is	  indicated	  in	  the	  x	  axes	  while	  the	  concentration	  of	  the	  species	  is	  on	  the	  y	  axes. ........96	  
Fig	  1.8	  –	  Results	  of	  the	  simulation	  of	  a	  hypothetical	  polymerase	  activity	  on	  the	  promoter	  of	  CDKN1A	  gene.	  Time	  and	  concentration	  of	  the	  polymerase	  are	  indicated	  on	  the	  x	  and	  y	  axes,	  respectively.	  Only	  the	  first	  8000	  seconds	  (133	  min	  =	  ~	  2	  hours)	  were	  taken	  in	  consideration	  as	  if	  the	  system	  goes	  into	  steady	  state	  after	  4000	  seconds. .....................................................................................................................................98	  
Fig	  2.1	  -­	  Representative	  cell	  cycle	  histogram.	  On	  the	  x	  axes	  the	  cell	  count	  and	  on	  the	  y	  axes	  the	  log	  intensity	  of	  the	  DNA	  content	  detected	  via	  Hoechst	  dye.	  The	  left	  side	  of	  the	  histogram	  indicates	  cells	  in	  G1	  phase,	  the	  flat	  part	  at	  the	  centre	  indicates	  cells	  in	  S	  while	  G2	  cells	  are	  on	  the	  far	  right	  of	  the	  histogram	  with	  the	  highest	  amount	  of	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Fig	  2.2	  –	  Theoretical	  example	  of	  the	  amplification	  curve	  of	  CYP24	  in	  treated	  (+ve)	  vs	  untreated	  (-­‐ve)	  PC-­‐3	  cells.	  Cycle	  thresholds	  (Cts)	  of	  the	  gene	  are	  related	  to	  18s’	  Cts.	  Fold	  changes	  are	  calculated	  as	  explained	  above.	  In	  this	  case	  1,25(OH)2D3	  treatment	  effectively	  promotes	  accumulation	  of	  CYP24	  mRNA	  as	  detected	  by	  the	  amplification	  curve	  shifted	  to	  the	  left	  if	  compared	  to	  the	  un-­‐treated	  sample. ................................. 111	  
Fig	  2.3	  –	  Description	  of	  the	  endonuclease	  activity	  of	  the	  taq	  polymerase.	  The	  more	  the	  probe	  is	  digested	  the	  more	  light	  is	  released	  by	  the	  report	  dye............................ 112	  
Fig	  2.4	  –	  Visual	  representation	  of	  the	  genes	  preloaded	  into	  the	  microfluidic	  gene	  card.	  Indicated	  are	  the	  sub-­‐cellular	  location	  and	  the	  main	  function	  (image	  from	  James	  Thorne,	  University	  of	  Birmingham,	  Birmingham,	  UK)...................................... 117	  
Fig	  2.5	  -­	  Example	  of	  linear	  regression	  curve	  obtained	  with	  standard	  BSA	  samples.	  The	  y	  axes	  indicates	  the	  absorbance	  that	  correlates	  with	  the	  concentration	  indicated	  on	  the	  x	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Fig	  2.7	  –	  ShRNA	  pathway:	  the	  Dicer	  complex	  processes	  the	  shRNA	  before	  it’s	  recognised	  by	  the	  RISC	  complex.	  This	  will	  lead	  the	  single	  stranded	  molecule	  to	  the	  target	  mRNA	  that	  will	  be	  degraded................................................................................... 130	  
Fig	  2.8	  –	  pcDNA	  3.1	  vector	  from	  Invitrogen.	  Human	  H1	  promoter	  was	  inserted	  by	  Farhat	  Khanim	  (University	  of	  Birmingham,	  Birmingham,	  UK)	  to	  substitute	  the	  original	  CMV	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Fig	  2.8	  –	  Layout	  from	  sequencing	  experiment.	  Each	  peak	  represents	  the	  probability	  of	  finding	  that	  specific	  nucleotide,	  its	  position	  is	  written	  below	  the	  sequence....... 136	  
Fig	  2.9	  –	  Transfection	  efficiency	  experiment.	  Method	  of	  transfection	  explained	  below,	  briefly,	  mid-­‐exponential	  growing	  PC-­‐3	  cells	  were	  transfected	  with	  different	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concentrations	  of	  plasmid/FUGENE6	  and	  analysed	  after	  24,	  48	  and	  96	  hr	  under	  the	  microscope.	  Pictures	  indicate	  cells	  in	  the	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  (TOP)	  while	  red	  cells	  indicate	  Renilla-­‐trasnfected	  cells	  after	  24	  hr	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Fig	  2.10	  –	  General	  workflow	  of	  an	  X-­‐ChIP	  experiment.	  DNA	  is	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  incubated	  with	  a	  primary	  antibody	  directed	  against	  the	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  The	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  the	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  from	  the	  DNA;	  next,	  DNA	  is	  extracted	  and	  quantified	  by	  PCR	  analysis.	  Image	  taken	  from	  www.bbioo.com. ................................................... 139	  
Fig	  3.1	  –	  Mytomycin	  C	  chemical	  structure	  (from	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Fig	  3.2	  –	  Scheme	  of	  how	  to	  pick	  colonies	  for	  PCR	  screening.	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  were	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  to	  the	  tip	  and	  were	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  in	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  Petri	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  the	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  then	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  the	  tube	  with	  Mastermix	  and	  worked	  as	  a	  template	  for	  the	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Fig	  3.3	  –	  Schematic	  representation	  of	  the	  capillary	  transfer	  of	  DNA	  into	  membrane.
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Fig	  3.4	  –	  Example	  of	  a	  southern	  blotting	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Fig	  4.1	  –	  Antiproliferative	  effect	  of	  nuclear	  receptor	  ligands	  in	  non	  malignant	  prostate	  epithelial	  cells	  RWPE-­‐1	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  and	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  PC-­‐3	  (red);	  2x103	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  were	  plated	  in	  a	  96	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  and	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  for	  96	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  with	  the	  indicated	  ligand,	  with	  a	  re-­‐dose	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  48	  hours.	  Bar	  charts	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  of	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  ATRA.	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  are	  the	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  at	  least	  biological	  triplicates	  +/-­‐	  S.E.M..	  Student	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  that	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  difference	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  between	  PC-­‐3	  and	  RWPE-­‐1	  cells	  was	  significant;	  **=p<0.01,	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Fig	  4.2	  –	  Representation	  of	  the	  physiological	  equilibrium	  between	  complexes	  that	  activate	  or	  repress	  transcription	  and	  nuclear	  receptors.	  Gene	  transcription	  (yellow	  triangle)	  is	  regulated	  by	  the	  amount	  of	  CoActivator	  complex	  (green	  triangle)	  and	  CoRepressors	  (orange	  triangle);	  when	  the	  concentration	  of	  corepressors	  rise	  and	  the	  amount	  of	  NR	  remain	  constants,	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  diminishes,	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  the	  balance	  of	  the	  equation	  is	  shifted	  towards	  repression	  and	  transcription	  is	  inhibited. ..................................... 183	  
Fig	  4.3	  –	  Basal	  mRNA	  levels	  of	  a	  selected	  cohort	  of	  corepressors	  in	  three	  different	  epithelial	  cell	  lines	  RWPE-­‐1	  (white),	  DU145	  (light	  grey)	  and	  PC-­‐3	  (dark	  grey).	  The	  results	  are	  the	  average	  of	  at	  least	  biological	  triplicate	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  was	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  and	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  axes	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  fold	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  to	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Fig	  4.4	  –	  Western	  immunoblot	  for	  NCOR1	  and	  NCOR2/SMRT	  in	  RWPE-­‐1,	  LNCaP,	  DU145	  and	  PC-­‐3	  cells	  (TOP)	  and	  HDAC3	  in	  malignant	  PC-­‐3	  and	  non-­‐malignant	  RWPE-­‐1	  cells.	  60	  µg	  of	  whole	  protein	  lysate	  was	  used	  were	  loaded	  into	  an	  SDS-­‐page	  and	  analysed	  with	  the	  antibodies	  listed	  in	  Materials	  and	  Methods.	  Chemoluminescent	  detection	  of	  the	  proteins	  occurred	  through	  HRP-­‐conjugated	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secondary	  antibody	  and	  ECL.	  The	  analysis	  was	  repeated	  in	  at	  least	  two	  biological	  replicates.	  Nucleolin	  was	  used	  a	  loading	  control	  for	  NCOR1	  and	  NCOR2/SMRT	  and	  
β-­‐actin	  for	  SLIRP	  and	  HDAC3	  western	  blotting	  because	  both	  proteins	  accurately	  reflect	  the	  total	  protein	  content	  independently	  from	  the	  cell	  background. ............. 185	  
Fig	  4.5	  –	  Basal	  nuclear	  receptor	  levels	  RWPE-­‐1,	  LNCaP,	  DU145	  and	  PC-­‐3.	  20	  µg	  of	  cytoplasmic	  (C)	  and	  nuclear	  (N)	  lysates	  were	  obtained	  from	  mid-­‐exponential	  growing	  cells,	  quantified	  and	  loaded	  in	  SDS-­‐page	  gel	  for	  Western	  immunoblotting;	  nitrocellulose	  membranes	  were	  probed	  with	  anti-­‐VDR,	  anti-­‐PPARα	  or	  PPARγ	  antibodies.	  Chemoluminescent	  detection	  of	  the	  proteins	  occurred	  through	  HRP-­‐conjugated	  secondary	  antibody	  and	  ECL.	  The	  analysis	  was	  repeated	  in	  at	  least	  two	  biological	  replicates.	  Equal	  loading	  was	  ensured	  by	  the	  detection	  of	  beta-­‐actin;	  although	  this	  protein	  is	  mainly	  located	  in	  the	  cytoplasm,	  several	  papers	  [197-­‐199]	  reported	  the	  presence	  of	  this	  protein	  in	  the	  nucleus. ................................................... 186	  
Fig	  4.6	  –	  Heatmap	  representing	  the	  genes	  differentially	  expressed	  between	  RWPE-­‐1	  and	  PC-­‐3	  cells	  in	  each	  of	  the	  three	  phases	  of	  the	  cell	  cycle.	  One	  sample	  student	  t-­‐test	  was	  made	  to	  establish	  the	  genes	  significantly	  differentially	  expressed	  between	  the	  two	  cell	  lines,	  p<0.01.	  Green	  boxes	  indicate	  downregulated	  genes	  and	  red	  boxes	  indicate	  upregulated	  genes.	  To	  better	  visually	  represent	  the	  data	  a	  hierarchical	  clustering	  was	  made	  using	  the	  Support	  Tree	  algorithm	  in	  TmeV,	  this	  function	  contstructs	  the	  tree	  resampling	  the	  gene	  values	  using	  iterations	  and	  the	  metric	  used	  was	  euclidean	  distance.	  Highlighted	  are	  corepressor	  and	  coactivator	  enzymes	  as	  well	  as	  histone	  modifiers	  linked	  with	  positive	  or	  repressive	  histone	  marks.	  Data	  are	  the	  mean	  of	  at	  least	  three	  biological	  replicate	  and	  technical	  quadruplicate	  from	  values	  obtained	  with	  Q-­‐RT-­‐PCRM	  analysis....................................................................... 189	  
Fig	  4.7	  –	  CYP24	  mRNA	  accumulation	  in	  sorted	  PC-­‐3	  cells	  treated	  for	  four	  hours	  with	  100	  nM	  of	  1,25(OH)2D3.	  RNA	  was	  extracted	  and	  reverse-­‐transcribed	  prior	  qRT-­‐PCR	  analysis.	  The	  results	  represent	  three	  biological	  replicates	  (black,	  green	  and	  red)	  and	  mRNA	  accumulation	  is	  shown	  as	  log10	  of	  the	  fold	  changes. ........................................ 191	  
Fig	  4.8	  –	  Heatmap	  representing	  mRNA	  accumulation	  of	  96	  genes	  in	  RWPE-­‐1	  and	  PC-­‐3	  cells	  treated	  for	  four	  hours	  with	  100	  nM	  of	  1,25(OH)2D3.	  Red	  and	  green	  bars	  represent	  up-­‐	  and	  down-­‐regulated	  genes,	  respectively.	  The	  represented	  values	  are	  three	  biological	  replicate	  and	  two	  technical	  replicates	  measured	  via	  microfluidic	  Q-­‐RT-­‐PCR..	  The	  right	  side	  of	  the	  heatmap	  contains	  the	  genes	  analysed	  and	  the	  top	  side	  indicates	  the	  sample	  names.	  Noticeable	  is	  the	  difference	  in	  the	  expression	  pattern	  between	  RWPE-­‐1	  and	  PC-­‐3	  cells	  being	  the	  first	  one	  constant	  across	  the	  phases	  (from	  G1	  towards	  G2)	  and	  the	  second	  one	  scattered	  with	  different	  variability	  across	  the	  phases...................................................................................................................................... 192	  
Fig	  4.9	  –	  Additive	  effect	  of	  0.5	  µM	  of	  SAHA	  (Vorinostat)	  in	  combination	  with	  nuclear	  receptor	  ligands,	  this	  concentration	  was	  chosen	  for	  its	  low	  toxicity	  and	  minimal	  antiproliferative	  and	  was	  obtained	  from	  an	  initial	  optimization	  experiment	  that	  aimed	  to	  find	  the	  ED25	  dose:	  (A)	  10	  nM	  ATRA	  (RAR),	  (B)	  10	  µM	  EPA	  (PPARα),	  (C)	  10	  
µM	  ETYA	  (PPARγ),	  (D)	  0.5	  µM	  Bezafibrate	  (PPARα,	  -­‐γ),	  (E)	  T3	  (TR),	  (F)	  100	  nM	  1,25(OH)2D3	  ,	  (VDR).	  Two	  thousand	  cells	  were	  plated	  in	  a	  96	  well/plate	  and	  treated	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with	  the	  ligand	  for	  96	  hours	  with	  a	  re-­‐dose	  at	  48	  hours.	  Results	  were	  compared	  to	  the	  same	  ligand	  in	  RWPE-­‐1	  cells.	  Strong	  additive	  effects	  (sa)	  were	  those	  where	  the	  experimental	  value	  were	  significantly	  higher	  than	  the	  predicted	  value,	  additive	  (a)	  effects	  were	  those	  where	  the	  experimental	  value	  did	  not	  significantly	  differ	  from	  the	  predicted	  value,	  sub-­‐additive	  (sb)	  effects	  were	  those	  where	  the	  experimental	  value	  was	  significantly	  less	  than	  the	  predicated	  value.	  Statistical	  significance	  was	  calculated	  using	  a	  one	  tailed	  Mann-­‐Whitney	  test	  (*	  p<0.05,	  **	  p<0.01)	  [208].	  Data	  represent	  the	  mean	  of	  biological	  triplicate	  undertaken	  in	  triplicate	  wells. ............. 194	  
Fig	  4.10	  –	  (A)	  Heatmap	  representing	  genes	  uniquely	  regulated	  by	  the	  double	  treatment	  with	  SAHA	  and	  bezafibrate,	  indicated	  is	  also	  the	  expression	  patter	  in	  cancer	  tissues	  retrieved	  by	  Oncomine	  and	  the	  Cancer	  Genome	  Anatomy	  Project.	  Green	  and	  red	  bars	  indicate	  down-­‐	  and	  up-­‐regulated	  genes,	  respectively.	  (B)	  Venn	  Diagram	  representing	  the	  previous	  data:	  10	  out	  of	  23	  upregulated	  gene	  were	  down-­‐regulated	  in	  cancer	  and	  the	  expression	  of	  17	  out	  of	  35	  downregulated	  genes	  in	  cancer	  was	  restored	  by	  the	  combined	  treatment. ......................................................... 196	  
Fig	  4.11	  –	  Schematic	  representation	  of	  genes	  found	  to	  be	  uniquely	  up-­‐regulated	  (A)	  and	  down-­‐regulated	  (B)	  by	  the	  double	  treatment	  with	  SAHA	  and	  bezafibrate.	  Blue	  and	  orange	  boxes	  indicate	  cytoplasmic	  and	  nuclear	  products,	  respectively.	  Yellow	  boxes	  indicate	  cellular	  functions;	  arrows	  indicate	  positive	  interaction	  between	  two	  genes	  and	  flat-­‐ended	  lines	  indicate	  inhibitory	  interaction. ......................................... 198	  
Fig	  4.12	  –	  Q-­‐RT-­‐PCR	  screening	  for	  16	  candidate	  genes	  identified	  via	  microarray	  analysis	  for	  being	  uniquely	  regulated	  by	  the	  double	  treatment	  with	  0.5	  µM	  SAHA	  and	  0.5	  µM	  Bezafibrate.	  PTGS2	  was	  identified	  via	  network	  analysis	  for	  being	  metabolically	  related	  to	  ALOX5.	  Shown	  are	  genes	  initially	  up-­‐regulated	  (A1	  to	  I2)	  and	  downregulated	  (F1	  to	  Q2).	  105	  PC-­‐3	  cells	  were	  plated	  per	  each	  well	  in	  a	  6	  well/plate,	  seeded	  for	  at	  least	  24	  hours	  and	  treated	  with	  the	  ligand	  for	  either	  6	  or	  12	  hours;	  total	  RNA	  was	  extracted	  and	  reverse-­‐transcribed	  prior	  Q-­‐RT-­‐PCR	  analysis.	  Assay	  on	  demand	  primers	  and	  probes	  were	  used	  as	  described	  in	  Materials	  and	  Methods.	  All	  the	  data	  are	  the	  mean	  value	  of	  at	  least	  biological	  triplicate	  datasets	  +/-­‐	  S.E.M......................................................................................................................................... 204	  
Fig	  4.13	  –	  Time	  course	  experiments	  for	  five	  selected	  genes:	  ALOX5	  (A),	  PTGS2	  (B),	  TGFBRAP1	  (C),	  CDC2	  (D)	  and	  FBXL6	  (E).	  RNA	  was	  extracted	  from	  mid-­‐exponentially	  growing	  PC-­‐3	  cells	  and	  reverse	  transcribed	  prior	  Q-­‐RT-­‐PCR	  analysis.	  Custom	  designed	  primers	  and	  probes	  were	  validated	  and	  used	  for	  this	  experiment;	  the	  complete	  list	  can	  be	  found	  in	  Materials	  and	  Methods.	  Experiments	  performed	  with	  the	  single	  ligands	  or	  with	  the	  combination	  of	  the	  two	  revealed	  several	  time	  points	  where	  the	  mRNA	  was	  uniquely	  regulated	  by	  the	  combined	  action	  of	  0.5	  µM	  SAHA	  and	  0.5	  µM	  bezafibrate.	  Each	  time	  point	  is	  the	  mean	  value	  of	  at	  least	  three	  biological	  replicates	  +/-­‐	  S.E.M..	  One	  way	  ANOVA	  was	  used	  to	  discover	  statistical	  significance	  of	  the	  double	  treatment	  with	  SAHA	  and	  bezafibrate,	  *=p<0.05. ..................................... 205	  
Fig	  4.14	  –	  (TOP)	  annealed	  oligos	  for	  shNCOR1	  and	  pcDNA3.1-­‐H1	  vectors	  loaded	  to	  ensure	  the	  ratio	  between	  vector/oligos	  in	  order	  to	  perform	  an	  efficient	  ligation.	  (BOTTOM)	  digestion	  with	  Acc65I	  and	  XbaI	  to	  show	  the	  presence	  of	  the	  inserted	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fragment	  (200	  bp).	  The	  ladder	  is	  over-­‐exposed	  due	  to	  the	  presence	  of	  a	  low	  concentration	  of	  digested	  product;	  however	  the	  samples	  were	  used	  successfully	  for	  sequencing	  as	  shown	  in	  Fig	  4.15. ...................................................................................... 207	  
Fig	  4.15	  –	  Sequencing	  results	  of	  the	  pcDNA3.1H1	  clones	  containing	  the	  inserts	  directed	  against	  exon	  5,	  38	  and	  44.	  Highlighted	  in	  blue	  are	  the	  sequences	  containing	  the	  hairpins,	  full	  sequences	  are	  available	  in	  the	  Materials	  and	  Methods	  chapter.	  Sequencing	  was	  performed	  by	  the	  Genomic	  Facilities	  in	  the	  School	  of	  Biosciences	  at	  the	  University	  of	  Birmingham,	  Birmingham,	  UK............................................................ 208	  
Fig	  4.16	  –	  Dose	  response	  of	  G418	  in	  PC-­‐3	  cells.	  This	  experiment	  was	  undertaken	  to	  find	  the	  concentration	  of	  G418	  suitable	  to	  maintain	  PC-­‐3-­‐	  shNCOR1	  resistant	  cells.	  two	  thousands	  cells	  were	  plated	  in	  flat	  white	  bottom	  a	  96	  well/plate,	  treated	  for	  96	  hours	  with	  the	  designed	  concentration	  of	  G418	  and	  re-­‐dosed	  after	  48	  hours.	  The	  percentage	  of	  proliferating	  cells	  was	  measured	  via	  ATP	  assay	  (described	  in	  Materials	  and	  Methods).	  Data	  shown	  are	  the	  average	  of	  a	  biological	  duplicate	  and	  technical	  triplicate	  (three	  wells	  per	  each	  sample	  per	  each	  replicate)	  +/-­‐	  S.E.M.. ... 209	  
Fig	  4.17	  –	  NCOR1	  knock	  down	  via	  shRNA	  in	  PC-­‐3	  cells	  at	  the	  protein	  (A)	  and	  mRNA	  (B)	  level.	  Nuclear	  lysate	  from	  mid-­‐exponential	  growing	  cells	  was	  used	  for	  Western	  immunoblotting	  analysis	  with	  the	  anti-­‐NCOR1	  antibody	  (listed	  in	  Materials	  and	  Methods).	  Total	  RNA	  was	  extracted	  from	  different	  clones	  and	  reverse	  transcribed	  prior	  qRT-­‐PCR;	  mRNA	  levels	  were	  compared	  to	  two	  different	  VO	  clones	  and	  VO-­‐2	  was	  chosen.	  Data	  shown	  are	  the	  results	  of	  biological	  triplicate	  +/-­‐	  S.E.M..	  For	  further	  analysis	  the	  clone	  38.2	  was	  selected. ............................................................................... 210	  
Fig	  4.18	  –	  Gene	  expression	  in	  shNCOR1-­‐PC-­‐3	  versus	  VO-­‐PC-­‐3.	  Data	  shown	  are	  the	  mean	  of	  at	  least	  biological	  duplicate	  and	  technical	  quadruplicate	  (tow	  set	  of	  probes	  were	  present	  in	  each	  well).	  (A)	  Genes	  significantly	  differentially	  expressed	  in	  at	  least	  one	  phase	  of	  the	  cell	  cycle	  between	  shNCOR1-­‐PC-­‐3	  and	  VO-­‐PC-­‐3,	  *=p<0.05.	  Statistical	  significance	  was	  measured	  with	  a	  one-­‐sample	  t-­‐test	  comparing	  the	  obtained	  values	  against	  the	  mean	  of	  1	  (index	  of	  no	  changes).	  (B)	  Heatmap	  showing	  genes	  significantly	  differentially	  expressed	  across	  the	  three	  phases	  of	  the	  cell	  cycle.	  Significance	  was	  measured	  via	  Significance	  Analysis	  of	  Microarray	  (SAM)	  test	  and	  cluster	  analysis	  was	  performed	  using	  Euclidean	  distance.	  Up-­‐	  and	  down-­‐regulated	  genes	  are	  represented	  by	  red	  and	  green	  boxes,	  respectively.	  NCOR1	  knock	  down	  levels	  are	  shown	  at	  the	  bottom	  of	  the	  image. ................................................................. 212	  
Fig	  4.19	  –	  Smoothed	  dose	  response	  curves	  for	  a	  cohort	  of	  nuclear	  receptor	  ligands	  comparing	  VO-­‐PC-­‐3	  (black)	  with	  shNCOR1-­‐PC-­‐3	  (red).	  Two	  thousand	  cells	  were	  plated	  in	  a	  flat-­‐bottom	  96	  well/plate	  and	  treated	  for	  96	  hours	  with	  the	  selected	  agonist	  with	  a	  re-­‐dose	  at	  48	  hours.	  Proliferation	  was	  measured	  via	  ATP	  assay	  comparing	  ligand-­‐treated	  cells	  versus	  diluent-­‐treated	  cells.	  The	  results	  show	  that	  shNCOR1-­‐PC-­‐3	  show	  a	  consistent	  increased	  sensitivity	  towards	  the	  ligands,	  except	  1,25(OH)2D3	  and	  thyroid	  hormone	  T3.	  Each	  data	  point	  represents	  the	  mean	  value	  of	  three	  separate	  experiments	  each	  undertaken	  in	  triplicate	  wells	  +/-­‐	  S.E.M..	  Student	  t-­‐test	  (Mann-­‐Whitney	  test)	  was	  performed	  to	  reveal	  whether	  shNCOR-­‐1-­‐PC-­‐3	  cells	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were	  significantly	  more	  sensitive	  than	  VO-­‐PC-­‐3	  cells	  to	  NR	  ligand;	  *=p<0.05,	  **=p<0.01,	  ***=p<0.001. ..................................................................................................... 213	  
Fig	  4.20	  –	  Bar	  chart	  indicating	  the	  average	  EC50s	  for	  EPA,	  ETYA,	  Bezafibrate,	  ATRA	  and	  SAHA	  the	  treatments	  in	  shNCOR1-­‐PC-­‐3	  (red)	  and	  PC-­‐3-­‐VO	  (blue).................... 214	  
Fig	  4.21	  –Summary	  table	  for	  the	  effect	  of	  NR	  ligands	  on	  PC-­‐3	  cells	  and	  their	  activity	  in	  combination	  with	  either	  SAHA	  or	  shNCOR1.	  From	  left	  to	  right	  the	  columns	  indicate	  the	  NR	  ligand,	  the	  effect	  in	  combination	  with	  SAHA	  and	  the	  enhanced	  effect	  by	  NCOR1	  knock	  down	  in	  shNCOR1-­‐PC-­‐3	  cells	  compared	  to	  VO-­‐PC-­‐3	  cells. ........... 215	  
Fig	  4.22	  –	  Nuclear	  Receptor	  phylogenetic	  tree.	  This	  image	  was	  downloaded	  from	  Wikipedia	  (www.wikipedia.org),	  was	  prepared	  using	  CLC	  Free	  Workbench	  Version	  3.2.2	  (http://www.clcbio.com)	  and	  the	  amino	  acid	  sequences	  was	  downloaded	  from	  the	  PubMed	  protein	  database	  (http://www.pubmed.gov).	  Highlighted	  in	  red	  are	  the	  NR	  that	  did	  not	  have	  an	  enhanced	  antiproliferative	  activity	  upon	  agonist	  treatment	  in	  shNCOR1-­‐PC-­‐3	  cells;	  highlighted	  in	  green	  are	  the	  NR	  whose	  antiproliferative	  activity	  was	  enhanced	  upon	  agonist	  treatment	  in	  shNCOR1-­‐PC-­‐3	  cells	  compared	  with	  VO-­‐PC-­‐3	  cells. ............................................................................................................... 216	  
Fig	  4.23	  -­	  PC-­‐3	  cells	  were	  treated	  with	  bezafibrate	  (0.5	  mM)	  plus	  vorinostat	  (0.5	  mM),	  and	  VO-­‐PC-­‐3	  and	  shNCOR1-­‐PC-­‐3	  	  cells	  were	  treated	  with	  bezafibrate	  (0.5	  mM)	  over	  a	  16	  hour	  time	  course,	  mRNA	  extracted	  and	  subjected	  to	  Q-­‐RT-­‐PCR.	  (A)	  mRNA	  levels	  at	  4	  hr	  (CDKN1A),	  5	  hr	  (ALOX-­‐5),	  2	  hr	  (CDC2,	  PTGS2,	  TGFBRAP11).	  (B)	  mRNA	  levels	  at	  3	  hr	  (CDKN1A,	  CDC2,	  ALOX5,	  PTGS2)	  and	  8	  hr	  (TGFBRAP1)	  in	  PC-­‐3	  shNCOR1	  cells	  and	  PC-­‐3	  VO	  cells.	  Each	  data	  point	  represents	  the	  mean	  of	  three	  separate	  experiments	  amplified	  in	  triplicate	  wells	  +/-­‐	  S.E.M.	  Student	  t-­‐test	  was	  used	  to	  measure	  statistical	  significance	  comparing	  knock	  down	  against	  vector	  only	  control	  samples	  (*p	  <	  0.05). ............................................................................................... 218	  
Fig	  4.24	  –	  1,25(OH)2D3	  action	  on	  CYP24	  (A)	  and	  CDKN1A	  (B)	  mRNA	  accumulation.	  Whereas	  CDKN1A	  expression	  does	  not	  change	  in	  shNCOR1-­‐PC-­‐3	  cells	  compared	  with	  PC-­‐3-­‐VO	  cells,	  CYP24	  is	  less	  upregulated	  in	  NCOR1	  knockdown	  cells.	  Total	  RNA	  was	  extracted	  form	  6	  well/plates	  and	  reverse-­‐transcribed	  prior	  qRT-­‐PCR.	  	  Student	  t-­‐test	  	  was	  performed	  to	  find	  significant	  differences	  in	  the	  induction	  of	  the	  two	  genes	  in	  PC-­‐3	  transfected	  with	  shNCOR1	  or	  VO,	  ***=p<0.01.	  Each	  graph	  is	  the	  average	  of	  three	  independent	  experiments	  +/-­‐	  S.E.M....................................................................... 219	  
Fig	  4.25	  –	  X-­‐ChIP	  showing	  the	  acetylation	  levels	  of	  lysine	  9	  in	  the	  histone	  H3	  (H3K9Ac)	  in	  TGFBRAP1	  (A)	  and	  CDKN1A	  (B).	  Mid-­‐exponential	  PC-­‐3	  cells	  were	  treated	  for	  3	  hours	  with	  0.5	  µM	  of	  either	  SAHA,	  bezafibrate	  or	  both.	  Cells	  were	  cross-­‐linked,	  chromatin	  extracted	  and	  immunoprecipitated	  with	  H3K9Ac	  antibody;	  DNA	  was	  isolated	  and	  used	  for	  qRT-­‐PCR	  (Sybr	  Green)	  with	  primers	  for	  the	  indicated	  regions	  of	  the	  TGFBRAP1	  and	  CDKN1A	  genes.	  Data	  shown	  are	  mean	  of	  two	  biological	  replicated	  +/-­‐	  S.E.M..	  Fold	  changes	  were	  calculated	  comparing	  the	  H3K9Ac	  samples	  with	  the	  corresponding	  inputs........................................................... 220	  
Fig	  4.26	  –	  Knock	  down	  of	  NCOR	  via	  siRNA	  compared	  to	  scramble	  siRNA	  (as	  in	  [200]).	  Mid	  exponentially	  growing	  PC-­‐3	  cells	  were	  trasnfectd	  with	  50	  ng	  of	  siRNA	  or	  scrambled	  vector	  and	  incubated	  over-­‐nigh	  at	  37ºC;	  the	  following	  morning	  cells	  were	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harvested,	  total	  RNA	  was	  extracted	  and	  reverse	  transcribed	  prior	  to	  Q-­‐RT-­‐PCR	  analysis.	  Data	  shown	  are	  the	  mean	  of	  a	  biological	  duplicate	  +/-­‐	  S.E.M.. ................... 221	  
Fig	  4.27	  –	  X-­‐ChIP	  showing	  the	  acetylation	  levels	  of	  lysine	  9	  in	  the	  histone	  H3	  (H3K9Ac)	  in	  TGFBRAP1	  (A)	  and	  CDKN1A	  (B).	  Mid-­‐exponential	  PC-­‐3	  cells	  were	  transfected	  with	  siNCOR	  or	  scramble	  siRNA	  (as	  in	  [200])	  and	  incubated	  over-­‐night;	  the	  media	  was	  changed	  the	  following	  morning	  and	  cells	  were	  treated	  for	  3	  hours	  with	  0.5	  µM	  of	  bezafibrate.	  Cells	  were	  cross-­‐linked,	  chromatin	  extracted	  and	  immunoprecipitated	  with	  H3K9Ac	  antibody;	  DNA	  was	  isolated	  and	  used	  for	  qRT-­‐PCR	  (Sybr	  Green)	  with	  primers	  for	  the	  indicated	  regions	  of	  the	  TGFBRAP1	  and	  CDKN1A	  genes.	  Data	  shown	  are	  mean	  of	  two	  biological	  replicated	  +/-­‐	  S.E.M..	  Fold	  changes	  were	  calculated	  comparing	  the	  H3K9Ac	  samples	  with	  the	  corresponding	  IgGs. ......................................................................................................................................... 222	  
Fig	  4.28	  –	  Schematic	  representation	  of	  the	  Cre-­‐Lox	  system:	  the	  Cre	  gene	  is	  driven	  by	  a	  general	  or	  cell	  type/tissue	  specific	  promoter	  while	  the	  floxed	  allele	  contains	  the	  sequence,	  mainly	  critical	  exons,	  of	  interested	  flanked	  by	  two	  LoxP	  sites	  (red	  triangles).	  The	  Cre	  enzyme	  recognizes	  the	  LoxP	  sequences	  and	  promotes	  the	  excision	  of	  the	  target	  sequence	  leaving	  a	  single	  LoxP	  site	  on	  the	  genome	  (image	  taken	  from	  [216]). ................................................................................................................ 224	  
Fig	  4.29	  –	  Representation	  of	  the	  ARR2PB	  prostate-­‐specific	  promoter.	  The	  promoter	  is	  divided	  into	  two	  androgen	  responsive	  regions	  (red)	  each	  one	  containing	  two	  androgen	  responsive	  elements	  (ARE1,	  ARE2	  –	  blue),	  the	  two	  androgen	  responsive	  regions	  are	  separated	  by	  a	  linker	  region	  of	  42	  nt	  present	  in	  the	  original	  probasin	  promoter	  sequence	  (black)	  and	  the	  promoter	  ends	  with	  the	  first	  28	  nt	  or	  the	  rat	  probasin	  promoter	  (green)................................................................................................. 225	  
Fig	  4.30	  –	  PCR	  amplification	  of	  the	  Ncor1	  (8.5	  kb)	  and	  Ncor2/Smrt	  (10	  kb)	  homology	  region,	  included	  in	  the	  gel	  also	  the	  empty	  Bluescript	  and	  TOPO	  vector	  used	  in	  the	  cloning	  process................................................................................................. 227	  
Fig	  4.31	  -­	  Digestion	  control	  of	  the	  pCR-­‐BluntII-­‐TOPO	  vector	  whitout	  a	  PvuI	  site.	  The	  modified	  vector	  contains	  only	  one	  EcoRI	  site,	  and	  the	  combined	  digestion	  with	  the	  PvuI	  and	  ScaI	  enzymes	  will	  linearize	  the	  vector	  instead	  of	  giving	  multiple	  fragments.
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Fig	  4.32	  –	  Digestion	  of	  the	  new	  samples	  ligated	  with	  Ncor1	  and	  Ncor2/Smrt	  clones.	  Highlighted	  in	  red	  are	  the	  positive	  samples	  for	  Ncor1,	  3	  kb	  vector,	  8.5	  kb	  homology	  region	  (TOP)	  and	  Ncor2/Smrt,	  3	  kb	  vector,	  10	  kb	  homology	  region	  (BOTTOM). .. 230	  
Fig	  4.33	  –	  PCR	  analysis	  of	  the	  LoxP	  sites	  inserted	  in	  the	  Ncor1	  (LEFT)	  and	  Ncor2/Smrt	  (RIGHT).	  Primers	  were	  flanking	  the	  insertion	  site	  and	  are	  listed	  in	  Table	  3.3.	  Red	  arrows	  indicate	  positive	  clones	  at	  ~220	  bp. ........................................ 231	  
Fig	  4.34	  –	  Scheme	  of	  the	  PL415	  vector	  (LEFT)	  from	  which	  the	  neo-­‐cassette	  was	  isolated	  and	  gel	  of	  the	  digestion	  with	  EcorV	  and	  NotI	  (RIGHT)	  showing	  the	  backbone	  of	  the	  vector	  and	  the	  neo	  cassette.	  The	  cassette	  was	  then	  isolated,	  purified	  and	  ligated	  into	  the	  Ncor1	  and	  Ncor2/Smrt	  vectors............................................................. 232	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Fig	  4.35	  –	  PCR	  screening	  for	  the	  Neo-­‐cassette.	  Highlighted	  in	  the	  dotted	  red	  boxes	  are	  the	  positive	  clones. ........................................................................................................ 232	  
Fig	  4.36	  –	  Schematic	  representation	  of	  the	  Ncor1	  and	  Ncor2/Smrt	  construct	  containing	  the	  neo-­‐cassette.	  Indicated	  is	  also	  the	  opposite	  orientation	  of	  the	  neo	  cassettes	  and	  the	  LoxP	  sites................................................................................................ 233	  
Fig	  4.37	  –	  Digestion	  control	  for	  Ncor1	  and	  Ncor2/Smrt	  clones.	  All	  the	  clones	  for	  Ncor1	  (TOP)	  are	  positive	  with	  the	  right	  pattern;	  Ncor2/Smrt	  (BOTTOM)	  is	  correctly	  fragmented	  with	  EcoRI	  and	  linearized	  with	  NotI	  digestion. ....................................... 234	  
Fig	  4.38	  –	  Schematic	  representation	  of	  the	  final	  constructs	  for	  Ncor1	  (TOP)	  and	  Ncor2/Smrt	  (BOTTOM).	  For	  both	  genes	  are	  indicated	  the	  sites	  where	  the	  LoxP	  sites	  were	  inserted	  (NcoI	  for	  Ncor1	  and	  PvuI	  for	  Ncor2/Smrt)	  and	  where	  the	  neo-­‐cassettes	  were	  ligated	  (SnaBI	  for	  Ncor1	  and	  ScaI	  for	  Ncor2/Smrt).	  The	  Ncor1	  and	  Ncor2/Smrt	  wild	  type	  alleles	  are	  shown	  at	  the	  top	  of	  each	  image	  with	  indicated	  exon	  numbers	  and	  restriction	  sites.	  The	  targeting	  constructs	  containing	  loxP	  sites	  and	  neo	  cassettes	  is	  shown	  below	  the	  wild	  type	  alleles.	  In	  case	  recombination	  happens,	  the	  resulting	  floxed	  allele	  is	  here	  represented	  by	  the	  recombined	  locus.	  Lastly,	  upon	  action	  of	  the	  Cre	  enzyme	  the	  targeted	  exons	  will	  be	  excided	  and	  the	  Cre	  recombined	  locus	  will	  contain	  only	  one	  loxP	  site.	  Primers	  shown	  are	  listed	  in	  Materials	  and	  Methods. ................................................................................................................................. 235	  
Fig	  4.39	  –	  Example	  of	  a	  colony	  plate.	  Colonies	  were	  picked	  with	  a	  p10	  tip	  under	  the	  microscope	  paying	  attention	  to	  isolate	  single	  colonies.	  Yellow	  wells	  contain	  cells	  that	  used	  all	  the	  nutrients	  and	  oxygen	  lowering	  the	  pH,	  hence,	  a	  shift	  in	  the	  color	  of	  the	  media.	  Red	  wells	  are	  instead	  empty	  due	  to	  manual	  error	  and	  the	  pH	  of	  the	  media	  remains	  unaltered. ............................................................................................................... 236	  
Fig	  4.40	  –	  Schematic	  representation	  of	  the	  region	  amplified	  in	  the	  PCR	  screening	  for	  the	  Ncor1	  colonies	  (TOP).	  The	  clones	  highlighted	  were	  then	  further	  screened	  (see	  below)	  to	  confirm	  the	  presence	  of	  the	  Neo-­‐cassette. .................................................... 238	  
Fig	  4.41	  –	  Schematic	  representation	  of	  the	  PCR	  screening	  for	  the	  Neo-­‐cassette	  in	  the	  Ncor2/Smrt	  clones	  (TOP).	  A	  2.9	  kb	  region	  was	  amplified	  (MIDDLE)	  and	  to	  better	  localize	  the	  positive	  clones	  a	  southern	  blotting	  was	  performed	  (BOTTOM)	  using	  the	  samples	  ran	  in	  the	  gels	  as	  template.	  The	  probe	  was	  the	  3’	  primer	  (Ncor2	  out	  Rev	  –	  Table	  3.6)	  used	  for	  the	  PCR.	  Red	  arrows	  indicate	  the	  positive	  clones	  used	  for	  further	  analysis. .................................................................................................................................. 239	  
Fig	  4.42	  –	  PCR	  screening	  for	  the	  Neo-­‐cassette	  in	  Ncor1	  clones	  (TOP)	  A2,	  B2,	  B4,	  E4,	  B8,	  F7,	  B10,	  C11	  and	  Ncor2/Smrt	  (BOTTOM)	  clones	  B9,	  E3,	  E10,	  E11,	  F8,	  G11,	  H5,	  H8.	  I	  performed	  two	  different	  PCRs	  for	  Ncor2/Smrt,	  A-­‐B,	  to	  confirm	  the	  results	  obtained	  in	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Fig	  4.43	  –	  PCR	  analysis	  to	  confirm	  the	  screening	  results	  for	  the	  presence	  of	  the	  LoxP	  sites	  in	  the	  electroporated	  ES	  cells.	  It	  was	  also	  confirmed	  that	  the	  loxP	  sites	  in	  the	  Ncor1	  and	  Ncor2/Smrt	  clones	  have	  opposite	  orientation........................................... 241	  
Fig	  4.44	  –	  PCR	  screening	  of	  the	  LoxP	  site	  in	  the	  Ncor2/Smrt	  samples.	  On	  top	  the	  first	  6	  kb	  PCR,	  the	  bands	  were	  purified	  and	  used	  as	  a	  template	  for	  the	  second	  PCR	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  4.46	  –	  Sequence	  of	  the	  LoxP	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  for	  the	  B9	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  Highlighted	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Fig	  4.48	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Fig	  4.50	  –	  PCR	  amplification	  of	  the	  ARR2PB	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  4.51	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  control	  of	  the	  pCRII-­‐TOPO	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Fig	  4.52	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  results	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  number	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  and	  the	  end	  of	  the	  sequenced	  promoter	  region. ............................................................ 250	  
Fig	  4.53	  –	  Time	  course	  for	  p21	  mRNA	  accumulation	  upon	  VitD3	  treatment	  (James	  Thorne,	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  were	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Fig	  4.54	  –	  miR-­‐106B	  time	  course	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  to	  1,25(OH)2D3	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Fig	  4.55	  –	  Phospho-­‐PolII	  binding	  at	  the	  TSS	  of	  p21	  (Craig	  Doig,	  University	  of	  Birmingham,	  Birmingham,	  UK).	  Mid-­‐exponential	  RWPE-­‐1	  cells	  were	  treated	  with	  100	  nM	  1,25(OH)2D3,	  chromatin	  was	  immunoprecipitated	  with	  anti-­‐phosho	  PolII	  antibody	  and	  qRT-­‐PCR	  was	  performed	  with	  primers	  covering	  the	  TSS	  region	  of	  the	  CDKN1A	  gene.	  Data	  shown	  are	  the	  mean	  of	  at	  least	  two	  biological	  replicate	  +/-­‐	  S.E.M..	  The	  bars	  indicate	  the	  amount	  of	  p-­‐polII	  bound	  to	  the	  TSS	  of	  CDKN1A	  relative	  to	  the	  input	  (non-­‐immunoprecipitated	  sample).	  An	  initial	  amount	  of	  phospho	  polymerase	  II	  is	  present	  at	  the	  transcription	  start	  site,	  if	  it	  moves	  into	  the	  gene	  regions,	  this	  would	  explain	  the	  lower	  amount	  of	  the	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  found	  at	  15	  min	  (0.25);	  after	  the	  polymerase	  moves	  into	  the	  gene	  body,	  new	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  is	  recruited	  at	  the	  TSS	  and	  it’s	  detected	  at	  45	  min	  (0.75). .................................................................................... 256	  
Fig	  4.56	  –	  Schematic	  representation	  of	  the	  activity	  of	  the	  poised	  phospho	  polymerase	  on	  the	  promoter	  region.	  The	  polymerase	  stops	  at	  the	  TSS	  waiting	  for	  a	  stimulus	  (1)	  to	  then	  move	  into	  the	  gene	  (2)	  while	  new	  polymerase	  is	  recruited	  (3).
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Fig	  4.57	  –	  Model	  describing	  the	  transcriptional	  regulation	  of	  CDKN1A	  and	  miR-­‐106B.	  Briefly:	  the	  complex	  VDR/D3	  activates	  at	  the	  same	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  the	  transcription	  of	  CDKN1A	  and	  miR-­‐106B	  via	  phospho-­‐PolII,	  after	  the	  initial	  transcription	  of	  the	  two	  molecules	  miR-­‐106B	  mediates	  CDKN1A	  degradation,	  altough	  both	  are	  still	  degraded	  also	  by	  independent	  mechanisms................................................................... 259	  
Fig	  4.58	  –	  Differential	  equations	  describing	  the	  model	  described	  above.	  Different	  parameter	  were	  tested	  in	  order	  to	  find	  the	  values	  that	  better	  fitted	  the	  model;	  listed	  are	  the	  differential	  equations	  (as	  d[x]/dt)	  with	  the	  respective	  reactions	  and	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Fig	  4.59	  –	  Simulation	  run	  for	  all	  the	  species:	  miR106b	  (red),	  CDKN1A	  (blue)	  and	  phospho-­‐polII	  (green	  dashed).	  The	  initial	  downregulation	  of	  pPol-­‐II	  is	  the	  one	  responsible	  for	  the	  induction	  of	  CDKN1A	  and	  miR-­‐106B	  and	  the	  first	  part	  of	  the	  steep	  peak	  at	  1800	  sec	  (30	  min);	  while	  their	  concentration	  increases	  miR-­‐106B	  from	  1800	  sec	  onwards	  quickly	  controls	  CDKN1A	  degradation	  leading	  to	  down	  regulation	  present	  in	  the	  second	  part	  of	  the	  steep	  peak.	  After	  that	  all	  the	  species	  return	  to	  steady	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Fig	  4.60	  –	  Three	  different	  simulations	  of	  the	  activity	  of	  CDKN1A	  (violet)	  miR-­‐106B	  (blue).	  In	  the	  left	  panel	  miR-­‐106B	  is	  degraded	  quicker	  than	  CDKN1A	  because	  it’s	  degraded	  by	  an	  independent	  mechanism;	  the	  center	  and	  right	  panels	  produce	  the	  same	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  both	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  CDKN1A.	  Time	  and	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  are	  indicated	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Fig.	  5.1	  –	  Representation	  of	  the	  proposed	  additive	  mechanism	  of	  action	  of	  SAHA	  and	  bezafibrate	  in	  PC-­‐3.	  (A)	  A	  pool	  of	  PPARs	  is	  acetylated	  due	  to	  the	  interaction	  with	  elevated	  levels	  of	  NCOR1	  and	  HDAC3	  that	  promote	  de-­‐acetylation	  of	  the	  receptor.	  Treatment	  with	  SAHA	  and	  bezafibrate	  restores	  acetylation	  levels	  and	  promotes	  ligand-­‐dependent	  receptor	  activation.	  (B)	  Interaction	  of	  NCORs/HDACs	  complexes	  with	  PPAR	  deacetylates	  the	  receptor,	  SAHA	  restores	  the	  acetylation	  levels	  and	  bezafibrate	  additively	  activates	  PPAR.	  Red	  circles	  indicates	  repressed	  receptor,	  light	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green	  circles	  indicates	  acetylated	  and	  physiologically	  active	  receptors	  (e.g.	  by	  endogenous	  ligand)	  and	  dark	  green	  circles	  indicate	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  additively	  activated	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PREFACE	  AND	  BACKGROUND	  EXPERIENCE	  
In	   March	   2006	   I	   started	   my	   PhD	   as	   a	   member	   the	   Marie	   Curie	   Research	   Training	  
Network	   entitled	   “NucSys”(Systems	   Biology	   of	   Nuclear	   Receptors).	   This	   consortium	  
was	  developed	  by	  Prof.	  Carsten	  Calberg	  (University	  of	  Luxembourg,	  Luxembourg)	  and	  
Dr.	  Moray	  Campbell	   (University	   of	  Birmingham,	  UK	  /	  Roswell	  Park	  Cancer	   Institute,	  
Buffalo,	  NY,	  USA)	  and	  in	  total	  included	  14	  teams	  from	  academia	  and	  industry	  based	  on	  
7	  EU	  countries.	  The	  aim	  of	  this	  training	  network	  was	  to	  educate	  18	  ESRs	  (Early	  Stage	  
Researchers)	  over	  a	  period	  of	  three	  years	  in	  different	  interdisciplinary	  fields;	  this	  was	  
undertaken	  through	  short	  term	  and	  long	  term	  experiences	  in	  different	  labs	  to	  acquire	  
new	  skills	  and	  approach	  new	  and	  multi-­disciplinary	  environments.	  	  
My	   project	   started	   at	   the	   University	   of	   Birmingham	   (Birmingham,	   UK)	   under	   the	  
supervision	  of	  Dr.	  Moray	  Campbell	  and	  Dr.	  Chris	  Bunce.	  Here	  I	  profiled	  the	  function	  of	  
NCOR1	  in	  prostate	  malignant	  PC-­3	  cells	  creating,	  and	  analysing,	  a	  stable	  NCOR1	  knock	  
down-­PC-­3	  cell	  line.	  When	  Dr.	  Moray	  Campbell	  re-­located	  to	  the	  USA,	  Dr.	  Chris	  McCabe	  
also	  contributed	  to	  supervision.	  
The	   second	   step	   was	   to	   define	   Ncor1	   and	   Ncor2/Smrt	   function	   in	   mouse	   prostate	  
development;	  this	  was	  done	  at	  the	  Max	  Planck	  Institute	  for	  Molecular	  Genetics	  (Berlin,	  
Germany)	   under	   the	   supervision	   of	   Dr.	   Heiner	   Schrewe.	   Here	   I	   generated	   targeting	  
constructs	  for	  Ncor1	  and	  Ncor2	  and	  prepared	  floxed	  ES	  cells	  that	  are	  currently	  being	  
used	   for	   blastocyst	   injection.	   These	   mice	   are	   being	   bred	   at	   Roswell	   Park	   Cancer	  
Institute	  (Buffalo,	  NY,	  USA).	  	  
The	  last	  project	  aimed	  to	  model	  with	  a	  Systems	  Biology	  approach	  the	  transcriptional	  
activation	   of	   the	   CDKN1A	   gene	   upon	   1,25(OH)2D3	   treatment.	   This	   was	  made	   at	   the	  
University	  of	  Luxembourg	   (Luxembourg,	  Luxembourg)	  under	   the	   supervision	  of	  Prof.	  
Carsten	   Calberg	   and	   Dr.	   Frank	   Bruggeman	   (Free	   University	   of	   Amsterdam,	  
Amsterdam,	  The	  Netherlands)	  with	  the	  collaboration	  of	  a	  fellow	  ESR	  Katja	  Rybakova.	  
Here,	   based	   on	   experimental	   data,	   I	   used	   an	   ordinary	   differential	   equation	   model	  
(ODE)	   to	   profile	   the	   initial	   mRNA	   events	   within	   the	   first	   hour	   of	   transcriptional	  
activation	  aiming	  to	  describe	  the	  mechanistic	  events	  that	  led	  to	  the	  accumulation	  and	  
steep	  degradation.	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1	  –	  INTRODUCTION	  
1.1	  -­	  The	  Prostate	  Gland	  The	  prostate	  is	  a	  tubuloalveolar	  exocrine	  gland	  that	  is	  found	  only	  in	  male	  mammals	  and	   surrounds	   the	   urethra	   at	   the	   base	   of	   the	   bladder.	   The	   main	   function	   of	   the	  prostate	   is	   to	   store	   and	   secrete	   a	   clear	   and	   slightly	   alkaline	   (pH	   7.29)	   fluid	   that	  constitutes	   10-­‐30%	   of	   the	   volume	   of	   the	   seminal	   fluid.	   This,	   together	   with	  spermatozoa	   forms	   the	   semen.	   The	   composition	   of	   prostatic	   secretions	   varies	  among	  the	  species;	  other	  than	  being	  alkaline,	  they	  are	  generally	  composed	  of	  simple	  sugars	   and	   less	   than	   1%	   of	   proteins,	   containing	   photolytic	   enzymes,	   acid	  phosphatase	  and	  Prostate	  Specific	  Antigen	  (PSA).	  The	  alkalinity	  of	  the	  seminal	  fluid	  helps	   to	   neutralize	   the	   acidity	   of	   the	   vaginal	   tract,	   prolonging	   the	   lifespan	   of	   the	  sperms.	  A	  healthy	  human	  prostate	  is	  slightly	  larger	  than	  a	  walnut.	  The	  prostate	  can	  be	  divided	  in	  to	  four	  lobes	  (Fig	  1.1):	  	  
- the	  Anterior	  lobe	  is	  the	  portion	  of	  the	  gland	  that	  lies	  in	  front	  of	  the	  urethra.	  It	  is	   devoid	   of	   glandular	   tissue	   being	   formed	   completely	   of	   fibromuscolar	  tissue;	  
- the	  Medial	  lobe	  is	  a	  coned	  shaped	  portion	  of	  the	  gland	  situated	  between	  the	  ejaculatory	  ducts	  and	  the	  urethra;	  
- the	  Lateral	   lobes	   (right	  and	   left)	   form	  the	  main	  mass	  of	   the	  gland,	   they	  are	  continuous	  posteriorly	  and	  separated	  by	  the	  prostatic	  urethra;	  
- the	  Posterior	   lobe	   is	  used	  to	  describe	   the	  postero-­‐medial	  part	  of	   the	   lateral	  lobes	   that	   can	   be	   palpated	   through	   the	   rectum	   during	   digital	   rectal	   exam	  (DRE).	  




Fig	   1.1	   –	  Diagrams	   of	   frontal	   and	   sagittal	   sections	   of	   the	  male	   urogenital	   complex	  
illustrationg	  the	  anatomical	  position	  of	   the	  adult	  prostate	  and	  associated	  structures.	  
The	  prostatic	  zones	  described	  by	  McNeal	  in	  1983	  [1]	  are	  indicated:	  central	  zone	  (CZ),	  
peripheral	  zone	  (PZ),	  anterior	   fibromuscular	  stroma	  (AFS),	  and	  transition	  zone	  (TZ).	  
(B)	  Male	  accessory	  sex	  organs	  of	  the	  adult	  male	  rat.	  A,	  anterior	  view;	  B,	  lateral	  view;	  C,	  
anterior	  view	  with	  the	  bladder	  deflected	  caudally.	  Ampullary	  gland	  of	  the	  vas	  deferens	  
(AG);	  bladder	  (B);	  coagulating	  gland	  (CG);	  dorsal	  prostate	  (DP);	  lateral	  prostate	  (LP);	  
seminal	   vesicle	   (SV);	   ventral	   prostate	   (VP);	   vas	   deferens	   (VD);	   deferential	   vein	   (DV).	  
Image	  taken	  from	  [2]	  
	  The	  prostate	  also	  contains	  a	  high	  concentration	  of	  smooth	  muscle	  that	  leads	  to	  the	  expulsion	   of	   products	   made	   in	   the	   branched	   secretory	   acini	   through	   a	   branched	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ductal	  system	  and	  thence	  the	  urethra.	  The	  anterior	  or	  ventral	  aspect	  of	  the	  gland	  is	  almost	   entirely	   fibromuscular,	   while	   the	   glandular	   region	   occupies	   the	   posterior	  part	  of	  the	  tissue	  and	  surrounds	  the	  ejaculatory	  ducts	  as	  they	  enter	  the	  urethra	  on	  each	  side	  of	  the	  verumontanum.	  	  
1.2	  –	  Normal	  Prostate	  Gland	  Development	  
1.2.1	  –	  Morphological	  aspect	  of	  prostate	  development	  The	  formation	  of	  the	  prostate	  occurs	  relatively	  late	  in	  gestation	  when	  compared	  to	  the	   genesis	   of	  most	   organs.	   In	   humans,	   the	   prostate	   starts	   to	   form	   between	   9-­‐12	  weeks	   of	   gestation;	   in	  mice	   prostatic	   development	   begins	   at	   E16.5	   and	   in	   rats	   at	  E17.5.	  The	  enlargement	  of	  the	  human	  prostate	  is	  a	  consequence	  of	  sequential	  prior	  events,	   including	  production	  of	   testosterone	  by	   the	   fetal	   testis	  at	  around	  8	  weeks.	  Final	   growth	   and	  maturation	   occur	   at	   puberty	  when	   circulating	   androgens	   levels	  rise	  sharply.	  The	   initial	  event	   in	  prostate	  morphogenesis	   is	   the	  outgrowth	  of	   solid	  epithelial	   buds	   from	   the	   urogenital	   sinus	   (UGS)	   into	   the	   surrounding	   urogenital	  mesenchyme	   (UGM)	   in	   response	   to	   the	   binding	   of	   5α-­‐dihydrotestosterone	   to	   the	  androgen	   receptor	   (AR)	   localized	   in	   the	   surrounding	   mesenchymal	   tissue	   [3-­‐5].	  Epithelial	   cells	   of	   the	   developing	   prostate	   buds	   are	   characterized	   by	   the	  coexpression	  of	  cytokeratins	  5,	  8,	  14	  and	  18	  and	  p63	  [6].	  Notably	  AR	  is	  not	  present	  in	  epithelia	  during	  organ	  induction	  but	  is	  expressed	  in	  the	  mesenchyme	  suggesting	  that	   essential	   components	   for	   bud	   induction	   are	   found	   within	   the	   mesenchyme.	  Indeed,	  certain	  androgenic	  effects	  are	  elicited	  via	  paracrine	  influences	  from	  the	  AR-­‐positive	  mesenchyme	  and	  do	  not	   require	  epithelial	  AR,	  whereas	   the	  expression	  of	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androgen-­‐dependent	   secretory	   proteins	   requires	   direct	   androgenic	   stimulation	   of	  the	   epithelium	   via	   epithelial	   AR.	   While	   mesenchymal	   effects	   on	   epithelial	  development	   form	   the	   basis	   of	   organogenesis	   during	   fetal	   and	   neonatal	   periods,	  analogous	   stromal-­‐epithelial	   interactions	   continue	   throughout	   life	   and,	   in	  adulthood,	   presumably	   have	   a	   homeostatic	   role	   [7].	   	   In	   the	   rat	   and	  mouse,	   as	   the	  solid	   epithelial	   buds	   canalize,	   the	   epithelium	   reorganizes	   in	   to	   two	   distinct	   cell	  populations:	   basal	   epithelial	   cells	   localize	   in	   the	   basal	   membrane	   to	   from	   a	  discontinuous	   layer	   of	   cells	   expressing	   cytokeratins	   5	   and	   14	   and	   p63	   while	   tall	  luminar	  cells,	  expressing	  cytokeratins	  8	  and	  18,	  form	  the	  ductal	  lumina.	  	  
	  
Fig	   1.2	   –	   A	   diagram	   of	   the	   prostate	   ductal-­cross	   section	   is	   shown	   with	   labels	  
indicating	   cell	   types	   that	   are	   present	   in	   prostatic	   ducts	   including	   luminal	   secretory	  
epithelial	   cells,	   basal	   epithelial	   cells,	   neuroendocrine	   cells,	   stromal	   smooth	   muscle	  
cells,	   and	   stem	   cell	   candidates.	   Beneath	   the	   label	   for	   each	   cell	   type	   is	   a	   list	   of	  
differentiation	  markers	   commonly	  used	   to	  distinguish	   these	   cell	   types.	   In	   the	   case	  of	  
stem	  cell	  candidates,	  two	  studies	  have	  associated	  expression	  of	  either	  a	  set	  of	  markers	  
including	  cytokeratins	  5,	  14,	  8,	  18,	  and	  19,	  GSTpi,	  and	  p63	  	  or	  high	  expression	  of	  α2β1-­
integrin	   with	   rare	   basal	   cells	   proposed	   as	   prostatic	   epithelial	   stem	   cell	   candidates.	  
Image	  taken	  from	  [8].	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  At	  the	  same	  time	  as	  the	  previous	  events	  happen,	  the	  prostate	  mesenchyme/stroma	  differentiates	  into	  a	  layer	  of	  smooth	  muscles	  that	  surrounds	  the	  prostatic	  buds.	  Both	  epithelial	   and	   mesenchymal	   cell	   differentiation	   is	   coordinated	   with	   branching	  morphogenesis	   and	   occurs	   in	   the	   proximal-­‐to-­‐distal	   direction	   [9,	   10].	   Notably	  mesenchyme-­‐epithelial	   cell-­‐cell	   interactions	  are	   initiated	   in	   fetal	  periods,	   in	  which	  an	   undifferentiated	   connective	   tissue	   (mesenchyme)	   induces	   epithelial	  development.	   It	   can	   also	   be	   considered	   as	   a	   reciprocal	   stimulation	   that,	   for	  many	  internal	  organs,	  means	  that	  epithelium	  induces	  smooth	  muscle	  differentiation.	  This	  indicates	   that	   the	  microenvironment	   that	   surrounds	   the	  adult	  prostate	  epithelium	  comprises	  mainly	  smooth	  muscle	  cells	  as	  well	  as	  extracellular	  matrix	  (ECM)	  [7],	   in	  fact	  about	  22%	  of	  the	  stroma	  is	  made	  of	  smooth	  muscle	  androgen	  receptor-­‐positive	  cells.	   Other	   less	   common	   cell	   types	   are	   neuroendocrine	   cells,	   present	   within	   the	  epithelial	   layer	  of	  both	  developing	  and	  adult	  human	  prostate,	  as	  well	  as	  rare	  basal	  epithelial	   cells	   with	   unique	   marker	   expression	   profiles	   similar	   to	   epithelial	   stem	  cells	   [6,	   11].	   Those	   cells	   are	   generally	   characterized	   by	   the	   lack	   of	   the	  AR	   or	   PSA	  expression;	  because	  of	  this	  and	  because	  circulating	  androgens	  do	  not	  influence	  their	  regulatory	  functions	  they	  can	  be	  considered	  androgen-­‐independent.	  Similarly,	  basal	  cells	  express	  the	  AR	  mRNA	  and	  low	  levels	  of	  the	  AR	  protein	  but	  do	  not	  secrete	  PSA	  [12].	   On	   the	   other	   hand	   secretory	   cells	   are	   androgen-­‐dependent	   because	   they	  require	   circulating	   androgens	   for	   their	   continuous	   maintenance	   and	   undergo	  apoptosis	  when	  androgens	  are	  withdrawn	  [13].	  Development	   of	   the	   prostate	   is	   spatially	   restricted	   by	   the	   availability	   of	   a	   few	  domains	  in	  the	  mesenchyme	  of	  the	  male	  urogenital	  tract	  that	  can	  produce	  prostate-­‐
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inducing	  paracrine	   signals.	  On	   the	  other	  hand	   the	  potential	   of	   the	   endothelium	   to	  respond	   to	   these	   signals	   is	   restricted	   to	   the	   endodermal	   epithelia	   with	   similar	  embryonic	   origins	   to	   the	   prostate	   [8].	   Although	   the	   morphology	   of	   the	   prostate	  changes	   from	   species	   to	   species,	   the	   signals	   coming	   from	   the	   UGM	   are	   highly	  conserved	  [2].	  	  
1.2.2	  –	  Signalling	  pathways	  in	  prostate	  development	  Stroma-­‐epithelial	   interactions	   lead	   to	   cell	   differentiation	   and	   branching	  morphogenesis	   through	   involvement	   of	   several	   key	  molecules,	   like	   the	   Fibroblast	  Growth	  Factors	  (FGFs),	  the	  Sonic	  HedgeHog	  (SHH)	  proteins,	  the	  Bone	  Morphogenic	  Proteins	   (BMPs,	   belong	   to	   the	   TGF-­‐β	   superfamily)	   and	   the	   Homeobox	   proteins	  HOXA13	   and	   HOXD13,	   in	   addition	   to	   a	   few	   others	   including	   the	   cell-­‐surface	  glycoprotein	   CD44	   and	   follistatin.	   CD44	   is	   expressed	   in	   both	   epithelial	   and	  mesenchymal	   cells	  while	   its	   ligand,	  hyaluronan,	   is	   a	  polysaccharide	  present	   in	   the	  stromal	   matrix.	   Gakunga	   et	   al	   demonstrated	   the	   importance	   in	   prostate	  morphogenesis	   of	   CD44/hyaluronan	   interactions	   by	   antagonizing	   them,	   which	  inhibited	   androgen-­‐stimulated	   ductal	   branching	   and	   prostate	   morphogenesis	   in	  serum-­‐free	  organ	  culture	  of	  mouse	  anterior	  prostate	   [14].	  Signaling	   includes	  FGF7	  (KGF)	   and	   the	   similar	   FGF10	   that	   from	   the	   mesenchyme	   bind	   to	   FGFR2	   on	   the	  prostatic	   epithelium	   leading	   to	   the	   maintenance	   of	   Shh	   expression	   [8,	   15].	   This	  positive	  regulation	  is	  limited	  by	  the	  negative-­‐feedback	  loop	  of	  downregulation	  of	  Fgf	  expression	  by	  SHH	  signalling.	  Mice	  lacking	  Shh	  fail	  to	  express	  Nkx3.1	  [16],	  a	  putative	  prostate	   tumor	   suppressor	   that	   is	   expressed	   in	   a	   largely	   prostate-­‐specific	   and	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androgen-­‐regulated	  manner	  and	   involved	   in	  epithelial	  homeostasis,	  have	   impaired	  prostate	  development.	  	  The	  mesenchymal	  homeobox	  genes	  Hoxa13	  and	  Hoxd13	  promote	  further	  growth	  of	  the	  prostatic	  ducts.	  Knockouts	  of	  either	  Hoxa13	  or	  Hoxd13	  lead	  to	  small	  prostates	  and	  reduced	  branching	  morphogenesis,	  with	  total	  absence	  of	  the	  anterior	  prostate	  in	  Hoxd13-­‐/-­‐	  mice.	  Most	  of	  these	  ducts	  remain	  unbranched	  until	  birth	  in	  rodents	  but,	  subsequently,	  epithelial–mesenchymal	  interactions	  result	  in	  further	  elongation	  and	  branching	  morphogenesis.	   Part	   of	   the	   fine	   control	   is	   exerted	  by	   the	  mesenchymal	  signalling	   factors	   BMP4	   and	   BMP7	   that	   inhibit	   ductal	   branching	   and	   budding	  (reviewed	   in	   [17]),	   and	   stimulated	   by	   antagonist	   of	   Bmps	   like	   Fgf10	   that,	   for	  example,	   represses	   Bmp4	   expression	   in	   opposition	   to	   the	   stimulation	   by	   Shh	  (reviewed	  in	  [8]).	  	  Notch1	  is	  another	  key	  player	  in	  prostate	  development.	  Notch1	  expression	  is	  down-­‐regulated	   in	   mature	   prostates	   but	   becomes	   up-­‐regulated	   in	   certain	   primary	   and	  metastatic	  tumor	  cells	  for	  example	  in	  the	  TRAMP	  (transgenic	  adenocarcinoma	  of	  the	  mouse	  prostate)	  model	  [18]	  suggesting	  a	  possible	  role	  for	  Notch1	  signaling	  during	  prostatic	   development	   and	   tumorigenesis.	   This	   was	   further	   confirmed	   by	   the	  ablation	   of	   Notch1-­‐expressing	   cells	   that	   profoundly	   prevented	   epithelial	   ductal	  outgrowth	   in	   the	   developing	   prostate	   and	   impaired	   prostatic	   re-­‐growth	   in	   adult	  mice	   [19].	   In	   addition,	   Notch1	   expression	   is	   elevated	   following	   castration	   but	  returned	   to	   normal	   levels	   after	   androgen	   replacement	   suggesting	   an	   inverse	  correlation	  between	  levels	  of	  ciculating	  androgens	  and	  Notch1	  levels.	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The	   WNT	   genes	   encode	   a	   large	   and	   highly	   conserved	   family	   of	   secreted	  glycoproteins	   and	   its	   signalling	  network	  plays	   a	   crucial	  morphogenic	   role	   in	  most	  organs.	   β-­‐catenin	   is	   activated	   by	   Wnts	   and	   constitutive	   expression	   of	   stable	   β-­‐catenin	  in	  prostate	  epithelium	  of	  transgenic	  mice	  resulted	  in	  epithelial	  hyperplasia	  and	  squamous	  metaplasias	  by	  8	  weeks	  of	  age	  [20].	  These	  findings	  suggest	  that	  the	  transdifferentiation	   of	   prostate	   epithelium	   into	   squamous	  metaplasias	   is	   an	   early	  response	  of	  endoderm-­‐derived	  cells	  to	  β-­‐catenin,	  and	  that	  the	  development	  of	  intra-­‐acinous	  hyperplasia	  or	  neoplastic	   foci	   is	   a	   later	  event.	  Both	  UGM	  and	  UGE	  display	  strong	  expression	  of	  numerous	  Wnt	  genes	  during	  early	  development,	   several	  Wnt	  family	   members	   demonstrated	   characteristic	   spatial	   and	   temporal	   patterns	   of	  expression	  during	  prostate	  development	  suggesting	  that	  the	  canonical	  Wnt	  pathway	  plays	   an	   important	   regulatory	   role	   on	   epithelial	   cell	   proliferation	   during	   prostate	  development	  [17].	  	  Finally,	  in	  a	  proximal	  to	  distal	  direction,	  the	  epithelial	  cell	  types	  differentiate	  under	  the	   control	   of	   different	   transcription	   factors	   such	   as	   the	   p53	   family	  member	   p63,	  and	   forkhead	   family	   members	   such	   as	   FOXA1,	   promoting	   smooth	   muscle	  differentiation	   and	   localization	   around	   the	   epithelium	   and	   the	   ductal	   lumen.	   P63,	  along	  with	  p73,	  is	  a	  homologue	  of	  the	  p53	  tumor	  suppressor	  gene	  [21],	  both	  human	  and	  mouse	  prostate	  basal	  cells	  express	  p63	  protein	  and	  it	  can	  be	  used	  as	  a	  prostate	  differentiation	   marker	   to	   identify	   prostate	   stem	   cells	   [22].	   Foxa1	   is	   expressed	  throughout	  prostate	  development	  and	  maturation	  in	  all	  the	  lobes	  but	  specifically	  in	  AR	  expressing	  cells,	  whereas	  Foxa2	  is	  present	  only	  during	  prostate	  budding	  and	  in	  cytokeratin	  14-­‐expressing	  basal	  epithelial	  cells	  [17].	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Fig	   1.3	   –	   Rat	   prostate	   developmental	   stages,	   timeline	   and	   morphoregulatory	   gene	  
expression.	   The	   days	   of	   fetal	   and	   postnatal	   life	   are	   shown	   at	   the	   bottom.	   Ventral	  
prostate	  morphology	  and	  developmental	   stages	   (top)	  are	   sequentially	  aligned	   to	   the	  
corresponding	  days	  that	  they	  appear.	  Note	  that	  cellular	  differentiation	  occurs	  during	  
the	  later	  days	  of	  branching	  morphogenesis	  as	  indicated	  by	  blue-­striped	  lines.	  Temporal	  
patterns	   of	  morphoregulatory	   genes	   expression	   are	   shown	   in	   black-­gray-­white	   bars	  
representing	  relative	  levels	  of	  gene	  expression	  as	  determined	  by	  quantitative	  real-­time	  
reverse-­transcriptase	  polymerase	  chain	  reaction.	  Image	  taken	  from	  [17].	  	  This	   intricate	   network	   of	   paracrine	   signalling	   interactions	   finely	   promotes	   and	  regulates	  prostatic	  bud	  induction	  and	  subsequent	  branching	  morphogenesis.	  These	  processes	  are	  androgen-­‐dependent	  and	  the	  lack	  of	  functional	  AR	  due	  to	  mutations	  in	  humans	   and	   mice	   leads	   to	   the	   absence	   of	   prostate	   [23,	   24];	   interestingly,	  development	  of	   the	  prostate	  gland	  was	  also	  observed	   in	   female	  urogenital	  sinuses	  after	  exposure	  to	  androgens	  [25].	  During	  the	  postnatal	  period,	  under	  the	  influence	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of	   androgens,	   the	   ducts	   form	   a	   patent	   lumen,	   and	   the	   epithelium	   lining	   the	   acini	  differentiate	  and	  synthesize	  a	  variety	  of	  secretory	  products.	  	  
1.2.3	  –	  Androgen	  and	  other	  hormonal	  aspects	  of	  prostate	  organogenesis	  
NRs	   are	   ligand-­‐inducible	   transcription	   factors	   activated	   by	   lipophilic	   molecules	  whose	   activity	   is	   finely	   controlled	   by	   several	   hetero-­‐complexes.	   With	   few	  exceptions,	  co-­‐repressors	  suppress	  NRs	  activity,	  enhancing	  their	  silencing	  effect	   in	  opposition	   to	   co-­‐activators	   that	   instead	   enhance	   NRs	   action.	   48	   human	   nuclear	  receptors	  has	  been	  described	  and	   they	  can	  be	  divided	   into	   three	  groups	  based	  on	  their	   affinity	   to	   their	   ligands:	   1)	   endocrine	   receptors	   (e.g.	   ERs,	   AR,	   VDR,	   RARs,	  TRs…),	   that	  bind	  their	   ligands	  with	  high	  affinity	  (Kd	  0.1-­‐1	  nM);	  2)	  adopted	  orphan	  receptors	   (e.g.	  RXRs,	  PPARs,	  LXRs,	  PXR…),	   that	  bind	  endogenous	   ligands	  with	   low	  affinity	   (Kd	  1-­‐1000uM)	  and	  3)	  orphan	  receptors	  (e.g.	  DAX-­‐1,	  SF-­‐1,	  SHP,	  ROR…)	   for	  whom	  a	   ligand	  still	  hasn’t	  been	  discovered.	  Upon	   ligand	  binding	  nuclear	  receptors	  undergo	   conformational	   changes	   that	   lower	   affinity	   for	   co-­‐repressor	   complexes	  promoting	  the	  interaction	  with	  co-­‐activator	  complexes	  that	  possesses	  histone	  acetyl	  transferase	   activity,	   which	   allows	   for	   transcriptional	   activation	   [26];	   this	   leads	   to	  the	   assembly	   of	   a	   pre-­‐initiation	   complex	   formed	   by	   p300/CPB	   (CREB	   binding	  protein),	  various	  TFs	  (e.g.	  TBP,	  TFIIB,	  TFIID)	  and	  Pol-­‐II	  [26].	  On	  the	  other	  hand,	  in	  absence	   of	   ligand,	   NRs	   seem	   to	   be	   bound	   to	   a	   ~2MDa	   repression	   complex	   that	  includes	   NCOR2/SMRT	   (Silencing	   Mediator	   of	   Retinoid	   and	   Thyroid	   hormone	  receptor	   [27]),	  NCOR1	  (Nuclear	  Corepressor),	  HDAC3,	  TBL1	  and	  TBLR1	  [26].	  This	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complex	   leads	   to	   silencing	   of	   positively	   regulated	   target	   genes	   repressing	  transcription	  initiation.	  
Androgen	   action	   is	   mediated	   through	   the	   interaction	   with	   the	   AR,	   and	   the	  determination	  and	   initiation	  of	  prostate	  organogenesis	   in	  both	  human	  and	   rodent	  fetus	   is	   entirely	   dependent	   upon	   androgens	   produced	   by	   the	   fetal	   testes.	   Surgical	  castration	   or	   administration	   of	   anti-­‐androgen	   drugs	   to	   rodents	   during	   fetal	   life	  results	   in	   inhibition	   of	   prostate	   development.	   In	   the	   ‘70s,	   it	   was	   determined	   by	  Wilson	   and	   Gloyna	   that	   the	   primary	   androgen	   responsible	   for	   prostatic	  development	  is	  dihydrotestosterone	  (DHT),	  the	  reduced	  metabolite	  of	  testosterone	  [28].	  DHT	  is	  formed	  intracellularly	  in	  the	  prostate	  epithelium	  by	  5α-­‐reductase	  and	  has	  been	  shown	  to	  have	  even	  higher	  affinity	  for	  the	  AR	  than	  testosterone	  [29].	  The	  fundamental	   role	   of	   AR	   in	   prostate	   development	   comes	   from	   the	   observation	   of	  prostatic	  absence	  in	  mice	  or	  humans	  with	  complete	  dysfunctional	  AR	  [30,	  31].	  AR	  is	  highly	   expressed	   in	   the	   UGS	   mesenchyme	   and	   responsible	   for	   prostate	  morphogenesis,	   whereas	   epithelial	   AR	   expression	   is	   induced	   after	   budding	   and	  branching	   morphogenesis	   has	   begun	   and	   is	   required	   for	   expression	   of	   secretory	  proteins	  in	  mouse	  and	  rat	  prostate	  [9].	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Fig	   1.4	   –	   Schematic	   representation	   of	   testosterone	   metabolites.	   The	   5α-­reductases	  
enzyme	  catalyzes	  the	  conversion	  of	  testosterone	  to	  5α-­dihydrotestosterone	  (DHT);	  the	  
β-­hydroxysteroid	   dehydrogenase	   converts	   testosterone	   into	   androstenedione;	   the	  
aromatase	  enzymes	  can	  convert	  further	  the	  androstenedione	  into	  estrogen.	  	  AR	   induction	   in	  prostate	  epithelium	  begins	  as	  early	  as	  postnatal	  days	  1–2	   (before	  cytodifferentiation	  of	  the	  epithelium	  and	  mesenchyme)	  [9].	  Therefore	  it	  is	  possible	  that	  androgen-­‐driven	  epithelial	  signals	  contribute	  to	  morphogenesis	  of	  the	  prostate	  by	   affecting	   the	   differentiation	   of	   adjacent	   mesenchymal	   cells.	   Non-­‐androgen	  stimulation	  is	  also	  possible	  due	  to	  the	  differential	  gene	  expression	  pattern	  along	  the	  proximal-­‐distal	  axis	  of	  the	  prostate	  while	  AR	  expression	  does	  not	  vary	  [9].	  The	  first	  known	  response	   to	  androgens	  by	   the	  murine	  urogenital	   sinus	   is	   the	  expression	  of	  the	  homeobox	  gene	  Nkx3.1	  in	  patches	  of	  UGE	  at	  15.5	  dpc,	  which	  is	  two	  days	  before	  the	  appearance	  of	  prostatic	  buds	  [8].	  Although	  expression	  of	   this	  gene	   in	  prostatic	  epithelium	   precedes	   AR	   expression,	   subsequent	   increased	   Nkx3.1	   expression	   is	  dependent	  upon	  androgen	  signalling	  [2].	  From	  this	  moment	  onwards	  the	  presence	  of	   testosterone	   and	  DHT	  are	   fundamental	   to	   achieve	   complete	   organ	   growth	  with	  full	   branching	   and	   complete	   cytodifferentiation.	   However	   ductal	   lumen	   formation	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does	   not	   occur	   and	   luminal	   epithelial	   cells	   fail	   to	   differentiate	   with	   a	   marked	  decrease	  in	  prostatic	  organ	  size	  relative	  to	  glands	  grown	  with	  testosterone	  [32].	  To	  capture	  the	  dynamics	  of	  AR	  signalling	  in	  vivo	  Hsieh	  and	  colleagues	  carried	  out	  a	  remarkable	   study	   creating	   a	   transgenic	   mouse	   where	   the	   sPSA	   (supra	   Prostate	  Specific	   Antigen)	   promoter	   drove	   the	   expression	   of	   the	   luciferase	   enzyme.	   They	  then	  monitored	   the	   luciferase	   activity	   during	   development	   in	   castrated	   and	   non-­‐castrated	   animals;	   the	   results	   confirmed	   the	   importance	   of	   DHT	   in	   prostate	  development	  due	  to	  the	  absence	  of	   luciferase	  activity	  in	  castrated	  mice.	  There	  was	  also	  a	  minor	  detection	  of	  signal	   in	   legs	  and	  bones	  of	  a	   few	  animals	  [33]	  that	  could	  interestingly	  correlate	  with	   the	   fact	   that	  some	  prostate	  cancers	  can	  metastasize	   in	  the	  bone.	  Estrogens	  also	  play	  an	  important	  role	  in	  prostate	  development;	  male	  ER	  knock	  out	  mice	   are	   infertile	   and	   have	   fewer	   epididymal	   sperm	   than	   heterozygous	   and	   wild	  type	   males	   [34].	   Disruption	   of	   spermatogenesis	   and	   degeneration	   of	   the	  seminiferous	   tubules	   progresses	   from	   caudal	   to	   cranial	   pole	   after	   10	   weeks	   of	  gestation;	   however	   prostate,	   seminal	   vesicles	   and	   epididymis	   appeared	  morphologically	   normal	   [35].	   Neonatal	   estrogens	   directly	   suppress	   Fgf10	   and	  FgfR2iiib	  expression	  both	  in	  vivo	  and	  in	  vitro	  in	  the	  lateral	  and	  dorsal	  prostate,	  but	  not	   the	  ventral	  prostate	  (VP).	  Furthermore,	  organ	  culture	  studies	  show	  that	  Fgf10	  replacement	  can	  rescue	  LP	  growth	  and	  branching	  inhibition	  as	  a	  result	  of	  estradiol	  administration	  [36].	  Another	  study	  unexpectedly	  showed	  that	  male	  embryos	  grown	  between	  two	  female	  embryos	  (relative	  to	  a	  male	  that	  develops	  between	  two	  males)	  have	  higher	  serum	  estradiol,	   lower	  testosterone,	   increased	  expression	  of	  Ar	   in	   the	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prostate	   and	   larger	   prostate	   in	   adulthood;	   this	  means	   that	   a	   small	   supplement	   of	  estrogen	   from	   adjacent	   female	   fetuses	   enhances	   androgen-­‐dependent	   accessory	  organ	  development	  [37].	  This	  is	  also	  confirmed	  by	  the	  finding	  that	  male	  rat	  fetuses	  exposed	  to	  very	  low	  environmental	  levels	  of	  estrogens	  (bisphenol	  A)	  show	  prostatic	  enlargement.	   On	   the	   other	   hand	  male	   embryos	   exposed	   to	   high	   concentrations	   of	  estrogens	  have	  reduced	  prostatic	  growth	  and	  compromised	  structural	  architecture	  in	  rats	  [38].	  	  	  It	  has	  been	  suggested	  that	  retinoids	  can	  mediate	  the	  estrogenic	  effects	  on	  prostate	  development.	   Vitamin	   A	   has	   a	   pronounced	   role	   in	   epithelial	   growth	   and	  differentiation;	   in	  mice,	   vitamin	  A	  deficiency-­‐induced	  keratinization	  of	   the	   vaginal	  epithelium	  and	  is	  similar	  to	  that	  seen	  with	  estrus	  and	  with	  neonatal	  estrogenization	  of	   the	   female	   reproductive	   tract,	   suggesting	   that	   retinoids	   may	   be	   mediating	   the	  action	   of	   estrogen	   [39].	   In	   support	   of	   this	   theory,	   neonatal	   estrogen	   induction	   of	  proliferation	   and	   cornification	   of	   the	   vaginal	   epithelium	   can	   be	   suppressed	   by	  coadministration	   of	   retinyl	   acetate	   [40].	   An	   RT-­‐PCR	   screen	   of	   the	   rat	   anterior	  prostate	   (coagulating	   gland)	   revealed	   the	   presence	   of	   RARβ	   and	   -­‐γ	   on	   day	   0,	  whereas	   RARγ	   and	   the	   RXR	   isomers	  were	   undetectable	   [41].	   As	   the	   prostatic	   cell	  population	  changes	  upon	  glandular	  development,	   the	  RAR	   levels	   shift	  accordingly,	  with	  an	  overall	  decrease	  in	  total	  RAR	  levels	  in	  the	  adult	  prostate.	  The	  normal	  adult	  prostate	  gland	  is	  less	  sensitive	  to	  retinoids	  than	  the	  immature	  developing	  prostate,	  which	   coincides	   with	   the	   known	   function	   of	   retinoids	   as	   regulators	   of	   tissue	  morphogenesis	   and	   differentiation.	   Similarly,	   the	   normal	   maturational	   decline	   in	  prostatic	  RARα	  mRNA	  levels	  did	  not	  occur	  in	  the	  estrogenized	  prostates,	  resulting	  in	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continued	  high	  expression	  into	  adulthood	  and	  permanent	  imprint	  of	  the	  expression	  pattern	  [42].	  	  In	   the	   prostate	   gland,	   androgens,	   estrogens,	   and	   retinoids	   act	   as	   upstream	  regulators	   of	   several	   of	   the	   critical	   developmental	   genes	   and	   timely	   expression	  of	  their	   cognate	   receptors	   is	   critical	   for	   normal	   morphogenesis.	   Transient	   and	  permanent	  disturbances	   in	   the	  expression	  of	   these	   transcription	   factors,	  as	  occurs	  after	  neonatal	  estrogen	  exposure,	  may	  consequently	   lead	   to	  abnormal	  or	  untimely	  expression	   of	   the	   prostatic	   master	   regulatory	   genes	   during	   the	   developmental	  critical	   windows.	   As	   development	   is	   an	   mono-­‐directional,	   that,	   in	   turn,	   leads	   to	  permanent	  disturbances	  in	  the	  structure	  and	  differentiation	  of	  this	  organ	  [42].	  These	   data	   together	   indicate	   that	   during	   prostate	   development	   the	   hormonal	  environment	   modulates	   gene	   expression	   temporally	   and	   spatially	   that,	   in	   turn,	  promotes	   ductal	   branching	   form	   the	   urogenital	   sinus	   and	   morphogenesis	   of	   the	  growing	  gland.	  The	  list	  of	  genes	  analyzed	  so	  far	  [8]	  could	  turn	  out	  to	  be	  even	  longer	  and	   will	   include	   further	   levels	   of	   regulation	   orchestrated	   by	   micro	   RNAs	   and	  epigenetic	  mechanisms	  that	  still	  need	  to	  be	  unveiled	  fully.	  Also,	  the	  role	  of	  NR	  such	  as	  VDR,	  PPARs,	  FXR	  and	  GR	  is	  still	  unclear.	  	  
1.3.3	  –	  Prostate	  stem	  cells	  and	  prostate	  cancer	  stem	  cells	  Organ	   stem	  cells	   are	   long-­‐lived	  and,	  during	   the	  process	  of	   aging,	   they	   can	  acquire	  epigenetic	  modifications	  and	  genetic	  mutations	  though	  exposure	  to	   insults	  such	  as	  oxidative	   stress	   and	   DNA	   damage,	   resulting	   in	   the	   disregulation	   of	   normal	   cells	  processes.	   Prostate	   Stem	   Cells	   (PSCs)	   represent	   approximately	   1%	   of	   the	   whole	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population;	  a	  common	  method	  used	  to	  isolate	  them	  is	  FACS	  (Fluorescence	  Activated	  Cell	  Sorting),	  based	  on	  the	  expression	  of	  stem	  cells	  surface	  markers	  like	  CD133.	  The	  existence	  of	  prostate	   stem	  cells	   comes	   from	  an	  experiment	  of	   androgen	  cycling	   in	  the	   rodent.	   The	   prostate	   gland	   undergoes	   involution	   after	   castration	   but	   can	  completely	   regenerate	   if	   androgen	   levels	   are	   restored.	  As	   this	   cycle	   of	   involution-­‐castration	   can	   be	   repeated	   many	   times,	   a	   population	   of	   long-­‐lived,	   androgen-­‐independent	  but	  responsive	  stem	  cells,	  responsible	  for	  the	  regeneration	  of	  the	  gland	  must	   exist	   [43].	   In	   the	   prostate	   approximately	   1%	   of	   basal	   cells	   express	  CD133+/α2β1hi	   [44,	   45]	   and	   it	   has	   been	   shown	   that	   prostate	   cells	   expressing	  CD133+	  exhibited	  characteristics	  of	  stem	  cells	  including	  prostasphere	  formation	  and	  the	   development	   of	   prostatic-­‐like	   acini	   when	   transplanted	   into	   immuno-­‐compromised	  male	  mice	  [46].	  	  Molecular	   profiling	   of	   CD133+/α2β1hi	   and	   CD133-­‐	   cells	   isolated	   from	   benign	  prostatic	   hyperplasia	   specimens	   revealed	   that	   CD133+/α2β1hi	   cells	   exhibited	   an	  expression	   profile	   associated	   with	   embryonic	   stem	   cells	   and	   embryonic	  development	   along	   with	   other	   groups	   representing	   ion	   homeostasis,	   response	   to	  chemical	   and	  biotic	   stimuli,	   cell	   communication	   and	   cell	   proliferation.	   In	   contrast,	  CD133-­‐	   cells	   expressed	   a	   profile	   resembling	   transit	   amplifying	   cells,	   with	   genes	  involved	  in	  cell	  cycle	  progression,	  RNA	  transcription	  and	  protein	  biosynthesis;	  key	  regulators	   of	   self-­‐renewal	   and	  differentiation	   such	   as	  TGF-­‐β,	   BMP,	  WNT,	   SHH	  and	  Notch	   pathways	  were	   also	   differentially	   regulated	   by	   CD133+/α2β1hi	   and	   CD133-­‐	  cells	   [47].	   Another	   study	   isolating	   cancer	   stem	   cells	   from	   human	   PCa	   tissues	  determined	  that	  CD44	  is	  expressed	  in	  normal	  PSCs	  (prostate	  stem	  cells)	  as	  well	  as	  in	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prostate	  CSCs	  (cancer	  stem	  cells);	  approximately	  0.1%	  of	  cells	  in	  a	  tumor	  expressed	  CD44+/CD133+/α2β1hi	   and	   they	   could	   re-­‐express	   AR	   under	   the	   appropriate	  microenvironment,	  implying	  that	  the	  stem	  cell	  niche	  was	  crucial	  in	  regulating	  CSCs	  phenotype	  and	  function	  [48].	  	  	  
1.3	  –	  Prostate	  neoplastic	  transformation	  and	  tumor	  progression	  
1.3.1	  –	  Introduction	  Various	  workers	   have	   suggested	   that	   the	   phenotypic	   characteristics	   of	   the	   cancer	  are	   determined	   by	   the	   stem	   or	   progenitor	   cell-­‐of-­‐origin	   [44].	   This	   has	   potentially	  very	   significant	   therapeutic	   implications	   in	   terms	   of	   understanding	   disease	  progression	   and	   relapse.	   An	   epigenetic	   progenitor	   model	   [44]	   is	   a	   multi-­‐step	  process	   in	   which	   epigenetic	   disruption	   of	   stem/progenitor	   cells	   is	   mediated	   by	  tumor	  progenitor	   genes.	   Subsequently,	   genetic	  mutations	   in	   gatekeeper	   genes	   are	  acquired	  along	  with	  genetic	  and	  epigenetic	  plasticity.	  This	  process	  could	  explain	  the	  late	   onset	   of	   prostate	   cancer	   and	   other	   adult	   cancers,	   tumor	  heterogeneity,	   latent	  cancers,	  the	  consequence	  of	  environmental	  effects,	  progression	  to	  recurrent	  disease,	  the	  genetics	  of	  cancer	  risk	  [49]	  and	  it	  indicates	  how	  the	  tumor	  characteristics	  could	  be	  determined	  by	  the	  stage	  at	  which	  these	  genetic	  alterations	  occurred	  [44].	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Fig	   1.5	   –	   The	   progenitor	   origin	   of	   cancer.	   Epithelial	   or	   neuroendocrine	   cells	   may	  
acquire	   epigenetic	   modifications	   and	   genetic	   mutations	   through	   DNA	   damage,	  
oxidative	   stress,	   etc.	   during	   the	   process	   of	   differentiation.	   The	   phenotypic	  
characteristics	  of	  the	  cancer	  would	  therefore	  be	  determined	  by	  the	  stem	  or	  progenitor	  
cell-­of-­origin.	  From	  left	  to	  right	  (undifferentiated	  to	  differentiated	  cells)	  is	  shown	  how	  
the	  initial	  onset	  of	  stem	  cells	  can	  differentiate	  into	  specific	  malignancies.	  Figure	  taken	  
from	  [44].	  	  As	  shown	  in	  Fig	  1.5	  mutations	  in	  embryonic	  stem	  cells	  would	  give	  rise	  to	  childhood	  tumors	   such	   as	   Wilms	   tumors	   and	   other	   embryonal	   tumors	   including	  teratocarcinomas	   and	   retinoblastoma	   [50].	   Mutations	   in	   early	   progenitor	   cells	  would	   promote	   the	   development	   of	   poorly	   differentiated	   cancers	   including	   solid	  tumors	   such	   as	   prostate,	   breast,	   and	   colon	   cancer	   [50].	   In	   contrast,	   well-­‐differentiated	   cancers	   would	   arise	   from	   late	   progenitor	   cells	   and	   benign	   tumors	  from	  cells	  just	  prior	  to	  terminal	  differentiation	  [50].	  	  The	  prostate	  cancer	  stem	  cell	  hypothesis	  has	  trigged	  new	  debates	  about	  the	  origins	  of	   PCas;	   whereas	   the	   roots	   of	   prostate	   cancer	  might	   be	   epigenetically	   written	   on	  certain	  stem	  cell	  lineages,	  the	  real	  origins	  of	  these	  aberrations	  remain	  unknown.	  The	  epigenetic	  lesions	  involved	  in	  cancer	  development	  are	  not	  fully	  understood	  because	  
Chapter	  1	  –	  Introduction	  	  
 51 
there	  is	  no	  clear	  explanation	  of	  where	  originally	  these	  corruptions	  arise	  from.	  Clues	  come,	  for	  example,	  from	  the	  over	  expression	  of	  the	  histone	  methyltransferase	  EZH2	  that,	  as	  a	  late	  event,	  is	  specifically	  overexpressed	  in	  metastatic	  and	  aggressive	  PCas.	  Although,	   the	   self-­‐renewal	   ability	   of	   stem	   cells	   and	   the	   immortalization	   of	   cancer	  cells	  share	  a	  common	  role:	  the	  maintenance	  of	  a	  proliferative	  and	  undifferentiated	  status	  that,	  independently	  from	  androgen	  and	  cellular	  control,	  indefinitely	  persist	  in	  its	   growth.	   Exploiting	   cancer	   stem	   cells	   could	   be	   clinically	   interesting	   because	   it	  could	  help	   identify	   the	  mechanistic	   susceptibility	   to	   certain	   tumors,	   thus,	   creating	  either	  a	  more	  targeted	  therapy	  or	  a	  more	  efficient	  program	  for	  cancer	  prevention.	  Prostate	  cancer	  (PCa)	  is	  a	  major	  problem	  at	  a	  worldwide	  level	  being	  a	  cause	  of	  death	  for	   more	   than	   220.000	   men	   annually	   worldwide	   [51].	   This	   disease	   is	   highly	  heterogenic	  and	  a	  number	  of	   theories	  propose	  how	  environment,	   lifestyle,	  genetic	  and	  epigenetic	  factors	  can	  lead	  to	  neoplastic	  transformation	  [52].	  Historically	  there	  is	   a	   higher	   incidence	   of	   prostate	   cancer	   in	   Western	   countries;	   this	   is	   mainly	  attributed	  to	  dietary	  and	  lifestyle	  factors,	  such	  an	  increased	  meat	  and	  dairy	  intake,	  in	   addition	   to	   reduce	   fruit	   and	   vegetable	   consumption	   and	   sedentary	   lifestyle,	  although	  this	  is	  a	  matter	  of	  some	  controversy.	  	  Histologically,	  progression	  to	  carcinoma	  is	  somewhat	  reminiscent	  of	  other	  epithelial	  cancers.	  The	   first	   identifiable	   lesion	   involves	  an	   inflammatory	   response	   inside	   the	  prostate	  and	  is	  named	  Proliferative	  Inflammatory	  Atrophy	  (PIA),	  the	  next	  step	  leads	  to	   the	   development	   of	   Prostatic	   Intra-­‐epithelial	   Neoplasia	   (PIN),	   characterized	   by	  nuclear	  and	  architectural	  changes	  in	  luminal	  epithelial	  cells	  with	  maintenance	  of	  the	  basal	   epithelium	   and	   basement	   membrane	   and	   it’s	   a	   widely	   accepted	   precursor	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lesion	   that	   can	   lead	   to	   adenocarcinoma	   [52].	   The	   hypothesis	   of	   an	   inflammatory	  response	   is	   coherent	  with	   the	  Western	   diet	   that	   is	   low	   in	   protective	   antioxidants	  and	  exercise	  and	  high	  in	  potential	  carcinogens.	  	  PCa	  is	  often	  multifocal	  and	  there	  can	  be	  several	  foci	  of	  PIA/PIN	  in	  a	  single	  prostate	  and	   each	   one	   of	   them	   can	   present	   different	   gene	   expression	   patterns	   and	   tissue	  organization.	   PCa	   is	  mostly	   graded	   by	   the	   Gleason	   score	   [53],	   where	   a	   low	   score	  mirrors	   the	   lesion’s	   grade	   on	   the	   basis	   of	   the	   glandular	   architecture.	   Beside	   this,	  even	  two	  histologically	  similar	  tumors	  can	  turn	  out	  to	  be	  clinically	  different	  due	  to	  intra-­‐tumoral	  and	  intra-­‐personal	  variability,	  complicating	  a	  possible	  prognosis.	  	  
	  1.3.2	  –	  Genetic	  aberrations	  and	  gene	  expression	  in	  PCa	  Several	   investigators	  worldwide	   reported	   candidate	   genes	   and	   pathways	   possibly	  involved	   in	   PCa	   progression	   reflecting	   epidemiological	   and	   molecular	   features	   of	  prostate	  cancer	  and	  neoplastic	  lesions.	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Fig	  1.6	  –	  Genetics	  alterations	  during	  prostate	  cancer	  progression.	  Photomicrographs	  
of	   hematoxylin	   and	   eosin-­stained	   sections	   representative	   of	   the	   indicated	   tissue	   or	  
lesion	   (10x	   original	   magnification,	   40x	   inserts).	   Arrows	   indicate	   proposed	   routes	   of	  
progression	   from	   normal	   (NOR)	   prostate	   glands	   to	   precursor	   lesions	   (PIN,	   PIA)	   to	  
localized	  PCa	  to	  metastatic	  disease	  (MET).	  Pathway	  and	  candidate	  gene	  names	  in	  blue	  
or	   red	   represent	   genes	   and	  pathways	  underexpressed	   or	   overexpressed,	   respectively,	  
during	  the	  indicated	  transition.	  Figure	  taken	  from	  [52].	  	  The	   genes	   highlighted	   in	   Fig	   1.6	   are	   the	   main	   players	   during	   the	   prostate	  tumorigenic	   processes;	   here	   they	   will	   be	   briefly	   described	   in	   the	   contest	   of	  histological	  progression	  to	  PCa.	  
1.3.2.1	   –	   Glutathione	   S-­Transferase	   Pi	   (GSTP1)	   in	   the	   protection	   against	  
xenobiotic	  nutrients	  Glutathione	  S-­‐transferases	  are	  enzymes	  that	  protect	  against	  cancer	  development	  by	  catalyzing	   the	   conjugation	   of	   the	   chemical	   scavenger	   glutathione	   to	   reactive	  chemical	   species	   and	   they	   are	   silenced	   in	   most	   PCas	   by	   hypermethylation	   of	   the	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CpG-­‐island	  sequences	  in	  the	  GSTP1	  promoter.	  The	  loss	  of	  GSTP1	  in	  PIN	  is	   likely	  to	  increase	  the	  vulnerability	  to	  electrophilic	  or	  oxidant	  carcinogens	  such	  as	  2-­‐amino-­‐1-­‐methyl-­‐6-­‐phenylimidazol(4,5)pyridine	   (PhIP)	   often	   found	   in	  well-­‐done	   or	   charred	  meat.	   These	   effects	   have	   been	   shown	   in	   different	   PCa	   cell	   lines	   including	   the	  androgen-­‐dependent	   cell	   line	  LNCaP	  and	   they	   support	   the	   role	  of	   inflammation	   in	  PCa	  development	  (reviewed	  in	  [52]).	  	  
	   1.3.2.2	  –	  Phosphate	  and	  Tensin	  Homolog	  (PTEN)	  In	  1997,	  PTEN	  was	  cloned	  and	  mapped	  to	  chromosome	  10q27,	  a	  region	  undergoing	  frequent	  deletions	  in	  a	  variety	  of	  tumors,	  including	  prostate	  cancer	  [54,	  55].	  Loss	  of	  heterozygosity	  (LOH)	  is	  found	  up	  to	  60%	  of	  the	  time	  whereas	  point	  mutations	  and	  deletions	   of	   the	   PTEN	   gene	   have	   also	   been	   reported	   in	   both	   PCa	   cell	   lines	   and	  xenograft	  models,	  as	  well	  as	  primary	  and	  metastatic	  tumors.	  Epigenetic	  inactivation	  of	  PTEN	  through	  promoter	  hypermethylation	  has	  been	  described	  in	  PCa	  xenografts,	  however	   the	   same	   phenomenon	   has	   not	   been	   yet	   identified	   in	   primary	   human	  tumors.	   The	   biological	   role	   of	   this	   protein	   is	   to	   suppress	   the	   PI3K/Akt	   signaling	  pathway	  that	  is	  often	  up-­‐regulated	  in	  cancer	  promoting	  cell	  survival,	  replication	  and	  growth.	  The	  neutral	  endopeptidase	  (NEP)	  recruits	  PTEN	  to	  the	  plasma	  membrane,	  which	   increases	   the	   stability	   and	   phosphatase	   activity	   of	   PTEN,	   resulting	   in	   Akt	  inactivation.	  Pten	  null	  mice	  are	  die	   in	  embryo	  and	  Pten-­‐/-­‐	  ES	  cells	   formed	  aberrant	  embryoid	   bodies	   displaying	   an	   altered	   ability	   to	   differentiate	   into	   endodermal,	  ectodermal	   and	   mesodermal	   derivatives.	   Prostate-­‐specific	   loss	   of	   Pten	   on	   both	  alleles	  results	   in	  completely	  penetrant	  high	  grade	  PIN	  and	  carcinoma	  with	  varying	  rates	  of	  metastatic	  disease	  [52].	  	  
Chapter	  1	  –	  Introduction	  	  
 55 
1.3.2.3	  –	  NK3	  Transcription	  Factor	  Related,	  Locus	  1	  (NKX3.1)	  The	  androgen-­‐regulated	  NKX3.1	   is	  an	  homeobox	  gene	   located	   in	  chromosome	  8	   in	  position	   p21	   that	   is	   frequently	   a	   site	   of	   LOH	   in	   PCa	   (90%)	   as	  well	   as	   PIN	   (60%)	  (reviewed	  in	  [52]).	  NKX3.1	  expression	  is	  largely	  dependent	  on	  androgen	  signalling,	  modulates	  PSA	  transcription	  (used	  as	  a	  marker	  for	  PCa)	  and	  acts	  as	  a	  transcriptional	  regulator	   [56].	   NKX3.1	   controls	   the	   rate	   at	   which	   proliferating,	   luminal	   epithelial	  cells	   exit	   the	   cell	   cycle	   and	   the	   deletion	   of	   one	   or	   both	   alleles	   extends	   the	  proliferative	   phase	   during	   prostate	   regeneration;	   this	   means	   that	   clusters	   of	  haploinsufficient	   and	   non-­‐haploinsufficient	   target	   genes	   have	   been	   elegantly	  identified	  with	  different	  patterns	  of	   expression	   from	  gene	   to	   gene	   [57],	   indicating	  the	  different	  sensitivity	  of	  target	  genes	  to	  NKX3.1.	  Knockout	  mice	  display	  increasing	  prostatic	  epithelial	  hyperplasia	  and	  dysplasia	  with	  age;	  by	  one	  or	  two	  years	  of	  age,	  the	  mice	   show	   features	   similar	   to	  PIN	  but	  don’t	   develop	   into	   carcinoma,	   however	  when	  Nkx3.1-­‐/-­‐	  mice	  are	  crossed	  with	  Pten+/-­‐	  mice	  the	  offspring	  show	  high	  grade	  PIN	  with	   strong	   activation	   of	  Akt,	   and	   older	  mice	   show	   invasive	   carcinoma	   and	   easily	  develop	   metastasis	   [52].	   These	   results	   together	   indicate	   the	   key	   role	   played	   by	  NKX3.1	  alone	  or	  in	  association	  with	  other	  transcription	  factor	  in	  the	  early	  stages	  of	  prostate	  tumorigenesis.	  
	   1.3.2.3	  –	  Nuclear	  receptors:	  AR,	  VDR,	  RARs,	  PPARs	  
	   	   -­	  AR	  As	   previously	   discussed,	   during	   prostate	   development	   cell	   survival	   is	   almost	  entirely	   dependent	   upon	   the	   AR.	  Most	   prostate	   tumors	   are	   initially	   responsive	   to	  androgen	   ablation,	   however	   almost	   all	   tumors	   eventually	   become	   androgen	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independent	  and	  proliferate	  despite	  androgen	  ablation.	  It	  has	  been	  demonstrated	  by	  microarray	   analysis	   that	   the	   expression	   of	   androgen-­‐dependent	   genes	   persisted	  after	   androgen	   ablation	   therapy	   [58],	   suggesting	   that	   those	   genes	   are	   likely	   to	   be	  involved	  in	  proliferation	  and	  survival	  of	  prostate	  cells.	  LNCaP	  cells,	  for	  example,	  can	  adapt	   to	   androgen	   deprivation	   by	   increasing	   their	   sensitivity	   to	   androgen	   by	  increasing	   AR	   expression	   [59].	   Other	   groups	   also	   showed	   that	   the	   AR	   undergo	  mainly	  two	  kind	  of	  mutation;	  the	  first	  kind	  of	  mutation	  localized	  at	  specific	  regions	  of	   the	   receptor	   that	   can	   result	   in	   alterations	   of	   the	   androgen	   receptor	   function,	  whereas	   the	   second	   kind	   of	   mutations	   are	   distributed	   differently	   among	   the	   AR	  open	  reading	  frame	  and	  could	  cause	  androgen	  insensitivity	  or	  disruption	  of	  the	  AR	  signaling	  pathway	  [60].	  In	  animal	  models	  xenografted	  with	  human	  prostate	  cancer	  cells	   that	  are	  AR-­‐sensitive	  and	  non-­‐sensitive,	   it	  has	  also	  been	  shown	   that	   the	  only	  gene	   expression	   change	   that	   was	   consistent	   with	   androgen	   independence	   was	   a	  two-­‐to	  five-­‐fold	  induction	  of	  the	  AR.	  This	  increase	  appeared	  necessary	  and	  sufficient	  for	  hormone-­‐independent	  progression	  in	  mice;	  in	  fact	  cells	  with	  a	  modest	  increase	  in	  AR	  expression	  are	  also	  highly	  sensitive	  to	  androgens	  [52].	  
	   	   -­	  VDR	  VDR	   function	   in	   prostate	   cancer	   has	   been	   extensively	   investigated;	   although	  polymorphisms	   of	   the	   VDR	   gene	   significantly	   correlate	   with	   prostate	   cancer	   risk	  [61],	  epidemiological	  studies	  revealed	  a	  strong	  evidences	  linking	  sunlight	  exposure	  and	   development	   of	   prostate	   cancer,	   with	   males	   at	   higher	   latitudes	   being	   more	  affected	   than	   those	   in	   warmer	   countries.	   This	   is	   related	   to	   the	   production	   of	   the	  natural	  agonist	  1,25(OH)2D3	  in	  the	  skin	  upon	  UV	  exposure;	  this	  exerts	  a	  protective	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effect	  towards	  breast,	  colon	  and	  prostate	  cancer.	  However,	   in	  prostate	  cancer	  cells	  VDR	  signalling	   is	  skewed	  by	  epigenetic	  mechanisms,	   including	  altered	  corepressor	  expression,	  that	  can	  be	  partially	  rescued	  with	  the	  use	  of	  HDACs	  inhibitors	  [62].	  Vdr	  deficient	   mice	   revealed	   the	   importance	   of	   this	   receptor	   in	   mammary	   gland	  development	   by	   regulating	   differentiation;	   also,	   the	   vdr	   ablated	   background	   have	  been	  crossed	  with	  tumourigenic	  models	  and	  support	  anti-­‐tumour	  chemoprevention	  roles	   for	  VDR	  at	   least	   in	  breast	  cancer	  (reviewed	  in	  [63]).	   It	  remains	  to	  be	  seen	  to	  what	  extent	  this	  occurs	  in	  PCa.	  
	   	   -­	  RARs	  Richter	  et	  al.	  showed	  an	  antagonistic	  effect	  between	  the	  AR	  and	  RAR	  signalling	  in	  rat	  prostate	   carcinoma	   and	   non-­‐carcinoma	   cell	   lines	   where	   testosterone	   effect	   was	  suppressed	  by	  treatment	  with	  retinoic	  acid	  (RA)	  [64].	  The	  antiproliferative	  action	  of	  RA	  is	  mainly	  mediated	  by	  binding	  with	  RARβ	  whose	  promoter	  has	  been	  shown	  to	  be	  significantly	  hypermethylated	  in	  PCa	  specimens	  [65];	  this	  was	  confirmed	  further	  by	  the	   lower	   mRNA	   levels	   of	   RARβ	   detected	   in	   prostate	   cancer	   tissues	   [66].	   This	  epigenetic	   silencing	   of	   the	   RARβ	   gene	   can	   partially	   explain	   the	   loss	   of	  responsiveness	   towards	   RA	   in	   PC-­‐3	   cells	   that	   will	   be	   discussed	   in	   the	   Results	  chapter.	  Ligand-­‐activation	  of	  RARs	   is	  also	  modulated	  by	   the	  concentration	  of	  RA	   inside	   the	  cell;	  in	  fact,	  it	  has	  been	  shown	  that	  prostate	  carcinoma	  tissue	  contained	  five	  to	  eight	  times	  less	  retinoic	  acid	  than	  normal	  prostate	  or	  BPH.	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-­	  PPARs	  Prostaglandins	   are	   readily	   secreted	   by	   the	   prostate	   and	   give	   rise	   to	   the	   H	   and	   D	  series	  prostaglandins	  and	  15d-­‐PGJ2.	  Equally,	  the	  biology	  of	  the	  prostate	  is	  associated	  with	  the	  metabolism	  of	  fatty	  acids	  15S-­‐HETE.	  Therefore,	  the	  prostate	  seems	  to	  be	  a	  tissue	   where	   PPARγ	   may	   play	   a	   strong	   role	   in	   governing	   cell	   growth	   and	  differentiation.	   For	   example,	   signals	   derived	   from	   PGDS	   activity	   in	   the	   adjacent	  stroma,	   such	   as	   PGD2,	   activate	   PPARγ,	   and	   control	   epithelial	   proliferation.	   PPARγ	  actions	   in	   prostate	   cancer	   cell	   lines	   and	   primary	   cancer	   models	   include	   the	  induction	  of	  type	  II	  programmed	  cell	  death	  also	  known	  as	  autophagy.	  While	  PPARα	  levels	   are	   comparable	   between	   PCa	   and	   normal	   tissues,	   PPARγ	   expression	   was	  strongly	   upregulated	   [67].	   These	   studies	   encouraged	   several	   groups	   to	   undertake	  clinical	  trials	  with	  PPARγ	  ligands	  and	  disease	  stabilization	  was	  reported	  (reviewed	  in	  [68]).	  	  
	   1.3.2.4	  –	  Myc	  c-­‐Myc	  is	  located	  at	  chromosome	  8q24,	  is	  a	  positive	  regulator	  of	  cell	  proliferation	  and	  the	   disregulation	   of	   the	  Myc	   family	   is	   one	   of	   the	  most	   common	   events	   in	   human	  cancer.	   Gains	   in	   chromosome	   8	   are	   one	   of	   the	   most	   common	   amplifications	   in	  human	  prostate	  tumors,	  even	  at	  the	  stage	  of	  PIN	  indicating	  that	  other	  genes	  in	  this	  region	   could	   be	   important	   for	   PCa	   progression	   [52].	   In	   LNCaP	   cells	   it	   has	   been	  shown	   that	   Myc	   over-­‐expressing	   cells	   can	   form	   colonies	   independently	   from	   the	  presence	  of	  androgens	  and	  Myc	  appears	  to	  be	  an	  important	  downstream	  effector	  of	  AR	   [69].	  Mice	   over-­‐expressing	  Myc	   in	   a	   prostate	   specific	  manner	   undergo	   PIN	   or	  carcinoma	   depending	   on	   the	   promoter	   used	   [52];	   microarray	   analysis	   of	   murine	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Myc-­‐PCa	   interestingly	   identified	   a	   signature	   based	   on	   the	   overexpression	   of	   the	  protein	   kinases	   PIM-­‐1,	   consistently	   with	   other	   findings	   of	   PIM-­‐1	   interacting	   with	  Myc,	   and	   PIM-­‐1	   predicts	   PSA	   recurrence	   in	   patients	   with	   localized	   PCa	   [52],	   and	  NKX3.1	  downregulation.	  
	   1.3.2.5	  –	  Hedgehog	  Pathway	  The	  SHH	  pathway	  is	  known	  for	  its	  crucial	  role	  in	  prostate	  development	  as	  well	  as	  in	  the	   formation	  of	  prostate	  metastasis.	   Secreted	  SHH	  molecules	  bind	   to	   the	  patched	  receptor	   (PTCH),	   relieving	   PTCH-­‐mediated	   inhibition	   of	   smoothened,	   a	   seven-­‐transmembrane	   G	   protein	   coupled	   receptor.	   Smoothened	   signaling	   leads	   to	  activation	   of	   downstream	   target	   genes	   through	   glioma-­‐associated	   oncogene	  homolog	   (GLI)-­‐dependent	   transcription.	   PTCH	   is	   also	   a	   target	   of	   GLI,	   forming	   a	  negative	  feedback	  loop	  [70].	  Several	  studies	  reported	  that	  the	  hedgehog	  pathway	  is	  activated	  in	  PCa	  in	  various	  frequency	  in	  benign	  prostate	  and	  localized	  or	  metastatic	  PCa.	   Subsequent	   treatment	   of	   xenografted	   cell	   lines	   with	   cyclospamide,	   a	   SHH	  pathway	   inhibitor,	   consistently	   inhibited	   growth,	   invasion	   and	  metastasis	   both	   in	  
vitro	  and	  in	  vivo	  [52].	  Several	  other	  groups	  published	  contrasting	  results	  regarding	  SHH	  expression	  in	  cancer	  cell	  lines	  [52]	  suggesting	  that	  the	  SHH	  signalling	  is	  highly	  contextual.	  These	   findings	   indicate	  that	   the	  SHH	  pathway	   is	  required	   for	  epithelial	  cell	   regeneration	   after	   androgen	   ablation,	   followed	   by	   androgen	   re-­‐treatment,	  suggesting	  that	  PCa	  might	  develop	  from	  the	  trapping	  of	  normal	  prostate	  stem	  cells	  in	  a	  SHH	  pathway-­‐dependent	  state	  of	  continuous	  renewal	  [71].	  The	  involvement	  of	  prostate	   stem	   cells	   and	   the	   recent	   identification	   of	   cells	   with	   stem	   cell-­‐like	  properties	   in	   other	   cancer	   has	   led	   to	   speculation	   that	   tissue-­‐specific	   stem	   cells,	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through	  the	  SHH	  pathway,	  may	  drive	  many	  cancers	  including	  PCa.	  This	  idea	  would	  be	   consistent	  with	   the	   role	  played	  by	  SHH	   in	  prostate	  development	   and	   in	   cancer	  progression	  in	  conjunction	  with	  its	  target	  gene	  NKX3.1	  and	  the	  AR.	  	  
	   1.3.2.6	  –	  Other	  candidate	  genes	  Different	  groups	  used	  microarray	  technology	  to	  identify	  genes	  involved	  in	  prostate	  cancer	   development	   and,	   despite	   technical	   and	  manual	   variances,	   there	   are	   a	   few	  interesting	   candidates	   also	   validated	   by	   functional	   studies	   for	   their	   role	   in	   PCa.	  These	   are	   hepsin	   (HPN),	   α-­‐methylacyl-­‐CoA	   racemase	   (AMACR)	   and	   enhancer	   of	  Zeste	  homolog	  2	  (EZH2).	  
	   	  
Hepsin	  (HPN)	  Hepsin	   is	   a	   type	   II	   serine	   protease	   identified	   nearly	   in	   every	   microarray	   study	  profiling	   PCa	   [72].	   HPN	   mRNA	   is	   upregulated	   in	   approximately	   90%	   of	   prostate	  tumours,	   with	   expression	   confined	   to	   epithelial	   cells	   while	   its	   role	   in	   PCa	  progression	   is	   still	  unclear.	  At	  a	  protein	   level	  HPN	   is	  mainly	  expressed	  during	   the	  PIN	   stage	   and	   decreases	   in	   the	   transition	   to	   metastatic	   cancer.	   An	   interesting	  example	  of	  the	  role	  of	  HPN	  in	  prostate	  cancer	  is	  the	  over-­‐expression	  of	  HPN	  in	  PC-­‐3	  cells	   (malignant,	   metastatic	   and	   androgen-­‐independent	   prostate	   cell	   line)	   led	   to	  reduced	  cell	  proliferation	  and	  invasion	  [52],	  suggesting	  that	  an	  upregulation	  of	  this	  protein	  at	  later	  stages	  of	  PCa	  could	  be	  evolutionarily	  counter-­‐productive.	  Mice	  with	  prostate-­‐specific	   overexpression	   of	   HPN	   showed	   no	   obvious	   abnormalities	   in	  proliferation	   or	   apoptosis	   in	   the	   prostate,	   however	   a	   weakening	   of	   epithelial-­‐
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stromal	   adhesion	   and	   disorganization	   and	   disruption	   of	   the	   basal	  membrane	  was	  apparent	  [73].	  
	   	  
α-­methylacyl-­CoA	  racemase	  (AMACR)	  The	   enzyme	   AMACR,	   which	   is	   involved	   in	   peroxisomal	   β-­‐oxidation	   of	   dietary	  branched-­‐chain	  fatty	  acids,	  has	  also	  been	  identified	  as	  an	  important	  contributor	  to	  PCa.	  The	   functionally	  active	  protein	   is	  specifically	  overexpressed	   in	  PCa	  compared	  with	  benign	  epithelium	  and	  AMACR	  mRNA	  is	  also	  upregulated	  in	  PIN	  [reviewed	  in	  52].	   The	   major	   dietary	   source	   of	   branched-­‐chain	   fatty	   acids,	   meat	   and	   dairy	  products,	   have	   been	   implicated	   in	   the	   increased	   incidence	   of	   PCa	   in	   Western	  countries;	  this	  is	  supported	  by	  higher	  levels	  of	  phytanic	  acid	  in	  PCa	  patients,	  which	  is	  caused	  primarily	  by	  dietary	  intake	  of	  dairy	  and	  red	  meat	  and	  requires	  AMACR	  for	  its	  metabolism.	  At	  the	  genetic	  level	  a	  single	  nucleotide	  polymorphisms	  (SNP)	  in	  the	  AMACR	  gene	  cosegregates	  with	  PCa	   in	  hereditary	  PCa	   families	  and	  knock	  down	  of	  this	   gene	   in	   androgen-­‐dependent	   PCa	   cell	   lines	   has	   been	   shown	   to	   inhibit	   cell	  proliferation	  [52].	  	  
	   Enhancer	  of	  Zeste	  Homolog	  2	  (EZH2)	  EZH2	  is	  a	  member	  of	  the	  polycomb	  group	  family	  of	  transcriptional	  repressors	  and	  is	  specifically	   overexpressed	   in	  metastatic	   and	   aggressive	   localized	  PCas,	   the	   finding	  that	   it	   is	   overexpressed	   in	   other	   kinds	   of	   cancer	   and	   its	   ability	   of	   conferring	  proliferation	  advantages	  to	  normal	  cells	  may	  classify	   it	  as	  an	  oncogene	  [74].	  EZH2	  acts	   primarily	   as	   histone	   methyltransferase	   promoting	   gene	   silencing	   but	   it	   has	  been	   shown	   that	   its	   expression	   is	   controlled	   by	   the	   pRB/E2F	   pathway	   and	   it’s	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essential	   for	   proliferation	   in	   transformed	   and	  primary	   human	   cells,	   including	  PCa	  [74].	  EZ2F	  is	  downregulated	  by	  p53,	  resulting	  in	  cell	  growth	  inhibition	  [52].	  Even	  if	  its	  involvement	  in	  tumor	  survival	  has	  been	  proven,	  more	  experiments	  are	  necessary	  to	  elucidate	  EZ2F’s	  role	  in	  prostate	  cancer	  pathogenesis	  more	  clearly.	  
	   Gene	  Fusion	  of	  TMPRSS2	  and	  ETS	  Family	  Members	  Many	   hematological	   malignancies	   display	   chromosomal	   aberrations,	   either	   as	   an	  inversion,	  like	  CBFb:MYH11	  in	  leukemia,	  or	  translocation,	  like	  the	  8;21	  resulting	  in	  AML:ETO	   fusion	   transcript	   (reviewed	   in	   [52]).	   Tomlins	   and	   colleagues	   indentified	  the	  fusion	  product	  between	  the	  5’	  region	  of	  the	  androgen	  regulated	  gene	  TMPRSS2	  (belongs	  to	  the	  serine	  protease	  family,	  upregulated	  in	  androgen	  dependent	  PCa	  and	  downregulated	   in	   androgen-­‐independent	   PCa)	  with	   ERG	   or	   ETV1	   (both	   belong	   to	  the	  ETS	   transcription	   factors	   family)	   in	  PCas	  with	   aberrant	   expression	  of	   the	  ETS	  family	   members.	   Combining	   gene	   expression	   data	   with	   FISH	   then	   revealed	   that	  rearrangements	  in	  ERG	  or	  ETV1	  loci	  occur	  in	  the	  majority	  of	  PCa	  cases	  [52].	  	  	  
1.4	  –	  PEROXISOME	  PROLIFERATOR	  ACTIVATED	  RECEPTORS	  (PPARs)	  The	   Peroxisome	   Proliferator	   Activated	   Receptors,	   or	   PPARs,	   are	   ligand	   inducible	  transcription	   factors	   that	   belong	   to	   the	   NR	   superfamily;	   they	   were	   identified	   in	  
Xenopus,	  rodents	  and	  human	  in	  the	  early	  nineties	  being	  described	  as	  the	  receptors	  for	  compounds	  that	  induces	  peroxisome	  (organelles	  involved	  in	  β-­‐oxidation	  of	  long	  chain	  FA	  and	  H2O2-­‐based	   respiration)	  proliferation	   [75].	  There	   are	   three	  different	  PPARs	   named	   as	   PPARα,	   PPARβ/δ	   and	   PPARγ	   respectively	   NR1C1,	   NR1C2	   and	  NR1C3	  [76]	  and	  they	  have	  emerged	  as	   important	  cellular	  sensors	  of	   levels	  of	   fatty	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acids	   and	   fatty	   acid-­‐derivatives	   mainly	   derived	   by	   the	   cyclooxigenase	   (COX)	  pathway.	  In	  fact,	  it	  was	  shown	  that	  polyunsaturated	  fatty	  acids	  bind	  the	  three	  PPAR	  isoforms	   with	   relative	   low	   affinity,	   whereas	   fatty	   acid	   derivatives	   show	   more	  selectivity	  [77,	  78].	  	  PPARs	  exhibit	  isotype-­‐specific	  tissue	  expression	  patterns,	  with	  PPARα	  expressed	  at	  high	  level	   in	  organs	  with	  a	  significant	  catabolism	  of	   fatty	  acids,	  PPARβ/δ	   in	  all	  cell	  types	   analyzed	   with	   levels	   depending	   on	   the	   extent	   of	   the	   cell	   proliferation	   and	  differentiation	   and	   PPARγ	   found	   at	   high	   levels	   in	   the	   adipose	   tissues	   and	   lower	  levels	  in	  colon,	  immune	  cells	  and	  other	  tissues	  [79].	  All	  the	  PPARs	  heterodimerize	  with	  RXR;	  interestingly	  synthetic	  agonists	  for	  RXR	  can	  activate	  the	  dimer	  exerting	  antidiabetic	  outcomes	  similar	  to	  those	  seen	  with	  PPAR	  ligands	  in	  mouse	  models	  of	  type	  2	  diabetes	  [80]	  suggesting	  that	  the	  PPARs	  are	  able	  to	  drive	  cellular	  responses	  despite	  the	  activating	  events.	  	  
1.4.1	  -­	  PPARα	  Pparα	   was	   the	   first	   PPAR	   identified	   [81].	   Human	   PPARα	   has	   been	   mapped	   to	  chromosome	   22	   adjacent	   to	   the	   region	   22q12-­‐q13.1	   [82]	   whereas	   the	   mouse	  homolog	   maps	   on	   chromosome	   15	   [83].	   The	   major	   function	   of	   PPARα	   is	   the	  regulation	   of	   energy	   homeostasis	   activating	   fatty	   acid	   catabolism,	   stimulating	  gluconeogenesis,	   ketone-­‐body	   synthesis	   and	   lipoprotein	   assembly	   [80].	   PPARα	   is	  activated	  by	  diverse	  class	  of	  compounds	  including	  saturated/unsaturated	  fatty	  acids	  (palmitic	   acid,	   oleic	   acid,	   linoleic	   acid	   and	   arachidonic	   acid)	   and	   hypolipidemic	  fibrates,	   that	   induce	   hepatic	   peroxisome	   proliferation,	   hepatomegaly	   and	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hepatocarcinogenesis	  in	  rodents;	  this	  can	  occur	  through	  the	  production	  of	  reactive	  oxygen	   species	   as	   a	   by-­‐product	   of	   β-­‐oxidation	   reactions	   [84].	   Pparα-­‐null	   mice	  created	   were	   indeed	   resistant	   to	   the	   toxicity	   induced	   by	   treatment	   with	   the	  peroxisome	   proliferator	   clofibrate	   and	   to	   hepatocellular	   carcinomas	   but	   on	   the	  other	   hand	   they	   presented	   more	   extended	   inflammatory	   response	   than	   the	   wild	  type	  when	   exposed	   to	   the	   leukotriene	   B4,	   a	   potent	   chemotactic	   agent,	   sustaining	  anti-­‐inflammatory	   role	   of	   Pparα.	   Interestingly	   fibrate	   compounds	  do	  not	   have	   the	  same	  toxic	  effect	  in	  humans.	  This	  is	  due	  to	  the	  reduced	  levels	  of	  PPARα,	  roughly	  10	  fold	   lower,	   in	   the	   human	   liver	   compared	   to	   the	   rodent	   liver;	   the	   PPREs	   (PPAR	  Responsive	   Elements)	   of	   genes	   involved	   in	   peroxisome	   proliferation,	   including	  acetyl	  CoA	  oxidase	  (ACO),	  also	  differ	  between	  rodents	  and	  humans	  and	  the	  human	  enhancer	   sequence	   of	   ACO	   cannot	   be	   activated	   by	   PPARα	   in	   transactivation	  experiments	  (reviewed	  in	  [80]).	  The	   wide	   range	   of	   action	   of	   PPARα	   ligands	   has	   made	   this	   receptor	   a	   common	  therapeutic	   target	   for	   the	   treatment	  of	  dyslipidaemia,	   cardiovascular	  diseases	  and	  as	  anti-­‐inflammatory	  agents.	  	  	  
1.4.2	  -­	  PPARγ	  	  This	   receptor	   was	   initially	   cloned	   from	   a	   Xenopus	   cDNA	   library	   in	   1992	   and	  subsequently	   from	   several	   mammalians	   including	   humans	   [80].	   Two	   PPARγ	  isoforms,	  γ1	  and	  γ2,	  are	  expressed	  at	  the	  protein	  level	  in	  mouse	  and	  human;	  the	  γ2	  form	   presents	   30	   additional	   amino	   acids	   at	   its	   N-­‐terminus	   due	   to	   differential	  promoter	  usage	  within	  the	  same	  gene	  and	  subsequent	  alternative	  RNA	  processing.	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Also,	   the	   localization	   of	   PPARγ2	   is	   primarily	   in	   adipose	   tissue	   while	   PPARγ1	   is	  widely	  expressed	  in	  heart,	  skeletal	  muscle,	  colon,	  small	  and	  large	  intestines,	  kidneys,	  pancreas	  and	  spleen	  [85].	  In	  many	  cell	  types,	  PPARγ	  activation	  has	  anti-­‐tumorigenic	  effects	  probably	  due	  to	  its	  anti-­‐proliferative	  and	  pro-­‐differentiation	  activities	  while	  other	  experiments	  showed	  that	   its	   activation	   could	   cause	   pro-­‐carcinogenic	   effects.	   This	   contrast	   complicates	  any	   absolute	   assumption	   regarding	   the	   phenotypical	   effects	   due	   to	   PPARγ	  activation.	   In	   mouse	   models	   of	   colon	   cancer	   PPARγ	   expression	   is	   increased	   and	  administration	   of	   troglitazone	   in	   xenografted	   animals	   inhibit	   the	   development	   of	  tumors	   derived	   from	   colon	   cancer	   cells	   and	   the	   formation	   of	   colitis	   (also	   an	  inflammatory	  condition),	  a	  risk	  factor	  for	  further	  colorectal	  cancer	  development	  in	  humans.	  Colon	  cancer	  development	  can	  be	  driven	  by	  environmental	  factors	  such	  as	  diet	  and	  lifestyle;	  it	  has	  been	  proposed	  that	  the	  increased	  incidence	  of	  colon	  cancer	  in	  individuals	  with	  high	  fat	  diet	  could	  be	  due	  to	  the	  constant	  activation	  of	  PPARγ	  by	  fatty	   acids	   [80].	   This	   contradictory	   result	   can	   be	   explained	   by	   the	   presence	   of	   an	  APC	  mutation	   in	   colon	   tissues;	   thus,	   an	   early	   treatment	  with	   PPARγ	   agonists	   can	  prevent	  the	  tumorigenic	  process	  while,	  as	  shown	  in	  APCmin	  mice,	  PPARγ	  activation	  after	  tumor	  initiation	  might	  be	  inefficient	  or	  deleterious	  [86].	  APCmin	  mice	  have	  high	  levels	  of	  Pparγ	  in	  the	  colonic	  cells	  and	  are	  inappropriately	  sequestrated	  by	  β-­‐catenin	  to	  a	  unique	  set	  of	  gene	  targets.	  Interestingly,	  PPARα	  ligands	  inhibit	  polyp	  formation	  in	   the	   APCmin	   model	   re-­‐enforcing	   the	   concept	   that	   the	   Thiazolidinediones	   (TZD)-­‐driven	   enhanced	   tumor	   formation	   in	   the	  APCmin	  mouse	   is	   a	  model	   artifact,	   or	   at	  least	  not	  general	  phenomena	  (reviewed	  in	  [68]).	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PPARγ	  agonists	  like	  troglitazone	  have	  been	  successfully	  studied	  in	  breast	  cancer	  for	  the	  prevention	  of	  mammary	  carcinogenesis;	  in	  vivo	  studies	  showed	  that	  this	  ligand	  reduces	  the	  development	  of	  tumors	  derived	  from	  MCF-­‐7	  cell	  line	  in	  nude	  mice,	  while	  GW7845	  prevents	  chemically	  induced	  breast	  carcinogenesis	  in	  rats[77].	  PPARγ	  also	  inhibits	   proliferation	  of	   prostate	   cancer	   cell	   lines	   and	  decreases	   the	   expression	  of	  PSA	   and	   this	   effect	   is	  maintained	   in	   vivo,	   as	   troglitazone	   treatment	   stabilizes	   PSA	  levels	  in	  patients	  with	  advanced	  prostate	  cancer,	  in	  an	  androgen	  dependent	  manner.	  It	  has	  also	  been	  shown	  that	  mutated	  PPARγ	  can	  be	  present	  in	  prostate,	  thyroid	  and	  colon	  cancer	  (reviewed	  in	  [77]);	  all	  of	  these	  mutations	  lead	  to	  a	  decrease	  in	  PPARγ	  activity,	  which	  confirms	  its	  anti-­‐carcinogenic	  effect.	  However,	  the	  frequency	  of	  these	  mutations	  is	  fairly	  low	  and	  the	  loss	  of	  both	  PPARγ	  alleles	  has	  never	  been	  described	  in	  any	  tumours	  so	  far,	  an	  observation	  that	  indicates	  that	  PPARγ	  might	  not	  be	  a	  true	  tumour	  suppressor.	  PPARγ	   is	   a	   potent	   regulator	   of	   cellular	   energy	   homeostasis;	   it	   has	   been	   shown	   to	  increase	  expression	  of	   the	  mitochondrial	  uncoupling	  proteins,	  UPC-­‐1,	   -­‐2	  and	   -­‐3,	   in	  
vitro	  and	  in	  vivo.	  On	  the	  other	  hand,	  it	  downregulates	  leptin	  expression,	  a	  secreted,	  adipocytes	   selective	   protein	   that	   inhibits	   feeding	   and	   augments	   catabolic	   lipid	  metabolism	   [80].	  PPARγ	   agonists	   are	   also	   able	   to	  modulate	   insulin	   action	   through	  inhibition	   of	   TNFα.	   TNFα-­‐induced	   insulin	   resistance	   in	   obese	   rodents	   and	   TNFα	  action	  in	  adipocytes	  in	  vitro	  (reviewed	  in	  [80])	  suggesting	  a	  key	  metabolic	  role	  for	  this	  nuclear	  receptor.	  The	  PPARγ	   pathway	   regulates	   the	   expression	   of	  β-­‐catenin	   upon	   the	  presence	   of	   a	  functional	   APC-­‐β-­‐catenin	   pathway,	   sustaining	   the	   idea	   of	   a	   link	   between	  mutated	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APC	  and	  PPARγ	  activation	  [86];	  in	  pre-­‐adipocytes	  and	  pituitary	  adenoma	  cells	  Pparγ	  activation	   negatively	   regulates	   the	   phosphorylation	   state	   of	   the	   Retinoblastoma	  Protein	   (Rb)	   inducing	   cell	   cycle	   arrest	   and	   S-­‐phase	   entry	  most	   probably	   through	  	  decrease	   expression	   or	   increased	   degradation	   of	   cyclin	   D1	   [77].	   To	   confirm	   the	  control	  exerted	  by	  PPARγ	  on	  the	  cell	  cycle	  it	  has	  been	  shown	  that	  CDKN2C	  (cyclin-­‐dependent	  kinase	   inhibitor	  2C)	  and	  p21waf1/cip1	  expression	  are	  positively	  regulated	  in	  a	   ligand-­‐dependent	  manner	  during	  adipogenesis	  and	   in	  breast	   cancer	  epithelial	  cell	   line	   [87].	   The	   NF-­‐κB	   pathway	   and	   the	   anti-­‐apoptotic	   protein	   Bcl-­‐2	   were	  inhibited	   by	   15-­‐deoxy-­‐PGJ2	   treatment,	   leading	   HT-­‐29	   colon	   cancer	   cell	   line	   to	  apoptosis	  [88]	  suggesting	  a	  PPARγ/Bcl-­‐2	  feedback	  look	  that	  might	  contribute	  to	  life-­‐death	   decision	   in	   colonic	   cells.	   Interestingly,	   in	   primary	  macrophages,	   breast	   and	  pancreatic,	   cancer	   cells	   treatment	  with	   the	  PPARγ	   agonist	   rosiglitazone	   stimulates	  expression	  of	   the	   tumour-­‐suppressor	  gene	  PTEN,	  with	  subsequent	  decreases	  PI3K	  kinase	  activity,	  by	  binding	  of	  PPARγ	  to	  two	  responsive	  elements	  present	  in	  the	  PTEN	  promoter	  [89].	  PPARγ	   ligands	   have	   been	   successfully	   used	   in	   clinical	   trials	   for	   the	   treatment	   of	  liposarcoma;	  however,	  some	  of	  the	  effects	  observed	  in	  cell	  culture	  can	  be	  different	  from	   those	  observed	   in	   clinic	  because	  of	  PPARγ-­‐independent	  events.	   For	  example,	  using	  colon	  cancer	  cells	  as	  a	  model,	  PPARγ	  agonists	  have	  been	  shown	  to	  be	  potent	  anti-­‐tumourigenic	  and	  anti-­‐proliferative	  agents	  but	  most	  of	   them	  can	  be	  beneficial	  only	   in	   the	  early	  steps	  of	  oncogenesis	  due,	   for	  example,	   to	   the	  APC	  background	  of	  colon	  cancer	  cells.	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1.4.3	  -­	  PPARβ/δ	  The	   third	   PPAR	   isotype	   was	   called	   PPARβ	   when	   firstly	   isolated	   from	   Xenopus	  oocytes	   [75],	   but	   the	  mammalian	  Pparβ	   gene	  was	  not	  homologous	   to	   the	  Xenopus	  gene,	  so	  it	  was	  named	  Pparδ	  in	  mouse,	  Faar	  (fatty-­‐acid	  activated	  receptor)	  in	  the	  rat	  and	  NUC1	   in	  humans	  where	   it	   is	   located	  on	   the	   chromosome	  6	   in	  position	  p21.1-­‐p21.2.	   Currently	   they	   are	   considered	   orthologues	   and	   are	   commonly	   named	   as	  PPARβ/δ	  [77].	  As	   the	   other	   PPARs,	   PPARβ/δ	   can	   be	   activated	   by	   prostaglandins	   as	   COX-­‐2	   again	  plays	   a	   key	   role	   to	   catalyze	   the	   rate	   limiting	   step	   in	   the	   production	   of	   ligands,	  including	  the	  prostacyclin	  eicosanoid	  that	  appears	  to	  serve	  as	  the	  natural	  agonist	  for	  PPARβ/δ.	   PPARβ/δ	   is	   expressed	   in	   the	   implantation	   sites	   within	   the	   uterus	   and	  strongly	  upregulated	  during	  the	  decidualization	  process	  in	  a	  manner	  similar	  to	  COX-­‐2	   [90].	   On	   the	   other	   hand	   Cox-­‐2	   null	   female	  mice	   display	   decreased	   fecundity,	   in	  part	   due	   to	   decreased	   blastocyte	   implantation,	   and,	   when	   Cox-­‐2	   null	   mice	   were	  treated	  with	   carboprostacyclin	  or	   the	  PPARβ/δ	   ligand	  L-­‐165041,	   the	   implantation	  was	  restored	  [90].	  PPARβ/δ	  is	  also	  expressed	  at	  high	  levels	  in	  the	  rat	  CNS	  at	  E18.5	  [79]	   suggesting	   that	   it	   might	   play	   a	   critical	   role	   in	   regulating	   neurogenesis	   and	  neuronal	  differentiation	  suggesting	  a	  possible	  cross-­‐talk	  with	  the	  RAR	  signalling.	  PPARβ/δ	   is	   also	   passively	   regulated	   by	   the	   APC/β-­‐catenin	   pathway	   in	   colorectal	  cancer	   cells	   where	   its	   levels	   are	   elevated;	   this	   repression	   occurs	   either	   through	  binding	   of	   the	   β-­‐catenin/TCF4	   complex	   on	   the	   PPARβ/δ	   promoter	   or	   through	  treatment	   with	   NSAID	   that	   disrupts	   the	   ability	   of	   the	   receptor	   to	   bind	   to	   its	  responsive	   elements	   [91].	   These	   results	   confirm	   the	   involvement	   of	   COX-­‐2	   in	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colorectal	  cancer	  where	  it	  can	  produce	  PPARβ/δ	  agonists	  like	  Prostaglandin	  I2	  [91]	  whereas	  lowering	  cyclooxigenase	  activity	  via	  Non-­‐Steroid	  Anti-­‐Inflammatory	  Drugs	  (NSAID)	   leads	   to	   beneficial	   outcomes.	   In	   a	   PPARβ/δ-­‐null	   colorectal	   cancer	   cell	  xenograft	   model	   tumorigenesis	   was	   decreased	   as	   well	   as	   polyp	   formation	   in	  Apcmin/Pparβ/δ-­‐null	  mice	   [92]	  suggesting	  multiple	   links	  with	   the	  APC	  pathway	  on	  PPAR	  signalling	  in	  colon	  cancer	  tumour	  progression.	  PPARβ/δ	  exerts	  its	  anti-­‐apoptotic	  function	  through	  increased	  expression	  of	  ILK	  and	  
PDK1	   to	   control	   cell	   adhesion,	   proliferation	   and	   survival;	   ILK	   and	   PDK1	   in	   turn	  phosphorylate	  and	  activate	  the	  survival	  factor	  AKT1	  [93].	  Therefore	  it	  is	  likely	  that	  this	  PPARβ/δ	  promotes	  cell	  viability	  in	  other	  cell	  lines	  too.	  	  
1.5	  –	  FIBRATES	  AND	  BEZAFIBRATE	  Fibrates	  are	  a	   class	  of	   amphipathic	   carboxylic	   acids	  mainly	  used	  as	  hypolipidemic	  compounds;	  it	  is	  well	  established	  that	  treatment	  with	  fibrates	  results	  in	  substantial	  decreases	  in	  triglyceride	  levels	  associated	  with	  a	  moderate	  increase	  in	  high-­‐density	  lipoprotein	  cholesterol	  (HDL-­‐C)	  levels	  and	  usually	  a	  small	  reduction	  in	  low-­‐density	  lipoprotein	   cholesterol	   (LDL-­‐C)	   levels.	   Clinical	   trials	   demonstrated	   that	   fibrate	  therapy	   improves	   both	   insulin	   sensitivity	   as	   blood	   lipid	   profiles	   thereby	  significantly	  attenuating	  the	  risk	  of	  long	  term	  major	  cardiovascular	  events	  [94].	  Bezafibrate	  was	  the	  first	  PPARα	  and	  -­‐γ	  agonist	  clinically	  tested	  [95,	  96]	  and	  it’s	  the	  sole	   PPAR	   activator	   with	   more	   than	   a	   quarter	   of	   a	   century	   of	   a	   therapeutic	  experience	  with	  a	  good	  safety	  profile.	  The	  beneficial	  effects	  of	  bezafibrate	  treatment	  were	   confirmed	   in	   the	   BIP	   (Bezafibrate	   Infarction	   Prevention)	   study	  where	   3090	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patients	  treated	  with	  400	  mg/day	  of	  bezafibrate	  showed	  that,	  especially	  those	  with	  high	  triglycerides	  levels	  (>200	  mg/dL),	  had	  a	  40%	  reduction	  of	  coronary	  risk	  after	  five	  years	  of	  medication	  [97].	  Patients	  in	  this	  trial	  treated	  with	  bezafibrate	  showed	  also	   a	   lower	   incidence	   of	   type	   2	   diabetes,	  moreover	   the	  mean	   time	   until	   onset	   of	  new	  diabetes	  was	  significantly	  delayed	  among	  the	  treated	  group	  with	  a	  significant	  30%	   reduction	   risk	   of	   new	   diabetes	   development.	   As	   insulin	   resistance	   is	  considered	   to	   occur	   before	   the	   appearance	   of	   diabetes,	   it	   is	   important	   to	   know	  whether	   a	   drug	   can	   prevent	   it	   or	   not.	   With	   this	   purpose,	   in	   vivo	   experiments	  demonstrated	  that	  bezafibrate-­‐treated	  overweight	  mice	  fed	  with	  a	  high-­‐fat-­‐sucrose	  diet	   had	   improved	   glucose	   tolerance	   and	   decreased	   body	   weight	   reducing	  adipocytes	   volume	   in	   most	   of	   the	   body	   [98].	   The	   mechanism	   through	   which	  bezafibrate	   lowers	   triglycerides	   levels	   was	   shown	   to	   be	   mediated	   by	   PPARα	  activation	   and	   PPARα-­‐independent	   downregulation	   of	   the	   transcription	   factor	  sterol	   regulatory	   element-­‐binding	   protein	   (SREBP)-­‐1c	   in	   mice,	   reducing	   sterols	  biosynthesis	  [99]	  and	  overall	  enhancing	  lipid	  metabolism.	  	  As	   PPAR	   signalling	   pathway	   appears	   to	   be	   involved	   in	   either	   proliferation	   or	  survival	  of	  malignant	  cells,	  several	  studies	  have	  been	  undertaken	  to	  profile	  the	  anti-­‐tumorigenic	   and	   preventive	   effect	   of	   fibrates	   on	   cancer	   cells.	   For	   example	   in	  glioblastoma	  cell	   lines	  bezafibrate,	  as	  well	  as	  ciglitazone	  and	  gemfibrozil,	   inhibited	  viability	   and	   induce	   cell	   cycle	   arrest	   throughout	   the	   re-­‐expression	   of	   the	   cyclins	  p27(Kip1)	   and	  p21(waf1/cip1)	   [100].	   In	  other	   studies	  bezafibrate	  has	  been	   successfully	  used	  in	  association	  with	  other	  drugs	  such	  as	  medroxyprogesterone	  acetate	  (MPA)	  in	  B-­‐cell	  chronic	  lymphocytic	  leukemia	  (CLL)	  [101]	  and	  acute	  myeloid	  leukemia	  (AML)	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[102]	  or	  with	  the	  NSAID	  nimesulide	  in	  colon	  cancer	  [103].	  Ogawa	  et	  al	  instead	  used	  bezafibrate	  in	  combination	  with	  tamoxifen	  in	  breast-­‐cancer	  patients	  to	  prevent	  non-­‐alcoholic	   steatohepatitis	   (NASH)	   induced	   by	   tamoxifen	   treatment,	   preventing	  further	  liver	  damage	  [104].	  	  	  
1.6	  –	  CO-­REPRESSORS	  ACTIVITY	  IN	  PHYSIOLOGY	  AND	  DISEASE	  Prostate	  development,	  as	  well	  as	  prostate	  tumourigenesis,	  is	  mediated	  by	  key	  genes	  (described	   above)	   whose	   transcription	   is	   regulated	   by	   a	   cohort	   of	   transcription	  factors	  and	  co-­‐regulator	  complexes.	  	  In	   the	   next	   section	   the	   key	   corepressors	   of	   the	   transcriptional	  machinery	  will	   be	  described	   to	   give	   an	   overview	   of	   their	   function	   in	   physiology	   and	   disease	   and	  illustrate	   some	   of	   the	   potential	   epigenetic	  mechanisms	   that	  may	   be	   important	   to	  cancer	  development.	  	  
1.6.1	  -­	  Co-­repressor	  proteins	  limit	  transcription	  factor	  actions.	  	  
Transcription	  factors	  in	  gene	  regulation	  The	  principal	  co-­‐repressor	  proteins	  were	  described	   for	   their	   capacity	   either	   to	   attenuate	   or	   suppress	   the	   transactivation	  function	   of	   transcription	   factors	   via	   epigenetic	   mechanisms.	   Among	   the	  transcription	  factors	  discovered,	  the	  superfamily	  of	  nuclear	  receptors	  (NRs)	  plays	  a	  key	   role	   in	   silencing	   or	   activating	   transcription	   of	   target	   genes	   involved	   in	  metabolism,	  development	  and	  reproduction	  [105].	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1.6.2	   -­	  Co-­repressors	   form	  a	  structurally	  diverse	  super-­family	  of	   functionally	  
related	  proteins	  
Different	   co-­‐repressor	   complexes	   share	   the	   same	   common	   endpoint	   in	   silencing	  gene	   transcription.	   Three	   of	   these	   complexes,	   Sin3,	   Mi2/NuRD	   and	   CoREST,	   are	  highly	  conserved	  among	  C.	  elegans,	  Drosophila	  melanogaster	  and	  vertebrates,	  while	  the	  NCOR2/SMRT	  complex	  resembles	  the	  components	  found	  only	  in	  Drosphila;	  they	  commonly	   recruit	   class	   I	   and	   class	   II	   histone	   deacetylases	   [106]	   modifying	   the	  chromatin	   three-­‐dimensional	   structure	   and	   its	   accessibility	   from	   transcription	  factors.	  	  
	  
1.6.2.1	  -­	  NCOR	  and	  NCOR2/SMRT	  
Cloning	   and	   structure.	   NCOR1,	   (Nuclear	   Co-­‐Repressor-­‐1)	   can	   be	   considered	   a	  proto-­‐typical	  co-­‐repressor	  and	  was	  described	  in	  1995	  by	  Rosenfeld	  and	  co-­‐workers.	  They	   used	   a	   yeast	   two-­‐hybrid	   approach	   to	   identify	   a	   270KDa	   protein	   (initially	  termed	   p270),	   which	   associates	   with	   DNA-­‐bound	   TR/RXR	   heterodimers,	   in	   the	  absence	   of	   thyroid	   hormone,	   but	   not	   in	   its	   presence[107].	   Subsequently	   human	  NCOR1	  was	  located	  to	  the	  small	  arm	  of	  the	  chromosome	  17	  (17p11.2)	  [108].	  Using	  a	  similar	   approach	   Chen	   et	   al	   isolated	   NCOR2/SMRT	   as	   a	   co-­‐repressor	   in	   RAR-­‐mediated	   repression	   of	   target	   genes	   [27].	   Human	   NCOR2/SMRT	   similarly	   has	   a	  molecular	  mass	  of	  273	  KDa	  and	  is	  located	  on	  chromosome	  12	  in	  position	  q24.	  	  
NCOR2/SMRT	  also	  encodes	  a	  2524-­‐aa	  protein	  that	  is	  related	  to	  the	  C-­‐terminal	  half	  of	  NCOR1	  [109].	  An	  N-­‐terminal	  domain,	  named	  NCOR2/SMRTe	  and	  NCOR1	  conserved	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(SNC)	   domain,	   between	   amino	   acids	   166	  and	   429	  is	   strikingly	   conserved	   between	  NCOR2/SMRT	  and	  NCOR1	  (86%	  identity	  and	  91%	  similarity).	  At	  the	  N	  terminus	  of	  the	   SNC	   domain,	   lays	   an	   amphipathic	   helix	   containing	   five	   hydrophobic	   heptad	  repeats.	  The	  SNC	  domain	  is	  followed	  by	  two	  conserved	  repeats	  known	  as	  the	  SANT	  domains.	   The	   two	   SANT	   (SWI3,	   ADA2,	   NCOR1	   and	   TFIIIB	   B)	   motifs	   are	   only	  marginally	  related	  to	  one	  another	  within	  the	  same	  protein	  (30%	  identity),	  whereas	  the	  individual	  motif	  is	  highly	  conserved	  between	  NCOR2/SMRT	  and	  NCOR1	  in	  both	  the	   human	   and	   mouse	   origins	   (>75%	   identity)	   [109].	   Two	   SANT	   DNA-­‐binding	  domains	  are	  present	  between	   the	   residues	  440-­‐488	  and	  627-­‐674	   [110];	  while	   the	  first	  SANT	  domain	  (SANT1)	   is	  dispensable,	  SANT2	   is	  essential	   for	   interaction	  with	  HDAC3	   [111].	   Other	   groups	   described	   the	   importance	   of	   these	   domains	   in	   the	  interaction	   with	   HDAC1	   [112,	   113]	   and	   in	   CoREST-­‐mediated	   neuronal	   gene	  regulation	   [113].	   NCOR1	   interacts	   with	   the	   otherwise	   inert	   HDAC3	   via	   the	  deacetylase	   interaction	  domain	  (DAD)	   located	  between	  amino	  acids	  313	  and	  1445	  [111];	   compared	  with	   the	  SANT	  domains	   this	   region	  has	   an	  additional	  N-­‐terminal	  helix	  and	  a	  significant	  difference	  in	  the	  angle	  of	  helix	  3	  that	  results	  in	  the	  formation	  of	  a	  nonpolar	  cleft	  on	  the	  surface	  of	  the	  domain	  [114].	  	  
Also,	   both	   NCOR1	   and	   NCOR2/SMRT	   contain	   three	   to	   four	   repression	   domains	  (RD1-­‐3)	  [109,	  115-­‐117]	  at	  the	  N-­‐terminal	  region;	  more	  precisely	  in	  NCOR1	  RD1	  and	  RD4	  are	  involved	  in	  the	  interaction	  with	  TBL1	  and	  TBLR1	  [118],	  two	  very	  small	  and	  highly	   related	   proteins	   containing	   a	   WD-­‐40	   repeats	   region	   and	   present	   in	   the	  corepressor	  complex.	  TBL1	  also	  interact	  through	  RD1	  with	  SMRT	  and	  RD2	  region	  is	  instead	   the	   bridge	   that	   connects	   HDAC3	   to	   both	   corepressors	   [119].	   Those	   two	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regions	   share	   45%	   of	   identity	   between	  NCOR1	   and	  NCOR2/SMRT	   supporting	   the	  idea	   of	   a	   functional	   conservation	   [120],	   and	   further	   supporting	   the	   concept	   that	  these	   large	   proteins	   act	   as	   facilitative	   central	   hubs	   in	   order	   to	   recruit	   other	  components	  of	  the	  corepressor	  complexes.	  	  
Complexes	  and	  function.	  NCOR1	  is	  able	  to	  form	  complexes	  with	  a	  very	  wide	  range	  of	   transcription	   factors	   and	   coregulator	   proteins,	   including	   Mad/Mxi,	   MyoD,	  BCL6/LAZ3,	  AML1-­‐ETO,	  CBF,	  TFIIB	  and	  REST/NRSF	  (reviewed	  in	  [121]),	  generally	  repressing	   transcription	   of	   target	   gene.	   Once	   activated,	   the	   target	   transcription	  factor	   displaces	   the	   corepressor	   complex	   in	   favor	   of	   the	   coactivator	   complex.	  Interaction	   between	   NRs	   and	   NCOR1	   involves	   remodeling	   of	   the	   trans-­‐activation	  domain	   AF2	   contained	   in	   the	   helix	   12;	   this	   structure	   can	   be	   next	   to	   the	   ligand-­‐binding	  domain	  (LBD)	   in	   the	  case	  of	  RAR-­‐alpha,	  TR-­‐beta,	  ER	  and	  PPAR-­‐gamma,	  or	  far	  away	  in	  the	  case	  of	  RXR	  (reviewed	  in	  [121]).	  Binding	  of	  the	  co-­‐repressor	  motif	  is	  further	  reinforced	  by	  antagonist	  binding,	  which	  blocks	  the	  AF2	  helix	  from	  adopting	  the	   active	   position	   [122];	   instead,	   when	   the	   AF2	   helix	   is	   in	   ligand-­‐bound	  conformation	  NCOR1	  and	  NCOR2/SMRT	  do	  not	   interact	  with	   the	  LBD.	   It	  has	  been	  proposed	  that	  co-­‐repressor/co-­‐activator	  exchange	  upon	  ligand	  binding	  is	  caused	  by	  the	  difference	   in	   length	  of	   the	   interacting	  motifs	   that	  can	  be	  accommodated	   in	   the	  binding	   pocket	   in	   the	   apo-­‐	   (unliganded)	   and	   holo-­‐	   (ligand-­‐bound)	   conformations	  [123].	   Co-­‐Activator	   interactions	   happen	   via	   the	   Leu-­‐x-­‐x-­‐Leu-­‐Leu	  motif,	   called	   “NR	  box”	   [121].	   There	   are	   three	   different	   Interaction	  Domains	   (IDs)	   in	  NCOR1	   (N1-­‐3)	  and	  NCOR2/SMRT	  (S1-­‐3),	  they	  contain	  similar	  motifs	  to	  the	  coactivators	  NR	  box	  and	  are	  named	  “CoRNR	  box”.	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The	   spacing	   of	   the	   NR	   responsive	   elements	   in	   the	   heterodimer	   determines	   the	  interaction	   with	   the	   1-­‐box	   NCOR2/SMRT	   isoforms,	   this	   binds	   TRα/RXRβ	   DR-­‐4,	  VDR/RXRβ	  DR-­‐3	  and	  RARα/RXRβ	  DR-­‐5	  complexes;	  the	  2-­‐box	  isoforms	  bind	  mostly	  TRα/RXRβ	  and	  TRβ/RXRα	   [124]	  heterocomplex;	   the	  3-­‐box	   isoforms	  bind	  NR-­‐DNA	  complexes	   weakly,	   with	   two	   exceptions:	   the	   “all-­‐exons”	   isoforms	   preferentially	  binds	   TRα/RXRβ	   and	   the	   Δ45b	   isoforms	   preferentially	   binds	   the	   VDR/RXRβ	  complex	   [125].	   Disruption	   of	   any	   of	   the	   CoRNR	   boxes	   in	   both	   NCOR1	   and	  NCOR2/SMRT	  does	  not	  abolish	   the	   interaction	  with	  TRα;	   in	  case	  of	  RARα	   instead,	  over	   that	   a	   higher	   affinity	   for	   NCOR2/SMRT,	   the	   disruption	   of	   any	   CoRNR	   box	   in	  either	  CoRs	   leads	   to	   a	   significantly	   reduced	   interaction	  with	  RARα,	   particularly	   in	  case	   of	   NCOR1	   [126].	  Within	   the	   three	   NCOR1	   interaction	   domains	   (N1-­‐3)	   it	   has	  been	  shown	  that	  N2	  is	  important	  for	  the	  binding	  of	  the	  corepressor	  with	  TRβ1	  but	  the	  specificity	  of	   this	   interaction	   is	  dictated	  by	  N3	   in	  vivo	   [127].	  This	  receptor	  has	  also	  been	  shown	  to	  bind	  NCOR1	  through	  three	  interaction	  domains,	  where	  each	  ID	  motif	   contains	   a	   conserved	   hydrophobic	   core	   (I/LXXII)	   that	   resembles	   the	  hydrophobic	  core	  of	  NR	  boxes	  (LXXLL)	   that	  mediates	  p160	  co-­‐activator	  binding	   to	  the	   liganded	  state	   [128].	  Hu	  et	  al	   established	   that	   these	  CoRNR	  (CoRepressor	  NR)	  boxes	   are	   required	   for	   NR	   interaction,	   and	   that	   CoRNR	   box	   peptides	   specifically	  block	  co-­‐repressor	  interactions	  in	  vitro	  and	  repression	  in	  vivo	  [129].	  	  
An	  interesting	  example	  of	  NCOR1	  mediated	  trans-­‐repression	  of	  positively	  regulated	  genes	  is	  NCOR1	  binding	  to	  PPAR-­‐γ	  that	  involves	  a	  ligand-­‐dependent	  sumoylation	  of	  the	   PPAR-­‐γ	   ligand-­‐binding	   domain,	   which	   targets	   PPARγ	   to	   NCOR1/HDAC3	  complexes	   on	   promoters	   of	   genes	   target.	   This	   prevents	   recruitment	   of	   the	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ubiquitylation/19S	   proteasome	   and	   NCOR1	   clearing	   from	   the	   promoter	   region	  [130].	  
Epigenetic	  mechanisms	  of	  NCOR1-­‐mediated	  gene	  silencing	  also	   involve	   interaction	  with	   the	   protein,	   Kaiso,	   a	  methylation	   dependent	   transcriptional	   repressor	   [131].	  This	   protein	   was	   found	   in	   the	   immunopurified	   NCOR1	   but	   not	   in	   NCOR2/SMRT	  complex	  and	  also	  doesn’t	  bind	  other	  key	  components	  of	  the	  repression	  complex	  as	  TBL1/TBLR1	  or	  HDAC3.	  Interaction	  between	  the	  POZ	  domain	  in	  Kaiso	  and	  the	  RD1	  repression	  domain	   in	  NCOR1	   allows	   this	   complex	   to	   interact	  with	   the	  methylated	  CpGs	  present	  in	  the	  promoter	  of	  target	  genes,	  silencing	  their	  transcription	  [132].	  
Due	   to	   the	  complex	  system	   involved	   in	  gene	  regulation,	   inhibition	  of	   transcription	  cannot	  be	  view	  as	  a	  static	  mechanism.	  An	  example	  of	  this	  dynamic	  machinery	  is	  the	  recruitment	   of	   corepressor	   complexes	   on	   the	   promoter	   region	   of	   inflammatory	  genes.	   After	   TNF-­‐α	   treatment	   a	   time-­‐dependent	   binding	   of	   NCOR1/HDAC3	   and	  NCOR2/SMRT/HDAC1	  complexes	  switch	  on	  the	  promoter	  region	  of	  IκBβ	  every	  30-­‐60	   minutes,	   similar	   to	   the	   pattern	   registered	   for	   SRC-­‐1	   and	   -­‐2	   whereas	   SRC-­‐3	  recruitment	  oscillated	  between	  two	  peaks	  at	  30	  and	  120	  minutes	  [133,	  134].	  	  
NCOR1	  is	  subjected	  to	  several	  post-­‐translational	  modifications;	  it	  has	  been	  reported	  that	   phosphorylated	   NCOR1	   and	   NCOR2/SMRT	   can	   be	   translocated	   from	   the	  nucleus	  into	  the	  cytoplasm	  in	  colon	  cancer	  [135]	  .	  
Embryo	  development,	  as	  cell	  differentiation,	  require	  a	  precise	  network	  of	  regulatory	  elements,	  many	  of	  which	  appear	  to	  be	  modulated	  by	  NCOR1	  and	  NCOR2/SMRT.	  In	  the	  case	  of	  adipocytes	  differentiation	  PPAR-­‐γ	  has	  been	  shown	  to	  drive	  this	  process	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upon	   ligand	   binding	   but	   its	   activity	   is	   dependent	   on	  NCOR1	   expression;	   lowering	  levels	   of	   NCOR1	   or	   NCOR2/SMRT	   leads	   to	   an	   increased	   expression	   of	   adipocyte-­‐specific	  genes	  and	  proteins	  suggesting	  that	  NR	  corepressors	  modulate	  adipogenesis	  via	  effects	  on	  PPAR	  gamma	  activity	  [136].	  	  
Differentiation	   of	   neural	   stem	   cells	   into	   astrocytes	   is	   highly	   Ncor1-­‐dependent;	  Hermanson	   et	   al	   demonstrated	   that	  Ncor1	   is	   a	   principal	   regulator	   in	   neural	   stem	  cells.	   Ncor1-­‐disrupted	   mice	   display	   impaired	   self-­‐renewal	   and	   spontaneous	  differentiation	   in	  astroglia-­‐like	  cells	   [137].	   In-­vivo	   experiments	  showed	   that	  Ncor1	  also	   exerts	   critical	   roles	   at	   specific	   steps	   in	   erythroid,	   thymocyte,	   central	   nervous	  system	  (CNS)	  development	  and	  haematopoietic	  differentiation;	  knockout	  mice	  show	  severe	  anemia	  and	  secondary	  edema,	  embryos	  are	  generally	  smaller	  than	  wild	  type.	  Ncor1−/−	   mice	   generally	   die	   at	   day	   15.5	   of	   gestation	   with	   just	   a	   few	   occasionally	  surviving	  a	  couple	  of	  days	  longer	  [138].	  
Ncor2/Smrt	   knock-­‐out	   is	   also	   lethal;	   Ncor2/Smrt−/−	   embryos	   generally	   die	   at	   ED	  16.5	   because	   of	   heart	   defects	   and	   present	   noticeable	   differences	   in	   CNS	  development.	   This	   is	   partially	   due	   to	   the	   activity	   of	   Jmjd3,	   a	   putative	   histone	  demethylase,	   responsible	   for	   demethylating	  H3K27me3	  during	  neuronal	   stem	   cell	  differentiation;	   its	  expression	   is	  promoted	  by	  RA	  (Retinoic	  Acid)	   in	  neuronal	  stem	  cells	   and	   de-­‐repressed	   by	   Ncor2/Smrt	   knock-­‐out	   demonstrating	   a	   Ncor2/Smrt-­‐dependent,	   RA-­‐receptor-­‐mediated	   regulation	   of	   this	   process	   [139].	   Nonetheless	  Ncor2/Smrt	   regulates	  with	   Foxp1,	   a	   forkhead	   protein	   that	   acts	   as	   transcriptional	  repressor,	  a	  cohort	  of	  genes	  necessary	  for	  a	  proper	  myocardial	  development.	  In	  wild	  type	  hearts	  Ncor2/Smrt	  and	  Foxp1	  are	  detected	   in	   the	  Cdkn1a	  promoter	   together	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with	   H3K9me2	   (mark	   associated	  with	   Cdkn1a	   repression	   [140,	   141])	   whether	   in	  both	   knockouts	   p21	   levels	   are	   elevated,	   leading	   to	   a	   block	   of	   proliferation	   and	  thinned	  myocardium	  [142].	  
An	  initial	  clue	  regarding	  NCOR1	  role	  in	  prostate	  cancer	  was	  revealed	  by	  Ting	  et	  al.	  publishing	   that	   NCOR1	   mediates	   VDR	   activation	   in	   different	   CWR22s	   prostate	  cancer	  cell	  line.	  The	  AR-­‐NCOR1	  interaction	  is	  key	  for	  the	  regulation	  of	  the	  androgen	  signaling,	  that	  is	  corrupted	  in	  prostate	  cancer.	  Hodgson	  et	  al.	  demonstrated	  that	  the	  AR-­‐antagonist	  Mifepristone	  (currently	  used	  in	  prostate	  cancer	  treatment)	  efficiently	  enhances	   this	   interaction	   at	   nanomolar	   concentrations	   [143]	   while	   other	  demonstrated	   that	   this	   interaction	   is	   already	   present	   in	   prostate	   cancer	   cell	   lines	  [144].	  
Based	  on	   these	  results	   it	   is	  possible	   to	  assume	   that	  NCOR1	  and	  NCOR2/SMRT	  are	  involved	   in	   several	   steps	  moving	   from	   totipotent	   stem	   cell	   towards	   differentiated	  organ	   with	   similarities	   among	   different	   tissues.	   Similarities	   are	   also	   present	  between	   cell	   differentiation	   and	   tumourigenesis	   processes	   and	   lies	   in	   the	   loss	   of	  gene	  regulation	  in	  malignancies.	  
	  
1.6.2.2	  -­	  CoREST	  	  
Cloning	   and	   structure:	   REST/NRSF	   (RE1	   silencing	   transcription	   factor/neural-­‐restrictive	   silencing	   factor)	   functions	   to	   block	   expression	   of	   its	   target	   genes,	  primarily	   type	   II	   sodium	   channels	   [145].	   These	   actions	   are	   mediated	   through	  interactions	  at	  the	  C-­‐terminal	  with	  a	  482-­‐aa	  protein	  named	  CoREST,	  which	  contains	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two	  50-­‐aa	  SANT	  domains	  separated	  by	  191aa	  and	  it	  is	  present	  in	  a	  wide	  variety	  of	  both	  neural	  and	  non-­‐neural	  cell	  types.	  Further,	  REST/NRSF	  is	  able	  to	  interact	  with	  a	  small	   C-­‐terminal	   fragment	   containing	   a	   zinc	   finger	  motif	   that	  mediates	   repressor	  activity	  [110].	  Most	  corepressors	  are	  found	  complexed	  with	  chromatin	  remodelling	  enzymes;	  in	  this	  case	  it	  has	  been	  shown	  that	  CoREST	  interacts	  with	  HDAC1	  through	  an	  ELM2	  domain	  [146].	  
Complexes	  and	  activity:	  CoREST	  is	  part	  of	  a	  multiprotein	  complex,	  termed	  BHC	  or	  BRAF-­‐HDAC	   [147],	   together	   with	   HDAC1,	   -­‐2,	   BHC80,	   BRAF35	   and	   LSD1	   (or	  BHC110),	   which	   is	   responsible	   for	   demethylating	   [148]	   mono-­‐	   and	   di-­‐	   methyl	  histone	   H3	   lysine	   4	   (H3K4)	   or	   lysine	   9	   (H3K9)	   (thereby	   de-­‐repressing	   AR	   target	  genes	  [149]).	  Together	  with	  LSD1,	  CoREST	  regulates	  transcriptional	  activity	  of	  Gfi-­‐1	  and	  Gfi-­‐1b	  (Growth	  factor	   independence	  -­‐1,	   -­‐1b),	  zinc	   finger	  repressors	  critical	   for	  various	   developmental	   processes.	   Any	   interaction	   occurs	   through	   the	   repression	  SNAG	  domains	  located	  at	  their	  N-­‐termini.	   It	  has	  also	  been	  shown	  that	  reduction	  of	  CoREST	   levels	   leads	   to	   increased	  expression	  of	  REST	   target	   genes	  and	   to	  a	  nearly	  fourfold	  increase	  of	  H3K4	  methylation	  [150].	  	  
The	  CoREST	   complex	   is	   also	   involved	   in	   the	  neoplastic	   transformation	   controlling	  key	   players	   of	   cell	   proliferation	   and	   immortalization.	   A	   component	   of	   this	  corepressor	   complex	   is	   ZNF217;	   this	   gene	   codes	   for	   a	   Kuppel-­‐like	   transcription	  factor	   and	   is	   a	   strong	   candidate	   oncogene	   found	   in	   breast	   cancer	   at	   the	   20q13.2	  amplicon	   [151].	   The	   CoREST/ZNF217	   complex	   has	   been	   found	   to	   sit	   on	   the	  promoter	  region	  of	  the	  p15INK4b	  gene	  [152];	  this	  is	  a	  member	  of	  the	  INK4	  family	  of	  CDKI	   that	   causes	   cell	   cycle	   arrest	   directly	   inhibiting	   CDK4	   and	   -­‐6	   and	   its	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loss/mutation	  has	  been	  reported	  in	  several	  cancers	  [153-­‐155].	  Downregulation	  via	  siRNA	   of	   ZNF217	   and	   TGF-­‐β	   treatment,	   that	   causes	   promoter	   release	   of	   ZNF217,	  mirror	   their	   effects	   with	   the	   upregulation	   of	   p15INK4	   [152]	   facilitating	   its	  transcriptional	   reactivation.	   CoREST	   contributes	   to	   the	   control	   of	   telomerase	  activity	   through	   repression	   of	   hTERT	   [156].	   This	   suggests	   a	   role	   for	   CoREST	   as	   a	  bridge	   between	   HDACs	   and	   LSD1	   in	   modulating	   histone	   modifications	   and	   gene	  repression	   in	   normal	   cells	   and	   contributing	   to	   the	   immortalization	   process	   in	  malignancies.	  
Another	   mechanism	   widely	   used	   to	   stably	   silence	   gene	   expression	   is	   DNA	  methylation	   at	   CpG	   islands;	  MeCP2	   specifically	   recognise	   symmetrical	  methylated	  CpG	   pairs	   [157,	   158].	   Lack	   of	   MeCP2	   leads	   to	   increased	   levels	   of	   CoREST	   and	  subsequent	  repression	  of	  the	  target	  genes	  such	  as	  the	  neurotrophic	  factor	  BDNF.	  
CoREST	  is	  involved	  in	  a	  so-­‐called	  “reversible	  repression”	  where	  it	  participates	  in	  the	  recognition	  of	  methylated	  DNA	  and	  histone	  lysines	  in	  an	  active	  locus	  and,	  recruiting	  MeCP2,	   LSD1	   and/or	   other	   histone	   modifiers,	   like	   HDACs,	   promotes	   a	   tight	  chromatin	  structure	  leading	  to	  an	  active	  repression	  [159].	  
	  
1.6.2.4	  -­	  LCOR	  	  
Cloning	  and	  structure:	  LCOR	  was	  firstly	  isolated	  from	  a	  fetal	  brain	  c-­‐DNA	  library	  in	  2001	  with	  a	  1299bp	  open	  reading	   frame	   fragment	   (433	  amino	  acids,	  47.006	  kDa)	  was	   named	   KIAA1795	   [160].	   The	   LCOR	   gene	   is	   located	   at	   the	   long	   arm	   of	   the	  chromosome	  10	  (10q24.1)	  covering	  4.8	  kb	  of	  cDNA	  sequence	  encompassing	  seven	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exons	   and	   including	   four	   5’UTR	   exons	   that	   contain	   several	   in-­‐frame	   stop	   codons.	  Structurally	  LCOR	  presents	  a	   single	  NR	  box	   (LXXLL	  motif)	   that	   is	  essential	   for	   the	  interaction	  with	  NR	  such	  as	  ERα.	  It	  also	  contains	  a	  PRKKRGR	  motif	  at	  position	  339	  that	  is	  homologous	  to	  a	  nuclear	  localization	  signal	  (NLS)	  of	  the	  SV40	  large	  T	  antigen-­‐type	  and	  lies	  at	  the	  N-­‐terminus	  of	  a	  putative	  helix-­‐loop-­‐helix	  domain.	  LCOR	  contains	  a	   consensus	   leptomycin	   B-­‐sensitive	   nuclear	   export	   signal	   at	   position	   149-­‐164	  suggesting	   that	   its	   access	   to	   transcription	   factors	   could	   be	   regulated	   by	   nuclear	  export	   under	   certain	   conditions	   [161]	   as	   demonstrated	   for	   NCOR1-­‐NF-­‐κB	  interaction	  [162].	  
Complexes	  and	   function:	  LCOR	   is	  mostly	   expressed	   in	  placenta,	  predominantly	   in	  the	  syncytiotrophoblasts,	   the	   layer	  where	  ER	  resides	  as	  well	  as	  progesterone	  (PR)	  and	   glucocorticoids	   (GR)	   receptors.	   This	   region	   represents	   a	   barrier	   between	  maternal	  and	  fetal	  circulation	  and	  a	  key	  site	  for	  hormone	  signalling,	  catabolism	  and	  biosynthesis	   [163].	   LCOR	   could	   then	   act	   as	   a	   modulator	   of	   transcription	   factor	  signalling	  in	  a	  place	  where	  waves	  of	  endogenous	  hormones	  continuously	  stimulate	  NR.	   Consistent	  with	   this	   hypothesis,	   LCOR	   has	   been	   proven	   to	   associate	  with	   the	  LBD	  of	  a	  range	  of	  nuclear	  receptors	  including	  ERα,	  VDR,	  RARα,	  -­‐ß	  and	  -­‐γ	  and	  GR	  in	  a	  ligand-­‐dependent	  manner.	  LCOR	  binds	  the	  AF-­‐2	  domain	  of	  ERα,	  and	  recognises	  the	  helix-­‐3	   where	   TIF-­‐2	   (or	   NCoA-­‐2,	   Nuclear	   CoActivator-­‐2)	   associates,	   suggesting	   a	  possible	  competition	  for	  that	  site.	  	  
LCOR	  could	  exert	  part	  of	  its	  repression	  activity	  through	  direct	  interaction	  with	  its	  C-­‐terminal	   part	   and	   HDAC-­‐3	   and	   -­‐6.	   Interestingly	   HDAC-­‐3	   is	   present	   in	   NCOR1	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complexes	   and	   this	   could	   suggest	   a	   cross-­‐talk	   or	   cooperation	   between	   these	   two	  corepressors.	   However,	   TSA	   treatment	   does	   not	   completely	   relieve	   VDR	   or	   PR	  LCOR-­‐mediate	  repression	  and	  so	  other	  mechanisms	  might	  be	  involved.	  
	  
1.6.2.6	  -­	  RIP140	  	  
Cloning	  and	  Structure:	  The	  receptor-­‐interacting	  protein-­‐140	  (RIP140),	   located	  on	  21q11	   [164],	  was	   first	   identified	   by	   Cavailles	   et	   al	   in	   1995	   as	   a	   1158	   amino	   acid	  protein	   that	  binds	   in	   a	   ligand-­‐dependent	  manner	  with	   the	  AF2	  domain	  of	  ERα.	   In	  this	   system	   RIP140	   can	   trans-­‐activate	   estrogen	   receptor	   activity	   upon	   ligand	  binding	  while	  strongly	  trans-­‐represses	  ER	  functions	  at	  higher	  concentrations	  [165].	  Interestingly,	   the	   C-­‐terminal	   domain	   of	   RIP140	   was	   shown	   to	   contain	   a	   stronger	  repressor	  activity	  then	  either	  the	  whole	  length	  protein	  or	  the	  two	  other	  repressive	  regions	  at	   the	  N-­‐termini	  [166];	   indeed	   it	  contains	   four	  repressor	  domains	  (RD1-­‐4)	  and	   two	   putative	   NLS.	   This	   protein	   also	   contains	   nine	   copies	   of	   the	   NR	   box,	   also	  found	   in	   SRC-­‐1	   and	  CBP,	   necessary	   and	   sufficient	   for	   the	  binding	   to	   liganded	  NRs	  [167].	   Those	  motifs	   are	   spread	   on	   the	  whole	   protein	  with	   the	   addition	   on	   the	   C-­‐terminus	   of	   a	   single	   LXXML	  motif	  where	   a	   leucine	   is	   substituted	   by	   a	  methionine	  [168].	  
Complexes	  and	   functions:	  The	  agonist-­‐dependent	  silencing	  activity	  of	  RIP140	  has	  been	  proven	  for	  a	  wide	  range	  of	  NR	  beside	  ERα.	  This	  list	  includes	  RARα/β,	  RXRα/β,	  TRα/β,	  GR,	  AR,	  VDR,	  PPARα/γ/δ,	  LXRα/β	  (reviewed	  in[169]).	  The	  main	  function	  of	  
Chapter	  1	  –	  Introduction	  	  
 83 
RIP140	   in	   these	   cases	   appears	   to	   be	   the	   limitation	   of	   the	   NR	   trans-­‐activation	  although	  a	  ligand-­‐dose	  dependent	  effect	  cannot	  be	  excluded.	  	  
RIP140	   participates	   in	   epigenetic	   mechanisms	   of	   gene	   regulation	   influencing	  chromatin	  conformation	  by	  recruitment	  of	  histone	  remodelling	  enzymes;	  necessary	  for	   this	   function	   is	   the	   region	   between	   amino	   acids	   78-­‐303	   that	   interacts	   with	  HDAC1	   and	   HDAC3	   [170]	   as	   well	   as	   HDAC2,	   -­‐5	   and	   -­‐6,	   even	   if	   their	   function	   in	  RIP140-­‐mediate	  repression	  resulted	  to	  be	  dispensable	  [166].	  Another	  mechanism	  of	  repression	  involves	  the	  C-­‐terminal	  Binding	  Proteins	  (CtBPs;	  -­‐1	  and	  -­‐2).	  these	  highly	  conserved	  corepressors	  modulate	  NR	  activity,	  cell	  cycle	  and	  development	  [171]	  and	  have	   been	   shown	   to	   interact	   with	   RIP140	   through	   different	   domains.	   This	  interaction,	   as	   well	   as	   those	   with	   HDACs,	   contributes	   to	   RIP140-­‐mediated	  repression,	  but	   it’s	  a	  component	  of	  a	  more	  complex	  mechanism	  that	  could	  explain	  the	   idea	   of	   RIP140	   being	   a	   common	   interacting	   protein	   for	   diverse	   co-­‐repressor	  complexes.	   This	   agonist-­‐dependent	   repression,	   as	   for	   LCOR,	   appears	   important	   in	  order	   to	   avoid	   an	   over-­‐activation	   of	   transcription	   factors,	   maintaining	   the	  physiological	   equilibrium	   requested	   for	   gene	   expression,	   metabolism	   and	  development.	  
	  
1.6.2.9	  -­	  SLIRP	  
Cloning	   and	   Structure:	   SLIRP	   (SRA	   stem-­‐loop	   interacting	   protein)	   has	   been	  recently	   identified	  by	  Hatchell	  et	   al.	   for	   its	   ability	   to	  bind	   STR7,	   a	   substructure	  of	  SRA	  (Steroid	  Receptor	  Activator),	  and	  modulate	  NR	  pathways.	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Isolation	   of	   SRA	   binding	   protein	   through	   yeast	   three-­‐hybrid	   screen	   of	   a	   primary	  human	  breast	  cancer	  cDNA	  revealed	  a	  predicted	  109	  amino	  acids	  sequence	  with	  a	  Mr	   of	   12.7kDa.	   This	   mitochondrial	   protein	   is	   composed	   almost	   entirely	   of	   an	   N-­‐terminal	  RNA	  recognition	  motif	   (RRM)	  containing	  RNP1	  and	  RNP2	  submotifs	  with	  considerably	   homologue	   to	   the	   SHARP	   (NCOR2/SMRT/HDAC1	   associated	  repressor)	   [172]	   and	   nucleolin	   RRM	   motifs.	   The	   amino	   acid	   sequence	   is	  interestingly	  highly	  conserved	  between	  species	  underlying	  the	  importance	  that	  this	  protein	  could	  hinge.	  
Human	  SLIRP	  is	  located	  in	  the	  chromosome	  14q24.3	  just	  1750	  nt,	  adjacent	  to	  SKIP,	  a	  corepressor	  involved	  in	  NR	  signalling,	  indicating	  that	  those	  two	  transcripts	  could	  be	  coordinately	  regulated	  [173].	  
Complexes	  and	  Functions:	  Immunoprecipitating	  SLIRP	  revealed	  in-­vivo	  association	  with	  STR7	  with	  high	  specificity;	  however,	  SHARP	  also	  binds	   tightly	   to	  STR7	  and	   it	  may	  compete	  with	  SLIRP	  for	  this	  interaction.	  SLIRP	  represses	  SRA	  coactivation	  in	  a	  dose-­‐dependent	  manner	  also	  enhancing	  Tamoxifen	  antagonistic	  activities.	  Its	  range	  of	  interactions	  widens	  through	  different	  NR	  such	  as	  GR	  (Glucorticoid	  Receptor),	  AR	  (Androgen	  Receptor),	  TR	  (Thyroid	  Receptor),	  VDR	  (Vitamin-­‐D	  Receptor)	  and	  PPAR-­‐
δ(Peroxisome	  Proliferator	  Activated	  Receptor)	  [173].	  	  
ChIP	   assays	   demonstrated	   that	   SLIRP	   is	   recruited	   on	   the	   E2-­‐responsive	   pS2	  promoter	   in	   the	   presence	   of	   SRA.	   Furthermore	   there	   is	   the	   possibility	   of	   a	  coordinative	   effect	   of	   SLIRP	   with	   NCOR1	   or	   other	   co-­‐repressors	   due	   to	   the	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undetectable	  amount	  of	  NCOR1	   in	   the	  promoter	  region	  when	   levels	  of	  SLIRP	  drop	  [173].	  	  
A	  wide	  variety	  of	  cell	   lines	  from	  different	  tissues	  express	  SLIRP	  and	  therefore	   it	   is	  possible	   that	   the	   role	   of	   this	   protein	   in	   physiological	   and	   pathological	   conditions	  could	  be	  crucial.	  Being	  a	  mitochondrial	  protein	  means	  that	  could	  be	  involved	  in	  the	  energy	  homeostasis	  pathway	  suggesting	  a	  role	  in	  other	  diseases.	  
	  
1.7	  -­	  HISTONE	  DEACETYLASES	  AND	  HISTONE	  DEACETYLASES	  INHIBITORS	  Around	   forty	   years	   ago,	   Vince	   Allfrey	   discovered	   the	   reversible	   acetylation	   of	  histone	   proteins	   and	   proposed	   that	   this	   post-­‐translational	   modification	   could	  regulate	   gene	   expression	   [174].	   The	   role	   of	   histone	   acetylation	   in	   transcriptional	  regulation	   remained	   controversial	   until	   1996,	   when	   two	   papers	   reported	   the	  identification	  of	  the	  first	  acetyltransferases,	  GCN5	  and	  the	  first	  histone	  deacetylase	  HDAC1	   [175,	  176].	  Eighteen	  potential	  human	  histone	  deacetylases	  were	   identified	  and	   divided	   in	   three	   families:	   Class	   I	   HDACs	   (HDAC1,	   -­‐2,	   -­‐3	   and	   -­‐8)	   and	   Class	   II	  (HDAC4,	   -­‐5,	   -­‐6,	   -­‐7,	   -­‐9,	   -­‐10	   and	   -­‐11),	   which	   are	   homologous	   to	   the	   yeast	   histone	  deacetylases	   Rpd3	   and	   Hda1,	   respectively,	   and	   share	   some	   degree	   of	   sequence	  homology	   while	   Class	   III	   histone	   deacetylases	   (SIRT1-­‐7)	   are	   homologous	   to	   the	  yeast	  protein	  Sir2	  and	  use	  NAD	  as	  a	  cofactor.	  	  
1.7.1	  –	  Biochemistry	  Of	  The	  HDAC	  Complexes	  Histone	  deacetylases	  play	  a	  key	  role	  in	  the	  regulation	  of	  transcription	  by	  modifying	  the	   chromatin	  environment;	   in	  order	   to	  perform	   this	   function	  and	  achieve	  proper	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modulation	  of	  their	  activity	  HDACs	  complex	  with	  other	  regulatory	  proteins,	  and	  in	  some	  cases,	  with	  themselves.	  
	  
1.7.1.1	  –	  Class	  I	  HDACs	  Class	   I	   HDACs	   exhibit	   very	  weak	   activity	   in	   isolation	   and	   their	  multiple	   functions	  require	   interactions	   with	   specific	   factors	   that	   modulate	   the	   response	   to	   different	  stimuli.	   Complexes	   have	   been	   described	   for	   HDAC1,	   -­‐2,	   -­‐3,	   while	   little	   is	   known	  about	  the	  proteins	  interacting	  with	  HDAC8,	  -­‐11.	  Class	  I	  deacetylases	  access	  specific	  regions	   of	   DNA	   but	   they	   lack	   DNA	   binding	   activity	   [177].	   Access	   to	   specific	  chromosomal	   regions	   is	   facilitated	   through	   the	   large	   number	   of	   transcription	   and	  chromatin	  related	  factors	  like	  the	  corepressors	  SMRT	  and	  NCOR,	  YY1,	  RUNX2,	  RBP-­‐1,	   SP-­‐1,	   CTCF,	   the	   DNA	   methyltransferases	   DNMT1,	   the	   H3	   histone	  methyltransferase	   Suv39H1	   	   and	   the	   retinoblastoma	   protein,	   Rb	   that	   binds	   to	  HDAC1	  (reviewed	  in	  [177]).	  The	   corepressor	   Sin3	   was	   shown	   to	   bind	   with	   a	   number	   of	   transcriptional	  regulators	   such	   as	   the	   helix-­‐loop-­‐helix	   heterodimers	   of	   the	  Mad	   family	   Mad/Max	  [178].	  Moreover,	   Sin3	   interacts	  with	   the	  18	   kDa	  protein	   Sap1830	   and	   the	  30	   kDa	  protein	   Sap30	   that	   was	   found	   to	   link	   the	   Sin3-­‐HDAC	   complex	   to	   Swi/Snf.	   This	  complex	   appears	   to	   function	   as	   a	   switchboard	   that	   coordinates	   the	   interactions	  between	  HDACs	  and	   sequence-­‐specific	  DNA	  binding	  proteins	  over	   than	   stabilizing	  the	   interaction	  between	  HDACs	  with	  NCOR1	  and	  NCOR2/SMRT	   [179].	  The	  human	  Sin3-­‐HDAC	  complex	  was	  able	  to	  deacetylate	  all	  of	  the	  core	  histone	  when	  in	  isolation,	  but	   not	   when	   composing	   nucleosomes,	   suggesting	   that	   chromatin	   remodeling	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precedes	  deacetylation	  in	  vivo	  [180].	  HDAC1	  and	  HDAC2	  are	  part	  of	  the	  complexes	  with	   the	  Nucleosome	  Remodeling	   and	  Deacetylase	   (NuRD)	   complex	   together	  with	  the	   methyl-­‐DNA	   binding	   protein	   MBD3,	   the	   corepressor	   Metastasis	   Associated	  Protein	  (MTA)	  1,	  -­‐2	  and	  -­‐3	   	  and	  the	  ATP-­‐dependent	  chromatin-­‐remodeling	  protein	  Mi2.	  HDAC1	  has	  also	  been	  found	  to	  interact	  with	  the	  CoREST/BHC	  complex	  through	  binding	  with	  the	  first	  SANT	  domain	  of	  the	  corepressor	  CoREST	  (reviewed	  in	  [177]).	  HDAC3	  is	  another	  member	  of	  the	  Class	  I	  HDACs	  but,	  unlike	  HDAC1	  and	  HDAC2,	  its	  function	   is	   less	   global	   and	   generally	   involved	   in	   the	   repression	   of	   target	   genes	  connected	   with	   the	   NR	   signalling.	   Most	   of	   the	   HDAC3-­‐containing	   complexes	   are	  rather	   large	   (1-­‐2	   MDa)	   and	   most	   of	   them	   share	   several	   subunits;	   the	   most	  convincing	   studied	   complex	   appeared	   to	   contains	   HDAC3,	   NCOR/SMRT,	  Transduction	   β-­‐Like	   protein	   (TBL1),	   Transducin	   β-­‐Like	   Related	   protein	   (TBLR1)	  and	  the	  G-­‐protein	  Pathway	  Suppressor-­‐1	  (GSP-­‐1).	  	  
1.7.1.2	  –	  Class	  II	  HDACs	  
	   -­	  HDACs	  Class	  IIa	  Class	   II	   HDACs	   consist	   of	   HDAC4,	   -­‐5,	   -­‐7,	   -­‐9	   and	   a	   splice	   variant	   of	   HDAC9	   that	  contains	  only	  the	  N-­‐terminus	  region	  of	  the	  protein	  named	  interacting	  transcription	  repressor	   (MITR);	   all	   of	   these	   enzymes	   contain	   binding	   sites	   for	   the	   myocyte	  enhancer	   factor	   2	   (MEF2)	   and	   CtBP	   [181].	   The	   most	   striking	   feature	   of	   Class	   II	  HDACs	  is	  their	  ability	  to	  shuttle	  between	  the	  nucleus	  and	  the	  cytoplasm;	  this	  occurs	  through	  phosphorylation	  of	  one	  or	   two	  of	   the	   three	  N-­‐terminal	  serines	  by	  calcium	  calmodulin-­‐dependent	   protein	   kinase	   (CaMK),	   which	   is	   activated	   by	   Ca2+	   release.	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Once	   the	   HDAC	   reaches	   the	   cytoplasm	   and	   is	   thus	   phosphorylated,	   complex	  formation	  with	  14-­‐3-­‐3	  sequesters	  the	  enzyme	  in	  the	  cytoplasm,	  thwarting	  its	  ability	  to	  repress	  transcription	  [177].	  	  Class	   II	   HDACs	   do	   not	   exhibit	   enzymatic	   activity	   in	   isolation	   but	   also	   only	   in	  conjunction	   with	   the	   NCOR1-­‐NCOR2/SMRT	   corepressor	   complex	   [182].	   However,	  given	   that	   this	   corepressor	   complex	   contains	   the	   Class	   I	   HDAC3,	   that	   is	  enzymatically	  active	  without	  Class	  II	  enzymes,	  the	  class	  II	  HDACs	  may	  be	  redundant,	  or,	  more	  likely,	  the	  enzymatic	  activity	  of	  the	  full	  complex	  (containing	  both	  HDACs)	  may	  target	  histone	  polypeptides	  as	  well	  as	  non-­‐histone	  substrates	  [177].	  	  
	   -­	  HDACs	  Class	  IIb	  Class	  IIb	  consist	  of	  HDAC6	  and	  -­‐10;	  HDAC6	  was	  found	  to	  be	  an	  α-­‐tubulin	  deacetylase	  and	   able	   to	   binds	   polyubiquitin	   chains	   on	   mis-­‐folded	   proteins.	   A	   link	   with	  Parkinson’s	   disease	   was	   revealed	   when	   HDAC6	   was	   found	   to	   interact	   with	  cytoplasmic	  dynein,	  a	  microtubule	  minus	  end-­‐directed	  motor	  protein	  necessary	  for	  the	  transport	  of	  mis-­‐folded	  proteins	  [183].	  This	  evidence	  suggests	  that	  HDAC6	  is	  an	  adapter	  protein	   that	  allows	  aggregated,	  mis-­‐folded	  and	  polyubiquitinated	  proteins	  to	   come	   together	   with	   dynein,	   with	   subsequent	   transport	   to	   aggresomes	   [177].	  Moreover,	   HDAC6	   colocalizes	   with	   ubiquitin	   conjugated	   and	   α-­‐synuclein	   in	  structures	  resembling	  neuronal	  inclusion	  bodies,	  Lewy	  bodies,	  a	  defining	  feature	  of	  Parkinson’s	  disease	  [184].	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Class	   III	  HDACs	  are	  related	  to	  the	  yeast	  NAD+-­‐dependent	  HDAC	  silent	   information	  regulator	   2	   (Sir2p),	  which	   is	   involved	   in	   gene	   silencing	   through	   the	   generation	   of	  heterochromatin-­‐like	   compacted	   chromatin	   that	   is	   hypoacetylated	   in	   histone	   H3	  and	  H4	  tails	  [185].	  Homologs	  of	  Sir2p	  are	  present	  in	  all	  higher	  organisms,	  including	  7	  homologs	  in	  human	  (SIRT1-­‐7)	  [186].	  	  SIRT1	  in	  its	  native	  form	  is	  a	  homomultimer	  of	  about	  400-­‐500	  kDa	  that	  most	   likely	  corresponds	   to	   a	   trimer	   although	   small	   amounts	   of	   the	   enzyme	   can	  be	  present	   in	  other	   complexes;	   it	   has	   a	   broad-­‐spectrum	   catalytic	   activity	   targeting	   all	   core	  histones	   (preferring	   H4K16Ac,	   H3K9Ac	   and	   H1bK26Ac)	   as	   well	   as	   p53,	   TAFI68,	  BCL6,	  FOXO,	  Ku70	  and	  NF-­‐κB	  (RelA/p65)	  (reviewed	  in	  [177]).	  SIRT2	   is	  almost	  exclusively	   located	   in	   the	  cytoplasm	  and	  was	  shown	  to	  co-­‐localize	  with	  tubulin	  and	  de	  deacetylate	  acetylated	  α-­‐tubulin.	  Interestingly	  it	  was	  shown	  to	  immunoprecipitate	   with	   the	   known	   tubulin	   deacetylase	   HDAC6,	   suggesting	   a	  functional	  complex	  between	  those	  proteins	  [187].	  Although	  SIRT3	  was	  shown	  to	  be	  cleaved	  at	  the	  N-­‐terminus	  it	  still	  hasn’t	  been	  found	  in	  multiprotein	  complexes	  [177],	  leaving	  its	  role	  unclear.	  	  It	   is	  clear	  that	  there	   is	  a	  strict	  cross-­‐talk	  between	  NR	  signalling,	  co-­‐repressors	  and	  HDACs	  activity	   that	  modulates	   the	   transcriptional	   landscape	  of	  prostate	   cells;	   this	  leads	   to	   dynamic	   responses	   of	   the	   system	   that	   influences	   cell	   viability	   and	  differentiation.	   This	   pathway	   can	   be	   modulated	   by	   endogenous	   and	   synthetic	  ligands	  either	  activating	  NRs	  or	  inhibiting	  HDACs	  in	  order	  to	  have	  an	  impact	  on	  the	  phenotype	  of	  normal	  and	  malignant	  prostate	  cells.	  	  
Chapter	  1	  –	  Introduction	  	  
 90 
	  
1.8	  –	  SYSTEMS	  BIOLOGY	  
1.8.1	  –	  Why	  do	  we	  model?	  	  Most	   of	   the	   pathways	   present	   in	   textbooks	   and	   papers	   are	   the	   results	   of	  experimental	   observation	   that	   described	   for	   example	   the	   physical	   interaction	  between	  two	  proteins;	  in	  a	  linear	  system	  we	  can	  intuitively	  predict	  that	  if	  we	  reduce	  the	   concentration	   of	   a	   component	   upstream	   this	   will	   decrease	   the	  activity/concentration	  of	  a	  downstream	  product.	  The	  numerous	  pathways	  inside	  of	  a	  cell	  cross-­‐talk	  between	  each	  other	  and	  there	  is	  little	  knowledge	  about	  what	  is	  the	  “weight”	   of	   each	   element	   in	   the	   network;	   knowing	   this,	   could	   1)	   explain	  mechanistically	   how	   certain	   reactions	   occur,	   2)	   allow	   researchers	   to	   precisely	  predict	   an	  outcome	  based	  on	  how	   the	  component	   interact	  with	  each	  other	  and	  3)	  suggest	   further	  experiment	   to	  validate	  experimental	  data	  and,	  on	  another	   level,	  4)	  help	  to	  predict	  patients	  sensitivity	  to	  treatments.	  	  Prostate	   malignancies	   remain	   a	   complex	   disease	   where	   multiple	   component	   are	  simultaneously	  corrupted;	  within	   this	   system,	  nuclear	  receptors	  play	  a	  key	  role	   in	  prostate	   epithelium	   viability	   and	   survival,	   modulating	   the	   transcriptome	   in	  coordination	   with	   chromatin	   modifying	   enzymes	   that	   mark	   the	   epigenome	  landscape	  to	  uniquely	  activate	  or	  repress	  gene	  transcription.	  Systems	  biology	  offers	  the	  mathematical	  tools	  to	  understand	  the	  single	  components	  of	  these	  networks.	   In	  this	   way	   it	   is	   anticipated	   that	   biology	   will	   transition	   from	   being	   qualitative	   and	  descriptive	  to	  quantitative	  and	  predictive	  [188,	  189].	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1.8.2	  –	  Concepts	  and	  Applications	  Biological	  networks	  can	  be	  simply	  described	  as	  a	  number	  of	  interactions	  happening	  within	   a	   system	   to	   produce	   a	   genotypic,	   metabolic	   or	   phenotypic	   effect.	   The	  “system”	  could	  be	  a	  single	  cell,	  where	  thousands	  of	  proteins	  interact	  with	  each	  other	  or	  with	  nucleic	  acids,	  or	  it	  could	  also	  indicate	  an	  organ	  where	  not	  only	  intra-­‐cellular	  reactions	  are	  taken	  in	  count,	  but	  also	  cell-­‐to-­‐cell	  interactions	  which	  contribute	  to	  the	  maintenance	  of	   the	  physiological	   functions	  of	   an	  organ.	  When,	   for	  any	   reason,	   the	  system	  get	  corrupted	  it’s	  possible	  that	  the	  equilibrium	  of	  these	  reactions	  is	  lost	  with	  a	  resulting	  disease	  or	  neoplastic	  transformation.	  All	  the	  components	  form	  networks	  that	  contain	  at	  least	  one	  hub	  that	  interacts	  with	  one,	  or	  more,	  single	  components	  or	  complexes.	  When	  one	  single	  component	  varies	  in	   concentration	   (i.e.	   because	   of	   up-­‐	   or	   down-­‐regulation	   of	   the	  mRNA)	   or	   activity	  (i.e.	   because	   of	   a	   mutation)	   the	   whole	   network,	   or	   system,	   is	   influenced.	   If	   this	  component	  is	  a	  key	  element	  of	  a	  hub	  the	  net	  result	  will	  be	  that	  part	  of	  the	  pathway,	  or	  pathways,	  will	  be	  heavily	  influenced	  by	  its	  physical	  or	  functional	  modification;	  on	  the	   other	   hand	   it’s	   also	   possible	   that	   if	   a	   non-­‐key	   component	   varies	   there	   are	   no	  noticeable	  functional	  changes	  in	  the	  pathway.	  Systems	  Biology	  is	  a	  relatively	  new	  field	  that	  focuses	  on	  mathematical	  modeling	  of	  biological	   and	   biochemical	   networks	   in	   order	   to	   understand	   mechanistically	   and	  dynamically	  deep	  functions	  of	  the	  single	  components	  of	  a	  network.	  This	  can	  refer	  to	  DNA	   binding	   proteins,	   histone	   modifications,	   protein-­‐protein	   interactions	   or	  biochemical	  reactions	  in	  normal	  or	  malignant	  cells,	  in	  physiology	  or	  disease.	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There	   are	   two	   approaches	   to	   modeling:	   bottom-­‐up	   and	   top-­‐down.	   The	   first	   one	  refers	   to	   the	   integration	   of	   all	   the	   pieces	   of	   data	   collected	   to	   build	   up	   a	   reliable	  model	  of	  a	  relative	  big	  system	  while	  the	  second	  approach	  is	   the	  opposite,	  where	  a	  greater	   system	   is	   broken	  down	   into	   its	   smallest	   components.	   For	   the	  purposes	   of	  this	   thesis	   the	   bottom-­‐up	   approach	  was	   undertaken,	   hence,	  mRNA	   and	   ChIP	   data	  were	  used	  as	  a	  starting	  point	  to	  model	  CDKN1A	  transcriptional	  initiation	  in	  prostate	  non-­‐malignant	  cells	  RWPE-­‐1.	  	  	  





AB 	   	   	   	  	   	   (a	  
and	   the	   correct	   equation	   to	   describe	   the	   variations	   in	   concentration	   of	   A	   and	   B	  would	  be:	  
€ 
d[AB]




dt 	   indicates	   the	  changes	   in	  concentration	  of	   the	  complex	  AB	   in	  time	  that	  are	  given	  by	  
€ 
k1[A]+ k1[B]− k2[AB],	  hence,	  by	  the	  initial	  concentration	  of	  A	  and	  B	  multiplied	   by	   the	   constant	   k1	   (indicating	   the	   speed	   of	   the	   reaction)	   minus	   the	  concentration	  of	  the	  complex	  multiplied	  by	  the	  disassociation	  constant	  k2.	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Ordinary	  differential	  equations	  (ODE)	  are	  a	  useful	  way	  to	  describe	  system’s	  dynamic	  when	  the	  initial	  concentration,	  or	  number,	  of	  molecules	  is	  high	  because	  it	  does	  not	  take	   into	   account	   the	   probability	   in	   time	   that	   the	   interaction	   between	   two	  components	   happens.	   In	   the	   case	   of	   a	   single	   cell	   system	   where	   the	   focus	   is	   on	  describing	   the	   interaction	   of	   a	   protein	   with	   a	   response	   element	   (e.g.	   promoter	  region)	  there	  are	  just	  a	  few	  molecules	  to	  deal	  with	  and	  it	  is	  important	  understanding	  that	  there	  is	  a	  probability	  for	  a	  certain	  reaction	  to	  happen	  that	  diminishes	  in	  time.	  For	  the	  purposes	  of	  this	  thesis,	  and	  my	  first	  steps	  in	  modeling,	  ordinary	  differential	  equations	  were	  used	  to	  describe	  CDKN1A	  induction.	  	  
1.9 – Model development 
1.9.1 – Software package 
The software Mathematica 6 (Wolfram) was used. This software is command line based 
and this means that each operation is recalled with a specific command; vectors 
containing the desired options were generated and implemented in mathematical 
functions used for the simulation. 
1.9.2 – Basic modeling scripts 
As stated above the software Mathematica was used; at the beginning of each simulation 
it is possible to define the initial conditions of the system, the kinetics of the reactions 
and the differential equations used to describe those reactions.  
For the simple system  
€ 
x v1⎯ → ⎯ y v2⎯ → ⎯ a           
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where the specie x is transformed in the intermediate specie y, at the rate v1 to become 
then a, at the rate v2, the initial conditions are the followings: 
 
where:  
- Var indicates the variables of the reaction (e.g. x) that vary in the time [t],  
- Balance indicates the ODE (ordinary differential equation) that describes that 
reaction, indicated as first derivate (e.g. x’) of the variable 
- Rates indicates the constants ks of each single reaction 
- Param indicates the values of the previous constants 
- Init indicates the initial conditions of the variables at the time [0]. 
 Once the initial constants are defined (for the purpose of this thesis the parameters were 
chosen in order to fit the biological data) they have to be implemented into equations as 
follow: 
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where: 
- Rates /. Param unifies constants and their values 
- Balance /. Rates /. Param implements the previous function in the ODEs 
At this point it is necessary to run the simulation, this is made recalling an algorithm, 
already into the software package, that follows the specified parameters to find the 
coordinates of each variables at each time-point. This is made with the following scripts: 
 
where: 
- Sol = NDSolve tells to the software to recall the algorithm NDSolve to solve 
the ODEs previously described. This command finds a numerical 
appriximation to a function that is equal to its first derivate at each point, 
hence obtaining the solution to the ordinary differential equations for the 
function described 
- the parameters that the algorithm will take in consideration are described 
within the square brackets 
- {t, 0, 10} indicates how long the simulation should run for. 
Finally to visualize, graphically, the results from the simulation the graph is recalled with 
the following script: 
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Fig	   1.7	   –	  Results	   of	   the	   simulation	   with	   ODEs.	   The	   accumulation	   of	   three	   different	  
species	   x	   (blue),	   y	   (violet)	   and	  a	   (yellow)	  based	  on	   the	   reaction	   x	  →	   y	  →	   a.	   Time	   is	  
indicated	  in	  the	  x	  axes	  while	  the	  concentration	  of	  the	  species	  is	  on	  the	  y	  axes.	  
 
where the software is told to Plot the variables in time x[t], represented in blue, y[t], 
represented in violet and a[t], represented in yellow, from time zero to time 10, {t, 0, 10}, 
within the selected range of values {0, 1}. 
 
1.9.3 – Advanced scripts 
With Mathematica, after creating the initial conditions and a table to recall them, it is 
possible to implement into the same vector ODEs, using If functions (to create time 
constraints) and species specifications (to take in consideration only a certain number of 
species, e.g. only the first 30 mRNA molecules produced). 
To explain this concept better, the next script indicates the differential equations, 
InitODEN, for n species of the variable polymerase pol at time [0] with initial 
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concentration equal to 1. An easier way to exemplify this command is to say that the 
formula takes into consideration a hypothetical Table with the list of pol from i to n and 
uses only the number of species specified in the equation: 
 
Subsequently construction of the algorithm occurs to describe the behavior of pol in the 
time [t]. For this example the operator If was used; this function creates constraints, such 
as time constraints, to investigate how the system behaves at specific time points in 
respect to certain conditions. 
 
In this case the algorithm contains three different Ifs, with three different time constrains 
each, but the common formatting is: 
If[constrain happens, condition 1 applies, otherwise condition 2 applies]. 
The remaining part of the script (VarsODEN[n_], InitODEN, ODEN, VarsODEN) 
implements the initial conditions of the variables to the differential equations. The time 
constraint in this algorithm were chosen to verify how the system behaves in the initial 30 
minutes. 
It is then possible to run the model with the following script: 
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which is similar to the one described above. The final graph can be visualized as follow: 
 
Fig	   1.8	   –	   Results	   of	   the	   simulation	   of	   a	   hypothetical	   polymerase	   activity	   on	   the	  
promoter	  of	  CDKN1A	  gene.	  Time	  and	  concentration	  of	  the	  polymerase	  are	  indicated	  on	  
the	  x	  and	  y	  axes,	  respectively.	  Only	  the	  first	  8000	  seconds	  (133	  min	  =	  ~	  2	  hours)	  were	  
taken	  in	  consideration	  as	  if	  the	  system	  goes	  into	  steady	  state	  after	  4000	  seconds.	  
 
The final graph indicates the recruitment of the polymerase on a hypothetical promoter 
region; this simulation will be implemented in a larger model with miR-106B and 
CDKN1A transcription. 
	  
1.9.4 – Parameter Estimation 
There are mainly three different ways to estimate the paramethers used in a model. 
The first option is to infer those data from literature and implement them in the 
algorithm; the second option is to obtain those data from experimental data appositely 
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designed for the model analysed; the third option, used for this model, implies the use of 
an empirical approach, hence running the model changing the paramenters to evaluate 
those that better describe the model. A more detailed explanation of the parameter 
























	  PROJECT	  AIMS	  
• profile	  the	  responsiveness	  of	  PC-­‐3	  cells	  towards	  a	  broad	  panel	  of	  NR	  ligands	  (ETYA,	  EPA,	  bezafibrate,	  ATRA,	  D3)	  
• identify	  the	  role	  of	  the	  HDACi	  SAHA,	  either	  as	  a	  single	  ligand	  or	  in	  combination	  with	  NR	  ligands,	  in	  	  
o cell	  proliferation	   	  
o transcriptional	  regulation	   	  
o epigenetic	  modification	  (H3K9Ac)	  of	  the	  promoter	  region	  of	  PPAR	  target	  genes	  
• evaluate	  the	  role	  of	  NCOR1	  in	  PC-­‐3	  cells	  via	  shRNA	  approach	  
o profile	  responsiveness	  of	  shNCOR1-­‐PC-­‐3	  cells	  towards	  NR	  ligands	  
o profile	  the	  transcriptional	  effect	  of	  bezafibrate	  in	  shNCOR1-­‐PC-­‐3	  on	  PPAR	  target	  genes	  
o identify	  the	  epigenetic	  modification	  (H3K9Ac)	  at	  the	  TSS	  region	  of	  PPAR	  target	  genes	  
• prepare	  Ncor1	  and	  Ncor2/Smrt	  constructs	  for	  prostate-­‐specific	  knock	  out	  of	  those	  genes	  
• prepare	  floxed	  ES	  cells	  
• prepare	  shRNA	  construct	  for	  Ncor1	  and	  Ncor2/Smrt	  controlled	  by	  a	  prostate-­‐specific	  promoter	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• model	  integration	  of	  experimental	  data	  on	  CDKN1A	  transcriptional	  activation	  by	  a	  NR.	  
Chapter	  2	  –	  General	  materials	  and	  methods	  	  
 102 
2	  -­	  GENERAL	  MATERIALS	  AND	  METHODS	  
2.1	  Cell	  culture	  The	  prostate	  cancer	  cell	  lines	  PC-­‐3,	  DU	  145,	  LNCaP	  and	  prostate	  non	  malignant	  cell	  line	   RWPE-­‐1	   were	   purchased	   from	   American	   Type	   Cell	   Culture	   Collection,	   ATCC,	  (http://www.lgcpromochem-­‐atcc.com/);	  PC-­‐3,	  DU	  145	  and	  LNCaP	  were	  maintained	  in	  RPMI1640	  media	   (Sigma-­‐Aldrich)	   supplemented	  with	  10%	  Fetal	  Bovine	  Serum,	  FBS,	   (Gibco)	   and	   2mM	  L-­‐Glutamine.	   RWPE-­‐1	   cells	  were	  maintained	   in	   KSF	  media	  supplemented	  with	  Bovine	  Pituitary	  Extract	   and	  EGF	   (all	   from	  Gibco).	   To	  prevent	  infections,	   all	   media	   also	   contained	   100	   units/ml	   penicillin	   and	   100	   µg/ml	  streptomycin	  (Gibco).	  All	  cells	  were	  incubated	  at	  37ºC	  in	  a	  humid	  atmosphere	  of	  5%	  CO2	  in	  air.	  Confluent	  cells	  were	  passaged	  by	  trypsinising	  with	  Trypsin-­‐EDTA	  (Sigma-­‐Aldrich),	  briefly:	  media	  was	  aspirated,	  cells	  washed	  with	  8	  mls	  of	  chilled	  Phosphate	  Buffer	  Saline,	  PBS	  (Sigma-­‐Aldrich)	  and	  incubated	  at	  37ºC	  for	  10	  mins	  with	  2mls	  of	  Trypsin-­‐EDTA.	   Detached	   cells	   were	   then	   collected	   with	   8mls	   of	   media	   and	  centrifuged	   1400rpm	   for	   5	   mins;	   the	   supernatant	   was	   discarded	   and	   pellet	  resuspended	   in	  10mls	  of	   fresh	  media.	  The	  dilution	  of	   cells	   seeded	  depends	  on	   the	  cell	  line	  which	  is	  summarised	  in	  Tab	  2.1.	  	   Cell	  line	   Dilution	  of	  cells	  seeded	  into	  a	  fresh	  flask	   No.	  of	  times	  per	  week	  cells	  were	  passaged	  RWPE-­‐1	   1:4	   1	  LNCaP	   1:7	   1	  DU	  145	   1:8	   2	  PC-­‐3	   1:8	   2	  
Table	  2.1	  -­	  Rate	  of	  passage	  for	  the	  prostate	  cell	  lines	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2.2	  Compounds	  Bezafibrate,	   Eicosatetraynoic	   acid	   (ETYA),	   Eicosapentaenoic	   acid	   (EPA),	   Thyroid	  Hormone	  (T3),	  chenodeoxycholic	  acid	  (CDA),	  1α,25,(OH)2D3	  (Sigma)	  and	  All	  Trans	  Retinoic	   Acid	   (ATRA)(Sigma)	   were	   stored	   as	   1mM	   solution	   in	   ethanol	   at	   20ºC,	  1α,25,(OH)2D3	   	   and	   ATRA	   were	   also	   protected	   from	   light.	   SAHA	   was	   a	   kind	   gift	  Merck	   (USA).	   For	   experimental	   dilutions	   all	   the	   compounds	   were	   diluted	   in	   the	  corresponding	  diluent	  control.	  	  
2.3	  Cell	  Proliferation	  Assay	  in	  Liquid	  Culture	  
2.3.1	  Principle	  The	   commercial	   kit	  Via	   Light	  Plus	  Cell	  Viability	   and	  Cytotoxicity	  BioAssay	   (Lonza,	  Switzerland)	  was	  used	   to	  quantify	   cell	  proliferation	   in	   liquid	  culture.	  This	  method	  exploits	   the	   bioluminescent	  measurement	   of	   ATP,	   present	   in	  metabolically	   active	  and	  viable	  cells;	  the	  enzyme	  luciferase	  catalyses	  the	  formation	  of	  light	  from	  ATP	  and	  luciferin:	  
ATP	  +	  luciferin	  +	  O2	  	  	  	  	  	  luciferase	  	  	  	  	  	  	  	  	  oxyluciferin	  +	  AMP	  +	  PPi	  +	  CO2	  +	  LIGHT	  
The	   intensity	   of	   the	   light	   emitted	   is	   then	   directly	   proportional	   to	   the	   amount	   of	  endogenous	  ATP,	  hence,	  to	  the	  number	  of	  proliferating	  cells.	  	  
2.3.2	  Method	  Exponentially	  growing	  PC-­‐3	  and	  RWPE-­‐1	  cells	  were	  plated	  at	  different	  densities	  due	  to	   their	   differential	   growth	   rates;	   PC-­‐3	   cells	   were	   seeded	   at	   2000	   cells/well	   and	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RWPE-­‐1	  at	  4000	  cells/well	  into	  80	  µl	  of	  the	  respective	  media	  into	  each	  well	  of	  a	  96-­‐well,	  white	  walled,	  tissue	  culture	  treated	  plates	  (Costar).	  Cells	  were	  dosed	  with	  the	  appropriate	  compounds	  after	  24	  hours	  from	  initial	  seeding	  and	  then	  re-­‐dosed	  after	  48	  hours,	  to	  resulting	  in	  a	  final	  volume	  of	  100	  µl.	  To	  harvest	  the	  total	  ATP	  in	  a	  well	  the	  manufacturer’s	   instructions	   were	   followed.	   Briefly:	   50	  µl	   of	   cell	   lysis	   reagent	  were	   added	   in	   each	  well	   with	   the	   use	   of	   a	  multichannel	   pipette	   and	   left	   at	   room	  temperature	  for	  >10	  mins;	  100	  µl	  of	  ATP	  monitoring	  reagent	  (containing	  luciferine	  and	  luciferase)	  were	  added	  in	  a	  dark	  environment	  and	  left	  	  >2	  minutes.	  A	  microplate	  luminometer	  (Berthold	  Id	  Detection	  System,	  Fisher	  Scientific	  Ltd,	  UK)	  was	  used	  to	  measure	  light	  emission.	  ATP	  levels	  were	  recorded	  in	  Relative	  Luciferase	  Units	  (RLU)	  and	   inhibition	   of	   proliferation,	   when	   present,	   was	   expressed	   as	   a	   percentage	  relative	  to	  negative	  control,	  treated	  with	  diluent	  media	  only.	  All	  final	  results	  are	  the	  result	  of	  triplicate	  biological	  experiments.	  	  
2.4	  Cell	  Sorting	  –	  Cell	  Cycle	  
2.4.1	  Principle	  Proliferating	  cells	  go	  through	  four	  different	  phases	  named	  G1,	  S,	  G2	  and	  M.	  There	  is	  also	  a	   fifth	  phase	  called	  G0	   that	   includes	  quiescent	  cells	  before	  going	   into	  G1.	  Each	  phase	  can	  be	  determined	  by	  detecting	  the	  relative	  amount	  of	  DNA	  in	  cells	  by	  using	  Hoescht	  (Roche)	  dye	  that	  binds	  nucleic	  acids.	  Cells	  that	  are	  in	  the	  G1	  phase	  have	  one	  copy	  of	  their	  DNA,	  while	  cells	  that	  are	  in	  G2	  phase	  and	  mitosis	  have	  two	  copies.	  Cells	  that	  are	  in	  S	  phase	  are	  actively	  copying	  their	  DNA	  and	  have	  a	  intermediate	  amount	  between	  G1	   and	  G2/mitosis	   phases.	   The	   live	   cells	   are	   incubated	  with	  Hoechst	   dye	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and	  then	  analyzed	  by	  Fluorescence-­‐activated	  cell	  sorting	  (MoFlo,	  Beckman	  Coulter,	  USA);	   this	   technology	   for	   sorting	   a	   heterogeneous	  mixture	   of	   biological	   cells	   into	  two	  or	  more	  containers,	  one	  cell	  at	  a	  time,	  based	  upon	  the	  specific	   light	  scattering	  and	  fluorescent	  characteristics	  of	  each	  cell.	  The	  Hoechst	  dye	  is	  excited	  by	  ultraviolet	  light	  at	  around	  350	  nm,	  and	  emits	  blue/cyan	  fluorescence	  light	  around	  an	  emission	  maximum	   at	   461	   nm,	   this	   characteristic	   profile	   allows	   recognition	   of	   cells	   based	  upon	  their	  total	  amount	  of	  DNA:	  cells	  that	  are	  in	  G2/mitosis	  have	  twice	  the	  amount	  of	  fluorescence	  than	  cells	  in	  G1,	  while	  cells	  in	  S	  phase	  have	  an	  intermediate	  amount	  (Fig	  2.1).	  This	  allows	  sorting	  of	  cells	  in	  different	  phases	  of	  the	  cell	  cycle	  and	  using	  them	  for	  further	  experiments.	  
	  
Fig	  2.1	  -­	  Representative	  cell	  cycle	  histogram.	  On	  the	  x	  axes	  the	  cell	  count	  and	  on	  the	  y	  
axes	  the	  log	  intensity	  of	  the	  DNA	  content	  detected	  via	  Hoechst	  dye.	  The	  left	  side	  of	  the	  
histogram	   indicates	   cells	   in	   G1	   phase,	   the	   flat	   part	   at	   the	   centre	   indicates	   cells	   in	   S	  
while	  G2	  cells	  are	  on	  the	  far	  right	  of	  the	  histogram	  with	  the	  highest	  amount	  of	  DNA.	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2.4.2	  -­	  Method	  Exponentially	   growing	   cells	   in	   T175	   flasks	   were	   treated	   for	   four	   hours	   with	  1α,25,(OH)2D3	   at	   a	   final	   concentration	   of	   100nM;	   cells	   were	   then	   trypsinized,	  resuspended	  in	   fresh	  media,	  centrifuged	  and	  resuspended	  with	  5mls	  of	  media	  and	  10uls	  of	  EDTA	  100uM.	  This	  suspension	  was	  then	  used	  to	  cell-­‐sort	  cells	  in	  G1,	  S	  and	  G2	  with	  a	  Mo-­‐Flow	  machine.	  Fractionated	  cells	  were	  then	  collected	  directly	  into	  TRI	  reagent	  (Ambion)	  and	  used	  for	  RNA	  extraction.	  	  
2.5	   RNA	   Extraction,	   Reverse	   Transcription	   and	   Polymerase	   Chain	   Reaction	  
(PCR)	  Before	  performing	  a	  quantitative	  Reverse	  Transcriptase-­‐Real	  Time	  PCR	  (Q-­‐RT-­‐PCR)	  there	   are	   other	   two	   steps:	   RNA	   extraction	   and	   cDNA	   synthesis	   by	   Reverse	  Transcription.	  	  
2.5.1	  RNA	  Extraction	  
2.5.1.1	  Principle	  To	  extract	  RNA	  from	  adherent	  cells	  they	  were	  first	  collected	  by	  trypsinization	  and	  the	  resulting	  pellet	  was	  lysed	  with	  TRI	  reagent.	  This	  solution	  contains	  guanidine	  isothiocyanate	  (a	  strong	  denaturant)	  and	  phenol,	  which	  lyses	  and	  denatures	  endogenous	  RNases	  to	  avoid	  digestion	  of	  nucleic	  acids.	  The	  addition	  of	  1-­‐bromo-­‐3-­‐chloro-­‐propane	  (Sigma)	  creates	  a	  second,	  organic,	  phase	  and	  centrifugation	  of	  this	  mixture	  results	  in	  the	  production	  of	  three	  phases:	  the	  dense,	  red	  organic	  phase	  containing	  proteins	  at	  the	  bottom;	  a	  white	  interphase	  containing	  DNA;	  an	  upper	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aqueous	  phase	  containing	  RNA.	  The	  RNA	  layer	  is	  pipetted	  off	  and	  then	  the	  RNA	  is	  precipitated	  with	  isopropanol	  (Sigma)	  and	  contaminants	  such	  as	  salt	  are	  removed	  by	  washing	  the	  RNA	  pellet	  with	  70	  %	  ethanol;	  ethanol	  takes	  away	  the	  hydration	  shell	  around	  the	  DNA,	  adding	  a	  cation	  like	  Na+	  or	  K+	  and	  not	  only	  takes	  away	  the	  hydration	  shell,	  but	  also	  stabilizes	  the	  phosphate	  groups	  by	  making	  them	  interact	  with	  an	  opposing	  charge	  instead	  of	  water,	  allowing	  for	  futher	  resuspension	  of	  the	  RNA	  in	  nuclease	  free	  water.	  
	  
2.5.1.2	  -­	  Method	  Exponentially	  growing	  cells	  were	  trypsinized,	  pellet	  was	  collected	  into	  10	  ml	  tubes,	  resuspended	  in	  1ml	  TRI	  reagent	  for	  approximately	  5	  million	  cells,	  transferred	  in	  a	  1.5	  ml	  eppendorf	  and	  incubated	  at	  room	  temperature	  for	  10	  mins:	  for	  each	  ml	  of	  TRI	  reagent,	  100	  µl	  of	  1-­‐bromo-­‐3-­‐chloro-­‐propane	  was	  added	  and	  the	  solution	  was	  then	  vortexed	  for	  15	  seconds	  and	  incubated	  at	  room	  temperature	  for	  further	  10	  mins.	  The	  three	  phases	  were	  then	  separate	  centrifuging	  the	  samples	  at	  12.000	  rpm	  for	  15	  mins	  at	  4ºC;	  the	  clear	  top	  phase	  containing	  RNA	  was	  immediately	  transferred	  to	  a	  new	  1.5	  ml	  eppendorf	  and	  resuspended	  with	  500	  ul	  of	  2-­‐propanol	  per	  each	  ml	  of	  TRI	  reagent.	  RNA	  was	  left	  to	  precipitate	  over	  night	  at	  4ºC	  (or	  at	  least	  20	  min	  at	  RT).	  Tubes	  were	  then	  centrifuged	  at	  12.000	  rpm	  for	  15	  mins	  at	  4ºC,	  pellet	  containing	  RNA	  was	  washed	  with	  1	  ml	  of	  ethanol	  70%	  and	  centrifuged	  at	  12.000	  rpm	  for	  10	  mins	  at	  4ºC.	  the	  supernatant	  was	  carefully	  removed	  and	  the	  pellet	  was	  left	  to	  air	  dry	  under	  a	  hood	  until	  any	  remaining	  ethanol	  had	  evaporated.	  The	  RNA	  was	  then	  resuspended	  in	  30	  ul	  of	  Nuclease	  Free	  Water	  (Promega)	  and	  stored	  at	  -­‐80ºC.	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2.5.1.3	  -­	  RNA	  quantification	  A	  NanoDrop	  Machine	  (ND100,	  Labtech	  International	   ,	  UK)	  was	  used	  to	  analyse	  the	  RNA	  extracted.	  Values	  obtained	  from	  reading	  1	  ul	  of	  sample	  were	  indicative	  of	  the	  quality	  of	  RNA,	  expressed	  from	  ratio	  λ260/λ280	  (to	  indicate	  nucleic	  acid	  content	  vs	  non-­‐nucleic	  acid	  content,	  good	  ratios	  are	  1.8<x<2);	  the	  concentration	  calculated	  by	  the	  NanoDrop	  Machine	  was	  expressed	  in	  ng/ml.	  	  
2.5.2	  Reverse	  Transcription	  
2.5.2.1	  Principle	  In	   order	   to	  measure	   the	   levels	   of	   extracted	  RNA	   in	   cells	   it’s	   easier	   to	   convert	   the	  mRNA	   into	   DNA,	   which	   is	   more	   stable	   and	   can	   be	   easily	   amplified	   by	   PCR	  (Polymerase	   Chain	   Reaction).	   An	   RNA-­‐dependent	   DNA	   polymerase	   (reverse	  transcriptase)	   ,	   extracted	   from	   viruses	   such	   as	   avian	   myeloblastosis	   (AMV),	  synthesises	  complementary	  copies	  of	  DNA,	  also	  called,	  cDNA	  from	  mRNA	  template.	  Primers,	   short	  nucleic	  acid	  binding	  oligonucleotides,	  provide	   the	  starting	  point	   for	  reverse	  transcriptase.	  The	  primers	  are	  generally	  oligo	  dTs	  that	  bind	  the	  polyA	  tail	  of	  mRNA	  or	  random	  hexamers	  (random	  sequence	  of	  six	  nucleotides)	  that	  can	  bind	  to	  the	  corresponding	  sequence	  anywhere	  in	  the	  mRNA	  transcripts.	  	  
2.5.2.2	  Method	  1	  ug	  of	  total	  RNA	  was	  initially	  heated	  at	  70ºC	  for	  10	  minutes	  in	  a	  total	  volume	  of	  10	  ul	  with	  nuclease	  free	  water	  to	  denature	  any	  RNA	  secondary	  structure.	  The	  RNA	  was	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then	  added	  to	  a	  10	  ul	  reaction	  mix	  containing	  4	  uls	  of	  25mM	  MgCl2,	  2	  uls	  of	  Random	  Primers	  (Promega	  –	  C1181)	  0.6	  ul	  of	  MMLV	  SuperScript™	  II	  Reverse	  Transcriptase	  (Invitrogen	  –	  18064-­‐014),	  2	  uls	  of	  RT	  10X	  buffer	   (50	  mM	  Tris-­‐HCl,	  pH	  8.3,	  50	  mM	  KCl,	   10	  mM	  MgCl2,	   0.5	  mM	   spermidine	   –helps	   preventing	   aspecific	   reactions–	   and	  10	  mM	  DTT	  –helps	  loosing	  the	  secondary	  structure	  of	  the	  RNA–),	  20	  units	  of	  RNase	  inhibitor	   (Invitrogen	   RNaseOUT	   -­‐	   10777019)	   and	   2	   uls,	   2.5	  mM	   each,	   of	   dNTPs	  (Invitrogen).	  Each	  reaction	  was	   then	  heated	   for	  60	  min	  at	  42ºC	  and	   inactivated	  at	  95ºC	  for	  5	  mins.	  Samples	  were	  stored	  at	  -­‐20ºC	  for	  future	  experiments.	  
	  
2.5.3	  Quantitative	  TaqMan	  Real	  Time	  Polymerase	  Chain	  Reaction	  (Q-­PCR)	  
2.5.3.1	  General	  Principle	  of	  Q-­PCR	  Real	   Time	   PCR	   is	   a	   very	   sensitive	   technique	   able	   to	   generate	   quantitative	   gene	  expression	   data	   (used	   for	   SNPs	   assay	   or	   DNA	   analysis	   as	   well)	   allowing	   a	   high	  throughput	   of	   samples,	   which	   don’t	   need	   any	   further	   processing	   afterwards.	   The	  first	  kind	  of	  Real	  Time	  PCR	  exploited	  a	   fluorescent	  dye	   such	  as	  ethidium	  bromide	  and	  SYBR	  Green	  that	   intercalates	   into,	  or	  binds	  to,	   the	  grooves	  of	  double-­‐stranded	  DNA.	   This	   method	   is	   still	   commonly	   used	   along	   with	   the	   newer,	   more	   specific	  method	   called	   TaqMan	   Real	   Time	   PCR,	   that	   requires	   a	   fluorescent	   probe	   that	  anneals	  only	  to	  a	  specific	  part	  of	  the	  amplified	  target	  DNA	  sequence.	  The	  polymerase	  used	   in	  TaqMan	  possesses	   exonuclease	  activity	   to	  digest	   the	  probe	  while	   the	  new	  strand	  is	  synthesized,	  below	  the	  mechanism	  of	  action	  will	  be	  explained	  in	  details.	  	  Real	   Time	   PCR	   machines	   are	   fluorescence-­‐detecting	   thermocyclers,	   which	  simultaneously	  amplify	  NDA	  sequences	  and	  measure	   their	   concentration	  once	  per	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cycle.	  This	  allows	  DNA	  quantification	  over	  the	  whole	  course	  of	  the	  PCR	  reaction.	  The	  accumulation	  of	  amplified	  product,	  and	  therefore	  the	  detectable	   fluorescence	   level	  from	  a	  highly	  expressed	  gene	  occurs	  at	  lower	  cycle	  number	  than	  a	  lowly	  expressed	  gene	  because	  the	  initial	  concentration	  of	  the	  cDNA	  is	  higher.	  The	  given	  level	  of	  fluorescence	  is	  always	  fixed	  in	  the	  exponential	  phase	  of	  the	  PCR	  when	  the	  reaction	  is	  not	   limited.	  The	  number	  of	  PCR	  cycles	  necessary	  to	  achieve	  a	  set	   level	   of	   fluorescence	   is	   termed	   ‘cycle	   threshold’	   (Ct).	   To	   normalise	   each	   cDNA	  sample,	  the	  Ct	  value	  of	  the	  housekeeping	  gene	  is	  subtracted	  from	  the	  Ct	  value	  of	  the	  target	  gene	  and	  this	  value	  is	  termed	  delta	  Ct	  (δCt).	  The	  δCt	  of	  an	  untreated	  control	  sample	   was	   then	   subtracted	   from	   a	   treated	   (e.g.	   1α,25(OH)2D3)	   sample	   giving	   a	  value	  termed	  delta	  delta	  Ct	  (δδCt).	  Finally	  the	  relative	  fold-­‐changes	  in	  mRNA	  levels	  were	  calculated	  using	  the	  equation:	  2-­‐δδCt.	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Fig	  2.2	  –	  Theoretical	  example	  of	  the	  amplification	  curve	  of	  CYP24	  in	  treated	  (+ve)	  vs	  
untreated	   (-­ve)	   PC-­3	   cells.	   Cycle	   thresholds	   (Cts)	   of	   the	   gene	   are	   related	   to	   18s’	   Cts.	  
Fold	   changes	   are	   calculated	   as	   explained	   above.	   In	   this	   case	   1,25(OH)2D3	   treatment	  
effectively	   promotes	   accumulation	   of	   CYP24	  mRNA	   as	   detected	   by	   the	   amplification	  
curve	  shifted	  to	  the	  left	  if	  compared	  to	  the	  un-­treated	  sample.	  	  
2.5.3.2	  Principles	  of	  TaqMan	  Real	  Time	  PCR	  The	  main	   characteristic	   of	   a	   TaqMan	   is	   the	   presence	   of	   a	   third	   oligonucleotide	   in	  addition	   to	   the	   two	  primers.	  This	  probe	  anneals	  within	   the	   region	   to	  be	  amplified	  and,	   in	   order	   to	   prevent	   amplification	   of	   genomic	   DNA,	   is	   designed	   to	   cross	   the	  exon-­‐exon	   boundary	   of	   the	   mRNA	   of	   interest.	   This	   oligonucleotide	   is	   chemically	  modified	  at	  its	  5’	  end	  with	  a	  fluorescent	  reporter	  dye	  (generally	  FAM)	  and	  at	  its	  3’	  with	   a	   quencher	   (generally	   TAMRA).	   While	   the	   probe	   is	   intact	   the	   dye	   is	   close	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enough	   to	   the	   quencher	   that	   it	   prevents	   any	   fluorescence	   emission.	   During	   the	  extension	   phase	   of	   the	   PCR	   reaction,	   the	   taq	   polymerase	   has	   5’	   to	   3’	   exonuclease	  activity	  and	  digests	  any	  annealed	  probe.	  This	  causes	   the	  release	  and	  separation	  of	  the	  reporter	  dye	  and	  quencher	  enabling	  fluorescence	  to	  be	  detected.	  	  
	  
Fig	  2.3	  –	  Description	  of	  the	  endonuclease	  activity	  of	  the	  taq	  polymerase.	  The	  more	  the	  
probe	  is	  digested	  the	  more	  light	  is	  released	  by	  the	  report	  dye.	  	  One	  advantage	  of	  TaqMan	  PCR	  is	  that	  only	  the	  amplification	  of	  the	  DNA	  sequence	  of	  interest	  causes	   fluorescence,	  unlike	  a	  generic	   fluorescent	  dye	  that	  can	  also	  bind	  to	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primer	  dimers	  or	  non-­‐specific	  amplified	  DNA.	  Also,	   the	  TaqMan	   thermocycler	   that	  was	   used	   for	   this	   thesis	   (ABI	   Prism	   7700,	   Applied	   Biosystems)	   can	   quantitate	  signals	  from	  different	  fluorescent	  dyes;	  therefore	  more	  than	  one	  DNA	  sequence	  can	  be	   amplified	   in	   the	   same	   reaction.	   Potential	   pipetting	   error	   was	   removed	   by	  amplifying	   the	   normalisation	   gene	   18S	   in	   the	   same	   PCR	   reaction	   as	   the	   gene	   of	  interest.	  	  
2.5.3.3	  Primers	  and	  Probes	  The	   sequences	  used	   to	  design	  primers	   and	  probes	   for	   the	  mRNA	  of	   interest	  were	  obtained	   from	   published	   gene	   sequences	   [62,	   190]	   and	   analysed	  with	   the	   Primer	  Express	  software	  (PE	  Applied	  Biosystem,	  UK).	  Primers	  were	  synthesised	  by	  Sigma-­‐Genosis	  (Sigma-­‐Aldrich).	  The	  18S	  housekeeping	  gene	  and	  gene	  expression	  assay	  on	  demand	  primers	  and	  probes	  were	  also	  from	  Applied	  Biosystem.	  	  	  	   Product	  Code	   Gene	  Name	  Hs00167536_m1	   Alox5	  –	  5-­‐lypoxigenase	  Hs00226123_m1	   FBXL6	  Hs00364015_m1	   SLIRP	  Hs00936775_m1	   CoREST	  Hs00940781_m1	   RIP140	  Hs00974040_m1	   LCoR	  000442	   miR106-­‐B	  001006	   RNU48	  
	  
Table	  2.2	  –	  List	  of	  gene	  expression	  assay	  on	  demand	  primers	  and	  probes	  obtained	  by	  
Applied	  Biosystem	  with	  relative	  product	  code.	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  Gene	  bank	  accession	  no.	   Primer	   Sequence	  (5’-­‐3’)	  NM_006311	   NCoR1	  Forward	  primer	   TGAAGGTCTTGGCCCAAAAG	  	   NCoR1	  Reverse	  primer	   TTTGTCTTGATGTTCTCATGGTA	  	   NCoR1	  Probe	   CTGCCACTGTATAACCAGCCATCAGATACCA	  NM_006312	   SMRT	  Forward	  primer	   CACCCGGCAGTATCATGAGA	  	   SMRT	  Reverse	  primer	   CGAGCGTGATTCCTCCTCTT	  	   SMRT	  Probe	   CTTCCGCATCGCCTGGTTTATT	  	  AF_120268	   TRIP15/Alien	  Forward	  primer	   CCTCATCCACTGATTATGGGAGT	  	   TRIP15/Alien	  Reverse	  primer	   CATCATAATTCTTGAAGGCTTCA	  	   TRIP15/Alien	  Probe	   CCCTCAAGTGCATTTTACCACCACATTCTCT	  NM_000782	   CYP24	  Forward	  primer	   CAAACCGTGGAAGGCCTATC	  	   CYP24	  Reverse	  primer	   ACTTCTTCCCCTTCCAGGATCA	  	   CYP24	  Probe	   ACTACCGCAAAGAAGGCTACGGGCTG	  NM_000389	   CDKN1A	  Forward	  primer	   GCAGACCAGCATGACAGATTTC	  	   CDKN1A	  Reverse	  primer	   GGATTAGGGCTTCCTCTTGGA	  	   CDKN1A	  Probe	   CCACTCCAAACGCCGGCTGATCTT	  NM_001924	   GADD45A	  Forward	  primer	   AAGACCGAAAGGATGGATAAGGT	  	   GADD45A	  Reverse	  primer	   GTGATCGTGCGCTGACTCA	  	   GADD45A	  Probe	   TGCTGAGCACTTCCTCCAGGGCAT	  NM_004257.3	   TGFBRAP1	  Forward	   GCGGCTGTGTCCTTTCCATA	  	  	   TGFBRAP1	  Reverse	   GCGTCTGCTTCTGTTGCTGAT	  	  	   TGFBRAP1	  Probe	   AGCGCTCGATGACGAATTCATCACAG	  	  NM_001786.2	   CDC2	  Forward	   CTAGCATCCCATGTCAAAAACTTG	  	  	   CDC2	  Reverse	   CAGTGCCATTTTGCCAGAAA	  	  	   CDC2	  Probe	   TTTGCTCTCGAAAATGTTAATCTATGATCCAGCC	  	  NM_000963.1	   PTGS2	  Forward	   GAATCATTCACCAGGCAAATTG	  	  	   PTGS2	  Reverse	   TCTGTACTGCGGGTGGAACA	  	  	   PTGS2	  Probe	   TGGCAGGGTTGCTGGTGGTAGGA	  	  	  
Table	   2.3	   –	   List	   of	   primers	   and	   probes	   used	   for	   this	   thesis	   with	   corresponding	  
sequences.	   Primers	   and	   probes	   were	   designed	   with	   the	   software	   “Primer	   Express”	  
(ABI)	  using	  the	  mRNA	  sequence	  of	  the	  gene	  of	  interest	  as	  input.	  Primers	  were	  ordered	  
from	  Sigma	  Aldricht.	  	  
Chapter	  2	  –	  General	  materials	  and	  methods	  	  
 115 
	  
2.5.3.4	  Calibration	  and	  Optimization	  of	  Primers	  and	  Probes	  Each	   set	   of	   primers	   and	   probes	   were	   calibrated	   to	   guarantee	   linearity	   of	  amplification.	   Primer	   efficiency	   experiments	   were	   carried	   out	   in	   order	   to	   ensure	  reliability	  on	  mRNA	  detection.	  This	  optimization	  step	  was	  undertaken	   to	  ensure	  a	  linear	  relationship	  between	  template	  concentration	  and	  Ct	  values	  when	  undertaking	  a	  multiplex	   reaction	  with	  both	  housekeeping	  genes	  and	   target	  genes.	  An	  optimum	  reaction	   yields	   Ct	   values	  which	   decrease	   for	   increasing	   cDNA	   concentrations	   in	   a	  linear	  manner.	  	  
2.5.3.5	  Method	  50	   ng	   of	   cDNA	   were	   amplified	   in	   a	   20	   µl	   reaction	   containing	   1x	   TaqMan	   PCR	  MasterMix	   (Sensimix	   dT	   -­‐	   QT6T3,	   Quantace,	   UK),	   125	   nM	   FAM-­‐TAMRA	   labelled	  probe	  and	  1	  uM	  of	  primers.	  All	  reactions	  were	  multiplexed	  with	  1x	  VIC-­‐TAMRA	  18S	  (ABI).	  An	  ABI	  PRISM	  7700	  sequence	  detector	  machine	  (Applied	  Biosystems,	  Foster	  City,	  CA,	  USA)	  was	  used	  under	  the	  following	  cycle	  conditions:	  50°C	  for	  2	  mins,	  95°C	  for	  10	  mins,	  40	  cycles	  of	  95°C	  for	  15	  secs,	  60°C	  for	  1	  min	  and	  72ºC	  for	  30	  secs.	  Final	  measurements	  were	  an	  average	  of	  a	  minimum	  of	  three	  independent	  experiments,	  in	  triplicate	   wells	   for	   each	   condition.	   Student’s	   t-­‐tests	   were	   performed	   to	   identify	  genes	  significantly	  expressed/regulated.	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2.5.4	  Microfluidic	  Gene	  Card	  
2.5.4.1	  General	  Principle	  Applied	   Biosystem	   developed	   a	   novel	   approach	   of	   analysing	   multiple	   gene	  expression	   profiles	   by	   using	   a	   custom	   array	   of	   gene-­‐specific	   primer	   and	   probe	  sequences	  preloaded	  in	  a	  384-­‐well	  micro	  fluidic	  card.	  In	  each	  plate	  any	  set	  of	  genes	  is	   already	   pre-­‐loaded	   into	   the	  well	   and	   present	   in	   duplicate	   copy	   arranged	   in	   96	  wells	   (96x2x2=384);	   this	   allows	   the	   researcher	   to	   analyse	   96	   genes	   in	   technical	  duplicate,	   for	   example	   running	   treated	   sample	  versus	  untreated	   in	  parallel	   on	   the	  same	  plate.	  The	  plate	  was	   run	  on	  a	  ABI	  7900H	   thermocycler	   (Applied	  Biosystem)	  and	  analysed	  as	  a	  normal	  TaqMan	  reaction.	  A	  selection	  from	  the	  list	  of	  the	  selected	  genes	  can	  be	  seen	  in	  Fig	  2.4.	  
	  
Chapter	  2	  –	  General	  materials	  and	  methods	  	  
 117 
Fig	  2.4	  –	  Visual	  representation	  of	  the	  genes	  preloaded	  into	  the	  microfluidic	  gene	  card.	  
Indicated	   are	   the	   sub-­cellular	   location	   and	   the	   main	   function	   (image	   from	   James	  
Thorne,	  University	  of	  Birmingham,	  Birmingham,	  UK).	  	  	  
2.5.4.2	  Method	  RNA	  concentration	  was	  set	  to	  be	  the	  lowest	  within	  the	  samples	  analysed.	  200	  µl	  of	  one-­‐step	  reaction	  Master-­‐Mix	  from	  Qiagen	  were	  added	  to	  the	  diluted	  RNA	  together	  with	  4	  µl	  of	  RT	  mix	  (Qiagen);	  100	  uls	  of	  the	  reaction	  mix	  were	  then	  dosed	  every	  two	  rows	   in	   the	   card.	   This	   was	   then	   centrifuged	   twice	   at	   1000	   rpm	   for	   2	  minutes	   to	  distribute	  homogeneously	  the	  sample	  into	  each	  well.	  Plate	  was	  then	  sealed	  and	  run	  on	   the	   ABI7900	   machine	   under	   the	   following	   cycle	   conditions:	   50ºC	   for	   30	   sec	  (reverse	   transcription),	   95ºC	   for	   15	   min	   (activation	   enzyme),	   94ºC	   for	   45	   sec	  (denaturation),	   56ºC	   for	   45	   sec	   (annealing),	   76ºC	   for	   45	   sec	   (elongation)	   for	   40	  cycles.	  Measurements	  were	  carried	  out	  on	  a	  minimum	  of	  three	  biological	  replicate	  for	  each	  condition	  (e.g.	  treated	  vs	  untreated).	  	  
2.5.4.3	  Data	  Analysis	  Due	   to	   the	   large	   volume	   of	   results	   obtained	  with	   this	  methodology,	   the	   use	   of	   an	  appropriate	   software	   able	   to	   manage	   high	   throughput	   data	   was	   compulsory;	   the	  choice	   was	   TMeV,	   a	   Java	   application	   freely	   available	   online	  (www.tm4.org/mev.html),	   that	  can	  be	  easily	  used	   to	  analyse	  microarray	  data.	  The	  statistical	  tests	  performed	  with	  this	  software	  are:	  
- Student’s	  t-­test:	  this	  analysis	  assesses	  wether	  the	  means	  of	  two	  groups	  (or	  genes)	   are	   statistically	   different	   from	   eachother.	   One	   sample	   t-­‐test	  was	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also	  used	   to	  determin	   if	  a	  group	  of	  genes	  was	  significanlty	  differentially	  expressed	  from	  an	  average	  value.	  
- ANOVA	  (Analysis	  of	  Variance):	  this	  analysis	  is	  an	  extension	  of	  the	  Student	  t-­‐test	   to	  more	   than	   two	  experimental	   conditions.	   It	   identifies	  genes	   that	  have	   significant	   differences	   in	   means	   across	   three	   or	   more	   groups	   of	  samples	  
- SAM	   (Significance	   Analysis	   of	   Microarray):	   this	   analysis	   can	   be	   used	   to	  identify	  significant	  genes	  based	  on	  differential	  expression	  between	  sets	  of	  samples.	   Significance	   is	   evaluated	   via	   permutation	   of	   the	   samples	   (or	  genes)	   calculating	   the	   FDR	   (False	   Discovery	   Rate),	   which	   is	   the	  proportion	   of	   genes	   likely	   to	   have	   been	   identified	   by	   chance	   as	   being	  significant.	  A	   heatmap,	   firstly	   used	   by	   Wishart	   in	   1997	   [191],	   	   represents	   visually	   the	   gene	  expression	  data	  collected,	  those	  generated	  for	  this	  thesis	  have	  in	  green	  and	  red	  bars	  down-­‐	   and	   up-­‐regulated	   genes,	   respectively.	   Heatmaps	   representing	   basal	   and	  treated	  PC-­‐3	  cells	  vs	  RWPE-­‐1	  cells	  were	  generated	  and	  hierarchical	  trees	  were	  built	  using	   Euclidean	   distance.	   This	   is	   a	  measurement	   of	   the	   geometric	   distance	   in	   the	  multidimensional	   space	   between	   two	   objects	   and	   it’s	   the	   most	   used	   method	   for	  cluster	  analysis.	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2.5.5	  Protein	  Extraction	  and	  Western	  Immunoblotting	  
2.5.5.1	  Western	  Immunoblotting	  –	  Introduction	  Western	  Immunoblotting	  is	  a	  widespread	  technique	  used	  to	  measure	  specific	  target	  protein	  expression.	  The	  overall	   idea	   is	   to	  resolve	   the	  proteins	  by	  size	  and	   identify	  the	  one	  of	  interest	  on	  a	  membrane	  using	  a	  specific	  antibody	  (Ab).	  A	  general	  protocol	  includes	  a	  separation	  of	  the	  extracted	  proteins	  in	  a	  polyacrylamide	  gel	  in	  presence	  of	   Sodium	   Dodecyl	   Sulfate	   (SDS).	   SDS-­‐PAGE	   (SDS	   polyacrylamide	   gel	  electrophoresis)	  maintains	  protein	  in	  a	  denatured	  state	  once	  they	  have	  been	  treated	  with	   strong	   reducing	   agents	   to	   remove	   secondary	   and	   tertiary	   structure	   (e.g.	   S-­‐S	  disulfide	   bonds	   to	   SH	   and	   SH)	   and	   thus	   allows	   separation	   of	   proteins	   by	   their	  molecular	  weight.	  Sampled	  proteins	  become	  covered	  in	  the	  negatively	  charged	  SDS	  and	  move	  towards	  the	  positively	  charged	  electrode	  through	  the	  acrylamide	  mesh	  of	  the	  gel.	  Smaller	  proteins	  migrate	  faster	  through	  this	  mesh	  and	  the	  proteins	  are	  thus	  separated	   according	   to	   size	   (usually	   measured	   in	   kilo	   Daltons,	   kDa).	   The	  concentration	  of	   acrylamide	  determines	   the	   resolution	  of	   the	  gel	   -­‐	   the	  greater	   the	  acrylamide	   concentration	   the	   better	   the	   resolution	   of	   lower	   molecular	   weight	  proteins.	  The	  lower	  the	  acrylamide	  concentration	  the	  better	  the	  resolution	  of	  higher	  molecular	  weight	  proteins.	  Proteins	   travel	  only	   in	  one	  dimension	  along	  the	  gel	   for	  most	  blots.	  Once	  the	  gel	  has	  been	  run	  the	  proteins	  are	  transferred	  onto	  a	  membrane,	  Polyvinylidene	  Fluoride	  (PVDF)	  or	  nitrocellulose.	  The	  membrane	  is	  then	  incubated	  with	  a	  solution	  at	  5%	  milk	  in	  order	  to	  avoid	  non-­‐specific	  binding	  of	  the	  antibody	  on	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the	  membrane.	   Incubation	   with	   the	   primary	   Ab	   specifically	   recognizes	   the	   target	  protein;	   to	  obtain	  a	   stable	   signal	   from	   the	  bound	  antibody	   the	  use	  of	   a	   secondary	  antibody	   is	   compulsory.	   This	   is	   conjugated	   with	   a	   detection	   moiety	   such	   as	   an	  enzyme	   named	   Horse	   Radish	   Peroxidase	   (HRP)	   and	   will	   recognize	   the	   primary	  antibody;	   this	   reaction	   is	   species-­‐specific,	   hence,	   the	   secondary	   antibody	   will	  recognise	   only	   primary	   antibodies	   that	   it	   was	   designed	   for.	   Using	   a	  chemoluminescent	   substrate	   to	   HRP	   (called	   ECL),	   containing	   Luminol	   and	   a	  Peroxide	  buffer,	  in	  combination	  with	  the	  HRP	  enzyme,	  it	  is	  possible	  to	  catalyze	  the	  oxidation	   of	   Luminol	   with	   creation	   of	   an	   excited	   state	   product	   called	   3-­‐aminophthalate*.	  This	  product	  decays	  to	  a	  lower	  energy	  state	  by	  releasing	  photons	  of	  light.	  Where	  this	  reaction	  happens	  is	  where	  the	  protein	  of	  interest	  is;	  this	  can	  be	  identified	  as	  a	  band	  impressed	  on	  a	  sheet	  of	  auto-­‐radiographic	  film.	  	  
2.5.5.2	  Protein	  Extraction	  Exponentially	   growing	   cells	  were	   trypsinized	   and	   pelleted	   in	   a	   10	  ml	   falcon	   tube.	  Either	  whole	  protein	  extract	  or	  nuclear	  and	  cytosolic	  fractions	  were	  prepared.	  
	  
2.5.5.2.1	  Whole	  Protein	  Extract	  Preparation	  Cells	  were	  lysed	  with	  buffer	  (containing	  50	  mM	  Tris-­‐HCl	  pH	  7.6-­‐8,	  150	  mM	  NaCl,	  1%	  NP-­‐40,	   1%	   sodium	   deoxycholate,	   0.1%	   SDS	   in	   250	   ml	   of	   ddH2O).	   For	   every	   ten	  million	   cells	   200uls	   of	   RIPA	   buffer	  were	   used.	   The	   pellet	  was	   resuspended	   in	   the	  appropriate	   volume	   of	   buffer,	   gently	   homogenized	   and	   transferred	   in	   a	   1.5	   ml	  eppendorf.	  A	  protease	  inhibitor	  cocktail	  (Sigma)	  was	  added	  at	  the	  concentration	  of	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one	  µl	   per	   each	  million	   cells.	   The	   vial	  was	   vortexed	   for	  15	   seconds	   at	   the	  highest	  settings	   and	   incubated	   at	   -­‐20ºC	   for	   20	  minutes.	   This	   cycle	  was	   repeated	   4	   times.	  Finally	   the	  sample	  was	  centrifuged	  at	  16000	  rpm	  for	  10	  minutes;	   the	  supernatant	  containing	  protein	  was	  transferred	  in	  a	  clean	  1.5	  ml	  eppendorf	  and	  stored	  at	  -­‐80ºC	  for	  future	  usage.	  	   	  
	   2.5.5.2.2	  Nuclear	  and	  Cytosolic	  Extract	  Preparation	  Separate	  nuclear	  from	  cytosolic	  fractions	  are	  important	  in	  case	  the	  aim	  is	  to	  analyze	  proteins	  expressed	  in	  a	  sub-­‐cellular	  location.	  A	  commercial	  kit	  from	  BioVision,	  USA,	  called	   Nuclear/Cytosol	   Fractionation	   Kit	   (K266-­‐100)	   was	   used.	   Instructions	   from	  the	   manufacturer	   were	   followed,	   briefly:	   cell	   pellet	   was	   resuspended	   in	   a	   lysis	  buffer,	   transferred	   into	   a	   1.5	   ml	   eppendorf,	   vortexed	   and	   incubated	   on	   ice.	   A	  Cytosolic	  Extraction	  Buffer	  was	  then	  added	  to	  the	  pellet;	  samples	  were	  incubated	  on	  ice	   and	   centrifuged	   to	   separate	   cytosolic	   protein	   from	   the	   nuclei.	   Supernatant,	  containing	   cytosolic	   proteins,	  was	   transferred	   into	   a	   clean	   1.5	  ml	   tube;	   the	   pellet	  was	   resuspended	  with	  a	  Nuclear	  Extraction	  Buffer,	   vortexed	  and	   incubated	  on	   ice	  for	   four	   cycles	   for	   a	   total	   of	   40	   minutes.	   Samples	   were	   centrifuged	   and	   the	  supernatant,	   containing	   nuclear	   proteins,	   was	   transferred	   into	   a	   clean	   1.5	   ml	  eppendorf.	  Tubes	  were	  stored	  at	  -­‐80ºC	  for	  future	  usage.	  	  
	  
2.5.5.3	  Protein	  Quantification	  The	  importance	  of	  knowing	  the	  concentration	  of	  the	  protein	  extracted	  is	  essential	  to	  load	  the	  same	  amount	  of	  protein	  for	  different	  samples	  in	  an	  SDS-­‐PAGE	  gel.	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For	  the	  purpose	  of	  this	  thesis	  the	  Bio-­‐Rad	  DC	  Protein	  assay	  kit	  was	  used	  (Reagent	  A	  500-­‐0113,	   Reagent	   B	   500-­‐01114,	   Biorad).	   This	   assay	   is	   based	   on	   the	   observation	  that	  the	  absorbance	  maximum	  for	  an	  acidic	  solution	  of	  Coomassie	  Brilliant	  Blue	  G-­‐250	   shifts	   from	   465	   nm	   to	   595	   nm	   when	   binding	   to	   protein	   occurs.	   Both	  hydrophobic	  and	   ionic	   interactions	  stabilize	   the	  anionic	   form	  of	   the	  dye,	  causing	  a	  visible	  color	  change,	  thus,	  the	  higher	  the	  concentration	  of	  protein	  is,	  the	  bigger	  will	  be	  the	  color	  change.	  
	  
2.5.5.3.1	  Method	  Standards	  were	  prepared	  at	  five	  different	  concentrations:	  0	  µg/µl,	  0.625	  µg/µl,	  1.25	  
µg/µl,	   2.5	  µg/µl	   and	   5	  µl/µl	   diluting	   Bovine	   Serum	   Albumine	   (BSA)	  with	   ddH2O.	  From	   each	   sample/standard	   5	   ul	   were	   loaded	   into	   a	   clear	   bottom	   96	   well/plate	  (Corning),	   25	  µls	   of	   Bradford	   reagent	   A	   and	   200	  µls	   of	   Bradford	   reagent	   B	  were	  added	   to	   each	   well,	   including	   two	   empty	   wells	   used	   to	   quantify	   the	   background	  noise.	  The	  plate	  was	  then	  incubated	  at	  room	  temperature	  for	  10	  minutes	  and	  read	  with	   the	   Victor3	   1420	  Multilabel	   Counter	   (Perkim	   Elmer).	   Results	   were	   exported	  into	   a	   spreadsheet	   and	   analyzed	   with	   Excel.	   The	   correlation	   between	   standard	  concentrations	  and	  their	  absorbance	  (x<1)	  was	  analyzed	  with	  liner	  regression;	  R2	  >	  0.98	  was	  accepted.	  Once	  obtained	  the	  equation	  describing	  the	  linear	  correlation	  of	  that	  curve,	  concentration	  of	  the	  sample	  was	  derived	  as	  follows:	  the	  equation	  y	  =	  ax	  +	  b	  where:	  
y	  =	  absorbance	  
a	  =	  slope	  (curve	  inclination)	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x	  =	  concentration	  of	  the	  sample	  
b	  =	  intercept	  (defines	  the	  elevation	  of	  the	  line)	  was	  transformed	  in	  x	  =	  (y-­b)/a	  to	  determine	  the	  sample	  concentrations.	  
	  
Fig	  2.5	  -­	  Example	  of	  linear	  regression	  curve	  obtained	  with	  standard	  BSA	  samples.	  The	  
y	   axes	   indicates	   the	   absorbance	   that	   correlates	  with	   the	   concentration	   indicated	   on	  
the	  x	  axes.	  	  
	  
2.5.5.4	  General	  Method	  For	  Western	  Immunoblotting	  	  For	  more	  detailed	  Western	  Immunoblotting	  protocols	  refer	  to	  Table	  2.5.	  	  
	   2.5.5.4.1	  Gel	  Preparation	  Polyacrylamide	  gels	  were	  prepared	  at	  different	  concentrations	  due	  to	  the	  molecular	  weight	  of	  the	  protein	  of	  interest.	  Resolving	  gels	  were	  prepared	  as	  follow:	  	  
Compound	   5%	   8%	   10%	   12-­1/2%	  
Amm-­SO4	   Spatula	  tip	   Spatula	  tip	   Spatula	  tip	   Spatula	  tip	  
dH2O	   6.7ml	   4.8ml	   3.5ml	   1.9ml	  
Stock	  2	   10ml	   10ml	   10ml	   10ml	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Acrylamide	   3.25ml	   5.2ml	   6.5ml	   8.1ml	  
T-­Med	   6.2µl	   6.2µl	   6.2µl	   6.2µl	  	  
STOCK2:	  (500ml)	  -­‐	  0.75M	  TRIS	  45.5g,	  0.2%	  SDS	  1g,	  pH	  8.8,	  made	  up	  with	  dH2O	  	  Stacking	  gels	  were	  prepared	  as	  follow:	  
Amm-­SO4	   Spatula	  tip	  
dH2O	   3.7ml	  
Stock	  1	   5ml	  
Acrylamide	   1.3ml	  
T-­Med	   3.4µl	  
	  
STOCK1:	  (500ml)	  -­‐	  0.2	  M	  TRIS	  15.15	  g,	  0.2%SDS	  1	  g,	  pH	  6.8,	  made	  up	  with	  dH2O	  Ammonium	  persulfate,	  T-­‐MED	  (Tetramethylethylenediamine)	  were	  from	  Sigma	  and	  Acrylamide	  (Acrylamide/Bis-­‐acrylamide	  30%solutions	  37.5:1)	  was	  from	  Gene	  Flow,	  UK.	  Gels	   were	   prepared	   to	   be	   1.5	   mm	   thick	   by	   pouring	   them	   into	   the	   appropriate	  glassware	  (Biorad)	  and	  10	  wells	  combs	  (Biorad)	  were	  used.	  	  While	  gels	  were	  polymerizing,	  the	  protein	  lysate	  (either	  whole	  cell	  lysate	  or	  nuclear	  and	  cytosolic	  extract)	  were	  prepared	  mixing	  20	  µg	  of	  protein	  with	  ddH2O,	  up	  to	  20	  
µl,	  and	  6.7	  µl	  of	  4X	  SDS-­‐Loading	  Buffer	  (for	  stock,	  7.5	  ml	  4X:	  1.5	  ml	  1	  M	  Tris-­‐HCl	  (pH	  6.8),	   3ml	   1M	   DTT,	   0.6g	   SDS	   powder,	   0.03g	   Bromophenol	   blue,	   3	   ml	   (100%	  Glycerol)).	  Samples	  were	  boiled	  at	  99ºC	  for	  10	  mins,	  quickly	  vortexed,	  placed	  on	  ice,	  centrifuged	  and	  then	  loaded	  into	  the	  appropriate	  wells.	  Gels	  were	  run	  at	  120	  Volts	  for	  1	  hour	  at	  room	  temperature	  in	  presence	  of	  1X	  running	  buffer	  (1lt	  10X:	  Glycine	  141.1g,	  TRIS	  30g,	  SDS	  10g	  (all	   from	  Sigma),	  made	  up	  1L	  dH2O)	  until	   the	  dye	   front	  reached	  the	  bottom	  of	  the	  gel.	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2.5.5.4.2	  Protein	  Transfer	  Proteins	  were	   transferred	   from	   the	   gel	   to	   an	   Immobilion	   P	  membrane	   (Millipore,	  USA);	   to	   do	   so	   the	   PVDF	   membrane	   was	   soaked	   in	   methanol	   for	   15	   sec	   (PVDF	  membrane	  is	  extremely	  hydrophobic	  and	  will	  not	  “wet”	  in	  aqueous	  solutions	  unless	  pre-­‐expanded	  in	  methanol	  before	  it	  is	  used),	  placed	  in	  ultrapure	  water	  for	  2	  minutes	  and	  then	  equilibrated	  in	  1X	  transfer	  buffer	  (1lt	  10X:	  TRIS	  30.28g,	  Glycine	  144g,	  SDS	  1g,	  made	  up	  1L	  dH2O	  –	  1X:	  100	  ml	  10X	  buffer,	  700	  ml	  dH2O,	  200	  ml	  methanol)	  for	  5	  minutes.	  	  To	  ensure	  a	  uniform	  contact	  between	  gel	  and	  membrane	  (thus	  an	  even	  transfer)	  the	  following	  sandwich	  was	  prepared:	  
Anode	  –	  Negative	  Pole	  Sponge	  Whatman	  Paper	  (X2)	  
Membrane	  
Gel	  Whatman	  Paper	  (X2)	  Sponge	  
Cathode	  –	  Positive	  
Pole	  	  These	  cassettes	  were	  places	  into	  appropriate	  boxes	  in	  presence	  of	  1X	  transfer	  buffer	  and	   transfer	   was	   run	   for	   1	   hour	   at	   80	   Volt	   at	   room	   temperature;	   an	   icebox	   was	  added	  to	  the	  transfer	  tank	  to	  chill	  the	  transfer	  buffer.	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   2.5.5.4.3	  Ponceau	  Staining	  Once	   the	   transfer	   was	   finished	   membranes	   were	   stained	   with	   Ponceau	   Solution	  (Sigma)	   for	   5	   minutes.	   This	   allows	   the	   detection	   of	   proteins	   on	   the	   membrane,	  checking	  also	  the	  quality	  of	  the	  transfer.	  Membranes	  were	  then	  washed	  with	  dH2O.	  	  
	   2.5.5.4.4	  Membrane	  Block	  To	   ensure	   that	   the	   primary	   antibody	   will	   bind	   only	   the	   desired	   protein	   the	  membrane	  was	   incubated	   for	   1	   hour	   at	   room	   temperature	  with	   a	   solution	   of	   5%	  milk	   dissolved	   in	   TBS-­‐T	   (1lt	   10X:	   50	  ml	   1M	  Tris-­‐HCl	   pH	  7.6,	  NaCl	   20g,	   Tween-­‐80	  0.625ml,	   dH2O	   2449.4	  ml).	   The	   proteins	   present	   in	  milk	   bind	   the	  membrane	   and	  prevent	  aspecific	  binding	  of	  the	  primary	  antibody.	  
	   2.5.5.4.5	  Primary	  Antibody	  The	  role	  of	  the	  primary	  antibody	  is	  to	  detect	  the	  protein	  of	  interest	  with	  the	  highest	  desirable	   specificity.	   The	   selected	   antibody	   was	   diluted	   at	   the	   indicated	  concentration	  (see	   table	  below)	   in	  TBS-­‐T	  with	  5%	  TBS-­‐T/milk	  and	   the	  membrane	  was	   incubated	   over	   night	   at	   +4ºC.	   The	   only	   exceptions	   were	   beta-­‐actin	   and	  Nucleolin	  that	  were	  incubated	  at	  room	  temperature	  for	  one	  hour.	  After	   the	   incubation	   time,	   the	  membrane	  was	  washed	   three	   times	   for	   5	  min	  with	  TBS-­‐T	  to	  remove	  the	  excess	  of	  antibody.	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Ab	  name	   Company	  -­	  Product	  Code	  NCoR1	   Abcam	  –	  ab24552	  NCoR2	   Abcam	  –	  ab24551	  PPAR-­‐gamma	   Santa	  Cruz	  –	  sc7273	  PPAR-­‐alpha	   Santa	  Cruz	  -­‐	  sc1985	  VDR	   Abcam	  -­‐	  ab3548	  COX2	   Santa	  Cruz	  -­‐	  sc19999	  5-­‐Lypoxigenase	   Santa	  Cruz	  -­‐	  sc8885	  SLIRP	   Abcam	  –	  ab51523	  HDAC3	   Santa	  Cruz	  -­‐	  sc130319	  SUMO-­‐1	   Cell	  Signaling	  -­‐	  4930	  SENP6	   Abcam	  –	  ab57239	  
β-­‐actin	   Abcam	  -­‐	  ab6276	  Nucleolin	   Abcam	  –	  ab13541	  	  
Table	  2.4	  -­	  List	  of	  the	  primary	  antibody	  used	  for	  this	  thesis	  
	   2.5.5.4.6	  Secondary	  Antibody	  The	   secondary	  antibody	   is	   generally	  HRP	  conjugated	  and	  permits	   recognition	  and	  detection	  od	  the	  primary	  antibody,	  hence	  proteins,	  on	  the	  membrane	  in	  presence	  of	  ECL.	  The	  origin	  of	  the	  primary	  antibody	  (mouse,	  rat,	  sheep)	  dictates	  the	  secondary	  chosen	   (anti-­‐mouse,	   anti-­‐rat,	   anti-­‐sheep)	   and	  was	   diluted	   in	   TBS-­‐T	  with	   5%	  milk.	  The	   membrane	   was	   then	   incubated	   with	   this	   solution	   for	   one	   hour	   at	   room	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temperature.	   Afterwards	   the	   membrane	   was	   washed	   three	   times	   for	   5	   min	   with	  TBS-­‐T	  to	  remove	  the	  excess	  of	  antibody.	  	  
	   2.5.5.4.7	  Chemoluminescent	  Detection	  of	  Protein	  Bands	  The	  HRP	  catalyses	  the	  release	  of	  light	  from	  Luminol	  and	  Peroxide	  in	  presence	  of	  ECL	  substrate.	   For	   the	   aim	   of	   this	   thesis	   the	   Pierce	   SuperSignal	   West	   Pico	  Chemiluminescent	   Substrate	   (Pierce	   –	   34078,	   USA)	  was	   used.	   One	  ml	   of	   reaction	  mix	  was	  spread	  on	  top	  of	  each	  membrane	  and	  incubated	  at	  room	  temperature	  for	  5	  min.	  The	  excess	  of	  ECL	  was	  removed	  by	  touching	  the	  corner	  of	  the	  membrane	  with	  a	  paper	   napkin;	   the	  membrane	  was	   then	   put	   between	   two	   layers	   of	   clinching	   film,	  exposed	   in	   the	  dark	   to	   the	  Amersham	  Hyperfilm	  ECL	  (28-­‐9068-­‐37)	  and	  ran	   into	  a	  developer	  machine	  	  (Kodak).	  Exposure	  time	  was	  then	  assessed	  based	  on	  the	  results	  of	  the	  first	  film.	  	  
	  
Fig	  2.6	  -­	  Example	  of	  evenly	  expressed	  beta-­actin	  between	  different	  samples.	  	  
2.5.5.5	  Specific	  Methods	  For	  Western	  Blotting	  	  Each	  antibody	  has	  a	  different	  efficiency	  and	  each	  protocol	  was	  optimized	  to	  obtain	  the	   most	   specific	   signal	   as	   possible	   with	   each	   analysis.	   In	   the	   table	   below	   are	  summarized	  the	  specifications	  for	  each	  different	  primary	  antibody.	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  Protein	   %	  Gel	  -­‐	  Run	   Transfer	   Blotto	   I	  Ab	   II	  Ab	  NCOR-­‐NCOR2/SMRT	   4%	  -­‐	  3.20	  hr	  -­‐100	  V	   4	  hr	  –	  60	  V	   O/N	   1:500	   1:2000	  PPAR-­‐γ	  /	  α	   10%	  -­‐	  1.15	  hr	  -­‐120	  V	   1.30	  hr	  –	  80	  V	   1.30	  hr	   1:1000	   1:1000	  SLIRP	   12.5%	  -­‐	  1	  hr	  –	  120	  V	   1.15	  hr	  –	  80	  V	   1.15	  hr	   1:5000	   1:5000	  SUMO1	   12.5%	  -­‐	  1	  hr	  –	  120	  V	   1.15	  hr	  –	  80	  V	   1.30	  hr	   1:1000	   1:2000	  COX2	  	   10%	  -­‐	  1.20	  hr	  –	  120	  V	   1.30	  hr	  –	  80	  V	   1.30	  hr	   1:500	   1:750	  5-­‐LO	   10%	  -­‐	  1.20	  hr	  –	  120	  V	   1.30	  hr	  –	  80	  V	   1.30	  hr	   1:500	   1:1000	  HDAC3	   10%	  -­‐	  1.20	  hr	  –	  120	  V	   1.30	  hr	  –	  80	  V	   1.30	  hr	   1:500	   1:1000	  SENP6	   8%	  -­‐	  1.20	  hr	  –	  120	  V	   1.30	  hr	  –	  80	  V	   1.30	  hr	   1:1000	   1:2000	  
β-­‐actin	   Any	  –	  1hr	  –	  120	  V	   1hr	  –	  80V	   1	  hr	   1:10000	   1:5000	  Nucleolin	   10%	  -­‐	  1.15	  hr	  –	  120	  V	   1.15	  hr	  –	  80	  V	   1	  hr	   1:5000	   1:2000	  
Tab	   2.5	   –	   Specification	   for	   the	  Western	   Blot	   experiments	   done.	   Indicated,	   from	   the	  
first	   column	  on	   the	   left	   to	   the	   last	   column	  on	   the	   right,	  are	   the	  name	  of	   the	  protein,	  
how	  long	  the	  gel	  ran	  for,	  how	  long	  was	  it	  transferred	  for,	  how	  long	  was	  the	  blotto	  (5%	  
milk	   in	   TBS-­T),	   the	   dilution	   of	   the	   primary	   antibody	   (in	   5%	  milk	   in	   TBS-­T)	   and	   the	  
dilution	  of	  the	  secondary	  antibody	  (5%	  milk	  in	  TBS-­T).	  
	   	  
2.5.6	  Knock-­Down	  of	  NCOR1	  using	  a	  short	  hairpins	  RNA	  strategy.	  
2.5.6.1	  Short	  Hairpin	  RNA	  -­	  Introduction	  The	   use	   of	   short	   hairpin	   RNAs	   (shRNAs)	   is	   common	   for	   the	   generation	   of	   stably	  transfected	   knock-­‐down	   cell	   lines.	   ShRNAs	   interfere	   with	   protein	   translation	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binding	   RNA	  molecules;	   this	   leads	   either	   to	   their	   compartmentalization	   into	   sub-­‐cellular	   compartments	   called	   P-­‐bodies,	   or	   to	   their	   degradation.	   The	   biological	  endpoint	   is	   always	   an	   efficient	   block	   of	   the	   translation	   machinery	   and	   drastic	  reduction	  of	  the	  endogenous	  target	  protein.	  For	  the	  purpose	  of	  this	  thesis	  a	  specific	  shRNA	  to	  target	  the	  human	  NCOR1	  was	  used.	  
	  
Fig	   2.7	   –	   ShRNA	   pathway:	   the	   Dicer	   complex	   processes	   the	   shRNA	   before	   it’s	  
recognised	   by	   the	   RISC	   complex.	   This	   will	   lead	   the	   single	   stranded	   molecule	   to	   the	  
target	  mRNA	  that	  will	  be	  degraded.	  
2.5.6.2	  Oligonucleotide	  Design	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NCOR1	  is	  a	  large	  protein:	  its	  transcript	  includes	  up	  to	  46	  exons	  with	  several	  splicing	  variants.	   To	   ensure	   the	   most-­‐effective	   knock-­‐down	   three	   different	   exons	   were	  targeted:	  exon	  5,	  exon	  38	  and	  exon	  44,	  plus	  a	  combination	  of	  all	  three	  of	  them.	  The	  oligos	   were	   designed	   to	   form	   a	   cassette	   that,	   once	   ligated	   into	   the	   vector,	   would	  have	  ensured	  shRNA	  transcription.	  (A	  scheme	  of	   the	  targeted	  exons	   is	  available	   in	  the	  Supplementary	  Images)	  The	  NCOR1	  mRNA	   sequence	  was	   taken	   from	  NCBI	   (NM_006311.2)	   and	  processed	  through	   the	  Qiagen	   siRNA	  design	  page	   (http://www.qiagen.com).	  A	   list	   of	   several	  possible	  oligos	  was	  screened	  and	  blasted	  to	  confirm	  which	  exon	  was	  targeted.	  The	  chosen	   sequences	   were	   then	   inserted	   into	   the	   cassette	   and	   ordered	   from	   Sigma-­‐Genosis.	  The	  final	  sequences	  are	  the	  following:	  
Exon	  5:	  AAGCTCCATCCTCTCCAATTT	  (700	  -­‐	  exon	  5)	  
Fw:5'-­‐GTACC-­‐AA(GCTCCATCCTCTCCAATTT)-­‐TTCAAGAGA-­‐	  (AAATTGGAGAGGATGGAGC)TT-­‐TTTTT-­‐GGAAAT-­‐3'	  
Rw:3'-­‐G-­‐TT(CGAGGTAGGAGAGGTTAAA)-­‐AAGTTCTCT-­‐(TTTAACCTCTCCTACCTCG)AA-­‐AAAAA-­‐CCTTT-­‐AGATC-­‐5'	  
Exon	  38:	  AAGGCAAATCAAGCGGAAAAT	  (6231	  -­‐	  exon	  38-­‐39)	   	  
Fw:5'-­‐GTACC	   -­‐AA(GGCAAATCAAGCGGAAAAT)-­‐TTCAAGAGA-­‐	   (ATTTTCCGCTTGATTTGCC)TT-­‐TTTTT-­‐GGAAAT-­‐3'	  
Rw:3'-­‐G-­‐TT(CCGTTTAGTTCGCCTTTTA)-­‐AAGTTCTCT-­‐(TAAAAGGCGAACTAAACGG)AA-­‐AAAAA-­‐CCTTT-­‐AGATC-­‐5'	  
Exon	  44:	  AAGGCTCTCATGGGAAGCTTT	  (7044	  -­‐	  exon	  44)	  
Fw:5'-­‐GTACC-­‐AA(GGCTCTCATGGGAAGCTTT)-­‐TTCAAGAGA-­‐	   (AAAGCTTCCCATGAGAGCC)TT-­‐TTTTT-­‐GGAAAT-­‐3'	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Rw3'-­‐G-­‐TT(CCGAGAGTACCCTTCGAAA)-­‐AAGTTCTCT-­‐(TTTCGAAGGGTACTCTCGG)AA-­‐AAAAA-­‐CCTTT-­‐AGATC-­‐5'	  	  
2.5.6.3	  Short	  Hairpin	  RNA	  construct	  To	  ensure	  an	  efficient	  production	  of	  the	  shRNA	  of	  interest	  the	  oligos	  containing	  the	  shRNA	  sequence	  were	  annealed	  and	   inserted	   into	  a	  pcDNA3.1	  vector	  (Invitrogen).	  In	  this	  vector	  the	  original	  CMV	  promoter	  has	  been	  substituted	  with	  the	  human	  H1	  promoter.	  	  
	  	  
Fig	   2.8	   –	   pcDNA	   3.1	   vector	   from	   Invitrogen.	   Human	   H1	   promoter	   was	   inserted	   by	  
Farhat	  Khanim	  (University	  of	  Birmingham,	  Birmingham,	  UK)	  to	  substitute	  the	  original	  
CMV	  promoter.	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2.5.6.3.1	  Annealing	  Method	  Oligos	   were	   resuspended	   in	   TE	   buffer	   (10mM	   Tris,	   1mM	   EDTA	   pH	   7.4)	   at	   the	  concentration	   suggested	   by	   Sigma-­‐Genosis	   (100	   uM).	   Before	   ligation	   into	   the	  pcDNA3.1-­‐H1	   vector	   oligos	   were	   annealed:	   2	   uls	   of	   each	   strand	   (forward	   and	  reverse)	  were	  resuspended	   in	  46	  uls	  of	  TE	  buffer,	  heated	  at	  80ºC	   for	  10	  mins	  and	  then	   cooled	   down	   at	   room	   temperature	   for	   about	   one	   hour.	   Samples	   were	   then	  stored	  at	  -­‐20ºC.	  	  
2.5.6.3.2	  Ligation	  Into	  pcDNA3.1-­H1	  Vector	  T4	   DNA	   Ligase,	   purified	   from	   E.Coli	   (Invitrogen	   SKU#15224-­‐017),	   catalyzes	   the	  formation	   of	   phosphodiester	   bonds	   in	   the	   presence	   of	   ATP	   between	   double-­‐stranded	  DNAs	  with	  3´	  hydroxyl	  and	  5´	  phosphate	  termini.	  For	  the	  ligation	  reaction:	  2	   uls	   of	   empty	   pcDNA3.1-­‐H1	   vector,	   1	   ul	   of	   ligated	   oligos,	   10X	   Reaction	   Buffer	  (Promega),	  1ul	  of	  T4	  DNA	   ligase	  and	  5	  uls	  of	  nuclease	   free	  ddH2O	  were	   incubated	  O/N	  at	  +4ºC.	  	  
2.5.6.3.3	  Transformation	  of	  Competent	  Cells	  –	  Introduction	  In	   microbiology,	   genetics,	   cell	   biology	   and	   molecular	   biology,	   competence	   is	   the	  ability	   of	   a	   cell	   to	   take	   up	   extracellular	   ("naked")	   DNA	   from	   its	   environment.	  Competence	  is	  distinguished	  into	  natural	  competence,	  a	  genetically	  specified	  ability	  of	   bacteria	   that	   is	   thought	   to	   occur	   under	   natural	   conditions	   as	   well	   as	   in	   the	  laboratory,	   and	   induced	   or	   artificial	   competence,	   arising	  when	   cells	   in	   laboratory	  cultures	  are	   treated	   to	  make	   them	   transiently	  permeable	   to	  DNA.	  Transformation,	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instead,	  is	  the	  genetic	  alteration	  of	  a	  cell	  resulting	  from	  the	  uptake	  and	  expression	  of	  foreign	  genetic	  material	  (DNA),	  in	  this	  case	  a	  plasmid.	  The	   idea	   behind	   transformation	   of	   artificially	   prepared	   competent	   cells	   is	   that	  chilling	  cells	  in	  the	  presence	  of	  divalent	  cations	  such	  as	  Ca2+	  (in	  CaCl2)	  prepares	  the	  cell	  walls	  to	  become	  permeable	  to	  plasmid	  DNA.	  Cells	  are	  incubated	  on	  ice	  with	  the	  DNA	  and	  then	  briefly	  heat	  shocked	  (eg	  42	  °C	  for	  30–120	  seconds),	  which	  causes	  the	  DNA	  to	  enter	  the	  cell.	  The	  last	  step	  is	  to	  select	  those	  cells	  containing	  the	  plasmid	  of	  interest,	  this	  can	  be	  done	  plating	  them	  in	  a	  Petri	  dish	  with	  an	  antibiotic;	  the	  plasmid	  contains	   an	   antibiotic	   resistance	   (Ampicillin	   in	   the	   case	   of	   the	   one	   used	   in	   this	  thesis),	   therefore	   only	   transformed	   cells	   are	   able	   to	   survive	   and	   grow	   in	   colonies	  that	  will	  be	  then	  selected.	  	  
2.5.6.3.4	  Method	  Competent	   cells	   from	   Invitrogen	   (12297-­‐016)	   were	   stored	   at	   -­‐80ºC	   and	   slowly	  thawed	   on	   ice.	   100	   uls	   were	   then	   resuspended	   with	   4	   uls	   of	   pcDNA3.1-­‐H1	   and	  incubated	  for	  30	  mins	  on	  ice.	  A	  brief	  heat	  shock	  was	  given	  bringing	  the	  reaction	  mix	  at	  37ºC	  for	  30	  seconds,	  samples	  were	  then	  returned	  to	  ice	  for	  2	  mins.	  250	  uls	  of	  pre-­‐warmed	  L-­‐Broth	  (Sigma)	  were	  added	   to	  each	  sample	  and	   these	  were	   incubated	  at	  37ºC	   shaking	   at	   225	   rpm	   for	   one	   hour.	   Tubes	  were	   briefly	   centrifuged	   at	   <	   2000	  rpm,	   most	   of	   the	   supernatant	   was	   poured	   off	   and	   the	   pellet	   was	   spread	   in	   Petri	  dishes	   containing	   L-­‐Broth	   (Sigma)	   plus	   100	   µg/ml	   of	   L-­‐Ampicillin.	   After	   an	   over-­‐night	   incubation	   at	   37ºC	   colonies	   were	   selected,	   picked	   up	  with	   a	   sterile	   tip	   and	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resuspended	   in	   5	  mls	   L-­‐Broth	   in	   a	   50	  ml	   falcon	   tube.	   This	  was	   then	   incubated	   at	  37ºC	  over	  night	  shaking	  at	  225	  rpm	  and	  used	  for	  Minipreps.	  	  
2.5.6.3.5	  Minipreps	  to	  isolate	  plasmid	  and	  Sample	  Digestion	  Once	   the	   liquid	   cultures	   were	   ready,	   one	   ml	   of	   each	   sample	   was	   used	   to	   check	  whether	   plasmid	   DNA	   was	   inside	   the	   transformed	   competent	   cells.	  Wizard®PlusMinipreps	  DNA	  Purification	  System	  form	  Promega	  (A7100)	  was	  used	  and	   the	   manufacturer’s	   instructions	   were	   followed.	   Briefly:	   cells	   were	   pelleted,	  resuspended	   and	   lysated;	   lysate	   was	   then	   filtered	   through	   a	   resin	   column	   and	  washed	   three	   times.	  The	   final	  eluted	  yields	  plasmid	  DNA	  that	  was	  resuspended	   in	  Nuclease	  Free	  Water,	  quantified	  and	  ran	   into	  a	  1.5%	  Agarose	  (Sigma)	  gel	   to	  check	  purity.	  Samples	  were	  then	  stored	  at	  -­‐20ºC.	  	  To	  confirm	  the	  presence	  of	  the	  oligo	  in	  the	  site	  of	  insertion,	  vector	  was	  digested	  with	  Acc65	   I	   and	   Xba	   I	   (both	   Promega)	   restriction	   enzymes:	   10	   µls	   of	   vector	   were	  resuspended	  with	  1	  µl	  Acc65	  I,	  1	  µl	  XbaI,	  2	  uls	  of	  10X	  Multicore	  Buffer	  (Promega)	  and	  6	  µls	  of	  dH2O.	  The	  reaction	  mix	  was	  incubated	  at	  37ºC	  for	  2	  hours.	  Afterwards	  the	  products	  were	  resolved	  on	  a	  2%	  agarose	  gel	  to	  check	  the	  presence	  of	  the	  insert.	  Once	   the	   presence	   of	   plasmid	   DNA	   was	   confirmed	   samples	   were	   sequenced	   to	  confirm	  that	  the	  insert	  was	  the	  sequence	  of	  interest.	  	  
	   2.5.6.3.7	  Sequencing	  of	  the	  shNOR1	  samples	  Samples	  were	  prepared	  The	  reaction	  mix	  containing	  0.4	  µgs	  of	  DNA,	  1	  ul	  of	  reverse	  primer	  and	  nuclease	  free	  water	  up	  to	  10	  µls	  was	  brought	  to	  the	  Genomic	  Facilities	  in	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the	   School	   of	  Biosciences	   (University	   of	  Birmingham,	  Birmingham,	  UK)	  where	   the	  sequencing	  experiments	  were	  undertaken.	  Results	   were	   analyzed	   with	   4Peaks	   for	   MacOSX,	   freely	   available	   online	  (http://mekentosj.com/4peaks).	   The	   different	   peaks	   refer	   to	   the	   probability	   of	  finding	  the	  nucleotide	  X	  in	  the	  position	  Y.	  	  
	  
Fig	  2.8	  –	  Layout	  from	  sequencing	  experiment.	  Each	  peak	  represents	  the	  probability	  of	  
finding	  that	  specific	  nucleotide,	  its	  position	  is	  written	  below	  the	  sequence.	  	  	  Once	  the	  presence	  of	  the	  insert	  has	  been	  assessed	  another	  liquid	  culture	  in	  500	  mls	  of	  L-­‐Broth	  was	  prepared	  and	  incubated	  over	  night	  at	  37ºC	  shaking	  at	  225	  rpm.	  	  
2.5.6.3.6	  Maxipreps	  to	  generate	  large	  quantity	  of	  plasmid	  DNA	  A	   large	   scale	   purification	   kit	   from	  Qiagen	  was	   used	   to	   extract	   plasmid	   DNA	   from	  liquid	   cultures.	   DNA	   obtained	   from	   maxipreps	   in	   more	   pure	   than	   the	   one	   from	  minipreps	   and	   can	   be	   used	   for	   transfection	   experiments	   in	   mammalian	   cells.	  Manufacturer’s	  instructions	  were	  followed,	  briefly:	  cells	  were	  pelleted,	  resuspended	  and	  lysed;	  lysate	  was	  then	  filtered	  though	  a	  resin	  column	  able	  to	  bind	  plasmid	  DNA.	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This	   was	   then	   washed	   and	   finally	   eluted	   in	   Nuclease	   Free	  Water,	   quantified	   and	  stored	  at	  -­‐20ºC.	  	  
2.5.6.4	  Transfection	  of	  Prostate	  Cancer	  Cells	  Transfection	   describes	   the	   introduction	   of	   foreign	   material	   into	   eukaryotic	   cells	  using	  a	  virus	  vector	  or	  other	  means	  of	  transfer.	  The	  term	  transfection	  for	  non-­‐viral	  methods	   is	  most	   often	  used	   in	   reference	   to	  mammalian	   cells.	   For	   the	  purposes	   of	  this	  thesis	  FuGENE	  6	  (Roche	  Diagnostic)	  was	  used	  for	  the	  trasnfections.	  	  	  
2.5.6.4.1	  Transfection	  Efficiency	  PC-­‐3	  cells	  were	  transfected	  with	  different	  concentrations	  of	  FuGENE6/DNA	  in	  order	  to	   deliver	   as	  much	   plasmid	   as	   possible	   inside	   the	   cell.	   The	   concentrations	   tested	  were	  0	  nM,	  25	  nM,	  50	  nM,	  100	  nM,	  150	  nM.	  A	  Renilla	   reporter	  plasmid	  (AM4630,	  Invitrogen)	  was	  used	  and	  after	  24,	  48	  and	  96	  hrs	  from	  initial	  transfection	  cells	  were	  checked	   under	   a	   fluorescence	   microscope,	   pictures	   were	   taken	   to	   identify	   the	  sample	  with	   the	  most	   efficient	   transfection.	   In	   this	   case	   50	   nM	   resulted	   to	   be	   the	  most	  efficient	  concentration.	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Fig	  2.9	  –	  Transfection	  efficiency	  experiment.	  Method	  of	  transfection	  explained	  below,	  
briefly,	   mid-­exponential	   growing	   PC-­3	   cells	   were	   transfected	   with	   different	  
concentrations	   of	   plasmid/FUGENE6	  and	  analysed	  after	   24,	   48	  and	  96	  hr	  under	   the	  
microscope.	  Pictures	   indicate	  cells	   in	  the	  plate	  (TOP)	  while	  red	  cells	   indicate	  Renilla-­





2.5.6.4.2	  Method	  Transfections	  were	  carried	  out	   in	  6	  well/plates,	  3	  wells/clone	   -­‐	   shNCoR	  vs	  Vector	  Only.	   PC-­‐3	   cells	   were	   plated	   10^5/well	   in	   3	   mls	   RPMI1640	   	   (Sigma)	   (10%	   FBS	  (Gibco),	  1%	  P/S	  (Invitrogen),	  1%	  L-­‐Glu	  (Invitrogen))	  and	  seeded	  for	  about	  36	  hrs.	  For	   three	   wells	   564	   uls	   of	   serum	   free	   media	   and	   36	   uls	   of	   FuGENE	   6	   were	   left	  incubating	  for	  5	  mins	  at	  room	  temperature	  in	  a	  1.5	  ml	  eppendorf,	  6	  ugs	  of	  plasmid	  were	   added	   and	   left	   incubating	   for	   further	   15	  mins	   at	   room	   temperature.	   At	   this	  point	  200	  uls	  of	  each	  reaction	  mix	  were	  placed	  in	  each	  well	  and	  after	  24	  hrs	  media	  was	  substituted	  with	  selective	  media	  containing	  G418	  1ug/ul	  (Sigma).	  After	  48	  hrs	  cells	  were	   plated	   in	   T25	   and	   clones	  were	   selected	   after	   96	   hr.	   The	   presence	   of	   a	  specific	   NCOR1	   knock-­‐down	   was	   tested	   by	   qRT-­‐PCR-­‐TaqMan	   and	   Western	  Imunoblotting.	  	  
2.6	  –	  Chromatin	  Immunoprecipitation	  Assay	  to	  Analyse	  H3K9	  acetylation	  
2.6.1	  –	  Background	  Chromatin	  immunoprecipitation	  (ChIP)	  is	  a	  method	  used	  to	  determine	  the	  location	  of	   DNA	   binding	   sites	   on	   the	   genome	   for	   a	   particular	   protein	   of	   interest.	   This	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technique	   gives	   a	   picture	   of	   the	   protein-­‐DNA	   interactions	   that	   occur	   inside	   the	  nucleus	   of	   living	   cells	   or	   tissues.	   Histone	  modifications	   can	   also	   be	   recognised	   by	  specific	  antibodies;	  for	  the	  purposes	  of	  this	  thesis,	  the	  acetylation	  of	  Lysine	  9	  of	  the	  histone	   H3	   (H3K9Ac)	   was	   analysed	   because	   this	   modification	   is	   a	   widely	   used	  marker	  for	  active	  promoter	  regions	  that	  positively	  regulate	  transcription	  .	  
	  
Fig	  2.10	  –	  General	  workflow	  of	  an	  X-­ChIP	  experiment.	  DNA	  is	  initially	  crosslinked	  to	  fix	  
the	  proteins	  to	  the	  DNA,	  DNA	  is	  sonicated	  and	  the	  fragments	  incubated	  with	  a	  primary	  
antibody	   directed	   against	   the	   selected	   epitope.	   The	   reverse	   crosslinking	   releases	   the	  
antibody/proteins	   from	   the	   DNA;	   next,	   DNA	   is	   extracted	   and	   quantified	   by	   PCR	  
analysis.	  Image	  taken	  from	  www.bbioo.com.	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2.6.2	  –	  Method	  Mid	   exponentially	   growing	   PC-­‐3	   cells	   were	   grown	   in	   10	  ml	   of	   RPMI	   1640	  media	  (previously	   described).	   Cells	   were	   first	   crosslinked	   adding	   270	   µl	   of	   37%	  formaldehyde	   (PS2301,	   Sigma).	   To	   fix	   the	   protein	   to	   DNA	   and	   then	   incubated	   at	  37ºC	  for	  8	  minutes;	  crosslinking	  was	  stopped	  adding	  1.5	  ml	  of	  1M	  Glycine	  directly	  to	  the	   culture	   medium	   and	   incubated	   at	   RT	   for	   5	   minutes	   with	   gentle	   shacking.	  Medium	  was	  aspirated	  and	  cells	  washed	  with	  PBS	  containing	  5	  mM	  of	  NaB	  (303410,	  Sigma)	  (NaB	  prevents	  the	  deacetylation	  events	  to	  occur	  maintaining	  the	  acetylation	  status	  of	  H3K9);	  pellet	  was	  collected	  in	  ice	  cold	  PBS+NaB	  by	  scraping	  the	  flasks	  on	  ice,	  transferred	  in	  a	  15	  ml	  falcon	  tube	  and	  centrifuged	  at	  700	  g	  for	  5	  minutes	  at	  4ºC.	  The	  cell	  pellet	  was	  resuspended	  in	  1	  ml	  of	  SDS-­‐Lysis	  buffer	  (1%	  SDS,	  10	  mM	  EDTA	  and	  50	  mM	  Tris-­‐HCl	  pH	  8.1)	  and	  transferred	  into	  a	  new	  1.5	  ml	  eppendorf	  tube.	  	  Samples	   were	   then	   sonicated	   at	   4ºC	   for	   5	   minutes	   at	   medium	   intensity	   with	   30	  seconds	   pulses	   to	   obtain	   DNA	   fragments	   of	   ~500	   bp.	   Debris	   were	   removed	   by	  centrifuging	   the	   samples	   at	   16000	   g	   for	   5	   minutes	   at	   4ºC;	   the	   supernatant	  containing	  the	  chromatin	  fragments	  was	  divided	  in	  4	  x	  200	  µl	  aliquots:	  one	  sample	  for	   stock,	   one	   sample	   for	   H3K9Ac	   immunoprecipitation,	   one	   sample	   for	   IgG	  immunoprecipitation	  (control	  IP)	  and	  one	  INPUT	  (non-­‐IP	  sample	  control).	  Aliquots	  were	   resuspended	   in	   further	   300	  µl	   of	   dilution	   buffer	   (0.01%SDS,	   1.1%	  Triton	  X-­‐100,	  1.2	  mM	  EDTA,	  16.7	  mM	  Tris-­‐HCl	  pH	  8.1	  and	  167	  mM	  NaCl).	   IgG	  and	  H3K9Ac	  samples	  were	  incubated	  for	  at	  least	  30	  minutes	  on	  a	  rotating	  platform	  with	  95	  µl	  of	  Protein	  A	  Agarose	  50%	  slurry	   (15918-­‐014,	   Invitrogen)	  and	  5	  µl	   of	  Herring	   sperm	  DNA	  (15634-­‐017,	  Invitrogen);	  this	  passage	  is	  a	  blocking	  step	  that	  reduces	  aspecific	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binding	  of	   the	   antibody	   to	   the	   epitopes.	   Samples	  have	   to	  be	  briefly	   centrifuged	   at	  170	  g	  for	  1	  minute	  to	  remove	  the	  pellet	  before	  adding	  the	  antibody.	  For	  the	  IP	  step,	  5	   µl	   of	   the	   antibodies	   –H3K9Ac	   (rabbit,	   gift	   of	   Prof.	   Brian	   Turner	   and	   Dr.	   Laura	  O’Neill,	   University	   of	   Birmingham,	   Birmingham,	   UK)	   and	   IgG	   (rabbit,	   ab49697,	  Abcam)–	  were	  added	  to	  the	  samples	  and	  incubated	  over-­‐night	  at	  4ºC	  on	  a	  rotating	  platform.	  Samples	   require	   a	   further	   step	   of	   purification	   to	   isolate	   the	   immunoprecipitated	  complexes;	   this	   was	  made	  with	  magnetic	   beads	   (Pure	   Proteome	   Prot	   A	  Magnetic	  beads,	  LSKMAGA10,	  Millipore).	  	  Initially	  50	  µl	  of	  beads/sample	  were	  put	  in	  a	  1.5	  ml	  eppendorf	  tube,	  mixed	  with	  500	  
µl	  of	  PBS	  with	  0.1%	  Tween	  20,	  placed	  on	  a	  magnetic	  rack,	  supernatant	  was	  taken	  off	  and	   beads	  were	   resuspended	   in	   further	   100	  µl	   of	   PBS/0.1%	  Tween	   20.	   This	  was	  added	   to	   the	  samples	  and	   incubated	  at	  4ºC	   for	  1	  hour	  on	  a	   rotating	  platform.	  The	  supernatant	  containing	  unbound	  DNA	  was	  discarded.	  Samples	  were	  then	  washed	  with	  500	  µl	  of	  the	  following	  buffers	  at	  RT	  for	  5	  minutes	  on	   a	   rotating	   platform,	   respectively:	   1X	   low	   salt	   immune	   complex	  washing	   buffer	  (0.1%	  SDS,	  1%Triton	  X-­‐100,	  2	  mM	  EDTA,	  20	  mM	  Tris-­‐HCl	  pH	  8.1	  and	  150	  mM	  NaCl),	  1X	   high	   salt	   immune	   complex	  washing	   buffer	   (0.1%	   SDS,	   1%Triton	   X-­‐100,	   2	  mM	  EDTA,	  20	  mM	  Tris-­‐HCl	  pH	  8.1	  and	  500	  mM	  NaCl),	  1X	  LiCl	  immune	  complex	  washing	  buffer	  (0.25	  M	  LiCl,	  1%	  NP40,	  1%	  deoxycholate,	  10	  mM	  Tris-­‐HCl	  pH	  8.1	  and	  1	  mM	  EDTA)	   and	   2X	   TE	   buffer	   (10	   mM	   Tris-­‐HCl	   pH	   8.0	   and	   1	   mM	   EDTA).	   The	   use	   of	  different	   types	   of	   salts	   improves	   the	   effective	   removal	   of	   non-­‐specific	   chromatin	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interactions	  with	  the	  magnetic	  beads.	  LiCl	  is	  also	  soluble	  in	  buffers	  containing	  high	  amounts	  of	  SDS.	  After	   the	   last	   wash	   samples	   were	   resuspended	   in	   500	   µl	   of	   elution	   buffer	   (0.1M	  NaHCO3	  and	  1%	  SDS)	  and	   incubated	  at	  RT	   for	  30	  minutes	  on	  a	   rotating	  platform;	  this	   passage	   will	   release	   the	   DNA	   and	   the	   associated	   proteins	   from	   the	  immunocomplexes.	  The	  supernatant	  containing	  DNA	  was	  transferred	  into	  a	  new	  1.5	  ml	  eppendorf	   tube,	  20	  µl	  of	  5	  M	  NaCl	  were	  added	  to	   the	  samples	  and	  to	   the	   input	  (prepared	   in	   DAY	   1);	   samples	  were	   then	   incubated	   over-­‐night	   at	   65ºC	   to	   reverse	  cross-­‐link,	  hence,	  release	  the	  DNA	  from	  the	  proteins.	  Subsequently,	   20	   µl	   of	   Tris-­‐HCl	   pH	   6.8,	   10	   µl	   of	   EDTA	   and	   2	   µl	   of	   Proteinase	   K	  (AM2546,	   Invitrogen)	  were	   added	   to	   the	   samples	   that	  were	   then	   incubated	   for	   1	  hour	  at	  45ºC.	  	  To	   isolate	   the	   DNA	   a	   phenol/chloroform	   extraction	   was	   performed.	   50	   µl	   of	  phenol/chloroform	   (P3803,	   Sigma)	   were	   added	   to	   each	   sample,	   vortexed	   and	  centrifuged	   at	   13000	   rpm	   for	   5	   minutes.	   The	   clear,	   organic	   top	   phase	   was	  transferred	   into	   another	   1.5	   ml	   eppendorf	   tube,	   500	   µl	   of	   chloroform	   (C2432,	  Sigma)	   were	   added,	   samples	   were	   vortexed	   and	   centrifuged	   at	   13000	   rpm	   for	   5	  minutes.	  The	  clear	  top	  phase,	  containing	  DNA	  was	  transferred	  into	  a	  new	  tube	  and	  mixed	  with	  100	  µl	  of	  4	  M	  LiCl,	  0.5	  µl	  of	  Glycogen	  (AM9510,	  Invitrogen)	  and	  1	  ml	  of	  ice-­‐cold	   100%	   EtOH;	   the	   samples	   were	   then	   incubated	   at	   -­‐80ºC	   for	   1	   hour.	   This	  passage	  will	  precipitate	  the	  DNA.	  The	  tubes	  were	  centrifuged	  at	  13000	  rpm	  for	  10	  minutes	  at	  4ºC,	  the	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  washed	  with	  100	  
µl	  70%	  EtOH.	  The	  samples	  were	  centrifuged	  again	  at	  13000	  rpm	  for	  5	  minutes;	  the	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supernatant	   was	   discarded,	   the	   pellet	   was	   left	   to	   air-­‐dry	   for	   ~10	   minutes	   and	  resuspended	  in	  40	  µl	  of	  Nuclease	  Free	  H2O.	  Finally,	   samples	   were	   quantified	   with	   the	   nanodrop	   (Thermo	   Scientific)	   and	  resuspended	  at	  the	  concentration	  of	  20	  ng/µl.	  	  
2.6.3	  –	  PCR	  analysis	  of	  the	  extracted	  DNA	  PCR	   analysis	   of	   the	   regions	   that	   were	   immunoprecipitated	   reveals	   whether	   the	  region	  of	  interest	  was	  enriched	  or	  depleted	  of	  the	  target	  protein/modification.	  	  For	   the	   purposes	   of	   this	   thesis	   the	   regions	   analysed	  were	   for	   CDKN1A	  TSS	   and	   a	  putative	  PPARα	  binding	  region	  at	  +3733	  nt	  from	  the	  TSS;	  for	  TGFBRAP1	  a	  region	  at	  	  +261	  bp	   from	   the	  TSS	   (this	  because	   the	  TSS	  was	  a	  GC	   rich	   region	  and	  no	   reliable	  primer	   sets	  were	   found)	   and	   a	   putative	   PPARα	   binding	   site	   at	   -­‐929	   from	   the	  TSS	  was	  analysed.	  Putative	  binding	  sites	  were	  identified	  via	  in	  silico	  screening	  by	  Merja	  Heinaniemi	  (University	  of	  Luxembourg,	  Luxembourg).	  Primers	  used	  are:	  Primer	   Sequence	  (5’-­‐3’)	  CDKN1A	  TSS	  Forward	   TATATCAGGGCCGCGCTG	  CDKN1A	  TSS	  Reverse	  	   GGCTCCACAAGGAACTGACTTC	  CDKN1A	  +3733	  Forward	   TTGAGGGCTCTGTCCACTGT	  CDKN1A	  +3733	  Reverse	   TTAAAGGGCAGGAGATGGAA	  TGFBRAP1	  +261	  Forward	   TGTGCGACTTGGTAGCTGTC	  TGFBRAP1	  +261	  Reverse	  	   GCACACTTCATCCCACACAC	  TGFBRAP1	  -­‐929	  Forward	  	   TTTTCCCAGGGATTTTCAGA	  TGFBRAP1	  -­‐929	  Reverse	   GCCTTCAGGGTTGGGATAAT	  	  
Table	  2.6	  –	  Sequences	  of	  the	  primers	  used	  in	  ChIP	  experiments	  in	  this	  thesis.	  Name	  of	  
the	  gene	  and	  position	  relative	  to	  the	  TSS	  are	  indicated	  on	  the	  left	  side.	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  40	   ng	   of	   DNA	   were	   amplified	   in	   a	   20	   µl	   reaction	   containing	   1x	   TaqMan	   PCR	  MasterMix	  and	  1x	  SYBR	  Green	  (both	   form	  the	  kit	  Sensimix	  dT	   -­‐	  QT6T3,	  Quantace,	  UK),	  with	  1	  µM	  of	  primers.	  An	  ABI	  PRISM	  7300	  sequence	  detector	  machine	  (Applied	  Biosystems,	   Foster	   City,	   CA,	   USA)	  was	   used	   under	   the	   following	   cycle	   conditions:	  95°C	  for	  10	  min,	  40	  cycles	  of	  95°C	  for	  15	  sec,	  60°C	  for	  1	  min	  and	  72ºC	  for	  30	  sec	  and	  lastly	   95ºC	   for	   15	   sec,	   60ºC	   for	   1	  min,	   95ºC	   for	   15	   sec	   and	   60ºC	   for	   15	   sec.	   The	  dissociation	   curve	  was	   checked	   for	   each	   sample	   after	   each	   experiment	   to	   confirm	  that	  the	  primers	  amplified	  only	  one	  region;	  samples	  with	  more	  than	  a	  single	  region	  amplified	  were	  excluded	  from	  the	  analysis.	  Final	  measurements	  were	  an	  average	  of	  a	  minimum	  of	  two	  independent	  experiments,	   in	  triplicate	  wells	   for	  each	  condition.	  Student’s	   T-­‐tests	   were	   performed	   to	   identify	   regions	   significantly	   enriched	   or	  depleted.	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3	  –	  EMBRYONIC	  STEM	  CELL	  CULTURE	  AND	  KNOCK-­OUT,	  -­DOWN	  METHODS	  
(Berlin	   -­	   DE	   -­,	   Max	   Planck	   Institute	   for	   Molecular	   Genetics,	   Dept.	   of	  
Developmental	  Genetics)	  
	  
3.1	  –	  Preparation	  of	  feeder	  cells	  from	  mouse	  embryos	  
3.1.1	  –	  Isolation	  of	  Mouse	  Embryonic	  Fibroblasts	  13.5-­‐14.5	   dpc	   (day	   post	   coitum)	   mouse	   embryos	   were	   dissected	   from	   sacrificed	  mice	  and	  placed	   in	  PBS.	  Head	  and	  soft	   tissues	  (e.g	   lung,	   liver,	  heart	  and	  gut)	  were	  discarded	   and	   the	   carcasses	  were	  washed	   twice	   in	   PBS	  before	   being	  minced	  with	  scissors	  into	  small	  pieces	  of	  about	  2-­‐3	  mm	  in	  diameter.	  These	  were	  then	  transferred	  into	  a	  150-­‐cm2	   flask	  with	  screw	  cap	  containing	  30	  ml	  of	  Trypsin-­‐EDTA	  (Sigma)	   to	  digest	   the	   tissues,	   and	   a	   stir	   bar	   with	   molded	   pivot	   ring.	   The	   flask	   was	   then	  incubated	  at	  37	  ºC	  for	  5	  minutes.	  The	  supernatant	  was	  transferred	  to	  a	  50	  ml	  falcon	  tube	   containing	   1.5	   ml	   of	   Fetal	   Calf	   Serum	   (FCS)	   to	   inactivate	   the	   trypsin.	   The	  previous	  step	  was	  repeated	  twice	  to	  digest	  as	  much	  tissue	  as	  possible.	  	  Digested	   cells	  were	   spin	  down	   for	  5	  min	   at	   1000	   rpm,	   resuspended	   in	   feeder	   cell	  medium	  (DMEM	  with	  4.5	  mg/ml	  glucose	  (Sigma),	  10%	  FCS,	  1%	  glutamine	  (Sigma,	  G7513),	  1%	  penicillin/streptomycin	  (Sigma,	  P0906))	  and	  incubated	  over	  night	  at	  37	  ºC.	  Cells	  at	   this	  stage	  were	  ready	  to	  be	  expanded	  and	  treated	  with	  mitomycin	  C	   in	  order	  to	  make	  them	  mitotically	  inactive.	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3.1.2	  –	  Mitomycin	  C	  Treatment	  
	   3.1.2.1	  –	  Introduction	  	  Mitomycin	   C	   is	   an	   aziridine-­‐containing	   product	   isolated	   originally	   from	  
Streptomyces	  lavendulae.	  It	  potently	  inhibits	  cell	  proliferation	  accomplishing	  this	  by	  reductive	   activation	   followed	   by	   two	  N-­‐alkylations.	   Both	   alkylations	   are	   sequence	  specific	  for	  a	  guanine	  nucleoside	  in	  the	  sequence	  5'-­‐CpG-­‐3'.	  	  
	  	  
Fig	  3.1	  –	  Mytomycin	  C	  chemical	  structure	  (from	  Wikipedia)	  	  
3.1.2.2	  –	  Method	  	  Due	  to	  its	  toxicity	  gloves	  were	  always	  worn.	  Once	  culture	  dishes	  were	  fully	  confluent,	  the	  media	  was	  aspirated	  and	  replaced	  with	  feeder	  media	  containing	  0.01	  mg/ml	  of	  mitomycin	  C	  (Sigma,	  M4287)	  and	  incubated	  for	   2-­‐3	   hours	   at	   37ºC.	   After	   that	   time	  media	  was	   carefully	   aspirated,	   plates	  were	  
Chapter	  3	  –	  Embryonic	  stem	  cell	  culture	  and	  knock-­‐out,	  -­‐down	  methods	  	  
 147 
washed	   three	   times	  with	  20	  ml	  of	  PBS,	  10	  ml	  of	   trypsin	  were	  added	   to	  each	  plate	  and	  incubated	  for	  10	  min	  at	  37ºC.	  Cells	  were	  collected	  in	  a	  50	  ml	  falcon	  tube,	  spin	  down,	   resuspended	   in	   feeder	   media,	   counted	   and	   either	   plated	   for	   stem	   cells	   or	  frozen.	  	  
3.1.3	  –	  Freezing/Thawing	  feeder	  cells	  
	   3.1.3.1	  –	  Freezing	  method	  -­‐	   Feeder	   cells	   were	   trypsinized	   and	   counted	   with	   a	   haemocytometer;	   cells	   were	  frozen	  in	  vial	  of	  2.5	  or	  5	  x	  106	  cells.	  Cells	  were	  resuspended	  in	  50%	  of	  the	  volume	  	  DMEM	  with	   20%	  FCS,	   the	   remaining	   50%	  of	   the	   volume	   consisted	   of	   2X	   freezing	  media	   (for	  100ml:	   60	  ml	  DMEM	  4.5	  mg/ml	   glucose	  w/o	   sodium	  pyruvate	   (Sigma,	  D9161),	   20	   ml	   FCS	   and	   20	   ml	   of	   Dimethylsulfoxide	   (DMSO)	   (Sigma,	   D2650)).	  Cryovials	   were	   transferred	   into	   freezing	   boxes	   (Nalgene)	   and	   cooled	   at	   -­‐70	   ºC	  overnight	  before	  being	  placed	  into	  liquid	  nitrogen.	  
	   3.1.3.2	  –	  Thawing	  method	  -­‐	  Frozen	  feeder	  cells	  were	  thawed	  slowly	  in	  a	  37	  ºC	  bath,	  samples	  were	  resuspended	  in	  warm	  feeder	  cells	  media,	  centrifuged	   for	  5	  min	  at	  1000	  rpm	  and	  the	  pellet	  was	  resuspended	  again	  in	  feeder	  cells	  media.	  	  
3.1.4	  –	  Plating	  feeder	  cells	  Mitomycin	  C	  treated	  embryonic	  fibroblasts	  can	  be	  plated	  in	  feeder	  cell	  media	  at	  the	  density	   of	   of	   3-­‐4	   x	   104	   cells/cm2.	   After	   already	   two	   hours	   they	  will	   attach	   to	   the	  
Chapter	  3	  –	  Embryonic	  stem	  cell	  culture	  and	  knock-­‐out,	  -­‐down	  methods	  	  
 148 
bottom	   of	   the	   well/plate	   giving	   a	   monolayer	   that	   can	   be	   used	   for	   further	  experiments.	  
	  
3.2	  –	  Culture	  of	  Mouse	  Embryonic	  Stem	  Cells	  	  
3.2.1	  –	  Preparation	  of	  gelatinized	  dishes	  for	  cell	  culture	  Dishes	  used	  for	  embryonic	  stem	  cells	  (ESCs)	  cells	  had	  to	  be	  gelatinized	  in	  order	  to	  help	  ESCs	  to	  adhere	  optimal	  to	  the	  bottom	  of	  the	  dish.	  Sterile	  2%	  gelatin	  (Sigma,	  G1393)	  was	  diluted	  to	  0.1%	  in	  Millipore	  water.	  Due	  to	  the	  diameter	  of	  the	  wells	  used	  from	  100	  µl	  to	  3	  ml	  of	  0.1%	  gelatin	  were	  added	  and	  left	  1	  to	  5	  minutes	  at	  room	  temperature.	  The	  gelatin	  was	  then	  aspirated	  and	  the	  dish	  or	  plate,	  was	  left	  to	  air-­‐dry	  under	  the	  hood.	  	  
3.2.2	  –	  Media	  for	  ES	  cells	  Embryonic	  Stem	  Cells	  media	  was	  prepared	  as	  follow	  for	  500	  ml:	  
- 400	   ml	   DMEM	   KO	   (Gibco,	   10829-­‐018),	   optimized	   for	   growth	   of	  undifferentiated	   ES	   cells	   and	   its	   osmolarity	   was	   similar	   to	   that	   of	   mouse	  tissues;	  
- 75	  ml	  FCS	  ES	  cell	  tested	  (Invitrogen,	  10439-­‐016),	  ES	  cell	  tested;	  
- 5	  ml	  100X	  glutamine,	  200mM	  (Gibco,	  25030);	  
- 5	   ml	   100X	   penicillin	   (5000	   U/ml)	   /	   streptomycin	   (5000	   µg/ml)	   (Gibco,	  15070);	  
- 5	  ml	  100X	  non-­‐essential	  amino	  acids	  (Gibco,	  11140);	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- 7	  ml	  freshly	  prepared	  β-­‐mercaptoethanol	  (2-­‐ME):	  7	  µl	  of	  β-­‐mercaptoethanol	  (Sigma,	  M7522)	  were	  resuspend	  in	  10	  ml	  of	  D-­‐PBS	  (Gibco	  14190),	  mixed	  well	  and	  5	  ml	  of	  the	  solution	  were	  filtered	  into	  the	  bottle	  of	  media.	  2-­‐ME	  was	  used	  to	  reduce	  the	  oxidative	  stress	  in	  ES	  cells;	  
- 5	  ml	  100X	  nucleosides;	  
- 50	  µl	  LIF	  (Murine	  Leukemia	  Inhibitory	  Factor)	  ESGRO	  (Chemicon);	  LIF	  was	  used	  as	  undifferentiating	  agent.	  	  
3.2.3	  –	  Passaging	  ES	  cells	  
	   3.2.3.1	  –	  In	  dishes	  The	   ES	   cell	   media	   was	   aspirated,	   dishes	   were	   washed	   with	   PBS	   and,	   for	   a	   6	   cm	  dishes,	  1	  ml	  of	  1X	  Trypsin	  (0.5	  g/l)-­‐EDTA	  (0.2	  g/l)	  (Sigma,	  3924)	  was	  added.	  Cells	  were	  then	  incubated	  at	  37	  ºC	  for	  10	  min,	  resuspended	  in	  ES	  cell	  media,	  centrifuged,	  resuspended	  again	  in	  ES	  cell	  media	  and	  plated	  in	  new	  gelatinized	  dished	  containing	  a	  monolayer	  of	  feeder	  cells.	  
	   3.2.3.2	  –	  In	  96-­well	  plates	  ES	  cells	  media	  was	  aspirated,	  wells	  were	  washed	  twice	  with	  100	  µl	  of	  D-­‐PBS	  and	  70	  
µl	  of	  Trypsin-­‐EDTA	  were	  added.	  Plates	  were	  incubated	  at	  37	  ºC	  for	  10-­‐15	  minutes	  and	   in	   the	   meanwhile	   a	   new	   96-­‐well	   plate	   was	   prepared	   with	   140	   µl	   of	   ES	   cell	  media.	   Trypsinization	   was	   stopped	   adding	   140	   µl	   of	   ES	   cell	   media;	   cells	   were	  pipetted	  up	  and	  down	  and	  70	  µl	  were	  transferred	  into	  the	  new	  plate.	  Another	  70	  µl	  of	  ES	  cell	  media	  was	  added	  to	  the	  original	  plate	  and	  all	  plates	  were	  placed	  back	  into	  the	  incubator.	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3.2.4	  –	  Freezing/Thawing	  ES	  cells	  
	   3.2.4.1	  –	  From	  dishes,	  freezing	  method	  -­‐	   ES	   cells	  were	   trypsinized	   and	   counted	  with	   a	   haemocytometer;	   2.5	   or	   5	  million	  cells	   were	   resuspended	   in	   50%	   of	   the	   volume	   in	   2X	   Bicarbonate	   free	   DMEM	  containing	  10	  mM	  Hepes	  and	  20%	  FCS,	  the	  remaining	  50%	  of	  the	  volume	  consisted	  of	  2X	  ES	   freezing	  media	   (for	  100ml:	  60	  ml	  Bicarbonate	   free	   	  DMEM	  containing	  10	  mM	   Hepes,	   20	   ml	   FCS	   and	   20	   ml	   Dimethylsulfoxide	   (DMSO)	   (Sigma	   D2650)).	  Cryovials	   were	   transferred	   into	   freezing	   boxes	   (Nalgene)	   and	   cooled	   at	   -­‐70	   ºC	  overnight	  before	  being	  placed	  into	  liquid	  nitrogen.	  
	   3.2.4.2	  –	  From	  dishes,	  thawing	  method	  -­‐	  Frozen	  ES	  cells	  were	  thawed	  slowly	  in	  a	  37	  ºC	  bath,	  samples	  were	  resuspended	  in	  warm	  ES	  cells	  media,	  centrifuged	  for	  5	  min	  at	  1000	  rpm	  and	  pellet	  was	  resuspended	  again	  in	  ES	  media.	  The	  next	  morning	  media	  was	  changed	  to	  remove	  any	  dead	  cells.	  Media	  was	  changed	  daily.	  
	   3.2.4.3	  –	  From	  96-­well	  plates,	  freezing	  method	  -­‐	   ES	  media	  was	   removed,	   cells	  were	  washed	   twice	  with	  100	  µl	   of	  D-­‐PBS,	   70	  µl	   of	  Trypsin-­‐EDTA	   were	   added	   and	   plates	   were	   incubated	   at	   37ºC	   for	   10-­‐15	   min.	  Trypsinization	  was	  blocked	  adding	  140	  µl	  of	  Bicarbonate-­‐free	  DMEM/10	  mM	  Hepes	  containing	  20%	  FCS	  and	  pipetting	  up	  and	  down	  a	   few	   times	  using	  a	  multichannel	  pipette.	  While	  cells	  were	  in	  the	  incubator	  a	  U-­‐bottomed	  96-­‐well	  plate	  was	  prepared	  containing	  70	  µl	  of	  2X	  Bicarbonate-­‐free	  ES	  cell	  freezing	  media,	  this	  plate	  will	  then	  be	  used	   for	   freezing	   ES	   cells.	   From	   the	   original	   plates	   70	   µl	   from	   each	   well	   were	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transferred	   into	   the	  previously	  prepared	  plate,	   this	  was	   then	  sealed	  with	  Parafilm	  and	  placed	  at	  -­‐80ºC;	  70	  µl	  of	  ES	  media	  were	  added	  to	  the	  original	  plate	  and	  this	  was	  placed	  in	  the	  incubator	  at	  37ºC.	  
	   3.2.4.4	  –	  From	  96-­well	  plates,	  thawing	  method	  -­‐	  Plates	  were	  taken	  out	  of	  the	  -­‐80ºC	  freezer	  and	  placed	  in	  a	  37	  ºC	  incubator	  to	  allow	  cells	  to	  thaw.	  Pipet	  up	  and	  down	  with	  a	  multichannel	  pipette	  and	  transfer	  cells	  in	  a	  new	  plate	  containing	  ES	  cell	  media.	  Plates	  were	   incubated	  at	  37ºC	  and	  media	  was	  changed	  daily.	  	  
3.2.5	  –	  Electroporation	  of	  ES	  cells	  Electroporation,	  or	  electropermeabilization,	  is	  a	  significant	  increase	  in	  the	  electrical	  conductivity	  and	  permeability	  of	  the	  cell	  plasma	  membrane	  caused	  by	  an	  externally	  applied	  electrical	   field.	  This	  process	   is	   able	   to	   create	   small	  breaks	   in	   the	  bacterial	  membrane	  that	  allows	  plasmid	  DNA	  to	  get	  into	  the	  host	  cell.	  
	   3.2.5.1	  -­	  Method	  ES	  cells	  were	  trypsinized	  and	  cells	  were	  counted	  with	  an	  haemocytometer.	  1	  x	  107	  cells	  were	  transfered	  to	  a	  fresh	  tube,	  centrifuged,	  resuspended	  in	  800	  µl	  of	  PBS	  and	  transferred	   into	   an	   electroporation	   cuvette	   (Gene	   Pulser	   Cuvette,	   Bio-­‐Rad,	  1652088).	  At	  this	  point	  25	  µg	  of	  plasmid,	  linearized	  for	  homologous	  recombination,	  in	  sterile	  PBS	  were	  added	  to	  the	  cells.	  The	  cuvette	  were	  placed	   in	  the	  Gene	  Pulser	  machine	  (Biorad)	  and	  cells	  were	  electroporated	  under	  the	  following	  conditions:	  
- voltage:	  240	  V	  
- capacity:	  500	  µF	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- resistance:	  ∞	  
- cuvette:	  4	  mm	  Straight	  after,	  cells	  were	  plated	  in	  6	  cm	  dishes	  containing	  neo-­‐resistant	  feeder	  cells	  EF/N.	  The	   next	   morning	   media	   was	   changed	   to	   remove	   dead	   cells	   and	   after	   36	   hours	  media	  was	  replaced	  with	  selection	  media	  containing	  G418,	  FIAU	  or	  both	  depending	  on	  the	  plasmid	  used.	  	  
3.2.6	  –	  Picking	  ES	  cell	  colonies	  After	  cells	  went	  through	  selection	  single	  colonies	  were	  picked	  from	  the	  dishes	  and	  plated	  in	  a	  96-­‐well	  plate,	  one	  colony	  per	  plate.	  Two	  96-­‐well	  plates	  containing	  25	  µl	  of	  Trypsin-­‐EDTA	  per	  well	  were	  prepared,	  this	  allowed	   a	   better	   detachment	   of	   cells	   within	   the	   colony	   for	   a	   more	   homogeneous	  expansion	   inside	   the	  well.	  Using	  a	  pipette	  set	  up	  at	  3	  µl,	  with	  a	  10	  µl	   tip,	   colonies	  were	  picked	  scraping	  the	  bottom	  of	  the	  dish	  and	  aspirating	  the	  cells.	  They	  were	  then	  placed	  into	  the	  different	  wells.	  After	  the	  plate	  was	  full	  it	  was	  placed	  in	  the	  incubator	  at	   37ºC	   for	  5-­‐10	  minutes.	  Trypsinization	  was	   stopped	  by	   adding	  100	  µl	   of	   ES	   cell	  media	   and	   cells	   were	   transferred	   into	   a	   96-­‐well	   plate	   containing	   a	   fresh	   layer	   of	  feeder	   cells.	   Media	   was	   changed	   daily.	   Once	   cells	   reached	   confluence	   they	   were	  further	   split	   into	  other	   two	  plates:	   two	   for	  DNA	  extraction	  and	  one	  was	   frozen	  as	  master	  plate.	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3.3	  –	  Nucleic	  acid	  extraction	  
3.3.1	  –	  DNA	  extraction	  
	   3.3.1.1	  –	  From	  dishes	  Cells	  were	  washed	  twice	  with	  PBS	  and	  500	  µl	  of	  Laird’s	  buffer	  (200	  mM	  NaCl,	  100	  mM	   Tris-­‐HCl	   pH	   8.3,	   5	   mM	   EDTA,	   0.2%	   sodium	   dodecyl	   sulfate,	   pH	   8,5)	   [192]	  containing	  150	  µg/ml	  of	  proteinase	  K	  were	  added.	  Samples	  incubated	  at	  37	  ºC	  over	  night.	   The	   following	  morning	   samples	  were	   transferred	   into	   an	   eppendorf	   1.5	  ml	  tube	  using	  tips	  with	  wider	  tip	  in	  order	  not	  to	  sheare	  the	  DNA,	  they	  were	  shaken	  at	  37	  ºC	  for	  one	  hour	  and	  centrifuged	  at	  RT	  for	  20	  minutes	  at	  full	  speed.	  Samples	  were	  then	   poured	   into	   eppendorf	   tubes	   containing	   500	  µl	   of	   2-­‐propanol	   and	   shaken	   to	  allow	   the	   DNA	   to	   precipitate.	   This	   precipitate	   was	   fished	   out	   with	   a	   tip	   and	  transfered	  into	  a	  new	  tube	  containing	  200	  µl	  of	  TE	  buffer	  (10	  mM	  Tris,	  pH	  7.5,1	  mM	  EDTA	  pH	  8.0).	  DNA	  was	  left	  resuspending	  for	  few	  hours.	  	  
3.3.1.2	  –	  From	  96-­well	  plate	  	  	  The	  original	  protocol	  is	  described	  in	  [193].	  Before	  starting	  the	  lysis	  a	  scan	  of	  the	  plate	  was	  taken	  to	  keep	  record	  of	  the	  empty	  well.	  Media	  was	  aspirated	  and	  wells	  washed	  twice	  with	  150	  µl	  of	  PBS,	  50	  µl	  of	  lysis	  buffer	  (for	  500	  ml:	  5	  ml	  10	  mM	  TrisHCl	  pH	  7.5,	  10	  ml	  10	  mM	  EDTA	  pH	  8.0,	  1	  ml	  10	  mM	  NaCl,	   12.5	  ml	   0.5%	   sacrosyl);	   Proteinase	   K	  was	   added	   to	   final	   concentration	   of	   1	  mg/ml	   prior	   to	   use,	   pre-­‐warmed	   at	   60	   ºC	   added	   to	   the	   wells	   and	   plates	   were	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incubated	  over	  night	  at	  60	  ºC	  inside	  a	  humid	  chamber	  (prepared	  with	  a	  tupperware	  containing	  wet	  towels)	  to	  avoid	  evaporation.	  	  The	  next	  day	  100	  µl	  of	  ice	  cold	  100%	  EtOH	  containing	  75	  mM	  of	  NaCl	  were	  added	  to	  each	  well	  without	  mixing;	  plates	  were	   left	  at	  RT	  for	  30	  mins,	  at	   this	   time	  the	  DNA	  formed	  jelly-­‐like	  transparent	  filaments	  at	  the	  bottom	  of	  the	  well.	  After	  this	  time	  the	  supernatant	  was	  discarded	   inverting	   the	  plates	  and	  wells	  were	  rinsed	   three	   times	  by	  adding	  200	  µl	  of	  70%	  EtOH.	  This	  was	  discarded	  by	   inversion	  and	  DNA	  was	   left	  drying	  on	  the	  bench.	  
	  
3.3.1.3	  –	  Phenol	  Chloroform	  extraction	  This	  procedure	  is	  used	  when	  there	  is	  the	  need	  of	  having	  high	  purity	  clean	  DNA.	  Phase	   Lock	   Gel	   Heavy	   1.5	   ml	   vials	   (Eppendorf,	   955154151)	   were	   used.	   These	  columns	  contain	  a	  semi-­‐solid	  gel	  solution	  that	  acts	  as	  a	  barrier	  between	  the	  organic	  and	  aqueous	  phases,	   allowing	   the	  nucleic-­‐acid-­‐containing	  phase	   to	  be	  decanted	  or	  pipetted	  off.	  	  Before	  use,	  tubes	  were	  firstly	  centrifuged	  at	  maximum	  speed	  for	  30	  seconds.	  After	  this,	  an	  equal	  volume	  of	  phenol	  and	  chloroform	  were	  well	  mixed	  and	  added	  to	  the	  DNA	  at	  a	  volume	  ratio	  1:1.	  Samples	  were	  vortexed	  and	  immediately	  transferred	  to	  the	   Phase	   Lock	   columns,	   centrifuged	   for	   5	  minutes	   at	   full	   speed	   and	   supernatant	  (~100	   µl)	   was	   transferred	   into	   a	   new	   1.5	   ml	   tube.	   100	   µl	   of	   H2O	   were	   added	  followed	  by	  20	  µl	  of	  3M	  NaAc	  pH	  5.2	  (In	  aqueous	  solution,	  sodium	  acetate	  breaks	  up	  into	  Na+	  and	   [CH3COO]-­‐;	   the	  positively	  charged	  sodium	   ions	  neutralize	  negatively	  charged	   backbone	   on	   the	   DNA,	   specifically	   the	   PO3-­‐	   groups	   on	   the	   nucleic	   acids,	  
Chapter	  3	  –	  Embryonic	  stem	  cell	  culture	  and	  knock-­‐out,	  -­‐down	  methods	  	  
 155 
making	   the	   nucleic	   acid	   molecule	   far	   less	   hydrophilic,	   and	   therefore	   much	   less	  soluble	  in	  water.)	  and	  660	  µl	  of	  100%	  cold	  EtOH	  (ethanol	  then	  makes	  much	  easier	  for	  Na+	   to	   interact	  with	   the	  PO3-­‐,	   shields	   their	   charge	  and	  makes	   the	  nucleic	  acid	  less	  hydrophilic,	  causing	  it	  to	  precipitate).	  Samples	  were	  well	  mixed	  and	  put	  at	  -­‐20	  ºC	   over	   night.	   The	   following	   day	   samples	   were	   centrifuged	   for	   30	   minutes	   at	  maximum	  speed	  at	  4	  ºC,	   supernatant	  was	  discarded	  and	  pellet	  washed	   twice	  with	  70%	  EtOH.	  After	  EtOH	  evaporated	  DNA	  was	  dissolved	  in	  50	  µl	  of	  TE	  buffer.	  
	  
3.3.1.5	  –	  DNA	  precipitation	  after	  digestion	  After	  that	  genomic	  DNA	  was	  digested	  with	  the	  appropriate	  restriction	  enzyme	  it	  had	  to	  be	  purified	  before	  being	  used	  in	  a	  Southern	  Blotting.	  	  Samples	  were	  brought	  to	  a	  volume	  of	  200	  µl	  with	  H2O,	  20	  µl	  of	  3M	  NaAc	  pH	  5.2	  were	  added	  and	  samples	  mixed.	  After	  that	  550	  µl	  of	  100%	  cold	  EtOH	  were	  added,	  samples	  were	  well	  mixed	  and	  incubated	  at	  -­‐80	  ºC	  for	  30	  minutes.	  Tubes	  were	  centrifuged	  at	  maximum	   speed	   for	   30	  minutes	   at	   4	   ºC.	   Pellet	   was	  washed	   twice	  with	   100	  µl	   of	  EtOH,	  left	  drying	  on	  the	  bench	  for	  15	  minutes	  and	  resuspended	  in	  20	  µl	  of	  TE	  buffer.	  To	   ensure	   that	   samples	   dissolved	   properly	   they	   were	   incubated	   at	   37ºC	   for	   20	  minutes.	  	  
3.4	  –	  Polymerase	  Chain	  Reactions	  
3.4.1	  –	  Amplification	  and	  screening	  of	  the	  homology	  region	  
3.4.1.1	  –	  Primers	  for	  the	  homology	  region	  The	  primers	  tested	  and	  used	  are	  listed	  in	  the	  following	  Table	  1:	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NAME	   SEQUENCE	  Ncor1	  Rev,	  I,	  II,	  III	   tttcttcctcatgccattcc	  Ncor1	  For	  I	   tttgcagcagagaagctttg	  Ncor1	  For	  II	   ccccattccctccaaagtat	  Ncor1	  For	  III	   gaaatccaagaggcatccaa	  Ncor2/Smrt	  Rev	   catacatgcaggtggagacg	  Ncor2/Smrt	  For	   ttgtgtgggccagagtagtg	  
	  
Table	  3.1	  –	  List	  of	  primers	  used	  for	  the	  amplification	  of	  the	  homology	  regions.	  
	  After	   the	   first	   round	   of	   amplifications	   the	   fragments	   had	   to	   be	  modified	   inserting	  restriction	  enzyme	  sites	  at	  the	  extremities	  to	  allow	  better	  ligation	  to	  the	  vectors,	  this	  was	  done	  using	  the	  following	  primers:	  	   	   NAME	   SEQUENCE	  Ncor1	  XhoI	  Rev	   cgtactcgagtttcttcctcatgccattcc	  Ncor1	  Sac1	  For	   gtcagagctcccccattccctccaaagtat	  Ncor2	  EcoRI	  Rev	   gcgagaattccatacatgcaggtggagacg	  Ncor2	  EcoRI	  For	   gcgagaattcttgtgtgggccagagtagtg	  	  
Table	   3.2	   –	   List	   of	   primers	   used	   to	   insert	   sticky	   ends	   to	   the	   homology	   regions	  
amplified.	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3.4.1.2	  –	  Primers	  for	  LoxP	  sites	  The	   insertion	   of	   LoxP	   sites	   in	   a	   target	   sequence	   of	   a	   gene	   is	   commonly	   used	   to	  conditionally	   knock	   out	   a	   gene,	   or	   part	   of	   it.	   The	   Cre	   enzyme	   catalyses	   the	  recombination	  within	  two	  LoxP	  sites	  exciding	  the	  sequence	  included	  within	  them.	  Primers	  used	  were	  the	  following	  (the	  uppercase	  sequence	  indicates	  the	  LoxP	  site):	  NAME	   SEQUENCE	  Ncor1	  LoxP	  Rev	   catggatccATAACTTCGTATAATGTATGCTATACGAAGTTATc	  Ncor1	  LoxP	  For	   catggATAACTTCGTATAGCATACATTATACGAAGTTATggatc	  Ncor2/Smrt	  LoxP	  Rev	   cgATAACTTCGTATAGCATACATTATACGAAGTTATgaattcgat	  Ncor2/Smrt	  LoxP	  For	   cgaattcATAACTTCGTATAATGTATGCTATACGAAGTTATcgat	  	  
Table	  3.3	  –	  Sequences	  of	   the	  oligonucleotides	  containing	  the	  LoxP	  sites,	   indicated	   in	  
uppercase	  
.	  In	  order	  to	  ensure	  the	  insertion	  of	  the	  desired	  LoxP	  site	  in	  the	  right	  position	  a	  PCR	  screening	   was	   performed	   using	   primers	   flanking	   the	   LoxP	   sites.	   Primers	   are	   the	  following:	   NAME	   SEQUENCE	  Ncor1	  NcoI	  Rev	   attttatgagttcagcctaatgtcc	  Ncor1	  NcoI	  For	   tgcagaactggtggcaaata	  Ncor2	  PvuI	  Rev	   tgagcaggtcacaccttcag	  Ncor2	  PvuI	  For	   cacgggaggtgatcaagact	  
Table	  3.4	  –	  Sequences	  of	  the	  primers	  used	  to	  validate	  the	  presence	  of	  the	  LoxP	  sites.	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3.4.1.3	  –	  Primers	  for	  Neo	  selection	  cassette	  	  A	  Neo-­‐cassette	  was	  insert	  to	  confer	  neomycin	  resistance	  to	  positive	  clones.	  To	  check	  the	  integration	  of	  this	  fragment	  into	  our	  construct	  the	  following	  primers	  were	  used:	  NAME	   SEQUENCE	  Ncor1	  SnaBI	  Rev	   ccaccacagatttgagcatc	  Ncor2	  ScaI	  For	   tctccctttctttccgttca	  Neo	  5’	  Rev	   atgtggaatgtgtgcgaggccag	  	  
Table	  3.5	  –	  Sequences	  of	  the	  primers	  used	  to	  validate	  the	  presence	  of	  the	  Neo	  cassette	  
	  The	   presence	   of	   two	   reverse	   primers	   for	   Ncor1	   is	   explainable	   because	   the	  orientation	   of	   the	   Neo	   cassette	   in	   this	   construct	   is	   opposite	   of	   the	   one	   of	  Ncor2/SMRT.	  	  
	   3.4.1.4	  –	  Primers	  for	  ES	  cells	  screening	  After	  that	  ESCs	  clones	  were	  isolated	  we	  sought	  to	  do	  a	  first	  screening	  by	  PCR	  where	  the	  first	  LoxP	  site	  and	  the	  presence	  of	  Neo	  cassette,	  including	  ~2	  kb	  outside	  of	  the	  homology	  region,	  were	  checked.	  	  Primers	  for	  the	  LoxP	  are	  listed	  above	  and	  those	  for	  the	  Neo	  cassette	  are	  the	  following	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NAME	   SEQUENCE	  Ncor1	  out	  Rev	   cactggggaagaagagctagga	  Ncor2	  out	  Rev	   ctccctaggcgcctttgtct	  Neo	  poly-­‐A	  For	   tgggaagacaatagcaggcatgc	  Ncor2	  LoxP	  out	  FW	   tagttcccaggcgtgtaacc	  Ncor2	  LoxP	  RW2	   gccaaggtctcatccgatcgat	  	  
Table	  3.6	  –	  Sequences	  of	  the	  primers	  used	  to	  screen	  the	  Neo	  cassette	  in	  electroporated	  
ES	  cells	  	   	  
	   3.4.1.5	  –	  Handling	  of	  primers	  Upon	  arrival	  all	  the	  primers	  were	  resuspended	  in	  TE	  buffer	  at	  the	  concentration	  of	  100	  µM	  (100	  pm/µl);	  the	  working	  solution	  was	  prepared	  using	  5	  µl	  of	  each	  primer,	  forward	  and	  reverse,	  with	  40	  µl	  of	  ddH2O	  for	  a	  final	  concentration	  of	  10	  µM.	  	   	  
3.4.2	  –	  PCR	  amplification	  Two	  different	  kits	  were	  successfully	  used	  to	  amplify	  the	  homology	  regions:	  Phusion	  High-­‐Fidelity	  DNA	  Polymerase	  (Finnzymes,	  F530L)	  and	  TaKaRa	  LA	  Taq	  (Takara	  Bio	  Inc,	   RR002A).	   Two	   different	   BACs	   containing	   genomic	   fragments	   including	   Ncor1	  (imaGenes,	  RPCIB731D07130Q)	  and	  Ncor2	  (imaGenes,	  RPCIB731F11335Q)	  regions	  were	  also	  ordered.	  Reaction	   mixes	   for	   the	   two	   different	   genes	   were	   prepared	   following	   the	  manufacturer’s	  instructions,	  briefly:	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PHUSION	   µl	  reagent	  (x1)	  
H20	   36.5	  
5X	  	  GC	  Reaction	  Buffer	   10	  
10	  mM	  dNTPs	   1	  
Primer	  Mix	   1	  
TaqPol	   0.5	  
DNA	   1	  
	  The	  thermal	  profile	  for	  the	  Phusion	  kit	  was	  the	  following:	  98	  ºC	  for	  30	  sec,	  35	  cycles	  with	  98	  ºC	  for	  20	  sec,	  65	  ºC	  for	  2	  min	  and	  72ºC	  for	  10	  min,	  72	  ºC	  for	  10	  min	  and	  4	  ºC	  for	  as	  long	  as	  it	  was	  needed.	  
TAKARA	   µl	  reagent	  (x1)	  
H20	   19.5	  
10X	  LA	  PCR	  Buffer	   5	  
25	  mM	  MgCl2	   5	  
10	  mM	  dNTPs	   8	  
Primer	  Mix	   1	  
TaKaRa	  LA	  Taq	   0.5	  
DNA	   1	  	  The	  thermal	  profile	  for	  the	  Takara	  kit	  was	  the	  following:	  98	  ºC	  for	  2	  min,	  35	  cycles	  with	  98	  ºC	  for	  10	  sec,	  60	  ºC	  for	  30	  sec	  and	  72	  ºC	  for	  10	  min,	  72	  ºC	  for	  10	  min	  and	  4	  ºC	  for	  as	  long	  as	  it	  was	  needed.	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  For	  all	  the	  samples	  G4	  ES	  cell	  DNA	  was	  used	  as	  negative	  control.	  
	  
3.4.3	  –	  Colony	  screening	  for	  DNA	  inserts	  and	  normal	  PCR	  
	   3.4.3.1	  -­	  Introduction	  Once	  competent	  cells	  are	  transformed,	  it	  is	  possible	  to	  check	  for	  the	  presence	  of	  the	  desired	  insert	  picking	  up	  a	  certain	  number	  of	  colonies	  (generally	  from	  30	  to	  50)	  and	  using	  as	  template	  for	  the	  PCR	  the	  bacteria	  that	  grew	  on	  the	  plate.	  
	   3.4.3.2	  -­	  Method	  Before	   starting	  with	   the	  PCR	  a	  Petri	   dish	   containing	  L-­‐broth	   agar	   and	   the	  desired	  antibiotic	  was	  prepared	  and	  a	  numbered	  grid	  drawn	  on	  the	  lid	  in	  order	  to	  precisely	  identify	  positive	  colonies	  after	  the	  screening.	  Mastermix	  was	  prepared	  as	  follow,	  all	  reagents	  were	  from	  Invitrogen:	  	  
Reagent	   µl	  (x1)	  
H20	   15.5	  
10X	  Buffer	  (Y02028)	   2.5	  
50	  mM	  MgCl2	  (Y02016)	   0.75	  
100	  mM	  dNTPs	  	   0.5	  
Primer	  Mix	   1	  
	  TaqPol	  (10342-­055)	   0.25	  	  The	   reaction	  mix	  was	   dosed	   into	   ABI	   tubes	   (ABI,	   Micro	   Amp	   Tube	   Strips	   0.2	  ml,	  N8010580).	   Using	   a	   sterile	   tip	   single	   colonies	  were	   picked	   from	   the	  master	   plate	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and	  quickly	   inoculated	   in	   the	  previously	  prepared	  dish,	   the	  same	  tip	  was	   then	  put	  into	  the	  tube	  to	  add	  template	  to	  the	  reaction.	   	  
	  
Fig	  3.2	  –	  Scheme	  of	  how	  to	  pick	  colonies	  for	  PCR	  screening.	  The	  colonies	  were	  quickly	  
touched	  with	   the	   tip,	   bacteria	   remained	  attached	   to	   the	   tip	  and	  were	   re-­plated	   in	  a	  
new	  Petri	   dish;	   the	   tip	  was	   then	  put	   into	   the	   tube	  with	  Mastermix	   and	  worked	  as	   a	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3.5	  –	  DNA	  digestion	  This	   procedure	   refers	   to	   an	   enzymatic	   reaction	   where	   the	   DNA	   is	   cleaved	   into	  smaller	  pieces	  by	  restriction	  enzymes	  that	  recognize	  precise	  sequences,	  catalyzing	  the	  digestion	  of	  that	  specific	  region.	  
3.5.1	  –	  Enzymes	  and	  buffers	  Each	  enzyme	  has	   its	  highest	  efficiency	  with	   its	  own	  buffer;	  all	   restriction	  enzymes	  were	  from	  Promega	  and	  are	  listed	  below,	  buffers	  were	  provided	  with	  the	  restriction	  enzyme:	   NAME	   BUFFER	  BamHI	  (R6025)	   E	  EcoRI	  (R6017)	   H	  EcoRV	  (R6355)	   D	  NcoI	  (R6515)	   D	  NotI	  (R6435)	   D	  PvuI	  (R6325)	   D	  SacI	  (R6065)	   J	  	   ScaI	  (R6211)	   K	  SnaBI	  (R6795)	   B	  XhoI	  (R6165)	   D	  BamHi	  HC	  (R4027)	   H	  EcoRI	  HC	  (R4017)	   H	  	  
Table	  3.7	  –	  List	  of	  the	  restriction	  enzymes	  used	  in	  this	  thesis	  with	  the	  corresponding	  
buffer.	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  In	  case	  of	  double	  digestion	  the	  right	  buffer	  was	  chosen	  using	  the	  software	  EnzymeX	  (freely	  available	  at	  http://mekentosj.com/enzymex).	  	  	  
3.5.2	  –	  Reactions	  
	   3.5.2.1	  –	  Digestions	  for	  cloning	  and	  screening	  Vectors,	   amplified	   fragments	   and	   DNA	   obtained	   from	   mini-­‐,	   midi-­‐preps	   were	  normally	  digested	  in	  a	  20	  µl	  reaction	  using	  1	  µl	  of	  enzyme,	  2	  µl	  of	  buffer,	  from	  2	  to	  8	  
µl	   of	  DNA	   and	  H2O	  until	   20	  µl.	   The	   tubes	  were	   incubated	   at	   37ºC	   for	   1	   hour	   and	  samples	  analyzed	  in	  a	  1%	  Agarose	  gel.	  
	   3.5.2.2	  –	  Genomic	  DNA	  digestion	  for	  Southern	  Blotting	  In	  case	  of	  genomic	  DNA	  digestion	  a	  higher	  concentration	  of	  restriction	  enzymes	   is	  required	  due	  to	  the	  high	  amount	  of	  target	  sequences	  that	  are	  present.	  Each	   reaction	   was	   set	   up	   in	   100	   µl	   volume	   using	   10	   µl	   of	   buffer,	   5	   µl	   of	   high	  concentrated	   enzyme	   (HC),	   50	   µl	   of	   DNA,	   1	   µl	   of	   spermidine	   (Sigma,	   enhances	  enzymes’	   specificity	   diminishing	   non-­‐specific	   cleavage	   of	   DNA),	   1	   µl	   of	   BSA	   (10	  mg/ml)	   (Promega,	   R396D	   –	   BSA	   is	   needed	   by	   some	   enzymes	   to	   prevent	   their	  adhesion	  to	  reaction	  tubes	  or	  pipette	  surfaces	  and	   it	  also	  stabilizes	  some	  enzymes	  during	   incubation),	   1	   µl	   of	   RNase	   A	   (10	   mg/ml)	   (Sigma	   –	   used	   to	   remove	   any	  remaining	  RNA	  from	  the	  template)	  and	  ddH2O	  to	  a	  total	  volume	  of	  100	  µl.	  Samples	  were	   incubated	   at	   37	   ºC	   over	   night	   and	   ran	   the	   following	  morning	   in	   an	  0.6%	  agarose	  gel.	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3.6	  –	  Creating	  blunt	  ends	  products	  
3.6.1	  -­	  Klenow	  treatment	  
	   3.6.1.1	  -­	  Introduction	  The	   DNA	   Polymerase	   I	   Large	   (Klenow)	   Fragment	   is	   a	   DNA-­‐dependent	   DNA	  polymerase	   that	   lacks	   the	   5´ 3´	   exonuclease	   activity	   of	   intact	   E.	   coli	   DNA	  Polymerase	   I	   but	   retains	   its	   5´ 3´	   polymerase,	   3´ 5´	   exonuclease	   and	   strand	  displacement	   activities.	   The	   enzyme	   is	   a	   68	   kDa	   C-­‐terminal	   fragment	   of	   DNA	  Polymerase	   I.	   In	   case	   of	   fragments	   with	   5’	   overhanging	   nucleotides,	   the	   5´ 3´	  polymerase	   activity	   of	   Klenow	  Fragment	   can	   be	   used	   to	   fill	   in	   5´-­‐protruding	   ends	  with	  unlabeled	  or	  labeled	  dNTPs.	  	  
	   3.6.1.2	  –	  Method	  	  The	  reaction	  was	  setup	  as	  follow:	  
Reagent	   µl	  (x1)	  
DNA	  Pol	  (M2201)	   2	  
Buffer	  D	   2	  
dNTPs	  (1	  mM)	   1	  
DNA	   10	  
ddH2O	   5	  	  Tubes	  were	   incubated	   for	  15	  minute	  at	  room	  temperature	  and	  10	  min	  at	  75	  ºC	   to	  inactivate	  the	  polymerase.	  Samples	  were	  then	  stored	  at	  -­‐20ºC.	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3.6.2	  -­	  T4	  polymerase	  treatment	  	  
	   3.6.2.1	  –	  Introduction	  	  T4	   DNA	   Polymerase	   catalyzes	   the	   5´ 3´	   synthesis	   of	   DNA	   from	   a	   primed	   single-­‐stranded	   DNA	   template.	   Although	   possessing	   a	   potent	   3´ 5´	   proofreading	  exonuclease,	  T4	  DNA	  Polymerase	  contains	  no	  5´ 3´	  exonuclease	  activity.	  In	  case	  of	  a	  fragment	  with	   3’	   overhanging	   nucleotides,	   it	   can	   be	   used	   at	   low	   temperatures	   to	  create	  blunt	  end	  products	  exploiting	  the	  3’ 5’	  exonuclease	  activity.	  
	   3.6.2.2	  –	  Method	  	  The	  reaction	  was	  set	  up	  as	  follow:	  
Reagent	   µl	  (x1)	  
T4	  Pol	  (M4211)	   2	  
dNTPs	   0.5	  
DNA	   10	  	  Samples	  were	   incubated	   at	   12ºC	   for	  15	  minutes	  before	  being	   stored	   at	   -­‐20	   ºC	   for	  further	  experiments.	  
	  
3.8	  –	  DNA	  ligation	  DNA	   ligation	   is	   an	   ATP-­‐dependent	   process	   that	   involves	   the	   formation	   of	   two	  covalent	  phosphodiester	  bonds	  between	  3'	  hydroxyl	  ends	  of	  one	  nucleotide	  with	  the	  5'	  phosphate	  end	  of	  another.	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3.8.1	  –	  Ligation	  of	  homology	  regions	  into	  vector	  Two	   different	   vectors	   were	   used,	   pBluescriptSK	   (Stratagene)	   for	   Ncor1	   and	   pCR	  BLUNT	   II	   TOPO	   (Invitrogen,	   Zero	   BLUNT	   TOPO	   PCR	   cloning	   kit,	   K2800-­‐20)	   for	  Ncor2.	  	  Fragments	   obtained	   from	   PCR	   amplification	   were	   ligated	   into	   their	   respective	  vectors	  using	  Promega	  reagents	  as	  follow:	  	  
Reagent	   µl	  (x1)	  
T4	  Ligase	  (M1794)	   1	  
10X	  T4	  Buffer	  (C126B)	   10	  
Vector	   0.5	  
Insert	   8	  	  Reaction	  mix	  was	  incubated	  for	  15	  minutes	  at	  room	  temperature	  and	  then	  put	  on	  ice	  for	  further	  experiments.	  	  
3.8.2	  –	  Ligation	  of	  LoxP	  sites	  and	  Neo	  cassette	  into	  homology	  region	  Vectors	   containing	   the	   homology	   region	   were	   previously	   digested	   with	   the	  appropriate	   enzyme,	   then	   the	  double	   strand	   (ds)	  DNA	  containing	   the	  LoxP	   site	  or	  the	  Neo-­‐cassette	  were	  ligated	  into	  that	  region.	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Reactions	  were	  setup	  as	  follow:	  
Reagent	   µl	  (x1)	  
T4	  Ligase	  (M1794)	   1	  
10X	  T4	  Buffer	  (C126B)	   5	  
Digested	  vector	   2	  
Oligos	   2	  	  Samples	  were	  incubated	  for	  15	  minutes	  at	  room	  temperature	  and	  then	  put	  on	  ice	  for	  further	  experiments.	  	  
	   3.8.2.1	  –	  Drop	  dialysis	  of	  ligation	  reaction	  Before	   transforming	   competent	   cells,	   the	   ligation	   reaction	   was	   placed	   on	   a	   small	  membrane	   in	   a	   dish	   containing	   ddH2O	   and	   incubated	   for	   20	   minutes	   at	   room	  temperature.	   For	   osmosis	   the	   water	   will	   move	   through	   the	   membrane	   into	   the	  samples,	  lowering	  the	  salt’s	  concentration.	  This	  process	  facilitates	  future	  ligase	  activity	  that	  could	  be	  otherwise	  affected	  by	  high	  salt	  concentration.	  	  
3.9	  –	  Transformation	  of	  competent	  cells	  and	  plasmid	  DNA	  isolation	  
3.9.1	  -­	  Electroporation	  Electrocompetent	  cells	  (Invitrogen,	  One	  Shot	  TOP10	  E.Coli,	  C4040-­‐52)	  were	  kept	  at	  -­‐80	   ºC	   and	   thawed	   on	   ice,	   2	  µl	   of	   DNA	  were	   added	   and	   reaction	  was	   transferred	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immediately	  into	  a	  pre-­‐chilled	  electroporation	  cuvette	  (Bio-­‐Rad,	  1652089).	  This	  was	  placed	  into	  the	  MicroPulser	  Electroporator	  (Bio-­‐Rad)	  and	  voltage	  was	  set	  to	  1.75	  V.	  After	   electroporation	   500	   µl	   of	   S.O.C.	   media	   (Invitrogen,	   46-­‐0700)	   were	   added,	  reaction	  was	  pipetted	  into	  1.5	  ml	  tubes	  and	  left	  for	  one	  hour	  at	  37ºC	  shaking.	  	  	  
3.9.2	  –	  Chemical	  transformation	  Home	  made	   DH5α	   or	   chemically	   competent	   cells	   (Invitrogen,	   One	   Shot	   TOP10	   E.	  Coli	  ,	  C4040-­‐03)	  were	  kept	  at	  -­‐80	  ºC	  and	  thawed	  on	  ice,	  2	  µl	  of	  DNA	  were	  added	  and	  cells	  were	   incubated	   in	   ice	   for	  5-­‐15	  minutes,	  heat-­‐shocked	  at	  42ºC	   for	  45	  seconds	  and	  placed	   in	   ice	   for	  2	  minutes.	  500	  µl	  of	  S.O.C.	  media	  (Invitrogen,	  46-­‐0700)	  were	  added,	  reaction	  was	  transferred	  into	  1.5	  ml	  tubes	  and	  incubated	  at	  37	  ºC	  shaking	  for	  one	  hour.	  After	  transformation	  all	  bacteria	  were	  plated	  in	  Petri	  dishes	  containing	  LB	  plus	  the	  necessary	  antibiotic	  for	  selection.	  
	  
3.9.3	  –	  DNA	  mini-­	  and	  midi-­preps	  After	   that	   single	   colonies	   were	   successfully	   isolated	   from	   the	   master	   plate,	   they	  were	   inoculate	   first	   in	   two	   ml	   of	   L-­‐Broth	   for	   mini-­‐preps	   and	   then	   into	   50	   ml	   of	  medium	   for	  midi-­‐preps.	   The	   first	   step	  was	   fundamental	   to	   screen	   positive	   clones	  and	  with	  the	  second	  step	  clean	  plasmid	  DNA	  was	  isolated	  for	  further	  experiments.	  
	   3.9.3.1	  –	  Mini-­preps	  The	   QIAprep	   Spin	   Miniprep	   Kit	   (Qiagen,	   27106)	   was	   used	   and	   all	   buffers	   were	  provided	   with	   the	   kit.	   Plasmid	   DNA	   was	   extracted	   following	   the	   manufacturer’s	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instructions.	  Chosen	  colonies	  were	  left	  growing	  over	  night	  in	  2	  ml	  of	  media	  at	  37ºC	  shaking,	  1	  ml	  was	  transferred	  into	  a	  1.5	  ml	  tube	  and	  centrifuged	  at	  maximum	  speed	  for	  3	  minutes.	  Pellet	  was	  kept	  and	  sequentially	  resuspended	  in	  P1	  buffer,	  P2	  buffer	  (lysis	  buffer)	  and	  P3	  buffer	  (containing	  LyseBlue	  reagent	  colors	  the	  sample	  in	  case	  of	   correct	   lysis).	   Samples	   were	   then	   centrifuged	   at	   maximum	   speed,	   supernatant	  was	  kept	  and	  flowed	  throw	  the	  Qiagen	  column	  where	  DNA	  bound	  to	  the	  membrane.	  Columns	  were	  then	  centrifuged	  and	  washed	  twice	  with	  PE	  buffer	  (containing	  EtOH).	  With	  the	  final	  spin	  DNA	  was	  eluted	  in	  50	  µl	  of	  TE	  buffer	  and	  collected	  in	  1.5	  ml	  tubes	  for	  further	  usage.	  
	   3.9.3.2	  –	  Midi-­preps	  QIAGEN	  Plasmid	  Midi	  Kit	  (Qiagen,	  12145)	  was	  used	  and	  buffers	  were	  provided	  with	  the	  kit.	  Plasmid	  DNA	  was	  purified	  following	  the	  manufacturer’s	  instructions.	  Previously	   checked	   colonies	  were	   inoculated	   into	   50	  ml	   of	  media	   per	   sample	   and	  incubated	  overnight	  at	  37ºC	  shaking.	  The	  day	  after	  whole	  volume	  was	  transferred	  in	  a	   50	  ml	   falcon	   tube	   and	   centrifuged	   at	  maximum	   speed	   for	   5	  minutes.	   Pellet	  was	  kept	   and	   resuspended	   as	   above	   for	   mini-­‐preps.	   Lysate	   was	   then	   poured	   into	   a	  syringe	  and	  transferred	   into	  columns	  after	  equilibration	  with	  QBT	  buffer;	   the	   flow	  through	  was	   discarded	   and	   columns	  washed	   twice	  with	   QC	   buffer.	   Samples	  were	  eluted	  with	  QF	  buffer	  into	  15	  ml	  eppendorf	  tubes,	  3.5	  ml	  of	  isopropanol	  were	  added	  and	  tubes	  were	  centrifuged	  for	  30	  min	  at	  maximum	  speed	  at	  4ºC	  to	  precipitate	  the	  DNA.	   Pellet	   was	   kept	   and	   washed	   with	   2ml	   of	   70%	   EtOH,	   air-­‐dried	   and	   finally	  resuspended	  in	  300	  µl	  of	  TE	  buffer	  for	  further	  experiments.	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3.10	  –	  Southern	  Blotting	  Southern	   blotting	   is	   a	   technique	   that	   allows	   the	   recognition	   of	   a	   specific	   DNA	  fragment	  bound	  to	  a	  membrane	  by	  a	  radiolabeled	  probe	  after	  that	  genomic	  DNA	  has	  been	  digested	  with	  the	  chosen	  restriction	  enzyme.	  	  
	  
3.10.1	  –	  General	  description	  Genomic	  DNA	  was	  digested	  and	  run	  in	  a	  low	  percentage	  gel.	  After	  capillary	  transfer	  onto	   a	   nylon	  membrane	   it	  was	   hybridized	   overnight	  with	   the	   radiolabeled	  probe;	  the	  following	  day	  series	  of	  washes	  reduced	  the	  unspecific	  binding	  to	  the	  membrane.	  The	  signal	  was	  then	  detected	  with	  a	  phosphorimager	  and	  analyzed.	  	  
3.10.2	  –	  Method	  	  
	   3.10.2.1	  –	  Solutions	  and	  kits	  
• SSC/SSC+SDS:	  SSC	   is	  a	  abbreviation	  of	  Sodium	  chloride	  and	  Sodium	  Citrate	  solution,	   which	   is	   normally	   used	   to	   transfer	   nuclear	   acid	   from	   gel	   to	  membrane	  DNA	  is	  transferred	  more	  efficiently	  to	  nitrocellulose	  membranes	  	   as	  a	  sodium	  salt	  where	  90%	  of	  the	  effective	  negative	  charge	  has	  been	  neutralized	   by	   sodium	   chloride/citrate.	   Also	   SSC	   and	   SDS	   determine	   the	  stringency	  of	  the	  washes;	  the	  lower	  the	  concentration	  of	  SSC	  the	  higher	  the	  stringency	  due	  to	  reduced	  salts	  concentration.	  20X	  SSC	  1	  liter:	  800	  ml	  H2O,	  175.3	  g	  NaCl,	  88.2	  g	  sodium	  citrate,	  pH	  7.0	  with	  NaOH,	  adjust	  to	  1	  lt.	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• NaOH:	  0.5M	  NaOH	  would	  separate	  double-­‐stranded	  DNA	  into	  single-­‐stranded	  DNA	  because	  only	  ssDNA	  can	  be	  transferred	  onto	  the	  membrane.	  
• HCl:	  0.25M	  HCl	  was	  used	  to	  depurinate	  DNA.	  Fragments	  greater	  than	  15	  kb	  are	  hard	  to	  transfer	  onto	  the	  blotting	  membrane	  and	  depurination	  with	  HCl	  takes	  the	  purines	  out,	  cutting	  the	  DNA	  into	  smaller	  fragments	  and	  allowing	  a	  more	  efficient	  transfer.	  	  
• Blotting	  Paper	  Sheets	  (Munktell,	  2.521.120140	  G)	  and	  Whatman	  paper	  were	  used	   to	   set	  up	   the	  blot	  and	   facilitate	   the	  capillary	   transfer	  of	  DNA	  onto	   the	  nylon	  membrane	  (Zeta-­‐Probe	  GT,	  Bio-­‐Rad,	  162-­‐0196).	  
• Express	  Hyb	   (Clontech,	   636831)	   as	  prehybridization	   solution	  was	   required	  before	  hybridization	   to	  block	  non-­‐specific	  binding.	   It	   contains	  concentrated	  salt	   and	   SDS	   that	   excludes	   water	   molecules	   from	   the	   probe	   and	   target,	  allowing	   better	   hybridization.	   Also,	   the	   more	   water	   molecules	   that	   are	  excluded,	  the	  tighter	  the	  interaction	  between	  the	  probe	  and	  target	  becomes.	  
• Radioactive	  [32P]-­‐dCTP	  was	  provided	  by	  Hartman	  Analysis	  (SRP405).	  
• Amersham	  Rediprime	  II	  (GE	  Healthcare,	  RPN1633)	  was	  used	  to	  label	  probes	  with	  [32P]-­‐dCTP.	  The	  primer-­‐template	  complex	  is	  a	  substrate	  for	  the	  Klenow	  fragment	   of	   DNA	   polymerase	   I.	   By	   replacing	   a	   non-­‐radioactive	   nucleotide	  with	  the	  radiolabelled	  equivalent	  in	  the	  reaction	  mixture,	  newly	  synthesized	  DNA	  is	  made	  radioactive.	  	  
• Columns	  (NICK	  Columns	  with	  Sephadex	  G-­‐50	  DNA	  grade,	  GE	  Healthcare,	  17-­‐0855-­‐02)	  to	  purify	  probes	  were	  used	  after	  labeling.	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3.10.2.2	  –	  Protocol	  DNA	  was	  digested	  overnight	  at	  37ºC	  as	  described	  in	  the	  previous	  section;	  DNA	  was	   precipitated	   as	   described	   in	   the	  DNA	   extraction	   paragraph,	   loaded	   into	   a	  0.6%	  Agarose	  gel	  and	  ran	  until	  the	  bands	  of	  interest	  were	  clearly	  separated	  and	  under	  UV	  lights,	  using	  a	  tip,	  the	  gel	  ladder	  was	  marked	  in	  the	  points	  of	  interest.	  Before	   blotting	   onto	   the	   membrane,	   the	   DNA	   in	   the	   gel	   had	   to	   be	   chemically	  denaturated,	   to	   do	   this	   the	   gel	   was	   washed	   twice	   with	   0.25	   M	   of	   HCl	   for	   10	  minutes,	  once	  with	  H2O	  for	  5	  minutes	  and	  once	  with	  0.5	  M	  NaOH	  for	  40	  minutes.	  The	   membrane	   was	   washed	   for	   2	   minutes	   in	   water	   and	   equilibrated	   for	   5	  minutes	  in	  0.5	  M	  NaOH	  before	  blotting.	  The	  capillary	  transfer	  was	  setup	  as	  following	  and	  left	  overnight	  on	  the	  bench:	  	  
	  
Fig	  3.3	  –	  Schematic	  representation	  of	  the	  capillary	  transfer	  of	  DNA	  into	  membrane.	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The	  following	  day	  slots	  and	  ladder	  were	  marked	  on	  the	  membrane	  with	  a	  pencil	  cause	  graphite	  absorbs	  radioactivity	  and	  permits	  to	  easily	  identify	  samples	  and	  length	  of	  the	  fragments.	  Membrane	   was	   then	   washed	   with	   2X	   SSC	   for	   10	   min	   at	   room	   temperature,	  placed	   into	   clean	   bottles	   and	   incubated	   at	   65ºC	   for	   30	  min	   rotating	  with	   pre-­‐hybridization	  solution.	  In	  the	  meanwhile	  probes	  were	  labeled	  as	  follow:	  1	  µl	  of	  probe	  (~30-­‐50	  ng)	  was	  diluted	  with	  44	  µl	  of	  TE	  buffer,	  denaturated	  at	  95ºC	  for	  3	  minutes	  and	  incubated	  in	  ice	  for	  further	  2	  minutes.	  The	  45	  µl	  were	  transferred	   to	   the	   Rediprime	   II	   solution	   without	   mixing;	   5	   µl	   of	   32P-­‐dCTP	  were	  added	  and	  gently	  mixed	  to	  turn	  the	  solution	  into	  violet.	  Samples	  were	  incubated	   at	   37ºC	   for	   10	   min;	   meanwhile	   columns	   were	   rinsed	   with	   TE	  buffer	  and	  equilibrated	  with	  3	  ml	  of	  TE	  buffer	   till	  all	   the	   liquid	   flushed	  out.	  The	   radioactive	   samples	   were	   added	   to	   the	   columns,	   400	   µl	   of	   TE	   were	  carefully	   pipetted	   on	   top	   of	   it	   and	   the	   first	   flow	   trough	  was	   collected	   and	  discarded;	  other	  400	  µl	  of	  TE	  buffer	  were	  added	  to	  elute	  the	  probe,	  this	  was	  collected	  into	  new	  tubes,	  denaturated	  at	  95ºC	  for	  3	  minutes	  and	  incubated	  on	  ice	  for	  2	  minutes.	  The	   labeled	   probes	   were	   carefully	   pipetted	   into	   the	   bottles	   containing	   the	  membranes	  and	  incubated	  overnight	  at	  65ºC	  slowly	  rotating.	  	  The	  next	  day	  2X	  SSC/1%SDS	  and	  0.1X	  SSC/0.1%	  SDS	  solutions	  were	  warmed	  up	  at	  65	   ºC;	   the	   bottles	  were	   emptied	   and	   rinsed	   twice	  with	   2X	   SSC,	   the	   first	   time	   the	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liquid	  was	  carefully	  discarded	  and	  the	  second	  time	  was	  poured	  with	  the	  membrane	  into	   a	   pizza-­‐box,	   this	  was	   then	   left	   shaking	   at	   room	   temperature	   for	   10	  minutes.	  Membranes	   were	   then	   washed	   with	   2X	   SSC	   1%	   SDS	   for	   15-­‐20	   minutes	   at	   65ºC,	  radioactivity	  was	   then	  checked	  and,	   if	   still	  hot,	   a	   further	  15-­‐20	  minutes	  wash	  was	  required	  with	  2X	  SSC	  1%	  SDS	  (not	  stringent)	  or	  0.1X	  SSC	  0.1%	  SDS	  (stringent).	  The	  final	  wash	  was	  made	  in	  2X	  SSC	  at	  room	  temperature	  for	  5	  minutes.	  Membranes	   were	   then	   wrapped	   up	   in	   clinching	   film	   and	   exposed	   in	   a	   cassette	  overnight.	  The	   phosphor	   screen	   was	   placed	   on	   the	   scanner	   and	   image	   analyzed	   with	   GIMP	  (freely	  available	  at	  www.gimp.org)	  .	  	  
	  
Fig	  3.4	  –	  Example	  of	  a	  southern	  blotting	  image.	  
	  
	  
3.11	  –	  shRNAs	  synthesis	  and	  cloning	  To	   clone	   the	   desired	   hairpins	   in	   order	   to	   perform	   an	   efficient	   knockdown	   the	   kit	  LOCK-­‐iT	  PolII	  miR	  RNAi	  Expression	  Vector	  Kit	  (Invitrogen,	  451102)	  was	  ordered;	  all	  buffers,	  vector	  and	  reagents	  were	  included	  in	  the	  kit.	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3.11.1	  –	  Oligonucleotides	  Oligonucleotides	   targeting	   the	  desired	   regions	  of	  Ncor1	   and	  Ncor2	  were	  designed	  and	   ordered	   from	   the	   Invitrogen	   website	   (www.invitrogen.com).	   A	   schematic	  representation	   of	   the	   murine	   Ncor1	   and	   Ncor2/Smrt	   with	   the	   targeted	   exons	   is	  available	  in	  the	  Supplementary	  Figures.	  Sequences	  are	  the	  following:	  	  	  
Oligo	  Name	   Target	   Sequence	  
ex11_top	   NCoR1	   TGCTGAATGGTGGCTGAAAGACCAGCGTTTTGGCCACTGACTGACGCTGGTCTCAGCCACCATT	  
ex11_bottom	   NCoR1	   CCTGAATGGTGGCTGAGACCAGCGTCAGTCAGTGGCCAAAACGCTGGTCTTTCAGCCACCATTC	  
ex27_top	   NCoR1	   TGCTGATAACATGGCCCTTGGATGCAGTTTTGGCCACTGACTGACTGCATCCAGGCCATGTTAT	  
ex27_bottom	   NCoR1	   CCTGATAACATGGCCTGGATGCAGTCAGTCAGTGGCCAAAACTGCATCCAAGGGCCATGTTATC	  
ex37_top	   NCoR1	   TGCTGTAACCTGGCAGCTTCATGCTTGTTTTGGCCACTGACTGACAAGCATGACTGCCAGGTTA	  
ex37_bottom	   NCoR1	   CCTGTAACCTGGCAGTCATGCTTGTCAGTCAGTGGCCAAAACAAGCATGAAGCTGCCAGGTTAC	  
ex8_top	   NCoR2	   TGCTGTACAAGATCAGCTTCTTCCGCGTTTTGGCCACTGACTGACGCGGAAGACTGATCTTGTA	  
ex8_bottom	   NCoR2	   CCTGTACAAGATCAGTCTTCCGCGTCAGTCAGTGGCCAAAACGCGGAAGAAGCTGATCTTGTAC	  
ex32_top	   NCoR2	   TGCTGTGTAGATGTCAGCTTCCGGTCGTTTTGGCCACTGACTGACGACCGGAATGACATCTACA	  
ex32_bottom	   NCoR2	   CCTGTGTAGATGTCATTCCGGTCGTCAGTCAGTGGCCAAAACGACCGGAAGCTGACATCTACAC	  
ex42_top	   NCoR2	   TGCTGTATTCTGGCTCGTTCCGGTTGGTTTTGGCCACTGACTGACCAACCGGAGAGCCAGAATA	  
ex42_bottom	   NCoR2	   CCTGTATTCTGGCTCTCCGGTTGGTCAGTCAGTGGCCAAAACCAACCGGAACGAGCCAGAATAC	  	  
Table	  3.8	  –	  Sequences	  of	  the	  hairpins	  used	  to	  target	  Ncor1	  and	  Ncor2/Smrt.	  Indicated	  
the	  exon	  number,	  the	  strand	  and	  the	  gene	  targeted.	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3.11.2	  –	  Annealing	  oligos	  Before	  being	  ligated	  into	  the	  vector	  all	  the	  pairs	  of	  oligos	  (top	  –	  bottom)	  had	  to	  be	  annealed.	  This	  was	  made	  following	  the	  manufacturer	  instructions,	  briefly:	  
Reagent	   µl	  (x1)	  
Top	  strand	  oligo	   5	  
Bottom	  strand	  oligo	   5	  
10X	  Annealing	  buffer	   2	  
DNase/RNase	  free	  H2O	   8	  	  Samples	  were	  heated	  at	  95ºC	   for	  4	  min	  and	   left	   cool	  down	  on	   the	  bench	   for	  5-­‐10	  minutes,	  briefly	  centrifuged,	  diluted	  at	   the	  concentration	  of	  10	  nM	  from	  the	   initial	  50	  µM	  and	  stored	  for	  further	  experiments.	  	  
3.11.3	  –	  Ligation	  reaction	  Double	  strand	  oligos	  were	  ligated	  into	  pcDNA	  6.2-­‐GW/EmGFP-­‐miR	  vector	  included	  in	  the	  kit	  as	  follow:	  
Reagent	   µl	  (x1)	  
5X	  reaction	  buffer	   4	  
Vector	   2	  
ds	  oligos	   4	  
T4	  DNA	  ligase	   1	  
DNase/RNase	  free	  H2O	   9	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Samples	  were	  mixed	  pipetting	  up	  and	  down,	   incubated	  at	  room	  temperature	   for	  5	  minutes	  and	  placed	  on	  ice.	  	  
3.11.4	  –	  Transformation	  of	  competent	  cells	  One	  Shot	  TOP10	  Competent	  E.Coli	  were	  provided	  with	   the	  kit	  and	   transformed	  as	  previously	  described.	  	  
3.11.5	  –	  Selection	  of	  positive	  clones	  Clones	  that	  grew	  on	  the	  selection	  plate	  were	  selected,	   inoculated	   in	  2	  ml	  of	  LB	  for	  minipreps,	  DNA	  extracted	  and	  the	  presence	  of	  the	  insert	  was	  assessed	  by	  restriction	  enzyme	   digestion.	   Positive	   clones	   were	   sent	   to	   sequencing	   to	   confirm	   that	   the	  correct	   ligation	   happened	   and	   then	   inoculated	   in	  midipreps	   to	   obtain	   high	   purity	  plasmid	  DNA	  for	  further	  experiments.	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4	  –	  RESULTS	  
4.1	  –	  LIGAND	  RESPONSIVENESS	  IN	  PROSTATE	  MALIGNANCIES	  	  Activation	   of	   NRs	   via	   lipophilic	   molecules	   has	   diverse	   transcriptional	   and	  phenotypical	  effects	   in	  prostate	  epithelial	  cells	   including	  activation	  of	   target	  genes	  that	   result	   is	   inhibition	   of	   proliferation.	   Different	   prostate	   cancer	   cell	   lines	   have	  different	   sensitivities	   to	   these	   molecules	   and	   this	   includes	   a	   significant	   loss	   of	  responsiveness.	  The	   following	  studies	  aim	   to	  describe	   these	  events	  with	   the	  aim	  of	  understanding	  how	  to	  restore	  the	  physiological	  activity	  of	  NR	   in	  vitro	  and	   in	  vivo.	  Specifically,	   the	  studies	  are	  focused	  on	  the	  epigenetic	  corruption	  of	  NR	  signalling	  in	  prostate	  cancer	  addressing	   to	   what	   extent	   it	   can	   be	   restored	   using	   either	   histone	   deacetylase	  inhibitors	   (SAHA)	   or	   a	   more	   targeted	   and	   specific	   approach	   knocking	   by	   down	  NCOR1	  via	  shRNA.	  	  
4.1.1	  –	  Cell	  proliferation	  in	  RWPE1	  vs	  PC-­3	  
Cell	  lines	  are	  described	  in	  Materials	  and	  Methods.	  The	  activity	  of	  NR	  agonists	  in	  PC-­‐3	  prostate	  cancer	  cells	  was	  compared	  to	  a	  parallel	  data	   set	   in	   non-­‐malignant	   epithelial	   cells	  RWPE-­‐1	   (RWPE-­‐1	   cells	   data	   from	   James	  Thorne,	   University	   of	   Birmingham,	   Birmingham,	   UK)	   using	   a	   high	   throughput	  proliferation	  assay	  based	  on	  cellular	  ATP.	  A	  cohort	  of	  ligands	  was	  chosen	  in	  order	  to	  screen	   the	   antiproliferative	   effect:	   bezafibrate	   (peroxisome	   proliferator	   activated	  receptors	   –	   PPARα	   and	   PPARγ),	   1,25(OH)2D3	   (vitamin	   D	   receptor	   –	   VDR),	  eicosapentaenoic	   acid	   (EPA,	   PPARα),	   eicosatetraynoic	   acid	   (ETYA,	   PPARγ),	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chenodeoxycholic	  acid	  (CDA,	  farnesoid	  X	  receptor	  –	  FXR),	  litocholic	  acid	  (LCA,	  VDR	  and	   farnesoid	   X	   receptor	   –	   FXR),	   docosahexaenoic	   acid	   (DHA,	   FXR,	   PPARα	   and	  PPARγ)	  and	  all-­‐trans	  retinoic	  acid	  (ATRA,	  retinoic	  acid	  receptor	  –	  RARs);	  cells	  were	  plated	  in	  96	  well	  plates	  and	  treated	  for	  96	  hours	  with	  the	  designed	  agonist	  with	  a	  re-­‐dose	  after	  48	  hours,	  after	   that	  cell	  proliferation	  was	  quantified.	  All	  agonists	  but	  DHA	   efficiently	   inhibited	   RWPE-­‐1	   cells	   (Fig	   4.1)	  while	   PC-­‐3	   cells	   demonstrated	   a	  consistent	  loss	  of	  sensitivity	  towards	  the	  ligands.	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Fig	  4.1	  –	  Antiproliferative	  effect	  of	  nuclear	  receptor	  ligands	  in	  non	  malignant	  prostate	  
epithelial	  cells	  RWPE-­1	  (blue)	  and	  malignant	  PC-­3	  (red);	  2x103	  cells	  were	  plated	  in	  a	  
96	  well/plate	  and	  treated	  for	  96	  hours	  with	  the	  indicated	  ligand,	  with	  a	  re-­dose	  after	  
48	   hours.	   Bar	   charts	   indicate	   inhibition	   of	   proliferation	   upon	   treatment	  with:	   1	  µM	  
bezafibrate,	  100	  nM	  1,25(OH)2D3,	  10	  µM	  EPA,	  10	  µM	  ETYA,	  10	  µM	  LCA,	  10	  µM	  DHA	  
and	  10	  µM	  ATRA.	  Data	  shown	  are	  the	  mean	  of	  at	  least	  biological	  triplicates	  +/-­	  S.E.M..	  
Student	  t-­test	  was	  performed	  to	  establish	  that	  the	  difference	  in	  proliferation	  between	  
PC-­3	  and	  RWPE-­1	  cells	  was	  significant;	  **=p<0.01,	  ***=p<0.001.	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These	   results	   demonstrated	   that	   PC-­‐3	   cells	   display	   suppressed	   anti-­‐proliferative	  ability	   for	   PPARα,	   PPARγ,	   VDR,	   RAR	   and	   FXR.	   Identifying	   the	   mechanisms	   that	  contribute	   to	   the	   agonist-­‐resistance	   in	   PC-­‐3	   cells	   has	   applications	   in	   translational	  research	   where	   androgen-­‐independent	   prostate	   cancer	   still	   remains	   the	   most	  common	  cause	  of	  mortality	  for	  this	  cancer.	  
	  
4.1.2	  –	  Gene	  regulation	  PC-­‐3	   cells	   remain	   phenotypically	   unaltered	   after	   treatment	  with	   nuclear	   receptor	  ligands.	  In	  the	  attempt	  to	  define	  the	  basis	  for	  this,	  the	  transcriptional	  responses	  in	  PC-­‐3	   cells	   were	   analysed.	   Previous	   studies	   in	   the	   group	   established	   in	   prostate	  cancer	   cells	   that	   elevated	   levels	   of	   NCOR2/SMRT	   act	   as	   one	   such	   mechanism	   to	  suppress	   VDR	   responsiveness	   [62,	   194];	   other	   workers	   have	   re-­‐enforced	   these	  concepts	   [195,	   196]	   Similarly,	   epigenetic	  mechanisms	  appear	   to	  disrupt	   the	  PPAR	  actions	   [197,	   198].	   Therefore	   the	   extent	   to	   which	   a	   similar	   mechanism	   was	  disrupting	  other	  NRs	  was	  investigated.	  	  
4.1.3	  –	  Corepressor	  and	  nuclear	  receptor	  expression	  in	  prostate	  cells	  In	  physiological	  conditions	  there	  is	  a	  balance	  between	  transactivation,	  mediated	  by	  activated	   transcriptional	   complexes	   that	   include	   co-­‐activator	   proteins,	   and	  repression,	   mediated	   by	   non-­‐activated	   transcription	   factors	   associated	   with	   co-­‐repressor	   complexes.	  For	  example,	   an	  equilibrium	   is	  due	   to	   the	   ratio	  between	   the	  amount	   of	   nuclear	   receptor	   and	   regulatory	   complexes.	   Hypothetically,	   if	   levels	   of	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nuclear	   receptors	   are	   unchanged	  while	   the	   regulatory	   complexes	   vary	   then	   there	  will	  be	  a	  loss	  of	  balance	  with	  higher	  activation	  or	  higher	  repression	  of	  target	  genes.	  
	  
Fig	   4.2	   –	   Representation	   of	   the	   physiological	   equilibrium	   between	   complexes	   that	  
activate	   or	   repress	   transcription	   and	   nuclear	   receptors.	   Gene	   transcription	   (yellow	  
triangle)	   is	   regulated	   by	   the	   amount	   of	   CoActivator	   complex	   (green	   triangle)	   and	  
CoRepressors	   (orange	   triangle);	  when	  the	  concentration	  of	  corepressors	  rise	  and	   the	  
amount	   of	   NR	   remain	   constants,	   or	   diminishes,	   then	   the	   balance	   of	   the	   equation	   is	  
shifted	  towards	  repression	  and	  transcription	  is	  inhibited.	  
	  The	  loss	  of	  responsiveness	  in	  prostate	  suggests	  that	  this	  balance	  is	  shifted	  towards	  transrepression.	   To	   investigate	   the	   basis	   for	   the	   loss	   of	   responsiveness,	   qRT-­‐PCR	  	  was	  used	  to	  measure	  the	  mRNA	  levels	  of	  a	  cohort	  of	  co-­‐repressor	  genes	  involved	  in	  transcriptional	  silencing;	  COPS2,	  CoREST,	  LCoR,	  NCOR1,	  NCOR2/SMRT,	  RIP140	  and	  SLIRP	   (described	   in	   the	   introduction)	   .	   Total	   RNA	   from	   mid-­‐exponentially	  proliferating	  RWPE-­‐1,	  DU145	  and	  PC-­‐3	  cells	  was	  extracted	  and	  reverse-­‐transcribed	  prior	  qRT-­‐PCR	  analysis.	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Fig	   4.3	   –	   Basal	   mRNA	   levels	   of	   a	   selected	   cohort	   of	   corepressors	   in	   three	   different	  
epithelial	   cell	   lines	   RWPE-­1	   (white),	   DU145	   (light	   grey)	   and	   PC-­3	   (dark	   grey).	   The	  
results	   are	   the	  average	  of	   at	   least	   biological	   triplicate	   experiments.	  Whole	  RNA	  was	  
extracted,	   quantified	   and	   reverse	   transcribed	   prior	   qRT-­PCR	   analysis.	   Student	   t-­test	  
was	  performed	  comparing	  DU145	  and	  PC-­3	  to	  RWPE-­1	  cells	  (*	  =	  p<0.05,	  **	  =	  p<0.01).	  
The	  y	  axes	  indicates	  the	  fold	  changes	  relative	  to	  RWPE-­1	  cells.	  
	  As	  shown	  in	  Fig	  4.3	  basal	  mRNA	  levels	  of	  NCOR1,	  LCoR	  and	  SLIRP	  were	  significantly	  upregulated	  in	  PC-­‐3	  cells	  (p<0.05)	  and	  RIP140	  was	  significantly	  reduced	  (p<0.05);	  a	  similar	  patter	  was	  present	  in	  DU145	  cells.	  	  Protein	   levels	   for	   the	   major	   co-­‐repressors,	   NCOR1,	   NCOR2/SMRT	   (Orla	   Maguire,	  Roswell	  Park	  Cancer	  Institute,	  Buffalo	  NY,	  USA)	  and	  SLIRP,	  were	  measured	  in	  mid-­‐exponentially	   growing	   RWPE-­‐1,	   LNCaP,	   DU145	   and	   PC-­‐3	   cells.	   Both	   NCOR1	   and	  NCOR2/SMRT	  complex	  with	  HDAC	  enzymes	  maintaining	  de-­‐acetylated	  histone	  tails	  in	   order	   to	   repress	   transcription;	   HDAC3	   is	   the	   best	   know	   HDAC	   that	   interacts	  allosterically	   with	   NCOR1	   and	   NCOR2/SMRT	   present	   in	   co-­‐repressor	   protein	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Fig	   4.4	   –	  Western	   immunoblot	   for	   NCOR1	   and	   NCOR2/SMRT	   in	   RWPE-­1,	   LNCaP,	  
DU145	  and	  PC-­3	  cells	  (TOP)	  and	  HDAC3	  in	  malignant	  PC-­3	  and	  non-­malignant	  RWPE-­
1	   cells.	   60	  µg	   of	   whole	   protein	   lysate	   was	   used	   were	   loaded	   into	   an	   SDS-­page	   and	  
analysed	   with	   the	   antibodies	   listed	   in	   Materials	   and	   Methods.	   Chemoluminescent	  
detection	   of	   the	   proteins	   occurred	   through	  HRP-­conjugated	   secondary	   antibody	   and	  
ECL.	   The	   analysis	   was	   repeated	   in	   at	   least	   two	   biological	   replicates.	   Nucleolin	   was	  
used	  a	  loading	  control	  for	  NCOR1	  and	  NCOR2/SMRT	  and	  β-­actin	  for	  SLIRP	  and	  HDAC3	  
western	   blotting	   because	   both	   proteins	   accurately	   reflect	   the	   total	   protein	   content	  
independently	  from	  the	  cell	  background.	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Compared	   to	   RWPE-­‐1	   cells,	   NCOR1	   levels	   are	   higher	   in	   all	   three	   cancer	   cell	   lines	  (PC-­‐3,	  DU145	  and	  LNCaP)	  while	  SLIRP	  levels	  also	  increase	  with	  malignancy.	  HDAC3	  levels	  are	  undetectable	  in	  RWPE-­‐1	  cells	  and	  clearly	  higher	  in	  PC-­‐3	  cells.	  These	   results	   suggested	   that	   co-­‐repressors	   mRNA	   and	   protein	   expression	   is	  elevated	   in	   prostate	   cancer	   cell	   lines	   Levels	   of	   PPARα,	   PPARα	   and	   VDR	   were	  analysed	   in	   mid-­‐exponentially	   growing	   RWPE-­‐1,	   LNCaP,	   DU145	   and	   PC-­‐3	   cells.	  PPARγ	  and	  VDR	  were	  expressed	  at	  comparable	   levels	   in	  all	   four	  cell	   lines	  whereas	  PPARα	  was	  absent	  in	  LNCaP	  cells.	  
	  
Fig	   4.5	   –	  Basal	   nuclear	   receptor	   levels	   RWPE-­1,	   LNCaP,	   DU145	   and	   PC-­3.	   20	  µg	   of	  
cytoplasmic	  (C)	  and	  nuclear	  (N)	  lysates	  were	  obtained	  from	  mid-­exponential	  growing	  
cells,	   quantified	   and	   loaded	   in	   SDS-­page	   gel	   for	   Western	   immunoblotting;	  
nitrocellulose	   membranes	   were	   probed	   with	   anti-­VDR,	   anti-­PPARα	   or	   PPARγ	  
antibodies.	   Chemoluminescent	   detection	   of	   the	   proteins	   occurred	   through	   HRP-­
conjugated	   secondary	   antibody	   and	   ECL.	   The	   analysis	   was	   repeated	   in	   at	   least	   two	  
biological	   replicates.	   Equal	   loading	   was	   ensured	   by	   the	   detection	   of	   beta-­actin;	  
although	   this	   protein	   is	   mainly	   located	   in	   the	   cytoplasm,	   several	   papers	   [199-­201]	  
reported	  the	  presence	  of	  this	  protein	  in	  the	  nucleus.	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Key	  NR	  analysed	  were	  essentially	  evenly	  expressed	  across	  RWPE-­‐1,	  DU145	  and	  PC-­‐3	  cells,	  while	  LNCaP	  cells	  showed	  a	  lower	  expression	  of	  both	  PPARα	  and	  PPARγ.	  These	  results	   supported	   the	   initial	  hypothesis	   that	  a	  key	  component	   in	   the	   loss	  of	  sensitivity	   towards	  NR	  agonists	   in	  prostate	   cancer	   cell	   lines	   is	   represented	  by	   the	  altered	   expression	   of	   co-­‐repressor	   complexes	   together	   with	   an	   unchanged	  expression	  of	  the	  receptors	  resulting	  in	  an	  altered	  ratio.	  This	  can	  lead	  to	  a	  chromatin	  environment	   that	   inhibits	   transcription	   factors	   from	   binding	   to	   their	   responsive	  elements,	  thus,	  blocking	  transcription.	  This	  may	  allow	  for	  selective	  repression	  of	  the	  gene	  targets.	  	  
4.1.3	  –	  Analysis	  of	  the	  nuclear	  receptor	  network	  using	  microfluidic	  Q-­RT-­PCRM	  	  To	  investigate	  relationships	  between	  the	  global	  loss	  of	  ligand	  responsiveness	  in	  PC-­‐3	   cells	   and	   the	   expression	   of	   the	  NR	  network	  microfluidic	  Q-­‐RT-­‐PCR,	   (qRT-­‐PCRM)	  was	   undertaken	   (gene	   list	   as	   in	   [202]).	   Initially	   the	   basal	   expression	   of	   the	   NR	  network	  was	  examined.	  96	  genes	  were	  examined	  that	  are	  involved	  in	  metabolism	  of	  NR	   ligands,	   transcriptional	   regulation	   by	   NR,	   cell	   cycle	   control,	   apoptosis	   and	  membrane	  transport	  of	  ligands.	  The	  basal	  expression	  of	  all	   the	  genes	  across	   the	   three	  phases	  of	   the	  cell	   cycle	  was	  analysed	   to	   unveil	   the	   phase-­‐specific	   differences	   between	  RWPE-­‐1	   and	  PC-­‐3	   cells.	  These	  expression	  patterns	  support	  the	  concept	  that	  loss	  of	  receptor	  responsiveness	  does	   not	   correlate	   fully	   with	   reduced	   receptor	   expression.	   To	   allow	   for	   cell	  population	  heterogeneity,	  differential	  proliferation	  rates	  and	  to	  reveal	  the	  impact	  of	  the	   cell	   cycle	   the	   NR	   network	   expression	   patterns	  was	   profiled	   by	   Q-­‐RT-­‐PCRM	   in	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different	   cell	   cycle	   phases.	   14	   of	   20	   NRs	   expressed	   in	   normal	   prostate	   [203]	   had	  differential	   expression	   through	   the	   cell	   cycle	   in	   PC-­‐3	   cells	   compared	   to	   RWPE-­‐1	  cells,	   	   9	   were	   up-­‐regulated,	   notably	   in	   G1	   and	   G2/M	   (e.g.	   PPARG,	   VDR),	   5	   down-­‐regulated	  in	  all	  phases	  (e.g.	  THRB)	  and	  the	  remaining	  receptors	  were	  undetected	  in	  either	  cell	   system	  (e.g.	  RARB).	  Also	  significantly	  up-­‐regulated	   in	  G1	  and	  G2/M	  cells	  were	   NR	   co-­‐regulators	   (e.g.	  NCOR2/SMRT,	  NCOA2,	   PPARGC1A),	   histone	   modifying	  enzymes	   (e.g.	  HDAC4,	  SIRT2,	   and	   the	  demethylase	  AOF2/LSD1),	   the	  EMT	  regulator	  
SNAI1	   and	   NF-­‐kB	   activators	   (IKBKB,	   IKBKG).	   Expression	   of	   VDR	   and	   PPAR	   target	  genes	   displayed	   both	   elevation	   (e.g.	   IGFBP1,	   G0S2,	   PTGS2	   (encodes	   COX-­‐2))	   and	  repression	  (e.g.	  CDH1,	  CDKN1A	  (encodes	  p21(waf1/cip1))	  [204-­‐209])	  and	  other	  targets	  (e.g.	   ALOX-­5	   (encodes	   5-­‐LO)),	   were	   undetected	   in	   PC-­‐3	   cells	   and	   omitted.	   SAM	  analyses	   of	   these	   data	   identified	   gene	   expression	   patterns	   that	   were	   significantly	  altered	   between	   all	   phases	   of	   the	   cell	   cycle	   and	   further	   distinguished	   PC-­‐3	   from	  RWPE-­‐1	  cells,	   including	  NCOR1	   and	  TRIP15/COPS2/Alien	  uniquely	  down	  regulated	  in	   S	   phase	   and	   re-­‐expressed	   in	   G2/M	   (Fig	   4.6).	   The	   findings	   suggest	   that	   ligand	  insensitivity	  correlates	  with	  a	  distorted	  NR	  network	  and	  this	   includes	  elevated	  co-­‐repressor	  levels	  and	  a	  condensed	  chromatin	  conformation.	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Fig	  4.6	   –	  Heatmap	   representing	   the	   genes	   differentially	   expressed	   between	  RWPE-­1	  
and	  PC-­3	  cells	   in	  each	  of	   the	  three	  phases	  of	   the	  cell	  cycle.	  One	  sample	  student	  t-­test	  
was	  made	  to	  establish	  the	  genes	  significantly	  differentially	  expressed	  between	  the	  two	  
cell	   lines,	   p<0.01.	   Green	   boxes	   indicate	   downregulated	   genes	   and	   red	   boxes	   indicate	  
upregulated	  genes.	  To	  better	  visually	  represent	  the	  data	  a	  hierarchical	  clustering	  was	  
made	   using	   the	   Support	   Tree	   algorithm	   in	   TmeV,	   this	   function	   contstructs	   the	   tree	  
resampling	   the	   gene	   values	   using	   iterations	   and	   the	   metric	   used	   was	   euclidean	  
distance.	   Highlighted	   are	   corepressor	   and	   coactivator	   enzymes	   as	   well	   as	   histone	  
modifiers	   linked	  with	   positive	   or	   repressive	   histone	  marks.	   Data	   are	   the	  mean	   of	   at	  
least	  three	  biological	  replicate	  and	  technical	  quadruplicate	  from	  values	  obtained	  with	  
Q-­RT-­PCRM	  analysis.	  
	  These	   cell	   cycle	   phase-­‐specific	   expression	  patterns	   suggest	   that	   the	   actions	   of	   the	  nuclear	   receptor	   network	   in	   PC-­‐3	   cells	   are	   skewed,	   rather	   than	   abrogated,	   with	  increased	   expression	   of	   receptors,	   and	   both	   positive	   and	   negative	   regulators	   of	  receptor	  activity,	  notably	  in	  G1	  and	  G2/M.	  Reflecting	  this,	  target	  genes,	  for	  example	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for	   VDR	   and	   PPARs,	   displayed	   both	   enhanced	   and	   diminished	   basal	   expression	  levels.	   Well-­‐established	   target	   genes	   for	   VDR	   and	   PPARs	   [204-­‐207]	   displayed	  significantly	   elevated	   levels	   in	   either	   all	   (IGFBP1,	   G0S2)	   or	   in	   G1	   and	   G2/M	   (e.g.	  
ACADM,	  PPARα,	  PPARγ,	  GADD45A)	  phases	  of	  the	  cell	  cycle	  in	  PC-­‐3	  cells.	  	  By	  contrast	  a	   cohort	   of	   targets	   were	   repressed	   in	   all	   phases	   (IGFBP3	   and	   ABCA1),	   whereas	  others	  were	  omitted	  from	  the	  heatmap	  analyses,	  as	  they	  were	  undetected	  in	  either	  one	  or	  more	  cell	  cycle	  phases	  in	  PC-­‐3	  cells	  (ALOX-­5,	  CDKN1A,	  CDH1,	  CDKN2A,	  CYP24,	  
PTGS1,	  CEBPA).	  	  Subsequently	  PC-­‐3	  cells	  were	  treated	  for	  4	  hours	  with	  1,25(OH)2D3	  and	  again	  sorted	  in	   the	   different	   phases	   of	   the	   cell	   cycle	   to	   capture	   the	   transcriptional	   dynamicity	  during	   the	   G1,	   S	   and	   G2/M	   phases.	   As	   a	   positive	   control	   for	   VDR	   activation	   by	  1,25(OH)2D3,	   CYP24	   expression	   was	   analysed	   by	   single	   gene	   Q-­‐RT-­‐PCR	   using	   the	  RNA	  extracted	  from	  sorted	  PC-­‐3	  cells.	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Fig	  4.7	  –	  CYP24	  mRNA	  accumulation	  in	  sorted	  PC-­3	  cells	  treated	  for	  four	  hours	  with	  
100	   nM	   of	   1,25(OH)2D3.	   RNA	   was	   extracted	   and	   reverse-­transcribed	   prior	   qRT-­PCR	  
analysis.	  The	   results	   represent	   three	  biological	   replicates	   (black,	  green	  and	  red)	  and	  
mRNA	  accumulation	  is	  shown	  as	  log10	  of	  the	  fold	  changes.	  
 
By	  comparison	  to	  CYP24,	  treatment	  with	  1,25(OH)2D3	  did	  not	  influence	  strongly	  the	  transcriptome	  of	  PC-­‐3	  cells.	  RWPE-­‐1	  cells	  demonstrated	  a	   significant	  upregulation	  in	  G1	  phase	  of	  many	  genes	  after	  treatment.	  ANOVA	  analysis	  revealed	  that	  in	  RWPE-­‐1	   cells	   approximately	   60	   genes	   were	   differentially	   expressed	   across	   the	   three	  phases	   (James	  Thorne,	  University	   of	   Birmingham,	  Birmingham,	  UK)	  while	   in	   PC-­‐3	  cells	   only	   two	   genes,	   apart	   from	   CYP24	   were	   highly	   induced	   across	   the	   phases.	  
CDKN1A	   and	   Cyclin	   E1	   (necessary	   for	   G1/S	   transition),	   were	   significantly	  differentially	   expressed	   (p<0.05).	   From	   Fig	   4.7	   is	   possible	   to	   see	   that	   a	   4	   hr	  treatment	  with	  100	  nM	  of	  1,25(OH)2D3	  	  did	  not	  upregulated	  genes	  in	  G1	  as	  much	  as	  in	  RWPE-­‐1	  cells	  and	  induced	  a	  different	  expression	  pattern	  in	  PC-­‐3	  cells;	  only	  very	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few	   genes	   were	   statistically	   significantly	   regulated	   probably	   due	   to	   the	   high	  variabillity	  across	  the	  replicates.	  
	  
	  
Fig	  4.8	  –	  Heatmap	  representing	  mRNA	  accumulation	  of	  96	  genes	  in	  RWPE-­1	  and	  PC-­3	  
cells	  treated	  for	  four	  hours	  with	  100	  nM	  of	  1,25(OH)2D3.	  Red	  and	  green	  bars	  represent	  
up-­	   and	   down-­regulated	   genes,	   respectively.	   The	   represented	   values	   are	   three	  
biological	  replicate	  and	  two	  technical	  replicates	  measured	  via	  microfluidic	  Q-­RT-­PCR..	  
The	  right	  side	  of	  the	  heatmap	  contains	  the	  genes	  analysed	  and	  the	  top	  side	  indicates	  
the	   sample	   names.	   Noticeable	   is	   the	   difference	   in	   the	   expression	   pattern	   between	  
RWPE-­1	  and	  PC-­3	  cells	  being	  the	  first	  one	  constant	  across	  the	  phases	  (from	  G1	  towards	  
G2)	  and	  the	  second	  one	  scattered	  with	  different	  variability	  across	  the	  phases.	  
	  These	   results	   suggest	   that,	   although	   PC-­‐3	   cells	   have	   a	   certain	   level	   of	   regulation	  mediated	   by	   ligand-­‐induced	   VDR,	   they	   present	   several	   levels	   of	   corruption	   that	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dynamically	  interact	  transforming	  a	  physiological	  NR	  system;	  understanding	  which	  hubs	   in	   this	   network	   are	   the	   most	   important	   would	   mean	   understanding	   which	  components	   rule	   and	   direct	   cancer	   cells	   through	   tumorigenic	   transformation.	   In	  turn	  these	  targets,	  or	  hubs,	  may	  be	  good	  candidate	  targets	  for	  therapy.	  	  	  
4.1.4	  –	  The	  effect	  of	  the	  HDAC	  inhibitor,	  SAHA,	  effect	  on	  the	  nuclear	  receptor	  
network	  in	  prostate	  epithelial	  cells	  The	  use	  of	  histone	  deacetylases	   inhibitors	  reverts	   the	  acetylation	  status	  of	  histone	  lysine	   residues.	   This	   can	   promote	   NR	   transcription	   via	   de-­‐stabilization	   of	   co-­‐repressor	   complexes;	   this	   hypothesis	   was	   tested	   using	   SAHA	   (suberoylanilide	  hydroxamic	   acid	   or	   Vorinostat)	   alone	   or	   in	   combination	   with	   nuclear	   receptor	  ligands	  and	  analyzing	  transcriptional	  changes	  and	  levels	  of	  proliferation.	  	  




Fig	  4.9	  –	  Additive	  effect	  of	  0.5	  µM	  of	  SAHA	  (Vorinostat)	  in	  combination	  with	  nuclear	  
receptor	   ligands,	   this	   concentration	   was	   chosen	   for	   its	   low	   toxicity	   and	   minimal	  
antiproliferative	  and	  was	  obtained	  from	  an	  initial	  optimization	  experiment	  that	  aimed	  
to	  find	  the	  ED25	  dose:	  (A)	  10	  nM	  ATRA	  (RAR),	  (B)	  10	  µM	  EPA	  (PPARα),	  (C)	  10	  µM	  ETYA	  
(PPARγ),	   (D)	  0.5	  µM	  Bezafibrate	   (PPARα,	   -­γ),	   (E)	  T3	   (TR),	   (F)	  100	  nM	  1,25(OH)2D3	   ,	  
(VDR).	  Two	  thousand	  cells	  were	  plated	  in	  a	  96	  well/plate	  and	  treated	  with	  the	  ligand	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for	  96	  hours	  with	  a	  re-­dose	  at	  48	  hours.	  Results	  were	  compared	  to	  the	  same	  ligand	  in	  
RWPE-­1	   cells.	   Strong	   additive	   effects	   (sa)	  were	   those	  where	   the	   experimental	   value	  
were	   significantly	   higher	   than	   the	   predicted	   value,	   additive	   (a)	   effects	   were	   those	  
where	  the	  experimental	  value	  did	  not	  significantly	  differ	  from	  the	  predicted	  value,	  sub-­
additive	   (sb)	   effects	   were	   those	  where	   the	   experimental	   value	  was	   significantly	   less	  
than	   the	   predicated	   value.	   Statistical	   significance	  was	   calculated	   using	   a	   one	   tailed	  
Mann-­Whitney	  test	  (*	  p<0.05,	  **	  p<0.01)	  [210].	  Data	  represent	  the	  mean	  of	  biological	  
triplicate	  undertaken	  in	  triplicate	  wells.	  	  The	  results	  suggest	  that	  SAHA	  has	  an	  antiproliferative	  effect	  irrespective	  of	  the	  cell	  background;	   in	   combination	   with	   PPARs	   and	   RAR,	   SAHA	   shows	   an	   additive,	  antiproliferative	   effect	   on	   prostate	   cancer	   epithelial	   cells	   whereas	   it	   does	   not	  enhance	   the	   antiproliferative	   effect	   of	   1,25(OH)2D3.	   This	   could	   be	   explained	   by	   a	  different	   cohort	   of	   HDACs	   recruited	   by	   the	   complex-­‐bound	   VDR;	   as	   previously	  demonstrated,	   1,25(OH)2D3	   shows	   additive	   effect	   with	   Trichostatin	   A	   (TSA)	   [62,	  211].	   However,	   this	   does	   not	   occur	   with	   SAHA	   suggesting	   that	   the	   combinatorial	  role	  of	  HDACs	  inhibitors	  and	  NR	  ligands	  is	  receptor-­‐specific.	  	  
4.1.5	   –	   Genome	   wide	   analysis	   of	   the	   combinatorial	   effect	   of	   SAHA	   and	  
bezafibrate	  on	  PC-­3	  cells.	  After	   assessing	   the	   phenotypical	   effect	   of	   SAHA	   in	   combination	   with	   NR	   ligands	  genome	   wide	   changes	   in	   gene	   expression	   mediated	   by	   the	   PPAR	   system	   were	  analysed,	   following	   5	   hours	   treatment	   with	   0.5µM	  Bezafibrate	   (PPAR-­‐α/γ	   ligand)	  and	  0.5	  µM	  SAHA,	  either	  separately	  or	  in	  combination.	  A	  30k	  probe	  array	  prepared	  in	  collaboration	  with	  the	  Cancer	  Research	  UK,	  DNA	  Microarray	  Facility	  (Institute	  for	  Cancer	  Research,	  Sutton,	  UK),	  identified	  62	  genes	  modulated	  in	  an	  additive	  manner	  (28	   and	   34	   elevated	   and	   repressed	   respectively).	   Gene	   ontology	   definition	   terms	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identified	   functionally-­‐related	   gene	   groups	   including	   transcriptional	   regulators,	  signal	   transduction	   components,	   lipid	   metabolism	   and	   protein	   stabilization.	  Comparing	  the	  expression	  patterns	  to	  those	  in	  prostate	  cancer	  libraries	  [203,	  212]	  refined	  this	  list	  further.	  Screening	  through	  prostate	  cancer	  libraries	  (Cancer	  Genome	  Anatomy	   Project	   (CGAP)	   and	   the	   Oncomine)	   revealed	   that,	   within	   the	   23	   genes	  uniquely	   upregulated	   by	   SAHA	   and	   bezafibrate,	   10	   of	   them	   were	   normally	  downregulated	  in	  prostate	  cancer	  while	  17	  of	  the	  35	  uniquely	  downregulated	  genes	  were	  initially	  upregulated	  in	  prostate	  cancer.	  
	  
Fig	   4.10	   –	   (A)	   Heatmap	   representing	   genes	   uniquely	   regulated	   by	   the	   double	  
treatment	  with	  SAHA	  and	  bezafibrate,	  indicated	  is	  also	  the	  expression	  patter	  in	  cancer	  
tissues	  retrieved	  by	  Oncomine	  and	  the	  Cancer	  Genome	  Anatomy	  Project.	  Green	  and	  red	  
bars	   indicate	   down-­	   and	   up-­regulated	   genes,	   respectively.	   (B)	   Venn	   Diagram	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representing	  the	  previous	  data:	  10	  out	  of	  23	  upregulated	  gene	  were	  down-­regulated	  in	  
cancer	  and	  the	  expression	  of	  17	  out	  of	  35	  downregulated	  genes	  in	  cancer	  was	  restored	  
by	  the	  combined	  treatment.	  
	  The	   initial	   list	   of	  more	   than	   60	   genes	   uniquely	   regulated	  was	   narrowed	   down	   by	  mining	   literature	   and	   online	   public	   databases	   such	   as	   SAGE	   Genie	  (http://cgap.nci.nih.gov/SAGE),	   Omim	   (http://www.ncbi.nlm.nih.gov/omim),	  Oncomine	   (http://www.oncomine.org)	   and	   Gene	   Cards	  (http://www.genecards.org/).	  This	  helped	  to	  focus	  mainly	  on	  genes	  involved	  in	  key	  cellular	  function	  like	  apoptosis,	  cell	  cycle,	  metabolism	  and	  NR	  signalling.	  A	  final	  list	  of	   genes	   for	   validation	   included	   16	   genes:	   8	   upregulated	   (JMY,	   ALOX5,	   ARID4B,	  TYRP1,	   TIAL1,	   TWIST2,	   TEAD2	   and	   NR4A3)	   and	   8	   downregulated	   (IL15R,	  TGFBRAP1,	  ELAV1,	  CDC2,	  TRIM66,	  FBXL6,	  PDCD6IP	  and	  CSDA)	  –	  Fig	  4.11	  A+B.	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Fig	  4.11	  –	  Schematic	   representation	  of	  genes	   found	   to	  be	  uniquely	  up-­regulated	   (A)	  
and	  down-­regulated	  (B)	  by	  the	  double	  treatment	  with	  SAHA	  and	  bezafibrate.	  Blue	  and	  
orange	   boxes	   indicate	   cytoplasmic	   and	   nuclear	   products,	   respectively.	   Yellow	   boxes	  
indicate	   cellular	   functions;	   arrows	   indicate	   positive	   interaction	   between	   two	   genes	  
and	  flat-­ended	  lines	  indicate	  inhibitory	  interaction.	  
 
4.1.6	  –	  Microarray	  validation	  of	  candidate	  genes	  uniquely	  regulated	  by	  SAHA	  
and	  bezafibrate	  To	  confirm	  that	  the	  double	  treatment	  with	  SAHA	  and	  Bezafibrate	  uniquely	  regulate	  this	  cohort	  of	  16	  genes	  we	  performed	  time	  course	  experiments	  up	  to	  24	  hours	  with	  0.5	   µM	   of	   either	   SAHA	   or	   Bezafibrate	   or	   the	   two	   together	   in	   mid-­‐exponentially	  growing	   PC-­‐3	   cells.	   Whole	   RNA	   was	   extracted	   and	   reverse	   transcribed	   before	  analyzing	   the	   candidate	   genes	   via	  Q-­‐RT-­‐PCR.	  The	   following	   screening	   criteria	  was	  undertaken	   to	   find	   those	   genes	   that	  were	   uniquely	   upregulated	   at	   either	   6	   or	   12	  hours	  with	  the	  double	  treatment	  of	  SAHA	  and	  Bezafibrate.	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Fig	   4.12	   –	   Q-­RT-­PCR	   screening	   for	   16	   candidate	   genes	   identified	   via	   microarray	  
analysis	  for	  being	  uniquely	  regulated	  by	  the	  double	  treatment	  with	  0.5	  µM	  SAHA	  and	  
0.5	  µM	  Bezafibrate.	  PTGS2	  was	  identified	  via	  network	  analysis	  for	  being	  metabolically	  
related	   to	   ALOX5.	   Shown	   are	   genes	   initially	   up-­regulated	   (A1	   to	   I2)	   and	  
downregulated	  (F1	  to	  Q2).	  105	  PC-­3	  cells	  were	  plated	  per	  each	  well	  in	  a	  6	  well/plate,	  
seeded	  for	  at	  least	  24	  hours	  and	  treated	  with	  the	  ligand	  for	  either	  6	  or	  12	  hours;	  total	  
RNA	  was	  extracted	  and	  reverse-­transcribed	  prior	  Q-­RT-­PCR	  analysis.	  Assay	  on	  demand	  
primers	  and	  probes	  were	  used	  as	  described	  in	  Materials	  and	  Methods.	  All	  the	  data	  are	  
the	  mean	  value	  of	  at	  least	  biological	  triplicate	  datasets	  +/-­	  S.E.M..	  	  	  After	   confirming	   which	   genes	   identified	   at	   the	   initial	   round	   of	   validation	   to	   be	  uniquely	  regulated	  by	   the	  double	   treatment,	  a	  cohort	  were	  profiled	   further	  with	  a	  detailed	  time	  course	  analysis	  over	  24	  hours	  (Fig	  4.13	  A-­D).	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Fig	   4.13	   –	  Time	   course	   experiments	   for	   five	   selected	   genes:	   ALOX5	   (A),	   PTGS2	   (B),	  
TGFBRAP1	  (C),	  CDC2	  (D)	  and	  FBXL6	  (E).	  RNA	  was	  extracted	   from	  mid-­exponentially	  
growing	  PC-­3	  cells	  and	  reverse	  transcribed	  prior	  Q-­RT-­PCR	  analysis.	  Custom	  designed	  
primers	  and	  probes	  were	  validated	  and	  used	  for	  this	  experiment;	  the	  complete	  list	  can	  
be	  found	  in	  Materials	  and	  Methods.	  Experiments	  performed	  with	  the	  single	  ligands	  or	  
with	   the	   combination	   of	   the	   two	   revealed	   several	   time	   points	  where	   the	  mRNA	  was	  
uniquely	   regulated	  by	   the	   combined	  action	  of	   0.5	  µM	  SAHA	  and	  0.5	  µM	  bezafibrate.	  
Each	  time	  point	  is	  the	  mean	  value	  of	  at	  least	  three	  biological	  replicates	  +/-­	  S.E.M..	  One	  
way	  ANOVA	  was	  used	  to	  discover	  statistical	  significance	  of	  the	  double	  treatment	  with	  
SAHA	  and	  bezafibrate,	  *=p<0.05.	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Statistical	   analysis	   demonstrated	   that	   the	   following	   genes	   were	   significantly	  regulated	  by	  the	  double	  treatment	  with	  0.5µM	  of	  both	  SAHA	  and	  bezafibrate:	  ALOX5	  (5	  hr),	  TGFBRAP1	   (2	  and	  16	  hr),	  FBXL6	   (5	  and	  6	  hr),	  PTGS2	   (1,	  2,	  5	  and	  6	  hr)	  and	  
CDC2	  (2	  hrs).	  Time	   course	   experiments	   demonstrated	   that	   all	   the	   genes	   are	   dynamically	   and	  uniquely	  regulated	  by	  the	  combined	  treatment	  at	  different	  time	  points;	  this	  suggests	  that	   the	   transcriptome	   of	   PC-­‐3	   cells	   was	   subject	   to	   different	   levels	   of	   regulation	  including	   chromatin	   remodeling	   and	   mRNA	   degradation	   events	   that	   dynamically	  modulate	  gene	  transcription.	  Even	  further,	  the	  possibility	  of	  re-­‐activating	  the	  PPAR	  signalling	   in	  prostate	  malignant	  cells	  using	  histone	  deacetylases	   inhibitors	  suggest	  that	   the	   NR	   network	   is	   squelched	   by	   a	   corrupted	   epigenome.	   Both	   SAHA	   and	  Bezafibrate	   are	   already	   used	   in	   clinical	   trials	   and	   have	   very	   good	   safety	   profile	  suggesting	  that	  they	  can	  be	  used	  in	  combination	  use	  for	  further	  trials.	  	  
4.1.7	  –	  NCOR	  Knock	  down	  approach	  through	  shRNA	  in	  PC-­3	  cells	  To	   investigate	   the	   hypothesis	   that	   a	   corrupted	   NR	   transcriptome	   occurs	   through	  elevated	   levels	   of	   NCOR1,	   a	   shRNA	   approach	   was	   undertaken	   to	   reduce	   NCOR1	  levels	   in	  PC-­‐3	  cells.	   	  A	  schematic	  representation	  of	   the	  NCOR1	  gene	  and	  the	  exons	  target	  by	  the	  shRNA	  approach	  is	  available	  in	  the	  Supplementary	  Figures.	  The	  exons	  targeted	  were	  number	  5,	  38	  and	  44	  (sequences	  available	  in	  Materials	  and	  Methods);	   the	   single	   stranded	   oligos	   were	   annealed	   and	   ligated	   into	   the	   empty	  pcDNA3.1-­‐H1	  vector	  (described	  in	  Materials	  and	  Methods);	  the	  ligation	  was	  checked	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via	  restriction	  enzyme	  digestion	  (Acc65	  and	  XbaI)	  (Fig	  4.14)	   and	  sequencing	  (Fig	  
4.15).	  	  	  
	  
Fig	   4.14	  –	   (TOP)	   annealed	   oligos	   for	   shNCOR1	   and	   pcDNA3.1-­H1	   vectors	   loaded	   to	  
ensure	   the	   ratio	   between	   vector/oligos	   in	   order	   to	   perform	   an	   efficient	   ligation.	  
(BOTTOM)	   digestion	   with	   Acc65I	   and	   XbaI	   to	   show	   the	   presence	   of	   the	   inserted	  
fragment	   (200	   bp).	   The	   ladder	   is	   over-­exposed	   due	   to	   the	   presence	   of	   a	   low	  
concentration	   of	   digested	   product;	   however	   the	   samples	   were	   used	   successfully	   for	  
sequencing	  as	  shown	  in	  Fig	  4.15.	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Fig	   4.15	   –	   Sequencing	   results	   of	   the	   pcDNA3.1H1	   clones	   containing	   the	   inserts	  
directed	  against	  exon	  5,	  38	  and	  44.	  Highlighted	  in	  blue	  are	  the	  sequences	  containing	  
the	   hairpins,	   full	   sequences	   are	   available	   in	   the	   Materials	   and	   Methods	   chapter.	  
Sequencing	  was	  performed	  by	  the	  Genomic	  Facilities	  in	  the	  School	  of	  Biosciences	  at	  the	  
University	  of	  Birmingham,	  Birmingham,	  UK.	  
	  PC-­‐3	  cells	  were	  then	  transfected	  with	  the	  single	  vector	  or	  with	  a	  combination	  of	  all	  the	   three	  different	   targeting	  constructs	  using	  FUGENE6	  (protocol	   in	  Materials	  and	  Methods);	  G418	   at	   the	   optimized	   concentration	  of	   1	  mg/ml	  was	  used	   for	   positive	  selection	  of	  cells	  with	  the	  insert.	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Fig	  4.16	  –	  Dose	  response	  of	  G418	  in	  PC-­3	  cells.	  This	  experiment	  was	  undertaken	  to	  find	  
the	   concentration	   of	   G418	   suitable	   to	   maintain	   PC-­3-­	   shNCOR1	   resistant	   cells.	   two	  
thousands	  cells	  were	  plated	  in	  flat	  white	  bottom	  a	  96	  well/plate,	  treated	  for	  96	  hours	  
with	  the	  designed	  concentration	  of	  G418	  and	  re-­dosed	  after	  48	  hours.	  The	  percentage	  
of	   proliferating	   cells	   was	   measured	   via	   ATP	   assay	   (described	   in	   Materials	   and	  
Methods).	   Data	   shown	   are	   the	   average	   of	   a	   biological	   duplicate	   and	   technical	  
triplicate	  (three	  wells	  per	  each	  sample	  per	  each	  replicate)	  +/-­	  S.E.M..	  
	  Serial	   dilutions	   were	   prepared	   in	   order	   to	   select	   single-­‐clone	   colonies;	   these	  colonies	  were	   expanded	   further	   and	   screened	   to	   check	   the	   knockdown	   levels	   via	  qRT-­‐PCR	  and	  Western	  blotting	  (Fig	  4.17).	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Fig	  4.17	  –	  NCOR1	  knock	  down	  via	  shRNA	  in	  PC-­3	  cells	  at	  the	  protein	  (A)	  and	  mRNA	  
(B)	   level.	   Nuclear	   lysate	   from	   mid-­exponential	   growing	   cells	   was	   used	   for	   Western	  
immunoblotting	   analysis	   with	   the	   anti-­NCOR1	   antibody	   (listed	   in	   Materials	   and	  
Methods).	  Total	  RNA	  was	  extracted	  from	  different	  clones	  and	  reverse	  transcribed	  prior	  
qRT-­PCR;	   mRNA	   levels	   were	   compared	   to	   two	   different	   VO	   clones	   and	   VO-­2	   was	  
chosen.	   Data	   shown	   are	   the	   results	   of	   biological	   triplicate	   +/-­	   S.E.M..	   For	   further	  
analysis	  the	  clone	  38.2	  was	  selected.	  	  The	   results	  demonstrated	   that	   the	   shNCOR1-­‐PC-­‐3	  38-­‐2	   clone	   showed	   the	   greatest	  knockdown	   at	   both	   protein	   and	  mRNA	   levels	   and	  was	   selected	   for	   all	   the	   further	  experiments.	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4.1.8	  –	  Microfluidic	  Gene	  Card	  analysis	  (Q-­RT-­PCRM)	  in	  shNCOR1-­PC-­3	  and	  VO-­
PC-­3	  cells	  A	  microfluidic	   Q-­‐RT-­‐PCR	   approach	  was	   used	   to	   investigate	   better	   the	   function	   of	  NCOR1	   in	   PC-­‐3	   cells	   and	   understand	   its	   regulatory	   function	   in	   the	   NR	   network.	  Again,	   to	   capture	   the	   dynamics	   of	   the	   cell	   cycle,	   untreated	   mid-­‐exponentially	  growing	   cells	   were	   FACS	   sorted	   in	   G1,	   S	   and	   G2	   phases	   and	   collected	   into	   TRI	  reagent;	   RNA	  was	   extracted,	   diluted	   at	   the	   appropriate	   concentration	   and	   loaded	  with	  the	  Qiagen	  one-­‐step	  Mastermix	  in	  the	  gene	  cards.	  Q-­‐RT-­‐PCRM	  analyses	  revealed	  that	   reducing	   NCOR1	   expression	   significantly	   re-­‐expressed	   genes	   across	   the	   cell	  cycle	   including	   CDH1	   (Fig	   4.18	   A).	   Subsequent	   SAM	   analyses	   identified	   a	   further	  cluster	   of	   genes	   significantly	   up-­‐regulated	   in	   G2	   phase,	   in	   response	   to	   lowered	  NCOR1,	  including	  ALOX-­5,	  CDKN1A,	  TP53	  (Fig	  4.18	  B).	  CDH1	  transcription	  leads	  to	  the	   translation	   of	   a	   transmembrane	   glycoprotein	   that	   controls	   intracellular	  adhesion	  and	  has	  been	  found	  to	  be	  down	  regulated	  in	  metastatic	  cancer	  [213-­‐215];	  the	   finding	   that	   NCOR1	   control	   its	   expression,	   together	   with	   CDKN1A	   and	   TP53,	  highlights	  the	  partially	  key	  role	  that	  NCOR1	  plays	  in	  the	  invasiveness	  of	  malignant	  cells.	  	  	  
Chapter	  4	  –	  Results	  –	  Nuclear	  Corepressors	  function	  in	  the	  prostate	  system	  	  
 212 
	  
Fig	   4.18	   –	   Gene	   expression	   in	   shNCOR1-­PC-­3	   versus	   VO-­PC-­3.	   Data	   shown	   are	   the	  
mean	  of	  at	   least	  biological	  duplicate	  and	   technical	  quadruplicate	   (tow	   set	  of	  probes	  
were	  present	   in	  each	  well).	   (A)	  Genes	  significantly	  differentially	  expressed	   in	  at	   least	  
one	  phase	  of	  the	  cell	  cycle	  between	  shNCOR1-­PC-­3	  and	  VO-­PC-­3,	  *=p<0.05.	  Statistical	  
significance	   was	  measured	  with	   a	   one-­sample	   t-­test	   comparing	   the	   obtained	   values	  
against	  the	  mean	  of	  1	  (index	  of	  no	  changes).	  (B)	  Heatmap	  showing	  genes	  significantly	  
differentially	   expressed	   across	   the	   three	   phases	   of	   the	   cell	   cycle.	   Significance	   was	  
measured	  via	  Significance	  Analysis	  of	  Microarray	  (SAM)	  test	  and	  cluster	  analysis	  was	  
performed	  using	  Euclidean	  distance.	  Up-­	   and	  down-­regulated	   genes	   are	   represented	  
by	   red	   and	   green	   boxes,	   respectively.	   NCOR1	   knock	   down	   levels	   are	   shown	   at	   the	  
bottom	  of	  the	  image.	  	  
4.1.9	  –	  Enhanced	  anti-­proliferative	  effect	  shNCOR1	  on	  NR	  responsiveness	  As	   first	  step	   the	  sensitivity	  of	  shNCOR1-­‐PC-­‐3	  towards	  a	  broad	  panel	  of	  NR	   ligands	  was	   analysed	   to	   check	   whether	   reduced	   levels	   of	   NCOR1	   altered	   the	  antiproliferative	  effect	  of	  NR	  ligands.	  Two	  thousand	  cells	  were	  plated	  per	  well	  in	  a	  96	  well/plate	  and	  treated	  for	  96	  hours	  with	  the	  selected	   ligand;	  ATP	  concentration	  was	  then	  measured	  in	  both	  shNCOR1-­‐PC-­‐3	   and	   VO-­‐PC-­‐3.	   At	   a	   phenotypical	   level,	   the	   antiproliferative	   effect	   of	   EPA	  (PPARα	   ligand),	   ETYA	   (PPARγ	   ligand)	   and	   ATRA	   (RAR	   ligand)	   were	   significantly	  enhanced	  by	  NCOR1	  knockdown,	   shNCOR1-­‐PC-­‐3	  were	  also	   slightly	  more	   sensitive	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to	  Bezafibrate	  but	  interestingly	  they	  were	  not	  sensitized	  further	  to	  1,25(OH)2D3	  and	  T3	  (Fig	  4.19).	  VDR	  was	  shown	  by	  others	  to	  bind	  SMRT	  preferentially	  over	  NCOR1,	  and	   as	   already	  mentioned,	   1,25(OH)2D3	   	   had	   additive	   effect	   only	  with	   TSA,	  while	  SAHA	  did	  not	  enhance	  its	  antiproliferative	  effect	  PC-­‐3	  cells	  [62,	  211].	  	  
	  
Fig	   4.19	   –	   Smoothed	   dose	   response	   curves	   for	   a	   cohort	   of	   nuclear	   receptor	   ligands	  
comparing	  VO-­PC-­3	  (black)	  with	  shNCOR1-­PC-­3	  (red).	  Two	  thousand	  cells	  were	  plated	  
in	  a	  flat-­bottom	  96	  well/plate	  and	  treated	  for	  96	  hours	  with	  the	  selected	  agonist	  with	  
a	   re-­dose	  at	  48	  hours.	   Proliferation	  was	  measured	   via	  ATP	  assay	   comparing	   ligand-­
treated	  cells	  versus	  diluent-­treated	  cells.	  The	  results	  show	  that	  shNCOR1-­PC-­3	  show	  a	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consistent	   increased	   sensitivity	   towards	   the	   ligands,	   except	   1,25(OH)2D3	   and	   thyroid	  
hormone	  T3.	  Each	  data	  point	  represents	  the	  mean	  value	  of	  three	  separate	  experiments	  
each	  undertaken	  in	  triplicate	  wells	  +/-­	  S.E.M..	  Student	  t-­test	  (Mann-­Whitney	  test)	  was	  
performed	   to	   reveal	   whether	   shNCOR-­1-­PC-­3	   cells	   were	   significantly	   more	   sensitive	  
than	  VO-­PC-­3	  cells	  to	  NR	  ligand;	  *=p<0.05,	  **=p<0.01,	  ***=p<0.001.	  	  The	  EC50s	  from	  the	  dose-­‐response	  curves	  to	  all	  NR	  ligands	  were	  measured	  and,	  in	  average,	  they	  were	  200	  nM	  lower	  in	  shNCOR1-­‐PC-­‐3	  than	  in	  VO-­‐PC-­‐3	  cells.	  	  	  	  	  
Fig	  4.20	  –	  Bar	  chart	  indicating	  the	  average	  
EC50s	   for	   EPA,	   ETYA,	   Bezafibrate,	   ATRA	  
and	  SAHA	  the	  treatments	  in	  shNCOR1-­PC-­3	  
(red)	  and	  PC-­3-­VO	  (blue).	  
	  Although	   shNCOR1-­‐PC-­‐3	   cells	   were	  selectively	  more	  sensitive	  to	  NR	  ligands	  their	  proliferation	  rate	  and	  morphology	  did	  not	  differ	  from	  PC-­‐3-­‐VO	  (data	  not	  shown).	  SAHA	  has	  a	  wide	  range	  of	  action	  affecting	  the	  acetylation	  state	  of	  histone	  and	  non-­‐histone	  proteins.	  Knocking	  down	  NCOR1	  using	   a	   shRNA	  approach	   created	   a	  more	  defined	  system	  that	  allowed	  the	  investigation	  of	  the	  activity	  of	  this	  gene	  in	  a	  cancer	  system.	  To	  demonstrate	  to	  what	  extent	  the	  effect	  of	  NCOR1	  resembles	  the	  activity	  of	  SAHA	  in	  PC-­‐3	  cells	   the	  effect	  of	  10nM	  ATRA,	  10	  µM	  EPA,	  10	  µM	  ETYA	  and	  0.5	  µM	  Bezafibrate	  either	  alone	  or	  in	  combination	  with	  0.5	  µM	  SAHA	  in	  LNCaP,	  DU145	  and	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wild	  type	  PC-­‐3	  cells	  (Fig	  4.9)	  was	  compared	  with	  the	  antiproliferative	  effect	  of	  10	  
µM	  ATRA,	  30	  µM	  EPA	  and	  20	  µM	  ETYA	  in	  PC-­‐3VO	  and	  shNCOR1-­‐PC-­‐3	  (Fig	  4.21).	  	  
LIGAND	   ADDITIVE	  TO	  SAHA	   ENHANCED	  BY	  shNCOR1	  ETYA	   +	   +	  EPA	   +	   +	  Bezafibrate	   +	   +/-­‐	  ATRA	   +	   +	  SAHA	   /	   +	  1,25(OH)2D3	   -­‐	   -­‐	  T3	   -­‐	   -­‐	  	  
Fig	  4.21	  –Summary	  table	  for	  the	  effect	  of	  NR	  ligands	  on	  PC-­3	  cells	  and	  their	  activity	  in	  
combination	  with	  either	  SAHA	  or	  shNCOR1.	  From	  left	  to	  right	  the	  columns	  indicate	  the	  
NR	   ligand,	   the	   effect	   in	   combination	  with	   SAHA	   and	   the	   enhanced	   effect	   by	   NCOR1	  
knock	  down	  in	  shNCOR1-­PC-­3	  cells	  compared	  to	  VO-­PC-­3	  cells.	  	  As	  shown	  by	  Fig	  4.19	  and	  Fig	  4.21	  the	  antiproliferative	  activity	  of	  NR	  ligands	  was	  enhanced	   by	   shNCOR1	   only	   in	   a	   selected	   cluster	   of	   receptors.	   These	   NR	   are	   all	  phylogenetically	  related	  suggesting	   that	  conserved	  sequences	  can	  partially	  explain	  why	  knocking	  down	  NCOR1	  does	  not	  globally	  enhance	  the	  antiproliferative	  effect	  of	  NR	  agonists.	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Fig	   4.22	   –	   Nuclear	   Receptor	   phylogenetic	   tree.	   This	   image	   was	   downloaded	   from	  
Wikipedia	   (www.wikipedia.org),	   was	   prepared	   using	   CLC	   Free	   Workbench	   Version	  
3.2.2	   (http://www.clcbio.com)	  and	   the	  amino	  acid	   sequences	  was	  downloaded	   from	  
the	  PubMed	  protein	  database	  (http://www.pubmed.gov).	  Highlighted	   in	  red	  are	  the	  
NR	  that	  did	  not	  have	  an	  enhanced	  antiproliferative	  activity	  upon	  agonist	  treatment	  in	  
shNCOR1-­PC-­3	  cells;	  highlighted	   in	  green	  are	   the	  NR	  whose	  antiproliferative	  activity	  
was	  enhanced	  upon	  agonist	  treatment	  in	  shNCOR1-­PC-­3	  cells	  compared	  with	  VO-­PC-­3	  
cells.	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4.1.10	  –	  Gene	  de-­repression	  in	  shNCOR1-­PC-­3	  cells	  Cells	   treated	   with	   single	   nuclear	   receptor	   agonists	   in	   combination	   with	   SAHA	  showed	   an	   additive	   effect	   towards	   both	   cell	   proliferation	   and	   gene	   transcription.	  The	  next	  step	  was	  to	  demonstrate	  whether	  NCOR1	  knockdown	  was	  able	  to	  regulate	  NR	  gene	  transcription	  in	  a	  manner	  that	  reflects	  SAHA	  co-­‐treatment.	  	  The	  first	  approach	  aimed	  to	  demonstrate	  that	  the	  genes	  uniquely	  expressed	  by	  the	  combination	   of	   SAHA	   and	   bezafibrate	   in	   the	  microarray	   (CDC2,	  TGBRAP1,	  ALOX5,	  
PTGS2	  and	  FBXL6)	  could	  be	  similarly	  regulated	  by	  the	  combination	  of	  NCOR1	  knock	  down	  and	  bezafibrate	   treatment.	  Mid-­‐exponential	  growing	  shNCOR1-­‐PC-­‐3	  and	  PC-­‐3-­‐VO	  were	  treated	  with	  single	  agents	  (0.5	  µM	  Bezafibrate	  or	  100	  nM	  1,25(OH)2D3)	  for	  3	  and	  8	  hours,	  whole	  RNA	  was	  extracted	  and	  reverse-­‐transcribed	  prior	  to	  Q-­‐RT-­‐PCR	   analysis.	   Interestingly,	   the	   results	   show	   that	   reduced	   levels	   of	   NCOR1	   affect	  both	  positively	  and	  negatively	  the	  mRNA	  accumulation	  of	  target	  genes,	  suggesting	  a	  ligand-­‐dependent	   mechanism	   of	   repression	   by	   NCOR1.	   The	   time	   points	   from	   the	  bezafibrate	  and	  SAHA	  time	  course	  experiments	  where	  the	  genes	  were	  uniquely	  and	  significantly	   regulated	   by	   the	   co-­‐treatment	   were	   found	   to	   mirror	   broadly	   the	  pattern	  of	  mRNA	  accumulation	  in	  shNCOR1-­‐PC-­‐3	  treated	  with	  bezafibrate	  alone.	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Fig	  4.23	  -­	  PC-­3	  cells	  were	  treated	  with	  bezafibrate	  (0.5	  mM)	  plus	  vorinostat	  (0.5	  mM),	  
and	  VO-­PC-­3	  and	  shNCOR1-­PC-­3	  	  cells	  were	  treated	  with	  bezafibrate	  (0.5	  mM)	  over	  a	  
16	  hour	  time	  course,	  mRNA	  extracted	  and	  subjected	  to	  Q-­RT-­PCR.	  (A)	  mRNA	  levels	  at	  4	  
hr	  (CDKN1A),	  5	  hr	  (ALOX-­5),	  2	  hr	  (CDC2,	  PTGS2,	  TGFBRAP11).	  (B)	  mRNA	  levels	  at	  3	  hr	  
(CDKN1A,	  CDC2,	  ALOX5,	  PTGS2)	  and	  8	  hr	  (TGFBRAP1)	  in	  PC-­3	  shNCOR1	  cells	  and	  PC-­3	  
VO	  cells.	  Each	  data	  point	  represents	  the	  mean	  of	  three	  separate	  experiments	  amplified	  
in	  triplicate	  wells	  +/-­	  S.E.M.	  Student	  t-­test	  was	  used	  to	  measure	  statistical	  significance	  
comparing	  knock	  down	  against	  vector	  only	  control	  samples	  (*p	  <	  0.05).	  The	   upregulation	   of	   CDKN1A	   caused	   by	   the	   combined	   treatment	   of	   SAHA	   and	  bezafibrate	   was	   mirrored	   by	   the	   bezafibrate-­‐alone	   treated	   shNCOR1-­‐PC-­‐3;	   CDC2,	  
PTGS2	   and	   TGFBRAP1	   downregulation	   was	   found	   also	   in	   the	   knock	   down	  bezafibrate-­‐treated	  cells	  while	  ALOX5	  pattern	  was	  interestingly	  opposite.	  It	  was	  also	  checked	  whether	  reduced	  levels	  of	  NCOR1	  could	  influence	  the	  expression	  of	   VDR	   target	   genes	   bearing	   in	  mind	   that	   NCOR1	   knockdown	   did	   not	   change	   the	  sensitivity	   of	   PC-­‐3	   cells	   towards	   1,25(OH)2D3.	   Two	   classic	   VDR	   target	   genes	  were	  also	   taken	   in	   consideration:	   CYP24	   (involved	   in	   1,25(OH)2D3	   catabolism),	   and	  
CDKN1A	  (involved	  in	  cell	  cycle	  control).	  CDKN1A	   levels	  were	  not	  influenced	  by	  the	  knockdown	  while,	   interestingly,	  CYP24	  mRNA	  accumulation	   in	  shNCOR1-­‐PC-­‐3	  was	  reduced	  at	  both	  3	  and	  8	  hours	  compared	  to	  PC-­‐3-­‐VO.	  However,	  these	  last	  results	  are	  not	   totally	   surprising	   because	   they	   show	   that	   the	   1,25(OH)2D3-­‐dependent	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upregulation	   of	   CYP24	   is	   not	   a	   mechanism	   driven	   uniquely	   by	   the	   vitamin	   D	  receptor	  and	  implies	  some	  secondary	  effects	  that	  loop	  in	  the	  system	  independently	  from	  NCOR1.	  Moreover,	   the	  CYP24	   data	   are	   consistent	  with	   previously	   published	  cyclohexamide	   data	   [62]	   where	   it	   has	   been	   shown	   that	   the	   combined	   treatment	  cyclohexamide	   and	   1,25(OH)2D3	   led	   to	   a	   significant	   reduction	   in	   the	   induction	   of	  
CYP24	   in	   PC-­‐3	   cells,	   supporting	   the	   concept	   that	   upregulation	   of	   this	   genes	   is	   not	  only	  a	  direct	  effect	  VDR-­‐mediated.	  
	  
Fig	  4.24	   –	  1,25(OH)2D3	   action	   on	  CYP24	   (A)	   and	  CDKN1A	   (B)	  mRNA	  accumulation.	  
Whereas	  CDKN1A	  expression	  does	  not	   change	   in	   shNCOR1-­PC-­3	  cells	   compared	  with	  
PC-­3-­VO	   cells,	   CYP24	   is	   less	   upregulated	   in	  NCOR1	   knockdown	   cells.	   Total	   RNA	  was	  
extracted	   form	   6	  well/plates	   and	   reverse-­transcribed	   prior	   qRT-­PCR.	   	   Student	   t-­test	  	  
was	  performed	  to	  find	  significant	  differences	  in	  the	  induction	  of	  the	  two	  genes	  in	  PC-­3	  
transfected	   with	   shNCOR1	   or	   VO,	   ***=p<0.01.	   Each	   graph	   is	   the	   average	   of	   three	  
independent	  experiments	  +/-­	  S.E.M..	  	  These	  data	  strongly	  indicate	  that	  NCOR1	  is	  not	  only	  involved	  in	  a	  direct	  repression	  of	  target	  genes	  but	  also	  in	  a	  ligand-­‐dependent	  transrepression	  of	  target	  genes.	  It	  has	  been	   shown	   that	   NCOR1	   is	   involved	   in	   a	   ligand-­‐dependent	   sumoylation	   of	   PPARγ	  that	   leads	   to	   recruitment	   of	   the	   corepressor	   complexes	   on	   the	  promoter	   of	   target	  genes	  and	  transcriptional	  inhibition	  [130].	  It	  is	  unclear	  if	  NCOR1	  either	  contributes	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to	   the	   recruitment	   of	   corepressor	   complexes	   upon	   ligand	   treatment,	   or	   acts	   as	   a	  repressor	  for	  other	  repressor	  proteins,	  explaining	  why	  lower	  levels	  of	  NCOR1	  lead	  to	  downregulation	  of	  some	  of	  the	  PPAR	  target	  genes.	  
	  
4.1.11	  –	  H3K9	  acetylation	  at	  the	  TSS	  region	  of	  PPAR	  target	  genes	  NCOR1	  complexes	  with	  several	  HDACs	  modulating	  the	  acetylation	  status	  of	  histones	  and	  non-­‐histone	  proteins.	  Histone	  3	  lysine	  9	  acetylation	  (H3K9Ac)	  is	  a	  widely	  used	  marked	   for	  active	  promoter	   regions	   that	  positively	   regulate	   transcription;	   the	  TSS	  region	  of	   two	  PPAR	   target	   genes,	  CDKN1A	   and	  TGFBRAP1	  were	   analysed	   to	   check	  whether	  0.5	  µM	  of	  either	  bezafibrate,	  SAHA	  or	  the	  combined	  treatment	  were	  able	  to	  promote	  H3K9	  acetylation	  in	  PC-­‐3	  cells.	  	  
	  
Fig	  4.25	  –	  X-­ChIP	  showing	  the	  acetylation	  levels	  of	  lysine	  9	  in	  the	  histone	  H3	  (H3K9Ac)	  
in	  TGFBRAP1	  (A)	  and	  CDKN1A	  (B).	  Mid-­exponential	  PC-­3	  cells	  were	  treated	  for	  3	  hours	  
with	   0.5	  µM	  of	   either	   SAHA,	   bezafibrate	   or	   both.	   Cells	  were	   cross-­linked,	   chromatin	  
extracted	  and	  immunoprecipitated	  with	  H3K9Ac	  antibody;	  DNA	  was	  isolated	  and	  used	  
for	  qRT-­PCR	  (Sybr	  Green)	  with	  primers	  for	  the	  indicated	  regions	  of	  the	  TGFBRAP1	  and	  
CDKN1A	   genes.	   Data	   shown	   are	   mean	   of	   two	   biological	   replicated	   +/-­	   S.E.M..	   Fold	  
changes	   were	   calculated	   comparing	   the	   H3K9Ac	   samples	   with	   the	   corresponding	  
inputs.	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As	  shown	  in	  Fig	  4.25,	  SAHA	  induced	  acetylation	  of	  H3K9	  at	  the	  TSS	  region	  of	  both	  
CDKN1A	   and	   TGFBRAP1	   as	   expected	   by	   the	   activity	   of	   a	   histone	   deacetylases	  inhibitor;	  interestingly	  bezafibrate	  not	  only	  didn’t	  induce	  any	  acetylation	  at	  the	  TSS	  but	   cleared	   part	   of	   the	   acetylation	   on	   CDKN1A	  promoting	   a	   repressive	   chromatin	  environment.	  There	   is	  an	   interesting	  similarity	   in	  the	  two	  datasets	  suggesting	  that	  the	  epigenetic	  modification	  at	  their	  promoter	  region	  might	  me	  commonly	  regulated	  by	  the	  combined	  treatment.	  	  To	   investigate	   better	   the	   involvement	   of	   NCOR1	   in	   the	   epigenetic	   regulation	   of	  
CDKN1A	  and	  TGFBRAP1	  and	  to	  confirm	  whether	  this	  would	  reflect	  the	  mRNA	  data,	  NCOR1	  was	  knocked	  down	   in	  PC-­‐3	  cells	  with	  a	  siRNA	  approach	  and	  ChIP	  analysis	  after	  3	  hours	  of	  0.5	  µM	  bezafibrate	  treatment	  was	  undertaken.	  
	  
Fig	  4.26	  –	  Knock	  down	  of	  NCOR	  via	  siRNA	  compared	  to	  scramble	  siRNA	  (as	  in	  [202]).	  
Mid	   exponentially	   growing	   PC-­3	   cells	   were	   trasnfectd	   with	   50	   ng	   of	   siRNA	   or	  
scrambled	  vector	  and	   incubated	  over-­nigh	  at	  37ºC;	   the	   following	  morning	  cells	  were	  
harvested,	   total	   RNA	   was	   extracted	   and	   reverse	   transcribed	   prior	   to	   Q-­RT-­PCR	  
analysis.	  Data	  shown	  are	  the	  mean	  of	  a	  biological	  duplicate	  +/-­	  S.E.M..	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Fig	  4.27	  –	  X-­ChIP	  showing	  the	  acetylation	  levels	  of	  lysine	  9	  in	  the	  histone	  H3	  (H3K9Ac)	  
in	  TGFBRAP1	  (A)	  and	  CDKN1A	  (B).	  Mid-­exponential	  PC-­3	  cells	  were	  transfected	  with	  
siNCOR	   or	   scramble	   siRNA	   (as	   in	   [202])	   and	   incubated	   over-­night;	   the	   media	   was	  
changed	   the	   following	   morning	   and	   cells	   were	   treated	   for	   3	   hours	   with	   0.5	   µM	   of	  
bezafibrate.	   Cells	   were	   cross-­linked,	   chromatin	   extracted	   and	   immunoprecipitated	  
with	   H3K9Ac	   antibody;	   DNA	   was	   isolated	   and	   used	   for	   qRT-­PCR	   (Sybr	   Green)	   with	  
primers	   for	   the	   indicated	   regions	  of	   the	  TGFBRAP1	  and	  CDKN1A	  genes.	  Data	   shown	  
are	   mean	   of	   two	   biological	   replicated	   +/-­	   S.E.M..	   Fold	   changes	   were	   calculated	  
comparing	  the	  H3K9Ac	  samples	  with	  the	  corresponding	  IgGs.	  	  	  The	   results	   show	   that	   H3K9	   acetylation	   at	   the	   TGFBRAP1	   +261	   region	   (chosen	  because	   the	   TSS	   region	   is	   rich	   in	   GC	   and	   no	   reliable	   primers	   were	   available)	   is	  reduced	  by	  lower	  levels	  of	  NCOR1	  while	  H3K9	  acetylation	  at	  the	  TSS	  of	  CDKN1A	  is	  increased.	   These	   results	   are	   consistent	   with	   the	   mRNA	   data	   from	   shNCOR1-­‐PC-­‐3	  cells	   where	   after	   treatment	   with	   bezafibrate	   the	   expression	   of	   TGBRAP1	   and	  
CDKN1A	   was,	   respectively,	   downregulated	   and	   upregulated.	   This	   suggests	   that	  NCOR1	   epigenetically	   modulates	   the	   ligand-­‐responsiveness	   of	   PPAR	   target	   genes	  through	   two	   different	   mechanisms:	   an	   active	   ligand-­‐independent	   repression	   on	  
CDKN1A	  and	  a	  ligand-­‐dependent	  trans-­‐activation	  on	  TGFBRAP1.	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4.2 – Ncor1 AND Ncor2/Smrt KNOCKOUT AND KNOCK DOWN IN THE MOUSE 
PROSTATE The	   importance	   of	   NCOR1	   in	   prostate	   cancer	   was	   previously	   demonstrated,	   and	  indeed,	  a	  lower	  levels	  of	  this	  protein	  leads	  to	  increased	  sensitivity	  towards	  nuclear	  receptor	   ligands	   and	   de-­‐repression	   of	   PPAR	   target	   genes.	   Another	   group	  demonstrated	   the	   key	   role	   of	   Ncor1	   and	   Ncor2/Smrt	   in	   development	   creating	  deficient	  mice	  that	  died	  at	  embryonic	  day	  (E)	  14.5	  and	  15.5,	  respectively;	  among	  the	  lethal	  heart	  defects,	  mutant	  mice	  showed	  abnormalities	  in	  neuronal	  and	  thymocyte	  development,	  as	  well	  as	  impaired	  erythropoiesis	  [139,	  216].	  	  	  These	  studies	  demonstrated	  that	  several	  organs	  are	  affected	  by	  the	  activity	  of	  both	  Ncor11	  and	  Ncor1/Smrt	  and,	   in	  addition	   in	  prostate	  malignant	  and	  non	  malignant	  cells.	  Therefore	  we	  decided	  to	  study	  the	  role	  of	  Ncor1	  and	  Ncor2/Smrt	  in	  prostate	  development	  by	  creating	  prostate-­‐specific	  knock	  out	  and	  knock	  down	  mice	  for	  both	  corepressors.	  	  
4.2.1 – Knock out strategy for Ncor1 and Ncor2/Smrt in the mouse prostate The	   initial	   approach	   aimed	   to	   design	   a	   reliable	   strategy	   to	   create	   a	   targeting	  construct	  that	  efficiently	  and	  selectively	  knocked	  out	  Ncor1	  and	  Ncor2/Smrt	  in	  the	  mouse	   prostate.	   The	   Cre-­‐LoxP	   system	   developed	   by	   Brian	   Sauer	   [217]	   has	   been	  widely	   used	   and	   exploits	   the	   ability	   of	   the	   Cre	   enzyme	   to	   recognize	   two	   specific	  sequences,	   LoxP	   sites,	   in	   the	   genome,	   bridge	   them	   together	   and	   exciding	   the	  sequence	  [218].	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Fig	  4.28	  –	  Schematic	  representation	  of	  the	  Cre-­Lox	  system:	  the	  Cre	  gene	  is	  driven	  by	  a	  
general	   or	   cell	   type/tissue	   specific	   promoter	   while	   the	   floxed	   allele	   contains	   the	  
sequence,	  mainly	  critical	  exons,	  of	  interested	  flanked	  by	  two	  LoxP	  sites	  (red	  triangles).	  
The	  Cre	  enzyme	  recognizes	  the	  LoxP	  sequences	  and	  promotes	  the	  excision	  of	  the	  target	  
sequence	  leaving	  a	  single	  LoxP	  site	  on	  the	  genome	  (image	  taken	  from	  [218]).	  
	  
	  Moreover,	  to	  create	  a	  prostate-­‐specific	  knock	  out,	  the	  Cre	  enzyme	  must	  be	  driven	  by	  a	  promoter	  active	  only	  in	  the	  mouse	  prostate;	  to	  do	  this	  we	  relied	  on	  the	  modified	  rat	   probasin,	   ARR2PB,	   promoter.	   This	   promoter	   has	   been	   shown	   to	   have	   high	  prostate	  specificity	  and	  it	  has	  been	  successfully	  used	  in	  the	  past	  anytime	  there	  was	  the	  need	  of	  a	  prostate-­‐specific	  activity	  [219].	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The	  promoter	  is	  less	  than	  500	  base	  pairs	  long,	  it	  contains	  two	  androgen	  responsive	  regions	  that	   include	  a	   total	  of	   four	  androgen	  responsive	  elements,	   followed	  by	  the	  first	  28	  base	  pairs	  of	  the	  rat	  probasin	  gene.	  
	  
Fig	  4.29	  –	  Representation	  of	  the	  ARR2PB	  prostate-­specific	  promoter.	  The	  promoter	  is	  
divided	  into	  two	  androgen	  responsive	  regions	  (red)	  each	  one	  containing	  two	  androgen	  
responsive	   elements	   (ARE1,	   ARE2	   –	   blue),	   the	   two	   androgen	   responsive	   regions	   are	  
separated	   by	   a	   linker	   region	   of	   42	   nt	   present	   in	   the	   original	   probasin	   promoter	  
sequence	   (black)	   and	   the	   promoter	   ends	   with	   the	   first	   28	   nt	   or	   the	   rat	   probasin	  
promoter	  (green).	  
	  The	  presence	  of	  this	  promoter	  upstream	  the	  Cre	  gene	  would	  assure	  that	  the	  enzyme	  will	  be	  specifically	  expressed	  only	  in	  the	  prostate	  lobes	  (ventral,	  lateral	  and	  dorsal)	  and	  epithelium;	  tissues	  that	  do	  not	  express	  Cre	  will	  be	  unaffected.	  The	   same	  promoter	   fragment	  will	  be	   inserted	   into	   the	  pDoner	  vector	   to	  drive	   the	  expression	   of	   the	   shRNAs	   for	   knock-­‐down	   Ncor1	   and	   Ncor2/Smrt	   selectively	   in	  prostatic	   tissues.	   The	   promoter	  will	   be	   driven	   by	   a	   tetracycline	   sensitive	   silencer	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that,	  in	  absence	  of	  antibiotic,	  will	  repress	  the	  ARR2PB	  promoter	  and	  no	  hairpins	  will	  be	   transcribed.	   Upon	   tetracycline	   treatment	   the	   silencer	   is	   inhibited	   and	   the	  ARR2PB	   promoter	   will	   be	   able	   to	   drive	   the	   expression	   of	   the	   hairpins	   that	   will	  knock	  down	  Ncor1	  and	  Ncor2/Smrt.	  	  
4.2.2 – Selection of the homology regions for Ncor1 and Ncor2/Smrt The	   homology	   region	   represents	   the	   fragment	   of	   DNA	   that	   will	   be	   modified	   to	  include	   critical	   exons	   flanked	   by	   LoxP	   sites	   and	   Neo-­‐resistance	   cassette.	   For	   the	  purposes	  of	  this	  thesis	  we	  will	  use	  the	  same	  homology	  regions	  as	  described	  for	  the	  conventional	   Ncor1	   and	  Ncor2/Smrt	   knock	   out	   [139,	   216];	   this	   should	   guarantee	  that	   the	   targeted	   gene	   is	   not	   able	   to	   produce	   any	   functional	   protein	   upon	   Cre-­‐mediated	  recombination.	  
 4.2.2.1 – Ncor1 For	  Ncor1	  a	  8.5	  kb	  region	  spanning	  exon	  7	  to	  exon	  11	  was	  chosen	  with	  the	  aim	  of	  knocking	  out	  the	  critical	  exons	  7	  and	  8.	  This	  would	  induce	  a	  frameshift	  mutation	  if	  the	  resulting	  mRNA	  were	  translated.	  
4.2.2.2 – Ncor2/Smrt The	  homology	  region	  chosen	  for	  Ncor2/Smrt	  is	  10	  kb	  long,	  from	  exon	  23	  to	  exon	  33,	  including	  then	  the	  critical	  exons	  26,	  27,	  28,	  29	  and	  30	  that	  will	  be	  flanked	  by	  LoxP	  sites..	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4.2.3 – Cloning the homology regions for Ncor1 and Ncor2/Smrt The	  first	  step	  to	  obtain	  a	  targeting	  construct	  was	  to	  clone	  the	  homology	  region.	  All	  primers,	  reagents	  and	  protocols	  are	  listed	  in	  Materials	  and	  Methods.	  The	  isolation	  of	  the	  homology	  region	  implies	  a	  PCR	  reaction	  and	  the	  purification	  of	  the	   bands	   from	   an	   agarose	   gel.	   The	   first	   attempts	   to	   amplify	   the	   region	   from	  genomic	  DNA	  from	  G4	  [220]	  and	  TS3	  ES	  cells	  (Shimizu	  and	  Schrewe,	  unpublished)	  were	   unsuccessful	   because	   no	   PCR	   product	   was	   amplified	   (data	   not	   shown).	  Therefore	  two	  different	  BACs	  were	  ordered,	  one	  for	  Ncor1	  and	  one	  for	  Ncor2/Smrt,	  in	  order	  to	  increase	  the	  specificity	  of	  the	  reaction	  and	  enrich	  the	  template	  with	  the	  fragments	  containing	  the	  homology	  region.	  
	  
Fig	  4.30	  –	  PCR	  amplification	  of	  the	  Ncor1	  (8.5	  kb)	  and	  Ncor2/Smrt	  (10	  kb)	  homology	  
region,	   included	   in	   the	   gel	   also	   the	   empty	   Bluescript	   and	   TOPO	   vector	   used	   in	   the	  
cloning	  process.	  
	  The	  desired	  fragments	  were	  successfully	  amplified	  from	  BAC	  DNA	  with	  the	  Phusion	  kit	   (see	  Materials	   and	  Methods)	   as	   seen	   in	   Fig	   4.30	   ;	   the	   8.5	   (Ncor1)	   and	   10	   kb	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(Ncor2/Smrt)	   bands	   were	   then	   purified	   and	   stored,	   ready	   to	   be	   ligated	   into	   the	  vector.	  	  
4.2.4 – Ligation of the homology regions into vectors Two	  different	  vectors	  were	  used	   to	   clone	   the	  homology	   regions,	  BluescriptSK	  and	  pCR-­‐BluntII-­‐TOPO	  for	  Ncor1	  and	  Ncor2/Smrt	  respectively.	  	  However,	   the	   original	   pCR-­‐BluntII-­‐TOPO	   vector	   contains	   a	   PvuI	   restriction	   site	   in	  the	   sequence;	   looking	   that	   the	   homology	   region	   contains	   already	   a	   PvuI	   site	  designed	  to	  accommodate	  a	  LoxP	  site,	  the	  presence	  of	  both	  of	  them	  would	  generate	  two	   separate	   fragments	   instead	   of	   just	   opening	   the	   vector	   upon	   digestion.	   To	  overcome	   this	   the	   pCR-­‐BluntII-­‐TOPO	   vector	   was	   digested	   with	   PvuI,	   blunt	   ended	  and	  re-­‐ligated	  in	  order	  to	  obtain	  a	  pCR-­‐BluntII-­‐TOPO	  without	  a	  PvuI	  site.	  To	  check	  that	   the	   vector	   didn’t	   contain	   the	   restriction	   site	   anymore,	   a	   single	   and	   double	  digestion	  was	  performed	  with	  PvuI	  and	  EcoRI	  ±	  PvuI	  or	  ScaI.	  As	  shown	  in	  Fig	  4.31	  the	  digestion	  with	  EcoRI,	  alone	  or	   in	  combination	  with	  PvuI	  or	  ScaI,	   linearized	  the	  vector	  while	   a	   supercoiled	  undigested	   vector	  was	  obtained	  digesting	  with	  PvuI	   in	  demonstration	  that	  the	  vector	  PvuI	  site	  was	  destroyed.	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Fig	  4.31	  -­	  Digestion	  control	  of	   the	  pCR-­BluntII-­TOPO	  vector	  whitout	  a	  PvuI	  site.	  The	  
modified	  vector	  contains	  only	  one	  EcoRI	  site,	  and	  the	  combined	  digestion	  with	  the	  PvuI	  
and	  ScaI	  enzymes	  will	  linearize	  the	  vector	  instead	  of	  giving	  multiple	  fragments.	  	  	  Initially	  the	  ligation	  was	  unsuccessful	  due	  to	  the	  size	  of	  the	  fragment,	  the	  presence	  of	  sticky	  ends	  was	  needed	   then	   in	  both	   fragment	  and	  vector.	  New	  primers	   (Ncor1	  XhoI	  Rev	  and	  Ncor1	  Sac1	  For	  for	  Ncor1	  -­‐	  Ncor2	  EcorI	  Rev	  and	  Ncor2	  EcoRI	  For	  for	  Ncor2.	  Sequences	  listed	  in	  Table	  3.2	  of	  	   Matherials	   and	   Methods)	   were	   used	   to	  amplify	  the	  homology	  region	  from	  the	  BACs.;	  the	  Ncor1	  fragment	  was	  then	  digested	  with	  XhoI	  and	  SacI	  and	  the	  Ncor2	  fragment	  with	  EcoRI.	  The	  BluescriptSK	  vector	  was	  digested	  with	  SacI	  and	  XhoI	  and	  the	  pCR-­‐BluntII-­‐TOPO	  was	  digested	  with	  EcoRI	  in	  order	  to	  create	  complementary	  ends	  to	  the	  amplified	  homology	  regions	  and	  ligation	  was	   performed.	   A	   control	   digestion	  was	  made	   to	   check	   the	   presence	   of	   the	   right	  insert	  as	  shown	  in	  Fig	  4.32.	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Fig	  4.32	  –	  Digestion	  of	   the	  new	  samples	   ligated	  with	  Ncor1	  and	  Ncor2/Smrt	  clones.	  
Highlighted	   in	   red	   are	   the	   positive	   samples	   for	  Ncor1,	   3	   kb	   vector,	   8.5	   kb	   homology	  
region	  (TOP)	  and	  Ncor2/Smrt,	  3	  kb	  vector,	  10	  kb	  homology	  region	  (BOTTOM).	  
	  	  
4.2.5 – Insertion of the first loxP site in the homology regions into into BluescriptSK 
and pCR-BluntII-TOPO vectors The	   Cre-­‐LoxP	   system	   requires	   the	   presence	   of	   two	   LoxP	   sites	   for	   a	   functional	  recombination.	  One	  LoxP	  site	  was	  cloned	  in	  the	  NcoI	  site	  in	  intron	  between	  exons	  8	  and	  9	  of	  the	  Ncor1	  gene	  and	  the	  PvuI	  site	  in	  intron	  between	  exons	  25	  and	  26	  of	  the	  Ncor2/Smrt	  gene.	  The	  presence	  of	  the	  insert	  was	  confirmed	  with	  PCR	  screening	  for	  both	  targeting	  constructs	  using	  flanking	  primers	  as	  in	  Fig	  4.33.	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Fig	  4.33	  –	  PCR	  analysis	  of	  the	  LoxP	  sites	  inserted	  in	  the	  Ncor1	  (LEFT)	  and	  Ncor2/Smrt	  
(RIGHT).	   Primers	   were	   flanking	   the	   insertion	   site	   and	   are	   listed	   in	   Table	   3.3.	   Red	  
arrows	  indicate	  positive	  clones	  at	  ~220	  bp.	  
	  
	  
4.2.6 – Isolation of the neo cassette and ligation into BluescriptSK and pCR-BluntII-
TOPO vectors The	   Neo-­‐resistance	   cassette	   was	   originally	   part	   of	   the	   PL451	   vector	   [221]	  containing	  a	  LoxP	  site	  and	  a	  neomycin	  selection	  cassette	  flanked	  by	  two	  FRT	  sites.	  Using	   the	   FLP-­‐recombinase	   enzyme	   that	   excides	   the	   sequences	   included	   between	  the	  two	  FRT	  sites,	  the	  neo	  cassette	  can	  be	  removed	  with	  a	  mechanism	  similar	  to	  the	  Cre-­‐Lox	   system.	   The	   fragment	   was	   isolated	   using	   EcoRV	   and	   NotI	   restriction	  enzymes,	   purified	   from	   agarose	   gel	   and	   Kleanow	   treated	   (to	   blunt	   the	   NotI	  restriction	  site).	  The	  pBluescript	  II	  SK-­‐Ncor1	  vector	  was	  digested	  with	  SnabI	  (blunt	  ends)	  and	  the	  pCR-­‐BluntII-­‐TOPO-­‐Ncor2/Smrt	  vector	  with	  ScaI	  (blunt	  ends)	  and	  the	  blunted	  neo	  cassette	  was	  then	  ligated	  in	  these	  sites.	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Fig	   4.34	   –	   Scheme	   of	   the	   PL415	   vector	   (LEFT)	   from	   which	   the	   neo-­cassette	   was	  
isolated	  and	  gel	  of	  the	  digestion	  with	  EcorV	  and	  NotI	  (RIGHT)	  showing	  the	  backbone	  
of	  the	  vector	  and	  the	  neo	  cassette.	  The	  cassette	  was	  then	  isolated,	  purified	  and	  ligated	  
into	  the	  Ncor1	  and	  Ncor2/Smrt	  vectors.	  
	  
Fig	  4.35	  –	  PCR	  screening	  for	  the	  Neo-­cassette.	  Highlighted	  in	  the	  dotted	  red	  boxes	  are	  
the	  positive	  clones.	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  The	   presence	   of	   the	   neo-­‐cassette	   was	   demonstrated	   via	   PCR	   analysis	   with	   the	  following	  combination	  of	  primers:	  Ncor1	  SnaBI	  Rev	  and	  Neo	  5’	  Rev	  for	  Ncor1,	  and	  Ncor2	   ScaI	   For	   and	   Neo	   5’	   For	   for	   Ncor2	   (sequences	   listed	   in	   Table	   3.5).	   Two	  reverse	  primers	  were	  used	  to	  screen	  the	  Ncor1	  construct	  because	  the	  neo	  cassette	  in	   the	   Ncor1	   construct	   has	   opposite	   orientation	   than	   the	   one	   in	   the	   Ncor2/Smrt	  construct.	  As	  shown	  in	  Fig	  4.35	  the	  presence	  of	  the	  neo	  cassette	  was	  confirmed	  in	  several	  clones.	  	  
	  
Fig	   4.36	   –	   Schematic	   representation	   of	   the	   Ncor1	   and	   Ncor2/Smrt	   construct	  
containing	   the	   neo-­cassette.	   Indicated	   is	   also	   the	   opposite	   orientation	   of	   the	   neo	  
cassettes	  and	  the	  LoxP	  sites..	  	  	  
4.2.7 – Digestions control and sequencing of candidate clones Samples	  were	  checked	   for	   the	  presence	  of	   the	  right	   inserts	  via	   restriction	  enzyme	  digestion	   and	   then	   sequenced.	   Previously	   identified	   clones	   were	   digested	   with	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BamH1	   (Ncor1)	   and	   EcoRI	   (Ncor2/Smrt)	   to	   check	   the	   fragments	   lengths;	   as	  expected,	  the	  pBluescript	  II	  SK-­‐Ncor1	  vector	  gave	  three	  fragments	  of	  6.7,	  4.7	  and	  1.8	  kb	  and	  the	  digested	  pCR-­‐BluntII-­‐TOPO-­‐Ncor2/Smrt	  gave	  three	  bands	  at	  3.4,	  4.2	  and	  5.7	  kb.	  	  
	  
Fig	  4.37	  –	  Digestion	  control	  for	  Ncor1	  and	  Ncor2/Smrt	  clones.	  All	  the	  clones	  for	  Ncor1	  
(TOP)	   are	   positive	   with	   the	   right	   pattern;	   Ncor2/Smrt	   (BOTTOM)	   is	   correctly	  
fragmented	  with	  EcoRI	  and	  linearized	  with	  NotI	  digestion.	  	  
	  The	  positive	  samples	  were	  then	  sent	  to	  MWG	  (www.mwg.com)	  for	  sequencing	  and	  the	  results	  indicated	  the	  correct	  presence,	  in	  both	  vector,	  of	  the	  right	  constructs.	  




Fig	   4.38	   –	   Schematic	   representation	   of	   the	   final	   constructs	   for	   Ncor1	   (TOP)	   and	  
Ncor2/Smrt	   (BOTTOM).	   For	   both	   genes	   are	   indicated	   the	   sites	  where	   the	   LoxP	   sites	  
were	  inserted	  (NcoI	  for	  Ncor1	  and	  PvuI	  for	  Ncor2/Smrt)	  and	  where	  the	  neo-­cassettes	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were	  ligated	  (SnaBI	  for	  Ncor1	  and	  ScaI	  for	  Ncor2/Smrt).	  The	  Ncor1	  and	  Ncor2/Smrt	  
wild	  type	  alleles	  are	  shown	  at	  the	  top	  of	  each	  image	  with	  indicated	  exon	  numbers	  and	  
restriction	   sites.	   The	   targeting	   constructs	   containing	   loxP	   sites	   and	   neo	   cassettes	   is	  
shown	  below	  the	  wild	  type	  alleles.	  In	  case	  recombination	  happens,	  the	  resulting	  floxed	  
allele	   is	   here	   represented	   by	   the	   recombined	   locus.	   Lastly,	   upon	   action	   of	   the	   Cre	  
enzyme	  the	  targeted	  exons	  will	  be	  excided	  and	  the	  Cre	  recombined	  locus	  will	  contain	  
only	  one	  loxP	  site.	  Primers	  shown	  are	  listed	  in	  Materials	  and	  Methods.	  	  
4.2.9 – Electroporation of ES cells and G418 selection After	  that	  positive	  clones	  were	  confirmed	  107	  G4	  [220]	  embryonic	  stem	  cells	  were	  electroporated	  with	  25	  µg	  of	  construct,	  the	  cells	  plated	  on	  four	  6	  cm	  dishes	  and	  after	  48-­‐72	  hours	  media	  was	  changed	  to	  selection	  medium,	  	  ES	  media	  plus	  350	  µg/ml	  of	  G418.	  After	   7-­‐8	   days	   of	   selection,	   approximately	   200	   single	   colonies	   were	   picked	   and	  expanded	  in	  96	  well	  plates	  to	  perform	  further	  screenings.	  
	  
Fig	  4.39	  –	  Example	  of	  a	  colony	  plate.	  Colonies	  were	  picked	  with	  a	  p10	  tip	  under	  the	  
microscope	  paying	  attention	  to	  isolate	  single	  colonies.	  Yellow	  wells	  contain	  cells	  that	  
used	  all	   the	   nutrients	   and	   oxygen	   lowering	   the	   pH,	   hence,	   a	   shift	   in	   the	   color	   of	   the	  
media.	   Red	   wells	   are	   instead	   empty	   due	   to	   manual	   error	   and	   the	   pH	   of	   the	   media	  
remains	  unaltered.	  	  
4.2.10 – Colony screening to identify positive clones via PCR and Southern blotting 
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In	  order	  to	  find	  which	  positive	  clones	  that	  contained	  the	  floxed	  allele	  (allele	  with	  the	  LoxP	  sites),	  the	  clones	  were	  screened	  via	  PCR	  and	  Southern	  blotting.	  	  
 4.2.10.1 – PCR screening of the candidate clones The	   first	   screening	   was	   PCR	   based	   amplifying	   a	   2.6	   kb	   fragment	   at	   the	   5’	   of	   the	  homology	   region	   for	   Ncor1.	   	   Primers	   used	   were	   Ncor1	   out	   Rev	   (outside	   of	   the	  homology	  region)	  and	  neo	  poly-­‐A	  For	  (on	  the	  poly-­‐A	  sequence	  of	  the	  neo	  cassette).	  Primer	  sequences	  are	  listed	  in	  Table	  3.6.	  	  	  	  	  	  	  	  	  	  	  	  	  




Fig	  4.40	  –	  Schematic	  representation	  of	  the	  region	  amplified	  in	  the	  PCR	  screening	  for	  
the	   Ncor1	   colonies	   (TOP).	   The	   clones	   highlighted	   were	   then	   further	   screened	   (see	  
below)	  to	  confirm	  the	  presence	  of	  the	  Neo-­cassette.	  
	  The	  PCR	  screening	  for	  the	  Ncor2/Smrt	  clones	  aimed	  to	  amplify	  a	  3	  kb	  fragment	  at	  the	  3’	  of	   the	  homology	   region	   for	  Ncor2/Smrt.	   	  Primers	  used	  were	  Ncor2	  out	  Rev	  (outside	  of	  the	  homology	  region)	  and	  neo	  poly-­‐A	  For	  (on	  the	  poly-­‐A	  sequence	  of	  the	  neo	  cassette).	  Primer	  sequences	  are	  listed	  in	  Table	  3.6.	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Fig	  4.41	  –	  Schematic	  representation	  of	  the	  PCR	  screening	  for	  the	  Neo-­cassette	  in	  the	  
Ncor2/Smrt	   clones	   (TOP).	   A	   2.9	   kb	   region	   was	   amplified	   (MIDDLE)	   and	   to	   better	  
localize	   the	   positive	   clones	   a	   southern	   blotting	  was	   performed	   (BOTTOM)	   using	   the	  
samples	   ran	   in	   the	   gels	   as	   template.	   The	   probe	  was	   the	   3’	   primer	   (Ncor2	   out	   Rev	   –	  
Table	  3.6)	  used	   for	   the	  PCR.	  Red	  arrows	   indicate	   the	  positive	  clones	  used	   for	   further	  
analysis.	  	  To	  confirm	  further	  the	  positive	  clones	  previously	  identified	  primers	  spanning	  the	  5’	  (Ncor1)	   and	   3’	   (Ncor2/Smrt)	   end	   of	   the	   Neo	   resistance	   cassette	   were	   used;	   the	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amplification	  of	  the	  3	  kb	  fragment	  would	  also	  confirm	  the	  presence	  one	  of	  the	  two	  LoxP	  sites	  needed	  for	  a	  correct	  Cre-­‐Lox	  recombination.	  	  
	  
	  
Fig	  4.42	  –	  PCR	  screening	  for	  the	  Neo-­cassette	  in	  Ncor1	  clones	  (TOP)	  A2,	  B2,	  B4,	  E4,	  B8,	  
F7,	  B10,	  C11	  and	  Ncor2/Smrt	   (BOTTOM)	  clones	  B9,	  E3,	  E10,	  E11,	  F8,	  G11,	  H5,	  H8.	   I	  
performed	  two	  different	  PCRs	  for	  Ncor2/Smrt,	  A-­B,	  to	  confirm	  the	  results	  obtained	  in	  
A.	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Next,	  second	  LoxP	  was	  checked	  expecting	  a	  ~220	  bp	  fragment	  for	  the	  floxed	  allele	  plus	  a	  ~180	  bp	  for	  the	  wild	  type	  allele.	  	  
	  
	  
Fig	  4.43	  –	  PCR	  analysis	  to	  confirm	  the	  screening	  results	  for	  the	  presence	  of	  the	  LoxP	  
sites	   in	   the	   electroporated	   ES	   cells.	   It	   was	   also	   confirmed	   that	   the	   loxP	   sites	   in	   the	  
Ncor1	  and	  Ncor2/Smrt	  clones	  have	  opposite	  orientation.	  
	  To	  confirm	  further	  the	  presence	  of	  the	  second	  LoxP	  site	  in	  the	  intron	  between	  exon	  25	  and	  26	  in	  the	  Ncor2/Smrt	  clones,	  a	  nested	  PCR	  was	  performed	  amplifying	  first	  a	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6	  kb	  fragment	  containing	  the	  LoxP	  site	  at	  the	  3’	  end	  and	  then,	  for	  the	  next	  PCR,	  a	  3’	  primer	   was	   designed	  with	   the	   last	   2	   nucleotides	   crossing	   the	   3’	   boundary	   of	   the	  LoxP	  site.	  This	  was	  enough	  to	  confer	  specificity	  to	  the	  reaction	  and,	  as	  shown	  by	  the	  gel	  below,	  the	  negative	  clone	  in	  lane	  6	  was	  the	  only	  one	  not	  amplified	  as	  well	  as	  the	  wild	  type	  band	  was	  not	  amplified.	  
	  
Fig	  4.44	  –	  PCR	  screening	  of	  the	  LoxP	  site	  in	  the	  Ncor2/Smrt	  samples.	  On	  top	  the	  first	  6	  
kb	  PCR,	  the	  bands	  were	  purified	  and	  used	  as	  a	  template	  for	  the	  second	  PCR	  showed	  at	  
the	  bottom.	  For	  the	   first	  6	  kb	  PCR	  primers	  used	  were	  Ncor2	  LoxP	  out	  FW	  and	  Ncor2	  
LoxP	  RW2	  and	   for	   the	  nested	  PCR	  the	  primers	  used	  were	  Ncor2	  PvuI	  For	  and	  Ncor2	  
LoxP	  RW2	  (sequences	  listed	  in	  Tab	  3.6).	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 4.2.10.2 – Southern blotting screening of the candidate clones In	  order	  to	  screen	  the	  opposite	  region	  of	  the	  construct	  Southern	  probes	  specific	  for	  our	  genes	  were	  designed.	  The	  probe	  was	  designed	  to	  detect	  a	  9	  and	  13.7	  kb	  band	  for	  Ncor1	  and	  Ncor2/Smrt,	  respectively.	   As	   is	   possible	   to	   see	   from	   the	   images	   below,	   Ncor1	   clones	   presents	  equimolar	  bands	  floxed	  and	  non-­‐floxed	  allele	  at	  the	  correct	  size	  while	  Ncor2/Smrt	  clones	  show	  the	  right	  wild	  type	  band	  and	  a	  ~14	  kb	  fragment	  for	  the	  floxed	  allele.	  	  	  	  	  	  	  	  	  




Fig	   4.45	   –	   Southern	   blotting	   for	   Ncor1	   (TOP)	   and	   Ncor2/Smrt	   (BOTTOM).	   Ncor1	  
clones	   show	   correctly	   the	   floxed	   allele,	   Ncor2/Smrt	   clones	   present	   instead	   a	   14	   kb	  
fragment	  instead	  of	  the	  predicted	  11	  kb.	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To	   understand	   weather	   the	   presence	   of	   a	   14	   kb	   fragment	   was	   caused	   by	   a	   non-­‐functional	  EcoRI	  site	  flanking	  the	  LoxP	  site,	  a	  6	  kb	  fragment	  that	  included	  the	  LoxP	  site	  was	  amplified	  and	  sequenced	  the	  PCR	  product;	  the	  results	  showed	  that	  the	  LoxP	  site	   is	   intact	   but	   when	   the	   probe	   was	   sequenced	   the	   sequence	   obtained	   did	   not	  match	  the	  original	  probe	  sequence	  explaining	  why	  the	  initial	  screening	  didn’t	  work.	  	  	  
	  
Fig	  4.46	  –	  Sequence	  of	   the	  LoxP	   site	   for	   the	  B9	  clone	  of	  Ncor2/Smrt.	  Highlighted	   in	  
blue	  is	  the	  LoxP	  sequence,	  containing	  the	  EcoRI	  site.	  	  	  However,	   the	   positive	   and	   selective	   results	   from	   the	   PCR	   in	   Fig	   4.44	   already	  confirmed	  the	  presence	  of	  the	  LoxP	  site	  in	  this	  region.	  The	   presence	   of	   the	   correct	   neo	   cassette	  was	   also	   analysed	   via	   Southern	   blotting	  and,	  as	  shown	  in	  Fig	  4.47	  B9,	  E11	  and	  F8	  for	  Ncor2/Smrt	  as	  well	  as	  B4	  for	  Ncor1	  were	  positive.	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Fig	  4.47	  –	  Southern	  blotting	  for	  Neo-­cassette	  in	  Nco2/Smrt	  and	  Ncor1	  clones	  digested	  
with	  EcoRI.	  The	  predicted	  size	  was	  4.7	  kb	  for	  Ncor2/Smrt	  and	  4.2	  kb	  for	  Ncor1.	  DNA	  
from	  G4	  cells,	  as	  expected,	  was	  negative.	  The	   final	   clones	   chosen	   were	   B9	   for	   Ncor2/Smrt	   and	   B4	   for	   Ncor1	   and	   they	  currently	  used	  at	  the	  Roswell	  Park	  Cancer	  Institute	  (Buffalo,	  NY,	  USA)	  for	  blastocyst	  injection	  in	  order	  to	  generate	  conditional	  knock-­‐out	  mice.	  
	  
4.2.11 – Knock down strategy via shRNA of Ncor1 and Ncor2/Smrt Obtaining	   a	   knock	   out	   animal	   will	   allow	   working	   with	   a	   clean	   system	   with	   no	  residual	  activity	  of	  the	  target	  protein;	  however,	  there	  is	  no	  temporal	  control	  on	  the	  activity	  of	  the	  Cre	  enzyme	  that	  will	  be	  transcribed	  only	  when	  the	  mice	  reach	  puberty	  and	  the	  ARR2PB	  promoter	  will	  be	  activated	  by	  the	  circulating	  hormones.	  To	  gain	  the	  temporal	   control	   over	   the	   knock	   down	   we	   sought	   to	   create	   an	   inducible	   system	  where	   the	   prostate-­‐specific	   promoter	   is	   controlled	   by	   a	   tetracycline-­‐regulated	  inhibitor,	   hence,	   treatment	   with	   Doxycycline	   will	   block	   the	   expression	   of	   the	  inhibitor	  allowing	  the	  short	  hairpin	  RNA	  to	  be	  transcribed.	  	  The	  vector	  was	  created	  at	  the	  Department	  of	  Molecular	  Genetics	  at	  the	  Max	  Planck	  Institute	   for	  Molecular	   Genetics	   in	   Berlin	   (Germany);	   the	   final	   version	   contains	   a	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Bluescript	   backbone,	   CMV	  promoter,	   eGFP	   reporter,	   ampicillin	   resistance	   and	  one	  insulator	   to	   avoid	   interferences	   on	   the	   promoter	   activity.	   	   The	   Doner	   vector	   can	  recombine	   with	   the	   ROSA26	   locus	   (ES	   cell	   containing	   the	   ROSA26	   locus	   were	  created	  at	  the	  Department	  of	  Developmental	  Genetics	  at	  the	  Max	  Plank	  Institute	  for	  Molecular	   Genetics	   in	   Berlin,	   Germany)	   that	   contains	   a	   tetracycline	   sensitive	  silencer.	   In	   the	   absence	   of	   tetracycline	   the	   silencer	   represses	   the	   activity	   of	   the	  ARR2PB	  promoter	  while	  upon	   tetracycline	   treatment	   the	  activity	  of	   the	   silencer	   is	  inhibited,	   allowing	   the	  activation	  of	   the	  promoter.	  This	  gives	   the	   temporal	   control	  over	   the	  production	  of	   the	  shRNAs,	  hence	  over	   the	  knockdown,	   that	  would	  not	  be	  possible	  to	  achieve	  in	  the	  knockout	  system.	  
	  
Fig	  4.48	  –	  Map	  of	  the	  pDoner	  vector	  that	  will	  be	  used	  to	  create	  the	  prostate	  specific	  
knock	  down	  of	  Ncor1	  and	  Ncor2/Smrt.	  The	  CMV	  promoter	  will	  be	  substituted	  with	  the	  
ARR2PB	  promoter	  and	  the	  hairpins	  inserted	  in	  the	  mir30	  site.	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Fig	   4.49	   –	   Scheme	   of	   the	   mechanism	   of	   action	   of	   the	   Doner	   vector	   inserted	   in	   the	  
ROSA26	   locus.	   In	   absence	   of	   tetracycline	   the	   silencer	   represses	   the	   activity	   of	   the	  
ARR2PB	  promoter,	  blocking	  the	  production	  of	  the	  shRNAs.	  The	  presence	  of	  tetracycline	  
inhibits	   the	   activity	   of	   the	   silencer,	   allowing	   the	   activation	   of	   the	   promoter	   and	  
transcription	  of	  the	  shRNAs,	  hence,	  the	  knockdown	  of	  the	  target	  genes.	  
	  
4.2.12 – Design shRNA for Ncor1-Ncor2/Smrt The	  first	  step	  in	  the	  creation	  of	  a	  knock	  down	  system	  was	  to	  design	  reliable	  hairpins	  that	   could	   efficiently	   target	   Ncor1	   and	   Ncor2/Smrt;	   to	   do	   this	   the	   online	   siRNA	  design	  tool	  form	  Invitrogen	  (http://www.invitrogen.com)	  was	  used,	  three	  hairpins	  for	  gene	  were	  designed	  targeting	  respectively	  exons	  11,	  27	  and	  37	  in	  Ncor1	  and	  8,	  32	  and	  42	  in	  Ncor2/Smrt.	  Sequences	  are	  available	  in	  Materials	  and	  Methods.	  	  
4.2.13 – Cloning, ligation and sequencing of the clones The	  hairpins	  were	  cloned	  into	  the	  vector	  obtained	  with	  the	  original	  kit	  following	  the	  manufacturer’s	   instructions	   (see	   Materials	   and	   Methods);	   digestion	   control	   was	  made	  from	  minipreps	  and	  samples	  were	  sent	  to	  sequencing	  to	  confirm	  the	  presence	  of	  the	  right	  hairpin.	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(at	  the	  moment	  of	  writing	  this	  thesis	  the	  sequencing	  data	  are	  stored	  at	  the	  Max	  Planck	  
Institute	  for	  Molecular	  Genetics,	  Berlin,	  Germany)	  
	  
4.2.15 – Cloning of the promoter and ligation into the pDoner vector In	  order	  to	  create	  a	  prostate-­‐specific	  knock	  down	  the	  original	  a	  CMV	  promoter	  had	  to	  be	  exchanged	  with	  the	  ARR2PB.	  An	   800	   bp	   region	   containing	   the	   AAR2PB	   promoter	   was	   amplified	   from	   genomic	  DNA	   coming	   form	   AAR2PB-­‐Cre	   mice	   (Roswell	   Park	   Cancer	   Institute,	   Buffalo,	   NY,	  USA),	   the	   product	   shown	   in	  Fig	   4.50	   was	   isolated	   and	   ligated	   in	   the	   pCRII-­‐TOPO	  vector	  for	  further	  cloning.	  
	  
Fig	  4.50	  –	  PCR	  amplification	  of	  the	  ARR2PB	  promoter	  from	  two	  samples	  with	  MIR13	  
FW	  and	  GFP	  RW	  primers.	  The	  bands	  were	  purified	  prior	  being	  digested	  with	  BamHI	  
and	  blunt	  ended.	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After	   that	   DNA	   was	   isolated	   from	   bacteria	   a	   first	   PCR-­‐based	   screening	   was	  performed	   to	   check	   which	   clones	   were	   positive.	   To	   do	   that	   primers	   outside	   the	  cloning	   region	   of	   the	   pCRII-­‐TOPO	   vector	  were	   used	   and	  minipreps	  were	   digested	  with	  EcoRI	  the	  positive	  clones	  to	  confirm	  the	  presence	  of	  the	  promoter.	  As	  shown	  in	  
Fig	  4.51	  the	  right	  construct	  was	  present	  in	  two	  of	  the	  clones	  	  
	  
Fig	   4.51	   –	   Digestion	   control	   of	   the	   pCRII-­TOPO	   vector	   containing	   the	   ARR2PB	  
promoter.	  Digestion	  of	  the	  clones	  8	  and	  9	  gave	  the	  right	  fragment	  length,	  those	  clones	  
were	  then	  sent	  to	  sequencing	  to	  confirm	  the	  presence	  of	  the	  promoter.	  
	  
	  
Fig	  4.52	  –	  Sequencing	  results	  for	  the	  clone	  number	  8	  that	  resulted	  to	  be	  the	  only	  one	  
with	  the	  promoter	  in	  the	  right	  orientation.	  Highlighted	  in	  blue	  the	  beginning	  and	  the	  
end	  of	  the	  sequenced	  promoter	  region.	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In	  the	  meanwhile	  the	  original	  CMV	  promoter	  was	  excised	  with	  NheI	  and	  SacII	  and	  the	  vector	  blunt	  ended	  before	  ligating	  the	  ARR2PB	  promoted	  into	  the	  pDoner	  vector.	  At	  the	  time	  of	  writing	  this	  thesis	  we	  are	  confirming	  the	  presence	  of	  the	  appropriate	  promoter	  into	  the	  vector.	  
	  
4.3	  – SYSTEMS BIOLOGY APPROACH TO MODEL CDKN1A TRASCTIPTIONAL 
INITIATION 
4.3.1 – CDKN1A time course upon 1,25(OH)2D3 treatment 
4.3.1.1 – Background   
The cyclin-dependent kinase inhibitor 1A (CDKN1A, encodes p21(waf1/cip1)) gene is 
located on human chromosome 6 in position p21.2 [222]; CDKN1A blocks cell cycle 
progression at G1 binding to, and inhibiting the activity of cyclin-CDK2 or -CDK4 
complexes, which is required for the phosphorylation of RB and the consequent release 
and activation of E2f-dependent gene expression; nonetheless, it is involved in the firing 
of replication origins and DNA synthesis (reviewed in [223]).  The expression of this 
gene is tightly controlled for example by the tumor suppressor protein p53, through 
which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a 
variety of stress stimuli [222]. However, activation of CDKN1A in a p53-independent 
fashion has also been reported.  CDKN1A does not only control cell cycle but also 
apoptosis; this can be accomplished in two different ways: 1) an active cell cycle is 
required to sense these agents and trigger apoptosis and the cytostatic effect of CDKN1A 
with the consequent inhibition of apoptosis, however, is counteracted by several 
mechanisms (i.e. downregulation of its expression) and 2) post-translational 
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modifications of CDKN1A such as its phosphorylation (which affects protein stability or 
cytoplasmic localization of CDKN1A) and its cleavage by caspase 3 also account for the 
differential effects on cell cycle arrest versus apoptosis [223]. Moreover, CDKN1A has a 
significant role in modulating DNA repair processes. First, by inhibiting cell cycle 
progression, p21 allows DNA repair to proceed while inhibiting apoptosis. Secondly, 
CDKN1A can compete for PCNA binding with several PCNA-reliant proteins that are 
directly involved in DNA repair processes [223]. 
Upon treatment, 1,25(OH)2D3 binds to VDR and activates responsive elements in the 
CDKN1A promoter leading to transcription. 1,25(OH)2D3 stimulation exerts profound 
anti-proliferative effect on non-malignant prostate cells RWPE-1 and G1 cell cycle arrest 
suggesting the involvement of the CDKN1A pathway. CDKN1A is also a Vitamin D 
Receptor target gene, ChIP analysis demonstrated indeed that the promoter region of 
CDKN1A contains three VDREs as well as p53 responsive elements [224, 225].  
The micro-RNA miR106-B is a newly-identified transcript present in the intronic region 
of the MCM7 gene and able to promote CDKN1A degradation [226]. Recently, miR-
106B was shown to be involved in multiple myeloma [227] and in chronic lymphocytic 
leukemia, the latter via association, and downregulation, of the E3-ubiquitinge ligase Itch 
with the net result of upregulating p73 and p53, favouring apoptosis [228]. To date, there 
are no publications showing the role of miR-106B in prostate cancer and preliminary 
results from our lab show that not only it’s a regulator of CDKN1A transcription and 
degradation and correlates with its expression in tumor samples (personal 
communication, data not shown). 
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4.3.1.2 – Background data 
Starting from the hypothesis that CDKN1A is involved in the antiproliferative effect of 
1,25(OH)2D3, a time course experiment over 24 hours was undertaken in RWPE-1 cells 
treated with 100 nM of 1,25(OH)2D3. RNA was extracted and random hexamers were 
used to reverse transcribe the samples. CDKN1A induction was quantified with qRT-PCR 
TaqMan as described in Materials and Methods, each time point had a time zero 
matching control and the time points were the followings (in hours): 0.00, 0.16, 0.25, 
0.32, 0.50, 0.66, 0.75, 0.82, 1.00, 1.16, 1.32, 1.50, 1.66, 1.82, 2.00, 3.00, 4.00, 5.00, 6.00, 
8.00, 10.00, 12.00, 16.00, 18.00, 19.00, 20.00, 21.00, 22.00, 23.00 and 24.00.  
The graph in Fig 4.53 shows CDKN1A mRNA accumulation upon 100 nM VitD3 
treatment. The presence of ~10 minutes time points within the first hour offers an 
interesting and precise insight on the possible mechanism of transcription initiation in 
response to 1,25(OH)2D3.  
 
Fig	   4.53	   –	   Time	   course	   for	   p21	   mRNA	   accumulation	   upon	   VitD3	   treatment	   (James	  
Thorne,	   University	   of	   Birmingham,	   Birmingham,	   UK).	  Mid-­exponential	   RWPE-­1	   cells	  
were	   treated	   with	   100	   nM	   1,25(OH)2D3,	   total	   RNA	   was	   extracted	   and	   reverse	  
transcribed	  prior	  qRT-­PCR.	  Student-­t	  test	  was	  used	  to	  confirm	  time	  points	  significantly	  
differentially	  expressed	  from	  the	  corresponding	  time	  zero	  control,	  *=p<0.01.	  Each	  data	  
point	  is	  the	  mean	  of	  at	  least	  three	  biological	  replicates	  +/-­	  S.E.M..	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The overall impression of the time course is that mRNA production and degradation 
follow a periodical pattern, reflected by peaks at 30 min, 8, 12 and 21 hours. The initial 
upregulation of CDKN1A at ~30 minutes just after an initial down-regulation of the 
mRNA levels and, very interestingly, the quick synthesis of mRNA was followed by an 
equally quick degradation of the detected mRNA. Taking in consideration the average 
time required by the RNA polymerase II to synthesize an RNA molecule (up to 3.6 
kb/min [229]) and the length of the initial transcript (~ 6 kb), it’s possible to estimate that 
it takes less than 2 minutes to synthesize one molecule of mRNA. Another variable that 
must also be considered is that random hexamers and not Oligo-dTs were used to reverse 
transcribe the RNA. This means that not only fully mature mRNA was synthesized but 
also non processed RNA molecules were used as template to produce cDNA. The time 
needed for the 1,25(OH)2D3-VDR bound complex to enrich the promoter region and 
sequestrate the Pol-II in order to start transcription is relative quick and it’s possible to 
assume that this happens in order of seconds. These data could easily sustain the idea that 
the initial peak could be caused by a quick stimulation mediated by the 1,25(OH)2D3-
VDR complex. 
However, all the above data still do not explain the rapid degradation that occurs straight 
after 30 minutes peak. Physiological mRNA decay does not explain this case because it 
occurs too quickly. Ivanovska and colleagues demonstrated that the micro RNA miR-
106B directly targets CDKN1A in two regions and that its silencing plays a key role in 
miR-106b-induced cell cycle phenotypes [230]. Time course experiments measuring 
miR-106b induction upon 100 nM VitD3 treatment was made to confirm at the following 
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time points (in hours): 0.00, 0.16, 0.25, 0.32, 0.50, 0.66, 0.75, 0.82, 1.00, 1.16, 1.32, 1.50, 
1.66, 1.82, 2.00, 3.00, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 18.00, 19.00, 20.00, 
21.00, 22.00, 23.00 and 24.00. The results shown in Fig 4.54, illustrate that the 
expression pattern of miR-106B strictly resembles CDKN1A time course. The initial peak 
at ~30 mins is still present with a rapid induction followed by an equally quick 
degradation, as already observed for CDKN1A; also, magnitude and amplitude of the 
peaks at 12 and 22 hours match the peaks detected for CDKN1A.  
 
Fig	  4.54	  –	  miR-­106B	  time	  course	   in	  response	  to	  1,25(OH)2D3	  (Orla	  Maguire,	  Roswell	  
Park	  Cancer	   Institute,	  Buffalo,	  NY,	  USA).	  Mid-­exponential	  RWPE-­1	  cells	  were	   treated	  
with	   100	   nM	   1,25(OH)2D3,	   total	   RNA	   was	   extracted	   and	   miRNA	   specific	   reverse	  
transcription	  was	  performed	  prior	  qRT-­PCR.	  Data	  shown	  are	  the	  mean	  of	  at	  least	  three	  
biological	  replicates.	  
 
These results suggest a role for miR-106B in CDKN1A degradation indicating that the 
steep peak of CDKN1A could be due to the simultaneous production of the micro-RNA 
that then promotes CDKN1A degradation. For this to be true two conditions are required: 
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1) VDR and Pol-II must act similarly on the two promoters and 2) the production rate of 
CDKN1A and miR-106B must be similar. 
To test the first hypothesis ChIP experiments for the phosphorylated form of the RNA 
Polymerase II on the CDKN1A promoter were performed at the following time points (in 
hours) upon 100nM of VitD3 treatment: 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 12 and 24. 
 
Fig	   4.55	   –	   Phospho-­PolII	   binding	   at	   the	   TSS	   of	   p21	   (Craig	   Doig,	   University	   of	  
Birmingham,	  Birmingham,	  UK).	  Mid-­exponential	  RWPE-­1	  cells	  were	  treated	  with	  100	  
nM	  1,25(OH)2D3,	  chromatin	  was	  immunoprecipitated	  with	  anti-­phosho	  PolII	  antibody	  
and	   qRT-­PCR	   was	   performed	   with	   primers	   covering	   the	   TSS	   region	   of	   the	   CDKN1A	  
gene.	  Data	  shown	  are	  the	  mean	  of	  at	  least	  two	  biological	  replicate	  +/-­	  S.E.M..	  The	  bars	  
indicate	  the	  amount	  of	  p-­polII	  bound	  to	  the	  TSS	  of	  CDKN1A	  relative	  to	  the	  input	  (non-­
immunoprecipitated	  sample).	  An	  initial	  amount	  of	  phospho	  polymerase	  II	  is	  present	  at	  
the	   transcription	   start	   site,	   if	   it	  moves	   into	   the	   gene	   regions,	   this	  would	   explain	   the	  
lower	  amount	  of	  the	  enzyme	  found	  at	  15	  min	  (0.25);	  after	  the	  polymerase	  moves	  into	  
the	  gene	  body,	  new	  enzyme	  is	  recruited	  at	  the	  TSS	  and	  it’s	  detected	  at	  45	  min	  (0.75).	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4.3.1.3 – Model assumption 
The interesting pattern shown in Fig 4.55 indicates a quick decrease of the initial amount 
of phospho-PolII at the TSS consistent of the concept that the enzyme moves out of the 
TSS downstream into the gene. Subsequently new polymerases are cyclically recruited at 
the transcription start site and this is demonstrated by the oscillatory pattern with peaks at 
45 minutes and 6 hours. The decrease in the enzyme’s concentration after 15 minutes 
could be consistent with the idea of a poised polymerase [231, 232]. Stalling at the TSS is 
detected at the time-zero but not after 15 minute; if this was true the quick induction of 
both miR-106B and CDKN1A would be easily explained, and the delay for the formation 
of the VDR-CoActivators-pre-initiation-PolII complex can be ignored.  
 
Fig	  4.56	  –	  Schematic	  representation	  of	  the	  activity	  of	  the	  poised	  phospho	  polymerase	  
on	  the	  promoter	  region.	  The	  polymerase	  stops	  at	  the	  TSS	  waiting	  for	  a	  stimulus	  (1)	  to	  
then	  move	  into	  the	  gene	  (2)	  while	  new	  polymerase	  is	  recruited	  (3).	  
 
 
4.3.1.4 - Poised Polymerase II, initial hypothesis 
The mechanism of degradation of miR-106B remains theoretical since there are no 
experimental data indicating in what manner, or how quickly, the mature miRNAs are 
degraded; the miRNA could be either re-used after the target sequence is degraded or 
cleaved with the targeted transcript.  
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To explain the production rate of CDKN1A and miR-106B it must be mentioned that the 
miR-106B, miR-93, and miR-25 belong to a cluster of intronic miRNAs hosted in the 
MCM7 gene, which is a DNA helicase [226]. The whole cluster is transcribed in presence 
of the right conditions; generally the first transcript is processed, in order, through the 
Drosha and Dicer enzymes and complexed with RISC to exert its silencing potential 
[233, 234]. These reactions require time and, as only the mature form of miR-106B was 
detected by PCR, it can be assumed that either 1) poised polymerase was present on the 
TSS of the miRNA cluster and 2) the whole process requires less than 30 minutes. The 
length of the transcript has also to be kept in consideration; the pre-miRNA initial 
transcript is a few kilobases long, CDKN1A transcript is around 6 kb and with a PolII 
moving at the maximum speed of 3.6 kb/min it would require no more than 2 or 3 
minutes to produce one RNA molecule that then has to be processed. To confirm this, 
ongoing experiments aim to quantify the basal number of CDKN1A and miR-106b 
molecules in RWPE-1 cells in order to understand which magnitude the fold changes 
refer to. For example, four fold induction with 10 initial molecules of either CDKN1A or 
miR-106B would indicate that 40 mature RNA molecules were detected; if instead the 
initial number of molecules was 200 it would means that the production rate would be 20 
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4.3.2 – CDKN1A model of transcriptional initiation 
4.3.2.1 – Model description 
The model can be schematically described as in Fig 4.57: here the complex VDR/D3 
promotes the activation of the poised phospho-PolII that sits on the promoter region of 
CDKN1A (pPolII/CDKN1A) and miR-106B (pPolII/miR106B) (or the gene MCM7 that 
contains the cluster with miR-106B); both species are quickly accumulated and the 
phospo-PolII can cycle (or be recruited “de-novo”) and promote the transcription of new 
CDKN1A and miR-106B. Moreover, miR-106B accumulation also promotes the 
degradation of CDKN1A and it is degraded by independent mechanism. 
 
 
Fig	  4.57	  –	  Model	  describing	  the	  transcriptional	  regulation	  of	  CDKN1A	  and	  miR-­106B.	  
Briefly:	   the	   complex	   VDR/D3	   activates	   at	   the	   same	   moment	   the	   transcription	   of	  
CDKN1A	   and	   miR-­106B	   via	   phospho-­PolII,	   after	   the	   initial	   transcription	   of	   the	   two	  
molecules	  miR-­106B	  mediates	  CDKN1A	  degradation,	  altough	  both	  are	   still	   degraded	  
also	  by	  independent	  mechanisms	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All the parameters implemented in the model above were empirically derived testing their 
validity inside of the ODE model. Several values were tested before choosing those listed 
in Fig 4.58. 
 
 
Fig	   4.58	   –	   Differential	   equations	   describing	   the	   model	   described	   above.	   Different	  
parameter	  were	   tested	   in	  order	   to	   find	   the	  values	   that	  better	   fitted	   the	  model;	   listed	  
are	   the	   differential	   equations	   (as	   d[x]/dt)	   with	   the	   respective	   reactions	   and	  
parameters.	  
 
Applying the functions described above to miR-106B and CDKN1A mRNA accumulation 
gave an interesting insight on the transcriptional initiation and mRNA degradation. 
The initial hypothesis, translated into time constraints and differential equations, 
hypothesized the presence of a poised polymerase in CDKN1A promoter; this allows a 
rapid production of the mRNA but at the same moment miR-106B production occurs at 
the same rate. The time constraints used assume that the production of both species is 
dependent of phospho-pol II activity with a higher production rate in the first 30 minutes 
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(~1800 seconds). After this time the degradation of CDKN1A is dependent on the 
presence of miR-106B that is then degraded by an independent pathway.  
For modeling, the focus was on the first 45 minutes of the time courses because of the 
frequency of time points chosen and because of the mechanistic events on the promoter 
region of CDKN1A that allow such an early peak to happen. All the constants were 
adjusted to reflect as much as possible the biological real values and the initial 
hypothesis.  
The ODE model demonstrates that the kinetics of CDKN1A closely reflect that of miR-
106b due to similar activity of the phospho-PolII on the respective promoter regions. To 
better isolate the temporal effect of p-PolII and miR-106B on the CDKN1A mRNA, time 
constraints were used and an algorithm was created where questioned: if within the first 
30 minutes (1800 sec) the production of miR-106B and CDKN1A depends on p-PolII and 
if after 30 minutes (>1800 sec) the miR-106B molecules are bound to CDKN1A mRNA 
leading to its rapid degradation then what would happen? The results show that this series 
of events can explain the quick peak in CDKN1A mRNA induction and the subsequent 
steep degradation before going back to steady state. P-PolII is possibly poised on the TSS 
region and, upon stimulation, quickly moves to transcribe the gene showing a quick 
down-regulation just before new p-PolII are recruited.  
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Fig	   4.59	   –	   Simulation	   run	   for	   all	   the	   species:	   miR106b	   (red),	   CDKN1A	   (blue)	   and	  
phospho-­polII	   (green	   dashed).	   The	   initial	   downregulation	   of	   pPol-­II	   is	   the	   one	  
responsible	  for	  the	  induction	  of	  CDKN1A	  and	  miR-­106B	  and	  the	  first	  part	  of	  the	  steep	  
peak	  at	  1800	  sec	  (30	  min);	  while	   their	  concentration	   increases	  miR-­106B	  from	  1800	  
sec	  onwards	  quickly	  controls	  CDKN1A	  degradation	  leading	  to	  down	  regulation	  present	  
in	  the	  second	  part	  of	  the	  steep	  peak.	  After	  that	  all	  the	  species	  return	  to	  steady	  state.	  
  
However, the limitations of this model reside on the fact that ODE can describe 
accurately the dynamic events in a system composed by a high number of molecules. 
This implies that two molecules have almost always a high probability to collide, or 
interact, due to their high number. In a few cells system, or in a single cell system, this is 
unlikely because, even if there might be a high number of transcription factors or 
enzymes, the number of responsive elements, or genes (e.g. CDKN1A) is limited and the 
probability that they “find” or “are found” by the respective counterparts must be taken 
into consideration. Furthermore these limitations are increased due to 
compartmentalization, and protein-protein interactions that may limit co-factor 
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availability. Beside the limitation that this model presents, it was anyway possible to 
confirmed the mechanistic events that can occur on the promoter region of CDKN1A and 
miR-106B, suggesting the regulatory role of the micro-RNA in CDKN1A mRNA 
accumulation and the dual action of VDR and 1,25(OH)2D3 on those two genes. 
 
To address these limitations an alternative modeling approach was used. A stochastic 
model was applied that had been built by Katja Rybakova, a fellow ESR in the NucSys 
network, (Free University of Amsterdam, Amsterdam, The Netherlands) to demonstrate 
the validity of the previous assumptions (poised polymerase and miR-106B controlling 
CDKN1A degradation). The simulation of the model was ran for 1000 cells and the 
population average for each time point was taken (reflecting what is measured in wet lab 
experiments).  
The model relies on few general assumptions:  
1. The polymerase is the present (poised) on the promoter of both CDKN1A and 
mir106B at t=0, start of the experiment (from the experimental data) 
2. The average time in which the promoters is active is 5 min and the average 
number of polymerases that leave during that time is 3  
3. Promoter(s) average reactivation time is 40 min, average time to elongate and 
process the mRNA and miR-106B is 15 min, the average degradation time of both 
is also 15 min (times taken to match the data observation) 
4. The promoter reactivation, elongation and degradation times all have gamma-
distributed waiting times (i.e. very reproducible times, that create delays between 
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the promoter activation events, elongation start and finish and mRNA production 
and destruction) – because they are all multiple-step processes. This also explains 
why stochastic rather than ODE framework is required. 
As the actual mechanism of the miR-106B degradation is unclear three different 
simulations were ran: 
 
Fig	   4.60	   –	  Three	   different	   simulations	   of	   the	   activity	   of	   CDKN1A	   (violet)	  miR-­106B	  
(blue).	   In	   the	   left	   panel	   miR-­106B	   is	   degraded	   quicker	   than	   CDKN1A	   because	   it’s	  
degraded	  by	  an	  independent	  mechanism;	  the	  center	  and	  right	  panels	  produce	  the	  same	  
kinetic	  for	  both	  miR-­106B	  and	  CDKN1A.	  Time	  and	  concentration	  are	  indicated	  on	  the	  x	  
and	  y	  axes,	  respectively.	  	  
 
In the first model miR-106B enhances the degradation of CDKN1A mRNA but it’s own 
degradation goes via independent mechanism; in the second model miR-106B enhances 
the degradation of CDKN1A mRNA which also leads to its own degradation; in the third 
model there is no interaction between the mRNA and mir-106B, but because the deg 
kinetics are similar the observed effect is the same. All the models gave very similar 
results, however, the hypothesis of miR-106B being responsible for the steep degradation 
of CDKN1A could be discriminated by inhibiting miR-106B via siRNA and repeating the 
first hour of the CDKN1A time course previously described. These experiments are in 
progress. 
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Neither of the models was used to simulate the behaviour of the system in case of siRNA 
against any of the species. This is a further step that will confirm the role of each 
component in the network and those data will be particularly interesting based on the fact 
that the VDR transcriptome, including CDKN1A transcription, is de-regulated in cancer. 
The results will also suggested a series of follow up wet-lab experiments to confirm 
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5	  –	  CONCLUSIONS	  AND	  FUTURE	  STUDIES	  
5.1	  –	  Project	  summary	  Multiple	  lines	  of	  evidence	  support	  the	  idea	  that	  the	  NR	  transcriptome	  is	  disrupted	  in	  prostate	   malignancies	   by	   altered	   nuclear	   co-­‐repressors	   expression	   leading	   to	  epigenetic	   silencing.	   This	   leads	   to	   a	   general	   loss	   of	   responsiveness	   towards	   NR	  ligands,	   hence,	   promoting	   survival	   of	   prostate	   cancer	   cells	   even	   upon	   agonist	  treatment.	  The	  use	  of	  the	  HDAC	  inhibitor	  SAHA	  in	  combination	  with	  NR	  ligands	  led	  to	   significant,	   but	   selective,	   increased	   antiproliferative	   effect.	   It	   was	   also	  demonstrated	   that	   elevated	  NCOR1	   levels	   contributed	   to	   the	   skewed	  NR	  network,	  by	   creating	   a	   stably	   transfected	   shNCOR1-­‐PC-­‐3	   cell	   line.	   This	   system	   had	   an	  increased,	   although	   selective,	   sensitivity	   towards	   NR	   ligands	   (EPA,	   ETYA,	  bezafibrate,	   ATRA)	   at	   the	   transcriptional	   (by	  modulation	   of	   the	   expression	   of	   NR	  target	   genes)	   and	   phenotypical	   (by	   increased	   anti-­‐proliferative	   effect	   of	   NR	  agonists)	   level.	   The	   specificity	   of	   NCOR1	   action	   in	   the	   epigenome	  was	   elucidated	  with	  ChIP	  experiments	  showing	  that	  the	  TSS	  regions	  of	  two	  different	  PPARα	  and	  -­‐γ	  target	   genes	   (CDKN1A	   and	   TGFBRAP1)	   were	   differentially	   affected	   by	   the	  knockdown	   of	   NCOR1.	   H3K9Ac	   increased	   at	   the	   CDKN1A	   TSS	   and	   reduced	   in	  
TGFBRAP1	  upon	  bezafibrate	   treatment.	  A	  systems	  biology	  approach	  was	  also	  used	  to	   generate	   a	   model	   of	   NR	   activation	   with	   which	   to	   quantitate	   the	   mechanistic	  events	   at	   the	  CDKN1A	   TSS	   region,	   suggesting	   that	   the	   early	   transcriptional	   events	  are	   regulated	   not	   only	   by	   epigenetic	   events	   and	   NR	   binding	   but	   also	   by	   miRNA	  activity.	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Finally,	  as	   in	  vivo	   experiments	  by	  other	  groups	  have	  demonstrated	   the	   lethality	  of	  Ncor1	   and	  Ncor2/Smrt	  knockouts,	   to	  date	  no	   group	  has	  demonstrated	   the	   role	  of	  those	   two	   corepressors	   in	   prostate	   development.	   As	   part	   of	   the	   project	   for	   this	  thesis,	  prostate-­‐specific	  knockout	  constructs	  were	  prepared	  and	  mice	  are	  currently	  being	  bred	  at	  the	  Roswell	  Park	  Cancer	  Institute	  in	  Buffalo,	  NY	  (USA).	  	  
5.2	  –	  Mechanism	  of	  action	  of	  the	  combined	  treatment	  NR	  ligands	  and	  SAHA	  As	  a	  general	  mechanism	  of	  action,	  ligand-­‐bound	  NRs	  change	  the	  conformation	  of	  the	  AF2	  chain.	  This	  displaces	  corepressor	  and	  HDAC-­‐containing	  complexes	  in	  favour	  of	  coactivator	   complexes.	   The	   presence	   of	   coactivator	   complexes	   leads	   to	   a	   more	  permissive	   chromatin	   conformation	   due	   to	   the	   presence	   of	   HAT	   proteins	   that	   in	  turn	   enables	   access	   to	   the	   basal	   transcription	   machinery.	   This	   physiological	  equilibrium	  between	  activation	  and	  repression	  can	  be	  modulated	  by	  administration	  of	   lipophilic	  NR	  agonist	  molecules	   thereby	  activating	   transcription	  of	   target	   genes	  and	  promoting	  downstream	  phenotypical	  effects.	  Banwell	  et.	  al.	  demonstrated	  that	  the	   NR	   function	   is	   epigenetically	   corrupted	   in	   breast	   cancer	   cells	   with	   a	   loss	   of	  responsiveness	   to	   1,25(OH)2D3;	   administration	   of	   the	   histone	   deacetylases	  inhibitors	   TSA	   restored	   VDR	   antiproliferative	   ability	   [190,	   235].	   	   A	   similar	   lesion	  was	   shown	   in	   prostate	   cancer	   cells	   where	   NCOR2/SMRT	   suppresses	   VDR	  responsiveness	   and	   result	   in	   1,25(OH)2D3	   insensitivity	   [62].	   Proliferation	   studies	  showed	   that	   the	  addition	  of	   an	  HDAC	   inhibitor	   (TSA	  or	  NaB)	   in	   combination	  with	  1,25(OH)2D3	   significantly	   potentiated	   the	   inhibition	   of	   aggressive,	   1,25(OH)2D3-­‐resistant	   prostate	   cancer	   cell	   lines,	   PC-­‐3	   and	   DU-­‐145	   [211].	   Furthermore,	   it	   was	  
Chapter	  5	  –	  Conclusions	  and	  future	  studies	  	  
 268 
shown	   that	   the	  anti-­‐proliferative	  1,25(OH)2D3-­‐target	  gene	  GADD45α,	  was	   silenced	  in	   prostate	   cancer	   cell	   lines	   and	   primary	   cultures,	   and	   the	   addition	   of	   TSA	   with	  1,25(OH)2D3	  enabled	  its	  re-­‐expression	  [62].	  The	  current	  study	  investigated	  to	  what	  extent	  there	  was	  a	  greater	  loss	  of	  NR	  responsiveness	  in	  PC-­‐3	  cells	  towards	  a	  panel	  NR	   ligands	   (ETYA,	   EPA,	   bezafibrate,	   RA,	   T3).	   Interestingly	   whilst	   the	   combined	  treatment	   of	   1,25(OH)2D3	   and	   TSA	   enhanced	   VDR	   activity,	   co-­‐treatment	   with	   the	  hydroxamic	  acid-­‐based	  HDACi	  SAHA	  neither	  enhanced	  VDR	  proliferation	  nor	  gene	  regulation,	  although	   it	  had	  super-­‐additive	  antiproliferative	  effect	   if	   combined	  with	  the	  other	  NR	  agonists,	  notably	  towards	  PPARs.	  SAHA	  targets	  classes	  I,	  II	  and	  IV,	  but	  not	  the	  NAD+-­‐dependent	  class	  III	  enzymes.	  This	  selectivity	  is	  due	  to	  the	  presence	  of	  a	  zinc	  atom	  at	  the	  bottom	  of	  the	  binding	  pocket	  of	  class	   I,	   II	  and	  IV	  HDACs	  that	   is	  recognised	  by	  the	  hydroxamic	  group	  of	  SAHA.	   It	  inhibits	  partially	  purified	  HDAC1	  and	  HDAC3,	  and	  causes	  accumulation	  of	  acetylated	  H2A,	   H2B,	   H3	   and	   H4.	   However,	   a	   number	   of	   non-­‐histone	   proteins	   such	   as	   YY1,	  MyoD,	  p53,	  GATA1,	  Rb,	  Tubulin	  and	  HSP90	  [236]	  are	  also	  targeted.	  SAHA	  has	  a	  very	  good	   safety	   profile,	   it	   is	   FDA-­‐approved	   and	   currently	   used	   in	   clinical	   trials	   for	  leukemia,	  myelodysplastic	  syndromes	  and	  renal	  cancer	  [236].	  	  Bezafibrate	  is	  also	  an	  FDA-­‐approved	  drug	  with	  a	  good	  safety	  profile	  mainly	  used	  for	  its	   antilipidemic	   action;	   its	   effects	   have	   been	   widely	   studied	   in	   patients	   with	  coronary	  diseases	  and	  diabetes.	  Recent	  trials	  also	  demonstrated	  its	  action	  on	  acute	  myeloid	   leukemia	   and	   CLL	   cell	   lines	   [101,	   102].	   Its	   action	   is	   mediated	   through	  binding	  PPARα	  and	  -­‐γ	  inducing	  release	  of	  the	  corepressor	  complexes	  and	  promoting	  transcription	  of	  the	  target	  genes.	  Bezafibrate-­‐bound	  PPARs,	  as	  well	  as	  other	  ligand-­‐
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bound	  NR,	  change	  the	  conformation	  of	  the	  AF2	  domain	  recruiting	  coactivators	  and	  releasing	   corepressor	   complexes.	   However,	   several	   holo-­‐NR	   undergoes	   post-­‐translational	  modifications	  such	  as	  phosphorylation,	  acetylation	  or	  sumoylation.	  To	  date,	  there	  have	  been	  no	  studies	  on	  the	  acetylation	  of	  PPARα	  or	  -­‐γ,	  however,	  SIRT1	  (HDAC	   class	   III)	   was	   shown	   to	   repress	   PPARγ	   by	   docking	   with	   both	   NCOR	   and	  NCOR2/SMRT	  [237].	  It	  is	  noteworthy	  to	  remember	  that	  SAHA	  does	  not	  to	  inhibit	  the	  SIRT	  enzymes,	   therefore	   suggesting	   that	   this	   enzyme	   in	  prostate	  might	  not	  play	   a	  strong	  repressive	  role	  on	  PPARγ.	  	  Previously,	  it	  was	  shown	  that,	  compared	  with	  wild-­‐type	  ERα,	  glutamine	  or	  arginine	  substitutions	  at	  ERα	  acetylation	  sites	  enhanced	  estrogen	  dependent	  activity	  of	  ERα	  suggesting	   that	   ERα	   acetylation	   by	   p300	   normally	   suppresses	   ligand	   sensitivity.	  However,	   ERα	   acetylation	   appears	   to	   augment	   unliganded,	   basal	   constitutive	  activity	  as	  TSA	  and	  NaB	  stimulated	  unliganded	  ERα	  activity	  and	  this	  induction	  was	  abolished	   in	   cells	   with	   acetylation-­‐deficient	   ERα	   mutants	   [238].	   Similarly,	  acetylation-­‐deficient	  AR	  mutants	  hindered	  the	  activation	  of	  the	  AR	  in	  the	  absence	  of	  ligand,	   but	   the	   hormone-­‐dependent	   transactivation	   was	   also	   abolished,	   implying	  that	  acetylation	  of	  the	  AR	  by	  p300	  is	  essential	  for	  full	  effective	  AR	  signalling	  [239].	  Compared	   with	   wild-­‐type	   AR	   in	   the	   presence	   of	   dihydrotestosterone,	   alanine	  substitutions	  at	  AR	  acetylation	  sites	  (630	  or	  632/633)	  showed	  a	  10-­‐fold	  increased	  binding	  of	  NCOR1	  [240].	  Thus,	  acetylation	  of	  the	  critical	  AR	  lysine	  residues	  appears	  to	   prevent	   the	   recruitment	   of	   corepressors	   and	   activate	   both	   unliganded	   and	  liganded	  AR	  signalling.	  There	  are	  several	  studies	  demonstrating	  that	  NCOR1	  is	  not	  involved	  only	   in	   ligand-­‐independent	   repression	  of	   target	  genes.	  An	  example	   is	   the	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ligand	  dependent	  transrepression	  of	  PPAR	  target	  genes	  was	  shown	  by	  Pascual	  et	  al.	  where	   a	   ligand-­‐dependent	   SUMOylation	   of	   the	   PPARγ	   ligand-­‐binding	   domain,	  targets	  PPARγ	  to	  NCOR1/HDAC3	  complexes	  on	  inflammatory	  gene	  promoters.	  This	  prevents	   recruitment	   of	   the	   ubiquitylation/19S	   proteosome	   machinery	   and	   the	  signal-­‐dependent	  removal	  of	  corepressor	  complexes	  required	  for	  gene	  activation.	  As	  a	  result,	  NCOR1	  complexes	  are	  not	  cleared	  from	  the	  promoter	  and	  target	  genes	  are	  maintained	  in	  a	  repressed	  state	  [130].	   	  If	   a	   post	   translational	   acetylation	   of	   PPARα	   and	   -­‐γ	   prevented	   NCOR1	   binding,	  treatment	  with	  SAHA	  may	  preserve	  the	  acetylation	  status	  of	  the	  receptor	  in	  favour	  of	  an	  active	  receptor.	  This	  could	  also	  suggest	  that	  in	  the	  pool	  of	  PPARs	  inside	  of	  the	  cell,	   only	   a	   certain	   number	   of	   them	   are	   bound	   to	  NCORs/HDACs,	   hence,	   silencing	  transcription,	   while	   a	   percentage	   are	   active	   [241].	   Treatment	   with	   SAHA	   would	  increase	  the	  amount	  of	  PPARs	  available	  (reducing	  the	  number	  of	   those	  complexed	  with	  NCORs/HDACs)	  and	   the	   co-­‐treatment	  with	  bezafibrate	  would	   then	  additively	  enhance	   the	   activity	   of	   PPARs	   and	   the	   activation	   of	   their	   target	   genes.	   However,	  further	   studies	   on	   the	   acetylation	   of	   PPARα	   and	   -­‐γ	   are	   necessary	   to	   support	   this	  hypothesis.	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Fig.	  5.1	  –	  Representation	  of	  the	  proposed	  additive	  mechanism	  of	  action	  of	  SAHA	  and	  
bezafibrate	   in	   PC-­3.	   (A)	   A	   pool	   of	   PPARs	   is	   acetylated	   due	   to	   the	   interaction	   with	  
elevated	   levels	   of	   NCOR1	   and	   HDAC3	   that	   promote	   de-­acetylation	   of	   the	   receptor.	  
Treatment	  with	  SAHA	  and	  bezafibrate	  restores	  acetylation	  levels	  and	  promotes	  ligand-­
dependent	  receptor	  activation.	  (B)	  Interaction	  of	  NCORs/HDACs	  complexes	  with	  PPAR	  
deacetylates	   the	   receptor,	   SAHA	   restores	   the	   acetylation	   levels	   and	   bezafibrate	  
additively	  activates	  PPAR.	  Red	  circles	  indicates	  repressed	  receptor,	  light	  green	  circles	  
indicates	  acetylated	  and	  physiologically	  active	   receptors	   (e.g.	  by	  endogenous	   ligand)	  
and	  dark	  green	  circles	  indicate	  receptors	  additively	  activated	  by	  bezafibrate.	  	  Interestingly,	   knocking	   down	   NCOR1	   in	   PC-­‐3	   cells	   via	   siRNA,	   modulated	   the	  acetylation	  of	  H3K9	  at	  the	  TSS	  region	  and	  closely	  reflects	  the	  mRNA	  levels	  of	  both	  
CDKN1A	   and	  TGFBRAP1	   being	  upregulated	   and	  downregulated,	   respectively,	   upon	  bezafibrate	   treatment	  either	  with	  SAHA	  or	   in	  shNCOR1	  background.	  This	  suggests	  that	  NCOR1	  negatively	  regulates	  the	  transcription	  of	  CDKN1A	  and	  at	  the	  same	  time	  mediates	  independent	  regulation	  of	  TGFBRAP1.	  For	   both	   CDKN1A	   and	   TGFBRAP1	   TSS	   regions,	   SAHA	   efficiently	   promoted	   H3K9	  acetylation	  while	   bezafibrate	   alone	  was	   not	   able	   to	   promote	   accumulate	  H3K9Ac;	  the	  combined	  treatment	  did	  not	  have	  any	  additive	  effect	  and	  the	  acetylation	  levels	  were	  comparable	  to	  those	  of	  bezafibrate	  alone.	  These	  data	  suggest	  that	  bezafibrate	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actually	   reduces	   the	   acetylation	   marks	   in	   opposition	   to	   SAHA’s	   activity	   although	  sustaining	  CDKN1A	  transcription	  and	  repressing	  TGFBRAP1	  mRNA	  accumulation.	  	  Another	   interesting	  NCOR1-­‐dependent	  mechanism	  of	  action	  has	  been	  described	   in	  pituitary	  cells	  where	  T3	  decreased	  transcription,	  increasing	  histone	  acetylation,	  of	  a	  reporter	   gene	   controlled	   by	   the	   TSHα	   promoter	   (-­‐840	   to	   +1).	   T3	   promotes	  acetylation	   of	   H3K9	   and	   H3K18	   and	   release	   of	   HDAC3,	   TBL-­‐1	   and	   NCOR1-­‐NCOR2/SMRT	   from	   the	   TSHα	   promoter.	   ChIP	   analyses	   of	   a	   positively	   regulated	  target	  gene	  showed	  increased	  histone	  acetylation	  and	  corepressor	  complex	  release	  with	  T3	  treatment.	  Microarray	  analyses	  suggested	  a	  subset	  of	  negatively	  regulated	  genes	  in	  response	  to	  increased	  histone	  acetylation.	  These	  findings	  demonstrated	  the	  role	  of	  NCOR1/HDAC3	  complex	  in	  negative	  regulation	  of	  TSHα	  gene	  expression	  and	  show	   that	   similar	   complexes	   and	   overlapping	   epigenetic	   modifications	   can	  participate	  in	  both	  negative	  and	  positive	  transcriptional	  regulation	  [242].	  Similarly,	  1.25α(OH)2D3	  treatment	  in	  MCF7	  cells	  was	  shown	  to	  recruit	  VDR,	  the	  transcription	  factor	  WSTF	   and	  HDACs	   to	   the	   1α(OH)ase	   promoter	   leading	   to	   reduced	   levels	   of	  H3K14Ac	  at	  the	  TSS	  and	  transcriptional	  silencing	  [243].	  	  These	  studies	  suggest	  that	  ligand-­‐dependent	  transrepression	  is	  actually	  a	  common,	  although	   selective,	   event	   shared	   between	   several	   NRs.	   However,	   it	   is	   still	   unclear	  why	  only	  certain	  genes	  are	  targeted	  and	  if	  this	  is	  a	  phenomena	  specific	  for	  a	  certain	  time	   points	   and/or	   corepressor	   complexes.	   The	   NR	   network	   is	   integrated	   at	  multiple	   levels	  with	   feed-­‐back	   and	   feed-­‐forward	   signalling	   loops	   that	  modulate	   in	  time	   the	   transcription	   of	   target	   genes.	   Time	   course	   analysis	   with	   SAHA	   and	  bezafibrate	   demonstrated	   a	   dynamic	   regulation	   of	   mRNA	   accumulation	   that	   can	  
Chapter	  5	  –	  Conclusions	  and	  future	  studies	  	  
 273 
either	   up-­‐	   or	   down-­‐regulate	   the	   same	   gene	   at	   different	   time	   points	   (e.g.	   PTGS2);	  although	  this	  modulation	  can	  be	   influenced	  by	  epigenetic	  modification	  at	  different	  regions,	  the	  cohort	  of	  complexes	  and	  TF	  interacting	  with	  PTGS2	  promoter	  can	  also	  vary	  through	  time,	  therefore,	  leading	  to	  different	  transcriptional	  responses.	  Further	  time-­‐resolved	  ChIP	  analysis	  could	  elucidate	  better	  the	  epigenetic	  mechanism	  behind	  the	  cyclical	  regulation	  of	  PPARα	  and	  -­‐γ	  target	  genes.	  Ellis	   et	   al.	   investigated	   the	   correlation	   between	   TSA	   treatment	   with	   histone	  modification	   and	   transcriptional	   activation/repression	   of	   target	   genes.	   They	  analysed	  CDKN1A	  and	  SRC	  promoters,	  being	  a	  positively	  and	  negatively	  regulated	  by	  TSA,	   respectively.	   A	   panel	   of	   histone	   acetylated	   residues	   such	   as	   H3K9,	   H3K14,	  H4K5,	  H4K8,	  H4K12	  and	  H4K16	  were	  analysed	  upon	  a	   time	  course	  experiment	   in	  two	   different	   cell	   lines	   treated	   with	   1	   µM	   of	   TSA,	   although	   this	   is	   a	   very	   high	  concentration	   when	   TSA	   IC50	   is	   approximately	   20nM.	   The	   results	   consistently	  showed	  increased	  acetylation	  at	  the	  TSS	  region	  of	  all	  the	  genes	  irrespectively	  from	  the	  mRNA	  regulation	  data	  [244].	  	  These	  observations	  indicate	  that	  the	  additive	  effect	  of	  SAHA	  and	  bezafibrate	  on	  the	  PPAR	  target	  genes	  is	  not	  caused	  only	  by	  modification	  of	  the	  chromatin	  environment	  but	   could	   also	   be	   mediated	   by	   the	   acetylation	   state	   of	   non-­‐histone	   protein	   (e.g.	  PPAR,	   Rb	   or	   p53)	   while	   bezafibrate	   promoted	   transrepression	   of	   TFBRAP1	   was	  already	   demonstrated	   by	   the	   reduced	   acetylation	   pattern	   of	   TGFBRAP1	   TSS	   in	  siNCOR1	  treated	  PC-­‐3	  cells.	  Although	  NCOR1	  regulate	  transcriptional	  plasticity	  over	  both	  target	  choice	  and	  periodicity,	  further	  time	  course	  studies	  could	  elucidate	  better	  the	   acetylation	   at	   the	   TSS	   at	   promoter	   regions	   of	   PPAR	   target	   genes	   while	   3C	  
Chapter	  5	  –	  Conclusions	  and	  future	  studies	  	  
 274 
experiments	   [245]	  could	   indicate	  possible	  distal	  spatial	  control	  over	   transcription.	  However,	   the	   novel	   finding	   is	   that	   NCOR1	   blocks	   both	   up	   and	   down	   regulated	  critical	  factors	  targetable	  with	  epigenetic	  therapy.	  	  
5.3 – Corepressor functions in prostate development 
In	   vivo	   experiments	   demonstrated	   that	   both	  Ncor1	   and	  Ncor2/Smrt	   knockout	   are	  lethal.	  Ncor1−/−	  mice	  die	  at	  ED	  15.5	  because	  of	  severe	  anemia	  and	  secondary	  edema	  [138],	   while	   Ncor2/Smrt-­‐/-­‐	   embryos	   die	   at	   ED	   16.5	   because	   of	   heart	   defects	   and	  defects	  in	  CNS	  development	  [139].	  Ncor1	  is	  also	  a	  key	  regulator	  in	  neural	  stem	  cells	  differentiation	   as	   Ncor1-­‐disrupted	   mice	   displayed	   impaired	   self-­‐renewal	   and	  spontaneous	   differentiation	   in	   astroglia-­‐like	   cells	   [137].	   Other	   studies	   highlighted	  that	   3T3-­‐L1	   cells	   with	   reduced	   levels	   of	   either	   NCOR1	   or	   NCOR2/SMRT,	   had	  increased	  expression	  of	  adiponectin,	  perilipin,	  and	  C/EBPα	  and	  adipogenic	  markers,	  upon	   PPARγ	   agonist	   treatment;	   these	   cells	   exhibited	   increased	   expression	   of	  adipocyte-­‐specific	   genes	   and	   increased	   production	   of	   lipid	   droplets,	   as	   compared	  with	   control	   cells	   [136].	   NCOR1	   and	   NCOR2/SMRT	   are	   negative	   regulators	   of	  transcription	  induced	  by	  the	  β-­‐catenin-­‐TCF4	  complex	  [246];	  this	  is	  activated	  by	  the	  WNT	   signalling	   that	   can	   modulate	   epithelial	   cell	   proliferation	   during	   prostate	  morphogenesis.	  	  
AR,	   ERα	   and	   RAR	   are	   regulated	   by	   both	   NCOR1	   and	   NCOR2/SMRT;	   Ar	   is	  fundamental	  for	  correct	  prostate	  development,	  as	  mice	  with	  dysfunctional	  Ar	  do	  not	  develop	   prostate,	   and	   tightly	   controls	   the	   expression	   of	   Nkx3.1	   that	   is	   detectable	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two	  days	  before	   the	   appearance	  of	  prostatic	  buds.	  ERα	   attenuates	   the	   androgenic	  effect	   in	   the	   developing	   gland	   while	   RAR	   cross	   talks	   with	   ERα	   during	   prostate	  development	   regulating	   fertility	   and	   gland	   morphology	   (described	   in	   the	  Introduction).	  	  
Therefore,	   it	   is	   possible	   to	   predict	   that	   prostate	   specific	   knock	   out	   of	   Ncor1	   and	  Ncor2/Smrt	   will	   interfere	   with	   the	   pathways	   of	   Ar,	   Er	   and	   Rar	   modifying	   the	  expression	   of	   downstream	   target	   genes.	   High	   estradiol	   levels	   lead	   to	   branching	  inhibition	  but	  action	  of	  the	  Er	  is	  also	  antagonized	  by	  Rar	  signalling;	  over-­‐activation	  of	   the	   Ar	   signalling	   could	   cause	   hyper-­‐proliferation	   of	   the	   prostate	   or	   irregular	  growth	   of	   the	   stroma	   and	   epithelia	   causing	   morphological	   and	   functional	  disfunctions.	   The	   β-­‐catenin-­‐Tcf4	   complex	   will	   be	   also	   hyper-­‐activated	   due	   to	   the	  lack	   Ncor1	   and	   Ncor2/Smrt	   possibly	   leading	   to	   epithelial	   hyperplasia	   and	   bigger	  prostate.	   However,	   the	   phenotype	   obtained	   could	   be	   different	   between	   the	   two	  knock	   outs	   as	   the	   classical	   knock	   outs	   of	  Ncor1	   and	  Ncor2/Smrt	   caused	   different	  phenotypical	  outputs.	  	  
	  
5.4 – Mechanistic modeling of CDKN1A transcriptional regulation A	   realistic	   approach	   for	   understanding	   biological	   network	   is	   the	   “bottom	   up”	  approach,	   where	   experimental	   data	   collected	   are	   used	   to	   and	   implemented	   into	  models	   to	   make	   predictions	   regarding	   the	   behavior	   of	   a	   certain	   network.	   Those	  predictions	   can	   then	   be	   confirmed	   with	   new	   wet-­‐lab	   experiments	   appositely	  designed	  to	  validate	  and	  support	  the	  in	  silico	  findings.	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The	  ODE	  model	  predicted	  that	  CDKN1A	  and	  miR-­‐106B	  are	  commonly	  regulated	  by	  p-­‐PolII	  while	  miR-­‐106B	  controls	  degradation	  of	  CDKN1A	  before	  that	  the	  system	  goes	  back	   to	   a	   steady	   state.	   	   Limitations	  of	  ODE	  models	   are	  principally	   that	   they	  won’t	  describe	  the	  accurately	  the	  events	   inside	  a	   few	  cell	  population.	  A	  stochastic	  model	  can	   overcome	   this	   and	   capture	   the	   dynamics	   of	   molecular	   systems	   within	   a	   few	  molecular	  species	  –	   i.e.	   transcriptional	   initiation	  from	  a	  single	  gene.	  This	  approach	  has	  been	  successfully	  used	  to	  describe	  the	  cycling	  of	  PPARδ	   to	  a	  response	  element	  within	   the	   promoter	   of	   the	   PDK4	   gene	   regulatory	   region	   [247]	   and,	   applied	   to	  
CDKN1A	   transcriptional	   events,	   closely	   reflect	  mRNA	  and	  ChIP	  data.	  Although	   this	  model	   has	   to	   be	   refined	   further,	   it	   strongly	   suggests	   that	   the	   timing	   of	   CDKN1A	  transcriptional	   activation	   and	   subsequent	   mRNA	   accumulation	   can	   be	   dependent	  upon	   miR-­‐106B	   action	   that	   not	   only	   is	   involved	   in	   the	   steep	   degradation	   at	   30	  minutes	  but	  also	  controls	  the	  timing	  of	  mRNA	  accumulation.	  	  However,	   it	   is	   important	   to	   run	   both	   stochastic	   and	   ODE	   models	   simulating	   the	  knock	   down	   of	   the	   species	   involved	   in	   order	   to	   precisely	   confirm	   the	   initial	  hypothesis.	  As	  wet-­‐lab	  validations,	  knock	  down	  of	  MCM7	  (the	  gene	  containing	   the	  mir106-­‐B	  cluster)	  and	  miR-­‐106B,	  and	  cycloheximide	  experiments	  could	  support	  the	  modeling	   results	   and	   confirm	   the	   direct	   effect	   of	   ligand-­‐bound	   VDR	   on	   CDKN1A	  transcriptional.	  Nonetheless,	   the	  results	  obtained	  so	   far	  suggest	   that	   the	  predicted	  double	  mechanism	  of	   action	   of	  miR-­‐106B	   can	  be	   extended	   to	   other	  miRNA	   target	  genes	   to	  describe	   their	  cyclical	  activation	  by	  NR	   ligands	  and	   their	   function	   in	  PCa.	  NCOR1	   and	   NCOR2/SMRT	   also	   play	   a	   repressive	   role	   in	   CDKN1A	   mRNA	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accumulation	  and	  implementing	  those	  data	  in	  the	  model	  could	  also	  help	  predicting	  the	  transcriptional	  events	  in	  Ncor1	  and	  Ncor2/Smrt	  knock	  out	  animals.	  	  	  
5.5 – Future directions The	  prostate	   specific	   knockout	  mice	   are	   currently	   being	  bred	   at	   the	  Roswell	   Park	  Cancer	  Institute	  in	  Buffalo,	  NY	  (USA)	  to	  better	  understand	  the	  dynamic	  contribution	  of	   Ncor1	   and	   Ncor2/Smrt	   in	   prostate	   development	   is	   necessary	   to	   monitor	   the	  expression	  of	   those	  two	  genes	   from	  embryonic	  (or	   from	  when	  the	   first	  prostate	   is	  detectable)	   to	   adult	   prostate.	   To	   date	   no	   such	   data	   are	   available	   even	   if	   several	  transcripts	   have	   been	   observed	   from	   bud	   induction	   to	   prostate	   gland	   formation	  such	  as	  Bmps,	  Hoxa	  and	  Wnt	  (reviewed	  in	  [17]).	  Once	  the	  knock	  out	  in	  the	  mice	  is	  confirmed,	   it	   will	   be	   possible	   to	   analyse	   the	   expression	   of	   key	   genes	   (Nkx3.1,	  
Hoxa13,	  Hoxd13)	   as	  well	   as	   it	  will	   be	   insightful	   to	   analyse	   the	   Shh,	  Wnt	   and	  Bmp	  pathways.	   The	   TGF	   signalling,	   already	   involved	   in	   the	   Bmp	   pathway,	   is	   also	  modulated	   by	   TGFBRAP1	   (PPAR	   target	   and	   regulated	   by	   Ncor1)	   binding	   to	   TGFβ	  receptors	  that	  was	  reported	  to	  relate	  to	  tumorigenesis	  [248,	  249].	  Moreover,	  the	  NR	  network	   will	   probably	   be	   affected	   by	   the	   lack	   of	   Ncor1	   and	   Ncor2/Smrt	   and	   the	  expression	   of	   downstream	   targets	   of	   AR,	   ERα	   and	   RAR	   will	   be	   measured.	  Immunohistochemical	   analysis	   of	   Ncor1-­‐/-­‐	   and	   Ncor2/Smrt-­‐/-­‐	   prostates	   will	   be	  undertaken	   to	  understand	   the	  histological	  and	  morphological	   consequences	  of	   the	  knockouts.	  To	  profile	  genome-­‐wide	  the	  transcriptome	  of	  Ncor1-­‐/-­‐	  and	  Ncor2/Smrt-­‐/-­‐	  prostates	   it	  will	  be	  worthwhile	   to	  undertake	  a	  microarray	  analysis	  comparing	  WT	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animals	  with	  the	  knock	  outs	  and	  the	  two	  knock	  outs	  with	  each	  other;	  this	  will	  help	  identify	  cohort	  of	  genes	  that	  will	  be	  uniquely	  or	  commonly	  regulated	  by	  Ncor1	  and	  Ncor2/Smrt.	  There	  will	  also	  be	  the	  possibility	  to	  cross	  these	  mice	  with	  either	  Pten-­‐/-­‐	  or	  TRAMP	  prostate	   cancer	  models	   to	   understand	   the	   combinatorial	   role	   or	  Ncor1	  and	  Ncor2/Smrt	  with	   other	   key	   regulators	   in	   a	   PCa	   background.	   It	  would	   be	   also	  interesting	  to	  test	  in	  these	  mice	  whether	  sensitivity	  of	  the	  growing	  tumour	  towards	  NR	   ligands	   (i.e.	   bezafibrate)	   is	   increased	   or	   decreased	   by	   the	   lack	   of	   Ncor1	   and	  Ncor2/Smrt.	   A	   further	   step	   in	   the	   understanding	   the	   combinatorial	   role	   between	  Ncor1	  and	  Ncor2/Smrt	  would	  be	  to	  cross	  the	  two	  single	  knock	  outs	  to	  create	  mice	  lacking	   both	   corepressors	   in	   the	   prostate;	   however,	   it	   is	   important	   initially	   to	  evaluate	   the	   consequences	   of	   the	   single	   knock	   out	   before	   undertaking	   this	  experiments.	  Saramaki	  et	  al.	  demonstrated	  the	  cyclical	  looping	  VDR-­‐mediated	  at	  in	  three	  different	  regions	   of	   the	   CDKN1A	   promoter	   that	   correlate	   with	   mRNA	   accumulation	   [250].	  Similarly,	   in	   breast	   cancer	   cell	   lines,	   the	   ERα	   has	   been	   shown	   to	   initiate	  interchromosomal	  contacts	  that	  generate	  specific	  and	  parallel	  transcription	  and	  co-­‐ordination	   of	   mRNA	   accumulation	   patterns	   [251].	   	   Applying	   this	   concept	   to	   the	  PPAR	  target	  genes	  could	  help	  understanding	  better	  the	  mechanism	  of	  action	  of	  the	  PPAR	   transcriptome	   in	   prostate	   malignancies.	   Also,	   to	   profile	   more	   precisely	   the	  epigenetic	   modification	   induced	   by	   bezafibrate	   in	   prostate	   cancer	   cells,	   a	   Native	  ChIP	  (N-­‐ChIP)	  approach	  [252]	  would	  be	  more	  suitable	  than	  a	  X-­‐ChIP	  approach;	  this	  would	   allow	   to	   capture	  with	   a	   better	   resolution	   and	   sensitivity	   the	   periodicity	   of	  histone	  modifications	  in	  prostate	  cancer	  cells.	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Finally	   the	   integration	   of	   those	   data	   in	   a	   stochastic	   model	   of	   the	   epigenetic	  modulation	  PPAR-­‐mediated	  in	  prostate	  cancer	  cells	  could	  help	  to	  formulate	  patients	  predictions	  on	  the	  effect	  of	  bezafibrate	  (already	  FDA	  approved)	  on	  prostate	  cancer.	  This	  model	  could	  be	  also	  be	  expanded	  to	  other	  NRs	  and	  it	  would	  also	  be	  interesting	  to	   compare	   the	   prediction	   of	   the	  model	  made	   for	   a	  malignant	   system	  with	   those	  obtained	   from	   a	   model	   designed	   for	   a	   non-­‐malignant	   system;	   this	   approach,	  together	   with	   the	   identification	   of	   markers	   dictating	   ligand	   insensitivity	   (i.e.	  corepressors),	   could	   help	   predict	   the	   sensitivity	   of	   patients	   to	  NR	   therapy,	   hence,	  reducing	   the	   risk	   for	   the	   patient	   to	   develop	   a	  more	   aggressive	   disease	   (i.e.	   in	   AR	  antagonist	  treated	  patients)	  and	  designing	  more	  personal	  and	  efficient	  treatments.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chapter	  5	  –	  Conclusions	  and	  future	  studies	  	  
 280 
	  	  	  	  
Journal	  publications	  related	  to	  this	  thesis	  	  
 281 
JOURNAL PUBLICATIONS RELATED TO THIS THESIS 	  Abedin	   SA,	   Thorne	   J,	   Battaglia	   S,	   Maguire	   O,	   Hornung	   LB,	   Doherty	   AP,	   Mills	   IG,	  Campbell	  MJ	  (2009).	  Elevated	  NCOR1	  disrupts	  a	  network	  of	  dietary-­‐sensing	  nuclear	  receptors	   in	  bladder	  cancer	  cells.	  Carcinogenesis	  Mar;30(3):449-­‐56.	  (impact	   factor	  5.4)	  	  	  
Battaglia	  S,	  Thorne	  J,	  Hornung	  L	  B,	  Doig	  CL,	  Liu	  S,	  Sucheston	  LE,	  Bianchi	  A,	  Khanim	  F,	  Gommersall	  LM,	  Coulter	  HSC,	  Rhaka	  S,	  Giddings,	   I.	   Cooper	  C,	  McCabe,	  CJ,	  Bunce	  CM,	   &	   Campbell	   MJ	   (2009).	   Elevated	   NCOR1	   disrupts	   PPAR	   signaling	   in	   prostate	  cancer	  and	  forms	  a	  targetable	  epigenetic	  lesion.	  (Submitted	  to	  Oncogene)	  	  	  Thorne	   JL,	   Maguire	   O,	   Doig	   CL,	  Battaglia	   S,	   O’Neill	   LP	   Turner	   BM,	   McCabe	   CJ	   &	  Campbell	   MJ	   (2009)	   Histone	   modifications	   and	   miRNA	   expression	   combine	   to	  determine	   CDKN1A	   (encodes	   p21(waf1/cip1))	   transcriptional	   periodicity	   and	   cell	  fate	  decisions	  (Submitted	  to	  Molecular	  Cell)	  	  	  
Battaglia	  S,	  Maguire	  O	  &	  Campbell	  MJ	  (2009).	  Transcription	  factor	  co-­‐repressors	  in	  cancer	  biology;	  disruption	  and	  targeting.	  (Submitted	  to	  Carcinogenesis)	  	  	  	  	  
Conference	  proceedings	  	  
 282 
CONFERENCE PROCEEDINGS 
 -­‐	   International	   Conference	   of	   System	   Biology;	   Sweden,	  Goteborg,	   Aug	   2008;	  poster:	  “NCoR	  Activity	  in	  the	  Prostate	  System”	  -­‐	  Keystone	  Meeting:	   Nuclear	  Receptor	   Steroids;	   Canada,	  Whistler	  March	   2008;	  poster:	  “NCoR	  activity	  in	  the	  prostate	  system”.	  
-­	  Diet	   and	   Cancer	  meeting;	   England,	   Nottingham,	   June	   2007;	   poster:	   “Epigenetic	  
corruption	   of	   fatty	   acid	   and	   bile	   acid	   signalling	   in	   prostate	  
malignancies”	  (poster	  prize)	  
-­	   Chromatin	   meeting;	   England,	   Nottingham,	   May	   2007;	   poster:	   “Chromatin	  
remodeling	  and	  nuclear	  receptors	  activity	  in	  prostate	  cancer”	  -­‐	  FEBS	  advanced	  course	  on	  system	  biology;	  Austria,	  Gosau,	  March	  2007;	  poster:	  
“Activity	  of	  the	  Vitamin	  D	  receptor	  during	  the	  cell	  cycle”	  -­‐	   International	   Conference	   on	   Differentiation	   Therapy	   	  and	   Innovative	  



















October	  2007	  -­‐	  “Advanced	  speaking	  and	  lecturing	  skills	  for	  international	  staff”,	  University	  of	  Birmingham,	  Birmingham,	  UK	  
September	  2007	  -­‐	  “Mechanism	  of	  gene	  expression”,	  University	  of	  Kuopio,	  Kuopio,	  Finland;	  held	  by	  Prof.	  Carsten	  Calberg.	  
June	  2007	  -­‐	  “Mouse	  embryonic	  stem	  cell	  culture	  training	  course”,	  Max	  Planck	  Institute	  for	  Molecular	  Genetics,	  Berlin,	  Germany;	  held	  by	  Dr	  Heiner	  Screwe.	  -­‐	  “Presentation	  skills”,	  University	  of	  Birmingham,	  Birmingham,	  UK.	  
October	  2006	  -­‐	   “Customer	   Training	   for	   GeneSpring	   Workshops,	   Intermediate	   Level	  (Microarray	  analysis)”,	  University	  of	  Birmingham,	  Birmingham,	  UK.	  
 
 
UNIVERSITY LECTURES: (University	  of	  Birmingham,	  Birmingham,	  UK)	  
- Getting	  published	  
- How	  to	  make	  the	  most	  of	  your	  research	  with	  business	  
- Multiplex	  fluorescent	  bead-­based	  assay	  
- Stem	  Cells:	  the	  basics,	  the	  hype	  and	  the	  reality	  
- What	  should	  I	  expect	  to	  achieve	  my	  PhD?	  
- Neuroimmunopharmacology	  -­	  Prozac,	  Ecstasy	  &	  Amphetamines:	  using	  
psychotropic	  drugs	  to	  beat	  cancer	  
- In	  situ	  hybridization:	  from	  theory	  to	  practice	  
- Immunohistochemestry:	  from	  theory	  to	  practice	  




1. McNeal, J.E., The prostate gland: morphology and pathobiology. Monogr. Urol, 
1983. 4: p. 3-37. 
2. Timms, B.G., Prostate development: a historical perspective. Differentiation, 
2008. 76(6): p. 565-77. 
3. Shannon, J.M. and G.R. Cunha, Autoradiographic localization of androgen 
binding in the developing mouse prostate. Prostate, 1983. 4(4): p. 367-73. 
4. Takeda, H., T. Mizuno, and I. Lasnitzki, Autoradiographic studies of androgen-
binding sites in the rat urogenital sinus and postnatal prostate. J Endocrinol, 
1985. 104(1): p. 87-92. 
5. Takeda, H. and C. Chang, Immunohistochemical and in-situ hybridization 
analysis of androgen receptor expression during the development of the mouse 
prostate gland. J Endocrinol, 1991. 129(1): p. 83-9. 
6. Wang, Y., et al., Cell differentiation lineage in the prostate. Differentiation, 2001. 
68(4-5): p. 270-279. 
7. Hayward, S.W., G.R. Cunha, and R. Dahiya, Normal development and 
carcinogenesis of the prostate. A unifying hypothesis. Ann N Y Acad Sci, 1996. 
784: p. 50-62. 
8. Marker, P.C., et al., Hormonal, cellular, and molecular control of prostatic 
development. Dev Biol, 2003. 253(2): p. 165-74. 
9. Prins, G.S. and L. Birch, The developmental pattern of androgen receptor 
expression in rat prostate lobes is altered after neonatal exposure to estrogen. 
Endocrinology, 1995. 136(3): p. 1303-14. 
10. Hayward, S.W., et al., Epithelial development in the rat ventral prostate, anterior 
prostate and seminal vesicle. Acta Anat (Basel), 1996. 155(2): p. 81-93. 
11. Collins, A.T., et al., Identification and isolation of human prostate epithelial stem 
cells based on alpha(2)beta(1)-integrin expression. J Cell Sci, 2001. 114(Pt 21): 
p. 3865-72. 
12. Magi-Galluzzi, C. and M. Loda, Molecular events in the early phases of prostate 
carcinogenesis. Eur Urol, 1996. 30(2): p. 167-76. 
13. Aumuller, G., Morphologic and endocrine aspects of prostatic function. Prostate, 
1983. 4(2): p. 195-214. 
14. Gakunga, P., et al., Hyaluronan is a prerequisite for ductal branching 
morphogenesis. Development, 1997. 124(20): p. 3987-97. 
15. Wilhelm, D. and P. Koopman, The makings of maleness: towards an integrated 
view of male sexual development. Nat Rev Genet, 2006. 7(8): p. 620-31. 
16. Schneider, A., et al., Targeted disruption of the Nkx3.1 gene in mice results in 
morphogenetic defects of minor salivary glands: parallels to glandular duct 
morphogenesis in prostate. Mech Dev, 2000. 95(1-2): p. 163-74. 
17. Prins, G.S. and O. Putz, Molecular signaling pathways that regulate prostate 
gland development. Differentiation, 2008. 76(6): p. 641-59. 
18. Greenberg, N.M., et al., Prostate cancer in a transgenic mouse. Proc Natl Acad 
Sci U S A, 1995. 92(8): p. 3439-43. 
References	  	  
 285 
19. Wang, X.D., et al., Notch1-expressing cells are indispensable for prostatic 
branching morphogenesis during development and re-growth following castration 
and androgen replacement. J Biol Chem, 2004. 279(23): p. 24733-44. 
20. Bierie, B., et al., Activation of beta-catenin in prostate epithelium induces 
hyperplasias and squamous transdifferentiation. Oncogene, 2003. 22(25): p. 
3875-87. 
21. Yang, A., et al., p63, a p53 homolog at 3q27-29, encodes multiple products with 
transactivating, death-inducing, and dominant-negative activities. Mol Cell, 
1998. 2(3): p. 305-16. 
22. Signoretti, S., et al., p63 is a prostate basal cell marker and is required for 
prostate development. Am J Pathol, 2000. 157(6): p. 1769-75. 
23. Brown, T.R., et al., Deletion of the steroid-binding domain of the human 
androgen receptor gene in one family with complete androgen insensitivity 
syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl 
Acad Sci U S A, 1988. 85(21): p. 8151-5. 
24. Charest, N.J., et al., A frameshift mutation destabilizes androgen receptor 
messenger RNA in the Tfm mouse. Mol Endocrinol, 1991. 5(4): p. 573-81. 
25. Takeda, H., I. Lasnitzki, and T. Mizuno, Analysis of prostatic bud induction by 
brief androgen treatment in the fetal rat urogenital sinus. J Endocrinol, 1986. 
110(3): p. 467-70. 
26. Cohen, R.N., et al., The nuclear corepressors recognize distinct nuclear receptor 
complexes. Mol Endocrinol, 2000. 14(6): p. 900-14. 
27. Chen, J.D. and R.M. Evans, A transcriptional co-repressor that interacts with 
nuclear hormone receptors. Nature, 1995. 377(6548): p. 454-7. 
28. Gloyna, R.E., P.K. Siiteri, and J.D. Wilson, Dihydrotestosterone in prostatic 
hypertrophy. II. The formation and content of dihydrotestosterone in the 
hypertrophic canine prostate and the effect of dihydrotestosterone on prostate 
growth in the dog. J Clin Invest, 1970. 49(9): p. 1746-53. 
29. Quigley, C.A., et al., Androgen receptor defects: historical, clinical, and 
molecular perspectives. Endocr Rev, 1995. 16(3): p. 271-321. 
30. Bardin, C.W., et al., Androgen metabolism and mechanism of action in male 
pseudohermaphroditism: a study of testicular feminization. Recent Prog Horm 
Res, 1973. 29: p. 65-109. 
31. Brown, T.J., M. Sharma, and N.J. MacLusky, Localization and measurement of 
occupied androgen receptors in thaw-mounted rat and human prostate tissue 
sections by in vitro autoradiography. Steroids, 1995. 60(2): p. 239-47. 
32. Lipschutz, J.H., B.A. Foster, and G.R. Cunha, Differentiation of rat neonatal 
ventral prostates grown in a serum-free organ culture system. Prostate, 1997. 
32(1): p. 35-42. 
33. Hsieh, C.L., et al., A luciferase transgenic mouse model: visualization of prostate 
development and its androgen responsiveness in live animals. J Mol Endocrinol, 
2005. 35(2): p. 293-304. 
34. Lubahn, D.B., et al., Alteration of reproductive function but not prenatal sexual 
development after insertional disruption of the mouse estrogen receptor gene. 
Proc Natl Acad Sci U S A, 1993. 90(23): p. 11162-6. 
References	  	  
 286 
35. Eddy, E.M., et al., Targeted disruption of the estrogen receptor gene in male mice 
causes alteration of spermatogenesis and infertility. Endocrinology, 1996. 
137(11): p. 4796-805. 
36. Huang, L., et al., The role of Fgf10 signaling in branching morphogenesis and 
gene expression of the rat prostate gland: lobe-specific suppression by neonatal 
estrogens. Dev Biol, 2005. 278(2): p. 396-414. 
37. Timms, B.G., S.L. Petersen, and F.S. vom Saal, Prostate gland growth during 
development is stimulated in both male and female rat fetuses by intrauterine 
proximity to female fetuses. J Urol, 1999. 161(5): p. 1694-701. 
38. Prins, G.S., Neonatal estrogen exposure induces lobe-specific alterations in adult 
rat prostate androgen receptor expression. Endocrinology, 1992. 130(4): p. 2401-
12. 
39. McDowell, E.M., K.P. Keenan, and M. Huang, Restoration of mucociliary 
tracheal epithelium following deprivation of vitamin A. A quantitative 
morphologic study. Virchows Arch B Cell Pathol Incl Mol Pathol, 1984. 45(2): p. 
221-40. 
40. De Luca, L.M., Retinoids and their receptors in differentiation, embryogenesis, 
and neoplasia. FASEB J, 1991. 5(14): p. 2924-33. 
41. Aboseif, S.R., et al., Effect of retinoic acid on prostatic development. Prostate, 
1997. 31(3): p. 161-7. 
42. Prins, G.S., et al., Retinoic acid receptors and retinoids are up-regulated in the 
developing and adult rat prostate by neonatal estrogen exposure. Endocrinology, 
2002. 143(9): p. 3628-40. 
43. Collins, A.T. and N.J. Maitland, Prostate cancer stem cells. Eur J Cancer, 2006. 
42(9): p. 1213-8. 
44. Kasper, S., Exploring the origins of the normal prostate and prostate cancer stem 
cell. Stem Cell Rev, 2008. 4(3): p. 193-201. 
45. Fargeas, C.A., et al., Identification of novel Prominin-1/CD133 splice variants 
with alternative C-termini and their expression in epididymis and testis. J Cell 
Sci, 2004. 117(Pt 18): p. 4301-11. 
46. Richardson, G.D., et al., CD133, a novel marker for human prostatic epithelial 
stem cells. J Cell Sci, 2004. 117(Pt 16): p. 3539-45. 
47. Shepherd, C.J., et al., Expression profiling of CD133+ and CD133- epithelial 
cells from human prostate. Prostate, 2008. 68(9): p. 1007-24. 
48. Collins, A.T., et al., Prospective identification of tumorigenic prostate cancer 
stem cells. Cancer Res., 2005. 65(23): p. 10946-10951. 
49. Feinberg, A.P., R. Ohlsson, and S. Henikoff, The epigenetic progenitor origin of 
human cancer. Nat Rev Genet, 2006. 7(1): p. 21-33. 
50. Sell, S., Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol 
Hematol, 2004. 51(1): p. 1-28. 
51. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 
55(2): p. 74-108. 
52. Tomlins, S.A., M.A. Rubin, and A.M. Chinnaiyan, Integrative biology of prostate 
cancer progression. Annu Rev Pathol, 2006. 1: p. 243-71. 
References	  	  
 287 
53. Gleason, D.F. and G.T. Mellinger, Prediction of prognosis for prostatic 
adenocarcinoma by combined histological grading and clinical staging. J Urol, 
1974. 111(1): p. 58-64. 
54. Steck, P.A., et al., Identification of a candidate tumour suppressor gene, MMAC1, 
at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 
1997. 15(4): p. 356-62. 
55. Li, J., et al., PTEN, a putative protein tyrosine phosphatase gene mutated in 
human brain, breast, and prostate cancer. Science, 1997. 275(5308): p. 1943-7. 
56. Chen, H., et al., NKX-3.1 interacts with prostate-derived Ets factor and regulates 
the activity of the PSA promoter. Cancer Res, 2002. 62(2): p. 338-40. 
57. Magee, J.A., S.A. Abdulkadir, and J. Milbrandt, Haploinsufficiency at the Nkx3.1 
locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor 
initiation. Cancer Cell, 2003. 3(3): p. 273-283. 
58. Mostaghel, E.A., et al., Intraprostatic androgens and androgen-regulated gene 
expression persist after testosterone suppression: therapeutic implications for 
castration-resistant prostate cancer. Cancer Res, 2007. 67(10): p. 5033-41. 
59. Kokontis, J.M., N. Hay, and S. Liao, Progression of LNCaP prostate tumor cells 
during androgen deprivation: hormone-independent growth, repression of 
proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle 
arrest. Mol Endocrinol, 1998. 12(7): p. 941-53. 
60. McPhaul, M.J., Mechanisms of prostate cancer progression to androgen 
independence. Best Pract Res Clin Endocrinol Metab, 2008. 22(2): p. 373-88. 
61. Slattery, M.L., Vitamin D receptor gene (VDR) associations with cancer. Nutr 
Rev, 2007. 65(8 Pt 2): p. S102-4. 
62. Khanim, F.L., et al., Altered SMRT levels disrupt vitamin D(3) receptor signalling 
in prostate cancer cells. Oncogene, 2004. 23(40): p. 6712-6725. 
63. Abedin, S.A., et al., Epigenetic corruption of VDR signalling in malignancy. 
Anticancer Res, 2006. 26(4A): p. 2557-66. 
64. Richter, F., et al., Retinoid and androgen regulation of cell growth, epidermal 
growth factor and retinoic acid receptors in normal and carcinoma rat prostate 
cells. Mol Cell Endocrinol, 1999. 153(1-2): p. 29-38. 
65. Jeronimo, C., et al., Quantitative RARbeta2 hypermethylation: a promising 
prostate cancer marker. Clin Cancer Res, 2004. 10(12 Pt 1): p. 4010-4. 
66. Campbell, M.J., et al., Expression of retinoic acid receptor-beta sensitizes 
prostate cancer cells to growth inhibition mediated by combinations of retinoids 
and a 19-nor hexafluoride vitamin D3 analog. Endocrinology, 1998. 139(4): p. 
1972-1980. 
67. Segawa, Y., et al., Expression of peroxisome proliferator-activated receptor 
(PPAR) in human prostate cancer. Prostate, 2002. 51(2): p. 108-16. 
68. Campbell, M.J., C. Carlberg, and H.P. Koeffler, A Role for the PPARgamma in 
Cancer Therapy. PPAR Res, 2008. 2008: p. 314974. 
69. Bernard, D., et al., Myc confers androgen-independent prostate cancer cell 
growth. J Clin Invest, 2003. 112(11): p. 1724-31. 
70. Taipale, J. and P.A. Beachy, The Hedgehog and Wnt signalling pathways in 
cancer. Nature, 2001. 411(6835): p. 349-54. 
References	  	  
 288 
71. Karhadkar, S.S., et al., Hedgehog signalling in prostate regeneration, neoplasia 
and metastasis. Nature, 2004. 431(7009): p. 707-12. 
72. Rhodes, D.R., et al., Meta-analysis of microarrays: interstudy validation of gene 
expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res, 
2002. 62(15): p. 4427-33. 
73. Klezovitch, O., et al., Hepsin promotes prostate cancer progression and 
metastasis. Cancer Cell, 2004. 6(2): p. 185-95. 
74. Bracken, A.P., et al., EZH2 is downstream of the pRB-E2F pathway, essential for 
proliferation and amplified in cancer. EMBO J., 2003. 22(20): p. 5323-5335. 
75. Dreyer, C., et al., Control of the peroxisomal beta-oxidation pathway by a novel 
family of nuclear hormone receptors. Cell, 1992. 68(5): p. 879-87. 
76. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999. 
97(2): p. 161-3. 
77. Michalik, L., B. Desvergne, and W. Wahli, Peroxisome-proliferator-activated 
receptors and cancers: complex stories. Nat.Rev.Cancer, 2004. 4(1): p. 61-70. 
78. Kersten, S. and W. Wahli, Peroxisome proliferator activated receptor agonists. 
EXS, 2000. 89: p. 141-51. 
79. Braissant, O., et al., Differential expression of peroxisome proliferator-activated 
receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the 
adult rat. Endocrinology, 1996. 137(1): p. 354-66. 
80. Berger, J. and D.E. Moller, The mechanisms of action of PPARs. Annu Rev Med, 
2002. 53: p. 409-35. 
81. Issemann, I. and S. Green, Activation of a member of the steroid hormone 
receptor superfamily by peroxisome proliferators. Nature, 1990. 347(6294): p. 
645-50. 
82. Sher, T., et al., cDNA cloning, chromosomal mapping, and functional 
characterization of the human peroxisome proliferator activated receptor. 
Biochemistry, 1993. 32(21): p. 5598-604. 
83. Jones, P.S., et al., Chromosomal localisation, inducibility, tissue-specific 
expression and strain differences in three murine peroxisome-proliferator-
activated-receptor genes. Eur J Biochem, 1995. 233(1): p. 219-26. 
84. Yeldandi, A.V., M.S. Rao, and J.K. Reddy, Hydrogen peroxide generation in 
peroxisome proliferator-induced oncogenesis. Mutat Res, 2000. 448(2): p. 159-
77. 
85. Fajas, L., et al., The organization, promoter analysis, and expression of the 
human PPARgamma gene. J Biol Chem, 1997. 272(30): p. 18779-89. 
86. Girnun, G.D., et al., APC-dependent suppression of colon carcinogenesis by 
PPARgamma. Proc Natl Acad Sci U S A, 2002. 99(21): p. 13771-6. 
87. Clay, C.E., et al., Early de novo gene expression is required for 15-deoxy-Delta 
12,14-prostaglandin J2-induced apoptosis in breast cancer cells. J Biol Chem, 
2001. 276(50): p. 47131-5. 
88. Chen, G.G., et al., Apoptosis induced by activation of peroxisome-proliferator 
activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human 
colon cancer. Life Sci, 2002. 70(22): p. 2631-46. 
References	  	  
 289 
89. Patel, L., et al., Tumor suppressor and anti-inflammatory actions of PPARgamma 
agonists are mediated via upregulation of PTEN. Curr Biol, 2001. 11(10): p. 764-
8. 
90. Lim, H., et al., Cyclo-oxygenase-2-derived prostacyclin mediates embryo 
implantation in the mouse via PPARdelta. Genes Dev, 1999. 13(12): p. 1561-74. 
91. He, T.C., et al., PPARdelta is an APC-regulated target of nonsteroidal anti-
inflammatory drugs. Cell, 1999. 99(3): p. 335-45. 
92. Barak, Y., et al., Effects of peroxisome proliferator-activated receptor delta on 
placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A, 2002. 
99(1): p. 303-8. 
93. Di-Poi, N., et al., Antiapoptotic role of PPARbeta in keratinocytes via 
transcriptional control of the Akt1 signaling pathway. Mol Cell, 2002. 10(4): p. 
721-33. 
94. Tenenbaum, A., et al., Bezafibrate for the secondary prevention of myocardial 
infarction in patients with metabolic syndrome. Arch Intern Med, 2005. 165(10): 
p. 1154-60. 
95. Peters, J.M., et al., Bezafibrate is a dual ligand for PPARalpha and PPARbeta: 
studies using null mice. Biochim Biophys Acta, 2003. 1632(1-3): p. 80-9. 
96. Cabrero, A., et al., Bezafibrate reduces mRNA levels of adipocyte markers and 
increases fatty acid oxidation in primary culture of adipocytes. Diabetes, 2001. 
50(8): p. 1883-90. 
97. Goldenberg, I., M. Benderly, and U. Goldbourt, Update on the use of fibrates: 
focus on bezafibrate. Vasc Health Risk Manag, 2008. 4(1): p. 131-41. 
98. Fernandes-Santos, C., et al., Pan-PPAR agonist beneficial effects in overweight 
mice fed a high-fat high-sucrose diet. Nutrition, 2009. 
99. Nakajima, T., et al., Bezafibrate at clinically relevant doses decreases serum/liver 
triglycerides via down-regulation of sterol regulatory element-binding protein-1c 
in mice: a novel peroxisome proliferator-activated receptor alpha-independent 
mechanism. Mol Pharmacol, 2009. 75(4): p. 782-92. 
100. Strakova, N., et al., Peroxisome proliferator-activated receptors (PPAR) agonists 
affect cell viability, apoptosis and expression of cell cycle related proteins in cell 
lines of glial brain tumors. Neoplasma, 2005. 52(2): p. 126-36. 
101. Hayden, R.E., et al., Treatment of primary CLL cells with bezafibrate and 
medroxyprogesterone acetate induces apoptosis and represses the pro-
proliferative signal of CD40-ligand, in part through increased 
15dDelta12,14,PGJ2. Leukemia, 2009. 23(2): p. 292-304. 
102. Tiziani, S., et al., Metabolomic profiling of drug responses in acute myeloid 
leukaemia cell lines. PLoS ONE, 2009. 4(1): p. e4251. 
103. Kohno, H., et al., Suppression of colitis-related mouse colon carcinogenesis by a 
COX-2 inhibitor and PPAR ligands. BMC Cancer, 2005. 5: p. 46. 
104. Ogawa, Y., et al., Follow-up CT findings of tamoxifen-induced non-alcoholic 
steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol 
Rep, 2003. 10(5): p. 1473-8. 
105. McKenna, N.J., R.B. Lanz, and B.W. O'Malley, Nuclear receptor coregulators: 
cellular and molecular biology. Endocr Rev, 1999. 20(3): p. 321-44. 
References	  	  
 290 
106. Cunliffe, V.T., Eloquent silence: developmental functions of Class I histone 
deacetylases. Curr Opin Genet Dev, 2008. 
107. Kurokawa, R., et al., Polarity-specific activities of retinoic acid receptors 
determined by a co-repressor. Nature, 1995. 377(6548): p. 451-4. 
108. Stacey, M.W., et al., Nuclear receptor co-repressor gene localizes to 17p11.2, a 
frequently deleted band in malignant disorders. Genes Chromosomes Cancer, 
1999. 25(2): p. 191-3. 
109. Park, E.J., et al., SMRTe, a silencing mediator for retinoid and thyroid hormone 
receptors-extended isoform that is more related to the nuclear receptor 
corepressor. Proc Natl Acad Sci U S A, 1999. 96(7): p. 3519-24. 
110. Aasland, R., A.F. Stewart, and T. Gibson, The SANT domain: a putative DNA-
binding domain in the SWI-SNF and ADA complexes, the transcriptional co-
repressor N-CoR and TFIIIB. Trends Biochem Sci, 1996. 21(3): p. 87-8. 
111. Zhang, J., et al., The N-CoR-HDAC3 nuclear receptor corepressor complex 
inhibits the JNK pathway through the integral subunit GPS2. Mol Cell, 2002. 
9(3): p. 611-23. 
112. Humphrey, G.W., et al., Stable histone deacetylase complexes distinguished by 
the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol 
Chem, 2001. 276(9): p. 6817-24. 
113. Andres, M.E., et al., CoREST: a functional corepressor required for regulation of 
neural-specific gene expression. Proc Natl Acad Sci U S A, 1999. 96(17): p. 
9873-8. 
114. Codina, A., et al., Structural insights into the interaction and activation of histone 
deacetylase 3 by nuclear receptor corepressors. Proc Natl Acad Sci U S A, 2005. 
102(17): p. 6009-14. 
115. Horlein, A.J., et al., Ligand-independent repression by the thyroid hormone 
receptor mediated by a nuclear receptor co-repressor. Nature, 1995. 377(6548): 
p. 397-404. 
116. Ordentlich, P., et al., Unique forms of human and mouse nuclear receptor 
corepressor SMRT. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2639-44. 
117. Privalsky, M.L., The role of corepressors in transcriptional regulation by nuclear 
hormone receptors. Annu.Rev.Physiol, 2004. 66: p. 315-360. 
118. Yoon, H.G., et al., Purification and functional characterization of the human N-
CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J., 2003. 22(6): p. 
1336-1346. 
119. Guenther, M.G., et al., A core SMRT corepressor complex containing HDAC3 
and TBL1, a WD40-repeat protein linked to deafness. Genes Dev, 2000. 14(9): p. 
1048-57. 
120. Li, H., et al., Characterization of receptor interaction and transcriptional 
repression by the corepressor SMRT. Mol Endocrinol, 1997. 11(13): p. 2025-37. 
121. Perissi, V. and M.G. Rosenfeld, Controlling nuclear receptors: the circular logic 
of cofactor cycles. Nat Rev Mol Cell Biol, 2005. 6(7): p. 542-54. 
122. Xu, H.E., et al., Structural basis for antagonist-mediated recruitment of nuclear 
co-repressors by PPARalpha. Nature, 2002. 415(6873): p. 813-817. 
123. Perissi, V., et al., Molecular determinants of nuclear receptor-corepressor 
interaction. Genes Dev., 1999. 13(24): p. 3198-3208. 
References	  	  
 291 
124. Goodson, M.L., B.A. Jonas, and M.L. Privalsky, Alternative mRNA splicing of 
SMRT creates functional diversity by generating corepressor isoforms with 
different affinities for different nuclear receptors. J.Biol.Chem., 2005. 
125. Faist, F., et al., Alternative splicing determines the interaction of SMRT isoforms 
with nuclear receptor-DNA complexes. Biosci Rep, 2008. 
126. Jonas, B.A., et al., Response of SMRT (silencing mediator of retinoic acid and 
thyroid hormone receptor) and N-CoR (nuclear receptor corepressor) 
corepressors to mitogen-activated protein kinase kinase kinase cascades is 
determined by alternative mRNA splicing. Mol Endocrinol, 2007. 21(8): p. 1924-
39. 
127. Cohen, R.N., et al., The specificity of interactions between nuclear hormone 
receptors and corepressors is mediated by distinct amino acid sequences within 
the interacting domains. Mol.Endocrinol., 2001. 15(7): p. 1049-1061. 
128. Webb, P., et al., The nuclear receptor corepressor (N-CoR) contains three 
isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol 
Endocrinol, 2000. 14(12): p. 1976-85. 
129. Hu, X. and M.A. Lazar, The CoRNR motif controls the recruitment of 
corepressors by nuclear hormone receptors. Nature, 1999. 402(6757): p. 93-96. 
130. Pascual, G., et al., A SUMOylation-dependent pathway mediates transrepression 
of inflammatory response genes by PPAR-gamma. Nature, 2005. 437(7059): p. 
759-763. 
131. Prokhortchouk, A., et al., The p120 catenin partner Kaiso is a DNA methylation-
dependent transcriptional repressor. Genes Dev, 2001. 15(13): p. 1613-8. 
132. Yoon, H.G., et al., N-CoR mediates DNA methylation-dependent repression 
through a methyl CpG binding protein Kaiso. Mol.Cell, 2003. 12(3): p. 723-734. 
133. Gao, Z., et al., Coactivators and corepressors of NF-kappaB in IkappaB alpha 
gene promoter. J Biol Chem, 2005. 280(22): p. 21091-8. 
134. Metivier, R., et al., Estrogen receptor-alpha directs ordered, cyclical, and 
combinatorial recruitment of cofactors on a natural target promoter. Cell, 2003. 
115(6): p. 751-763. 
135. Fernandez-Majada, V., et al., Aberrant cytoplasmic localization of N-CoR in 
colorectal tumors. Cell Cycle, 2007. 6(14): p. 1748-52. 
136. Yu, C., et al., The nuclear receptor corepressors NCoR and SMRT decrease 
PPARgamma transcriptional activity and repress 3T3-L1 adipogenesis. 
J.Biol.Chem., 2005. 
137. Hermanson, O., K. Jepsen, and M.G. Rosenfeld, N-CoR controls differentiation of 
neural stem cells into astrocytes. Nature, 2002. 419(6910): p. 934-939. 
138. Jepsen, K., et al., Combinatorial roles of the nuclear receptor corepressor in 
transcription and development. Cell, 2000. 102(6): p. 753-63. 
139. Jepsen, K., et al., SMRT-mediated repression of an H3K27 demethylase in 
progression from neural stem cell to neuron. Nature, 2007. 450(7168): p. 415-9. 
140. Nishio, H. and M.J. Walsh, CCAAT displacement protein/cut homolog recruits 
G9a histone lysine methyltransferase to repress transcription. 
Proc.Natl.Acad.Sci.U.S.A, 2004. 101(31): p. 11257-11262. 
References	  	  
 292 
141. Duan, Z., et al., Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by 
recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. 
Mol Cell Biol, 2005. 25(23): p. 10338-51. 
142. Jepsen, K., et al., Cooperative regulation in development by SMRT and FOXP1. 
Genes Dev, 2008. 22(6): p. 740-5. 
143. Hodgson, M.C., et al., The androgen receptor recruits nuclear receptor 
corepressor (N-CoR) in the presence of mifepristone via its amino and carboxy 
terminii revealing a novel molecular mechanism for androgen receptor 
antagonists. J.Biol.Chem., 2004. 
144. Cheng, S., et al., Inhibition of the dihydrotestosterone-activated androgen 
receptor by nuclear receptor corepressor. Mol.Endocrinol., 2002. 16(7): p. 1492-
1501. 
145. Chong, J.A., et al., REST: a mammalian silencer protein that restricts sodium 
channel gene expression to neurons. Cell, 1995. 80(6): p. 949-57. 
146. Ding, Z., L.L. Gillespie, and G.D. Paterno, Human MI-ER1 alpha and beta 
function as transcriptional repressors by recruitment of histone deacetylase 1 to 
their conserved ELM2 domain. Mol Cell Biol, 2003. 23(1): p. 250-8. 
147. Hakimi, M.A., et al., A core-BRAF35 complex containing histone deacetylase 
mediates repression of neuronal-specific genes. Proc Natl Acad Sci U S A, 2002. 
99(11): p. 7420-5. 
148. Shi, Y., et al., Histone demethylation mediated by the nuclear amine oxidase 
homolog LSD1. Cell, 2004. 119(7): p. 941-53. 
149. Metzger, E., et al., LSD1 demethylates repressive histone marks to promote 
androgen-receptor-dependent transcription. Nature, 2005. 437(7057): p. 436-9. 
150. Lee, M.G., et al., An essential role for CoREST in nucleosomal histone 3 lysine 4 
demethylation. Nature, 2005. 437(7057): p. 432-5. 
151. Collins, C., et al., Positional cloning of ZNF217 and NABC1: genes amplified at 
20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A, 1998. 
95(15): p. 8703-8. 
152. Thillainadesan, G., et al., Genome analysis identifies the p15ink4b tumor 
suppressor as a direct target of the ZNF217/CoREST complex. Mol Cell Biol, 
2008. 28(19): p. 6066-77. 
153. Almeida, L.O., et al., Mutational analysis of genes p14ARF, p15INK4b, 
p16INK4a, and PTEN in human nervous system tumors. Genet Mol Res, 2008. 
7(2): p. 451-9. 
154. Noda, H., et al., Promoter hypermethylation of tumor-related genes in sporadic 
colorectal cancer in young patients. J Exp Clin Cancer Res, 2007. 26(4): p. 521-6. 
155. Rosu-Myles, M. and L. Wolff, p15Ink4b: dual function in myelopoiesis and 
inactivation in myeloid disease. Blood Cells Mol Dis, 2008. 40(3): p. 406-9. 
156. Zhu, Q., et al., Lysine-specific demethylase 1 (LSD1) Is required for the 
transcriptional repression of the telomerase reverse transcriptase (hTERT) gene. 
PLoS ONE, 2008. 3(1): p. e1446. 
157. Nan, X., et al., DNA methylation specifies chromosomal localization of MeCP2. 
Mol Cell Biol, 1996. 16(1): p. 414-21. 
References	  	  
 293 
158. Meehan, R.R., J.D. Lewis, and A.P. Bird, Characterization of MeCP2, a 
vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids 
Res, 1992. 20(19): p. 5085-92. 
159. Lunyak, V.V., et al., Corepressor-dependent silencing of chromosomal regions 
encoding neuronal genes. Science, 2002. 298(5599): p. 1747-1752. 
160. Nagase, T., et al., Prediction of the coding sequences of unidentified human 
genes. XX. The complete sequences of 100 new cDNA clones from brain which 
code for large proteins in vitro. DNA Res, 2001. 8(2): p. 85-95. 
161. Fernandes, I., et al., Ligand-dependent nuclear receptor corepressor LCoR 
functions by histone deacetylase-dependent and -independent mechanisms. Mol 
Cell, 2003. 11(1): p. 139-50. 
162. Baek, S.H., et al., Exchange of N-CoR corepressor and Tip60 coactivator 
complexes links gene expression by NF-kappaB and beta-amyloid precursor 
protein. Cell, 2002. 110(1): p. 55-67. 
163. Pepe, G.J. and E.D. Albrecht, Actions of placental and fetal adrenal steroid 
hormones in primate pregnancy. Endocr Rev, 1995. 16(5): p. 608-48. 
164. Katsanis, N., et al., Localisation of receptor interacting protein 140 (RIP140) 
within 100 kb of D21S13 on 21q11, a gene-poor region of the human genome. 
Hum Genet, 1998. 102(2): p. 221-3. 
165. Cavailles, V., et al., Nuclear factor RIP140 modulates transcriptional activation 
by the estrogen receptor. Embo J, 1995. 14(15): p. 3741-51. 
166. Castet, A., et al., Multiple domains of the Receptor-Interacting Protein 140 
contribute to transcription inhibition. Nucleic Acids Res, 2004. 32(6): p. 1957-66. 
167. Heery, D.M., et al., A signature motif in transcriptional co-activators mediates 
binding to nuclear receptors. Nature, 1997. 387(6634): p. 733-6. 
168. Treuter, E., et al., A regulatory role for RIP140 in nuclear receptor activation. 
Mol Endocrinol, 1998. 12(6): p. 864-81. 
169. Augereau, P., et al., The nuclear receptor transcriptional coregulator RIP140. 
Nucl Recept Signal, 2006. 4: p. e024. 
170. Wei, L.N., et al., Receptor-interacting protein 140 directly recruits histone 
deacetylases for gene silencing. J Biol Chem, 2000. 275(52): p. 40782-7. 
171. Chinnadurai, G., CtBP, an unconventional transcriptional corepressor in 
development and oncogenesis. Mol Cell, 2002. 9(2): p. 213-24. 
172. Shi, Y., et al., Sharp, an inducible cofactor that integrates nuclear receptor 
repression and activation. Genes Dev, 2001. 15(9): p. 1140-51. 
173. Hatchell, E.C., et al., SLIRP, a small SRA binding protein, is a nuclear receptor 
corepressor. Mol Cell, 2006. 22(5): p. 657-68. 
174. Allfrey, V.G., R. Faulkner, and A.E. Mirsky, Acetylation and Methylation of 
Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl 
Acad Sci U S A, 1964. 51: p. 786-94. 
175. Brownell, J.E., et al., Tetrahymena histone acetyltransferase A: a homolog to 
yeast Gcn5p linking histone acetylation to gene activation. Cell, 1996. 84(6): p. 
843-51. 
176. Taunton, J., C.A. Hassig, and S.L. Schreiber, A mammalian histone deacetylase 




177. Verdin, E., Histone Deacetylases - Transcriptional Regulation and Other Cellular 
Functions. Humana Press, 2006. 
178. Grandori, C., et al., The Myc/Max/Mad network and the transcriptional control of 
cell behavior. Annu Rev Cell Dev Biol, 2000. 16: p. 653-99. 
179. Laherty, C.D., et al., SAP30, a component of the mSin3 corepressor complex 
involved in N-CoR-mediated repression by specific transcription factors. 
Mol.Cell, 1998. 2(1): p. 33-42. 
180. Zhang, Y., et al., SAP30, a novel protein conserved between human and yeast, is 
a component of a histone deacetylase complex. Mol Cell, 1998. 1(7): p. 1021-31. 
181. Verdin, E., F. Dequiedt, and H.G. Kasler, Class II histone deacetylases: versatile 
regulators. Trends Genet, 2003. 19(5): p. 286-93. 
182. Fischle, W., et al., Enzymatic activity associated with class II HDACs is 
dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. 
Mol.Cell, 2002. 9(1): p. 45-57. 
183. Kawaguchi, Y., et al., The deacetylase HDAC6 regulates aggresome formation 
and cell viability in response to misfolded protein stress. Cell, 2003. 115(6): p. 
727-38. 
184. Tran, P.B. and R.J. Miller, Aggregates in neurodegenerative disease: crowds and 
power? Trends Neurosci, 1999. 22(5): p. 194-7. 
185. Gartenberg, M.R., The Sir proteins of Saccharomyces cerevisiae: mediators of 
transcriptional silencing and much more. Curr Opin Microbiol, 2000. 3(2): p. 
132-7. 
186. Frye, R.A., Characterization of five human cDNAs with homology to the yeast 
SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein 
ADP-ribosyltransferase activity. Biochem Biophys Res Commun, 1999. 260(1): 
p. 273-9. 
187. North, B.J., et al., The human Sir2 ortholog, SIRT2, is an NAD+-dependent 
tubulin deacetylase. Mol Cell, 2003. 11(2): p. 437-44. 
188. Bruggeman, F.J. and H.V. Westerhoff, The nature of systems biology. Trends 
Microbiol, 2007. 15(1): p. 45-50. 
189. Hornberg, J.J., et al., Cancer: a Systems Biology disease. Biosystems, 2006. 83(2-
3): p. 81-90. 
190. Banwell, C.M., et al., Altered nuclear receptor corepressor expression attenuates 
vitamin d receptor signaling in breast cancer cells. Clin.Cancer Res., 2006. 12(7): 
p. 2004-2013. 
191. Wishart, D., ClustanGraphics: Interactive Graphics for Cluster Analysis. 
Computing Science and Statistics, 1997. 29: p. 48-51. 
192. Laird, P.W., et al., Simplified mammalian DNA isolation procedure. Nucleic 
Acids Res, 1991. 19(15): p. 4293. 
193. Ramirez-Solis, R., A.C. Davis, and A. Bradley, Gene targeting in embryonic stem 
cells. Methods Enzymol, 1993. 225: p. 855-78. 
194. Rashid, S.F., et al., 1alpha,25-dihydroxyvitamin D(3) displays divergent growth 
effects in both normal and malignant cells. Steroids, 2001. 66(3-5): p. 433-440. 
195. Kim, J.Y., Y.L. Son, and Y.C. Lee, Involvement of SMRT Corepressor in 
Transcriptional Repression by the Vitamin D Receptor. Mol Endocrinol, 2008. 
References	  	  
 295 
196. Ting, H.J., et al., Increased expression of corepressors in aggressive androgen-
independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin 
D3 responsiveness. Mol Cancer Res, 2007. 5(9): p. 967-80. 
197. Annicotte, J.S., et al., Peroxisome proliferator-activated receptor gamma 
regulates E-cadherin expression and inhibits growth and invasion of prostate 
cancer. Mol Cell Biol, 2006. 26(20): p. 7561-74. 
198. Chang, T.H. and E. Szabo, Enhanced growth inhibition by combination 
differentiation therapy with ligands of peroxisome proliferator-activated 
receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the 
lung. Clin.Cancer Res., 2002. 8(4): p. 1206-1212. 
199. McDonald, D., et al., Nucleoplasmic beta-actin exists in a dynamic equilibrium 
between low-mobility polymeric species and rapidly diffusing populations. J Cell 
Biol, 2006. 172(4): p. 541-52. 
200. Dundr, M., et al., Actin-dependent intranuclear repositioning of an active gene 
locus in vivo. J Cell Biol, 2007. 179(6): p. 1095-103. 
201. Ou, H., et al., Effect of nuclear actin on endothelial nitric oxide synthase 
expression. Arterioscler Thromb Vasc Biol, 2005. 25(12): p. 2509-14. 
202. Abedin, S.A., et al., Elevated NCOR1 disrupts a network of dietary-sensing 
nuclear receptors in bladder cancer cells. Carcinogenesis, 2009. 
203. Lal, A., et al., A public database for gene expression in human cancers. Cancer 
Res., 1999. 59(21): p. 5403-5407. 
204. Zandbergen, F., et al., The G0/G1 switch gene 2 is a novel PPAR target gene. 
Biochem.J., 2005. 392(Pt 2): p. 313-324. 
205. Matilainen, M., et al., Regulation of multiple insulin-like growth factor binding 
protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res., 2005. 
33(17): p. 5521-5532. 
206. Towsend, K., et al., Identification of VDR-responsive gene signatures in breast 
cancer cells. Oncology, 2006. 71(1-2): p. 111-123. 
207. Degenhardt, T., et al., The insulin-like growth factor binding protein 1 gene is a 
primary target of peroxisome proliferator-activated receptors. J.Biol.Chem., 
2006. 
208. Chene, G., et al., n-3 and n-6 polyunsaturated fatty acids induce the expression of 
COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim 
Biophys Acta, 2007. 1771(5): p. 576-89. 
209. Janabi, N., Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-
Delta(12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in 
human brain macrophages. J Immunol, 2002. 168(9): p. 4747-55. 
210. Khanim, F.L., et al., Altered SMRT levels disrupt vitamin D3 receptor signalling 
in prostate cancer cells. Oncogene, 2004. 23(40): p. 6712-25. 
211. Rashid, S.F., et al., Synergistic growth inhibition of prostate cancer cells by 1 
alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in 
combination with either sodium butyrate or trichostatin A. Oncogene, 2001. 
20(15): p. 1860-1872. 
212. Rhodes, D.R., et al., Oncomine 3.0: genes, pathways, and networks in a collection 
of 18,000 cancer gene expression profiles. Neoplasia, 2007. 9(2): p. 166-80. 
References	  	  
 296 
213. Debruyne, P., S. Vermeulen, and M. Mareel, The role of the E-cadherin/catenin 
complex in gastrointestinal cancer. Acta Gastroenterol.Belg., 1999. 62(4): p. 393-
402. 
214. Morin, P.J., beta-catenin signaling and cancer. Bioessays, 1999. 21(12): p. 1021-
1030. 
215. Lang, S.H., et al., Prostate epithelial cell lines form spheroids with evidence of 
glandular differentiation in three-dimensional Matrigel cultures. Br.J.Cancer, 
2001. 85(4): p. 590-599. 
216. Jepsen, K., et al., Combinatorial roles of the nuclear receptor corepressor in 
transcription and development. Cell, 2000. 102(6): p. 753-763. 
217. Sauer, B., Manipulation of transgenes by site-specific recombination: use of Cre 
recombinase. Methods Enzymol, 1993. 225: p. 890-900. 
218. Rosenthal, N. and S. Brown, The mouse ascending: perspectives for human-
disease models. Nat Cell Biol, 2007. 9(9): p. 993-9. 
219. Wu, X., et al., Generation of a prostate epithelial cell-specific Cre transgenic 
mouse model for tissue-specific gene ablation. Mech Dev, 2001. 101(1-2): p. 61-
9. 
220. George, S.H., et al., Developmental and adult phenotyping directly from mutant 
embryonic stem cells. Proc Natl Acad Sci U S A, 2007. 104(11): p. 4455-60. 
221. Liu, P., N.A. Jenkins, and N.G. Copeland, A highly efficient recombineering-
based method for generating conditional knockout mutations. Genome Res, 2003. 
13(3): p. 476-84. 
222. El-Deiry, W.S., et al., WAF1, a potential mediator of p53 tumor suppression. 
Cell, 1993. 75(4): p. 817-825. 
223. Abbas, T. and A. Dutta, p21 in cancer: intricate networks and multiple activities. 
Nat Rev Cancer, 2009. 9(6): p. 400-14. 
224. Saramaki, A., et al., Regulation of the human p21(waf1/cip1) gene promoter via 
multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res., 
2006. 34(2): p. 543-554. 
225. Friedman, S.L., et al., Resistance to p53-mediated growth arrest and apoptosis in 
Hep 3B hepatoma cells. Oncogene, 1997. 15(1): p. 63-70. 
226. Petrocca, F., et al., E2F1-regulated microRNAs impair TGFbeta-dependent cell-
cycle arrest and apoptosis in gastric cancer. Cancer Cell, 2008. 13(3): p. 272-86. 
227. Pichiorri, F., et al., MicroRNAs regulate critical genes associated with multiple 
myeloma pathogenesis. Proc Natl Acad Sci U S A, 2008. 105(35): p. 12885-90. 
228. Sampath, D., et al., Specific activation of microRNA106b enables the p73 
apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin 
ligase Itch for degradation. Blood, 2009. 113(16): p. 3744-53. 
229. Darzacq, X., et al., In vivo dynamics of RNA polymerase II transcription. Nat 
Struct Mol Biol, 2007. 14(9): p. 796-806. 
230. Ivanovska, I., et al., MicroRNAs in the miR-106b family regulate p21/CDKN1A 
and promote cell cycle progression. Mol Cell Biol, 2008. 28(7): p. 2167-74. 
231. Margaritis, T. and F.C. Holstege, Poised RNA polymerase II gives pause for 
thought. Cell, 2008. 133(4): p. 581-4. 
232. Muse, G.W., et al., RNA polymerase is poised for activation across the genome. 
Nat Genet, 2007. 39(12): p. 1507-11. 
References	  	  
 297 
233. Tijsterman, M. and R.H. Plasterk, Dicers at RISC; the mechanism of RNAi. Cell, 
2004. 117(1): p. 1-3. 
234. Wiemer, E.A., The role of microRNAs in cancer: no small matter. Eur J Cancer, 
2007. 43(10): p. 1529-44. 
235. Banwell, C.M., et al., Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative 
insensitivity in breast cancer cells by co-treatment with histone deacetylation 
inhibitors. J.Steroid Biochem.Mol.Biol., 2004. 89-90(1-5): p. 245-249. 
236. Marks, P.A. and R. Breslow, Dimethyl sulfoxide to vorinostat: development of this 
histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol, 2007. 25(1): 
p. 84-90. 
237. Picard, F., et al., Sirt1 promotes fat mobilization in white adipocytes by repressing 
PPAR-gamma. Nature, 2004. 429(6993): p. 771-6. 
238. Wang, C., et al., Direct acetylation of the estrogen receptor alpha hinge region by 
p300 regulates transactivation and hormone sensitivity. J Biol Chem, 2001. 
276(21): p. 18375-83. 
239. Fu, M., et al., p300 and p300/cAMP-response element-binding protein-associated 
factor acetylate the androgen receptor at sites governing hormone-dependent 
transactivation. J Biol Chem, 2000. 275(27): p. 20853-60. 
240. Tilley, W.D., et al., Mutations in the androgen receptor gene are associated with 
progression of human prostate cancer to androgen independence. Clin Cancer 
Res, 1996. 2(2): p. 277-85. 
241. Molnar, F., M. Matilainen, and C. Carlberg, Structural determinants of the 
agonist-independent association of human peroxisome proliferator-activated 
receptors with coactivators. J Biol Chem, 2005. 280(28): p. 26543-56. 
242. Wang, D., et al., Negative regulation of TSHalpha target gene by thyroid 
hormone involves histone acetylation and corepressor complex dissociation. Mol 
Endocrinol, 2009. 23(5): p. 600-9. 
243. Kato, S., et al., Ligand-induced transrepressive function of VDR requires a 
chromatin remodeling complex, WINAC. J Steroid Biochem Mol Biol, 2007. 
103(3-5): p. 372-80. 
244. Ellis, D.J., Z.K. Lawman, and K. Bonham, Histone acetylation is not an accurate 
predictor of gene expression following treatment with histone deacetylase 
inhibitors. Biochem Biophys Res Commun, 2008. 367(3): p. 656-62. 
245. Simonis, M., J. Kooren, and W. de Laat, An evaluation of 3C-based methods to 
capture DNA interactions. Nat Methods, 2007. 4(11): p. 895-901. 
246. Song, L.N. and E.P. Gelmann, Silencing mediator for retinoid and thyroid 
hormone receptor and nuclear receptor corepressor attenuate transcriptional 
activation by the beta-catenin-TCF4 complex. J Biol Chem, 2008. 283(38): p. 
25988-99. 
247. Degenhardt, T., et al., Population-level transcription cycles derived from 
stochastic timing of single-cell transcription. Cell, 2009. in press. 
248. Charng, M.J., et al., A novel protein distinguishes between quiescent and 
activated forms of the type I transforming growth factor beta receptor. J Biol 
Chem, 1998. 273(16): p. 9365-8. 
249. Wurthner, J.U., et al., Transforming growth factor-beta receptor-associated 
protein 1 is a Smad4 chaperone. J Biol Chem, 2001. 276(22): p. 19495-502. 
References	  	  
 298 
250. Saramaki, A., et al., Cyclical chromatin looping and transcription factor 
association on the regulatory regions of the p21 (CDKN1A) gene in response to 
1alpha,25-dihydroxyvitamin D3. J Biol Chem, 2009. 284(12): p. 8073-82. 
251. Hu, Q., et al., Enhancing nuclear receptor-induced transcription requires nuclear 
motor and LSD1-dependent gene networking in interchromatin granules. Proc 
Natl Acad Sci U S A, 2008. 105(49): p. 19199-204. 
252. O'Neill, L.P. and B.M. Turner, Immunoprecipitation of native chromatin: NChIP. 
Methods, 2003. 31(1): p. 76-82. 
 	  
